<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis - Gonzalez-Lorenzo, M - 2024 | Cochrane Library</title> <meta content="Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis - Gonzalez-Lorenzo, M - 2024 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011381.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis - Gonzalez-Lorenzo, M - 2024 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011381.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011381.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis" name="citation_title"/> <meta content="Marien Gonzalez-Lorenzo" name="citation_author"/> <meta content="Istituto di Ricerche Farmacologiche Mario Negri IRCCS" name="citation_author_institution"/> <meta content="Ben Ridley" name="citation_author"/> <meta content="IRCCS Istituto delle Scienze Neurologiche di Bologna" name="citation_author_institution"/> <meta content="Silvia Minozzi" name="citation_author"/> <meta content="Lazio Regional Health Service" name="citation_author_institution"/> <meta content="Cinzia Del Giovane" name="citation_author"/> <meta content="Guy Peryer" name="citation_author"/> <meta content="University of East Anglia (UEA)" name="citation_author_institution"/> <meta content="Thomas Piggott" name="citation_author"/> <meta content="Matteo Foschi" name="citation_author"/> <meta content="Graziella Filippini" name="citation_author"/> <meta content="Carlo Besta Foundation and Neurological Institute" name="citation_author_institution"/> <meta content="Irene Tramacere" name="citation_author"/> <meta content="Fondazione IRCCS Istituto Neurologico Carlo Besta" name="citation_author_institution"/> <meta content="Elisa Baldin" name="citation_author"/> <meta content="IRCCS Istituto delle Scienze Neurologiche di Bologna" name="citation_author_institution"/> <meta content="Francesco Nonino" name="citation_author"/> <meta content="IRCCS Istituto delle Scienze Neurologiche di Bologna" name="citation_author_institution"/> <meta content="f.nonino@ausl.bologna.it" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD011381.pub3" name="citation_doi"/> <meta content="2024" name="citation_date"/> <meta content="2024/01/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011381.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011381.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011381.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Alemtuzumab [therapeutic use]; Cladribine [therapeutic use]; Daclizumab [therapeutic use]; Dimethyl Fumarate [therapeutic use]; Fingolimod Hydrochloride [therapeutic use]; Glatiramer Acetate [therapeutic use]; Immunologic Factors [therapeutic use]; *Immunosuppressive Agents [therapeutic use]; Interferon beta-1a [therapeutic use]; Interferon beta-1b [therapeutic use]; *Multiple Sclerosis, Relapsing-Remitting [drug therapy]; Natalizumab [therapeutic use]; Network Meta-Analysis; Recurrence" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011381.pub3&amp;doi=10.1002/14651858.CD011381.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6zFwvAqw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011381\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011381\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ko","pt","ms","hr","fr","zh_HANT","ja","id","fa","pl"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD011381.pub3",title:"Immunomodulators and immunosuppressants for relapsing\\u2010remitting multiple sclerosis: a network meta\\u2010analysis",firstPublishedDate:"Jan 4, 2024 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011381.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011381.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011381.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011381.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011381.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011381.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011381.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011381.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011381.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011381.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7553 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011381.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-sec-0108"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-sec-0055"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-sec-0094"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/appendices#CD011381-sec-0113"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/supinfo/CD011381-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/supinfo/CD011381-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information#CD011381-cr-0004">Marien Gonzalez-Lorenzo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information#CD011381-cr-0005">Ben Ridley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information#CD011381-cr-0006">Silvia Minozzi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information#CD011381-cr-0007">Cinzia Del Giovane</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information#CD011381-cr-0008">Guy Peryer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information#CD011381-cr-0009">Thomas Piggott</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information#CD011381-cr-0010">Matteo Foschi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information#CD011381-cr-0011">Graziella Filippini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information#CD011381-cr-0012">Irene Tramacere</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information#CD011381-cr-0013">Elisa Baldin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information#CD011381-cr-0014"><i class="icon corresponding-author fa fa-envelope"></i>Francesco Nonino</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information/en#CD011381-sec-0135">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 January 2024 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011381.pub3">https://doi.org/10.1002/14651858.CD011381.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011381-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011381-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011381-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011381-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011381-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011381-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011381-abs-0007">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011381-abs-0001" lang="en"> <section id="CD011381-sec-0001"> <h3 class="title" id="CD011381-sec-0001">Background</h3> <p>Different therapeutic strategies are available for the treatment of people with relapsing‐remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biological agents. Although each one of these therapies reduces relapse frequency and slows disability accumulation compared to no treatment, their relative benefit remains unclear. </p> <p>This is an update of a Cochrane review published in 2015.</p> </section> <section id="CD011381-sec-0002"> <h3 class="title" id="CD011381-sec-0002">Objectives</h3> <p>To compare the efficacy and safety, through network meta‐analysis, of interferon beta‐1b, interferon beta‐1a, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, pegylated interferon beta‐1a, daclizumab, laquinimod, azathioprine, immunoglobulins, cladribine, cyclophosphamide, diroximel fumarate, fludarabine, interferon beta 1‐a and beta 1‐b, leflunomide, methotrexate, minocycline, mycophenolate mofetil, ofatumumab, ozanimod, ponesimod, rituximab, siponimod and steroids for the treatment of people with RRMS. </p> </section> <section id="CD011381-sec-0003"> <h3 class="title" id="CD011381-sec-0003">Search methods</h3> <p>CENTRAL, MEDLINE, Embase, and two trials registers were searched on 21 September 2021 together with reference checking, citation searching and contact with study authors to identify additional studies. A top‐up search was conducted on 8 August 2022. </p> </section> <section id="CD011381-sec-0004"> <h3 class="title" id="CD011381-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) that studied one or more of the available immunomodulators and immunosuppressants as monotherapy in comparison to placebo or to another active agent, in adults with RRMS. </p> </section> <section id="CD011381-sec-0005"> <h3 class="title" id="CD011381-sec-0005">Data collection and analysis</h3> <p>Two authors independently selected studies and extracted data. We considered both direct and indirect evidence and performed data synthesis by pairwise and network meta‐analysis. Certainty of the evidence was assessed by the GRADE approach. </p> </section> <section id="CD011381-sec-0006"> <h3 class="title" id="CD011381-sec-0006">Main results</h3> <p>We included 50 studies involving 36,541 participants (68.6% female and 31.4% male). Median treatment duration was 24 months, and 25 (50%) studies were placebo‐controlled. </p> <p>Considering the risk of bias, the most frequent concern was related to the role of the sponsor in the authorship of the study report or in data management and analysis, for which we judged 68% of the studies were at high risk of other bias. The other frequent concerns were performance bias (34% judged as having high risk) and attrition bias (32% judged as having high risk). </p> <p>Placebo was used as the common comparator for network analysis.</p> <p><b>Relapses over 12 months:</b> data were provided in 18 studies (9310 participants). Natalizumab results in a large reduction of people with relapses at 12 months (RR 0.52, 95% CI 0.43 to 0.63; high‐certainty evidence). Fingolimod (RR 0.48, 95% CI 0.39 to 0.57; moderate‐certainty evidence), daclizumab (RR 0.55, 95% CI 0.42 to 0.73; moderate‐certainty evidence), and immunoglobulins (RR 0.60, 95% CI 0.47 to 0.79; moderate‐certainty evidence) probably result in a large reduction of people with relapses at 12 months. </p> <p><b>Relapses over 24 months:</b> data were reported in 28 studies (19,869 participants). Cladribine (RR 0.53, 95% CI 0.44 to 0.64; high‐certainty evidence), alemtuzumab (RR 0.57, 95% CI 0.47 to 0.68; high‐certainty evidence) and natalizumab (RR 0.56, 95% CI 0.48 to 0.65; high‐certainty evidence) result in a large decrease of people with relapses at 24 months. Fingolimod (RR 0.54, 95% CI 0.48 to 0.60; moderate‐certainty evidence), dimethyl fumarate (RR 0.62, 95% CI 0.55 to 0.70; moderate‐certainty evidence), and ponesimod (RR 0.58, 95% CI 0.48 to 0.70; moderate‐certainty evidence) probably result in a large decrease of people with relapses at 24 months. Glatiramer acetate (RR 0.84, 95%, CI 0.76 to 0.93; moderate‐certainty evidence) and interferon beta‐1a (Avonex, Rebif) (RR 0.84, 95% CI 0.78 to 0.91; moderate‐certainty evidence) probably moderately decrease people with relapses at 24 months. </p> <p><b>Relapses over 36 months</b> findings were available from five studies (3087 participants). None of the treatments assessed showed moderate‐ or high‐certainty evidence compared to placebo. </p> <p><b>Disability worsening over 24 months</b> was assessed in 31 studies (24,303 participants). Natalizumab probably results in a large reduction of disability worsening (RR 0.59, 95% CI 0.46 to 0.75; moderate‐certainty evidence) at 24 months. </p> <p><b>Disability worsening over 36 months</b> was assessed in three studies (2684 participants) but none of the studies used placebo as the comparator. </p> <p><b>Treatment discontinuation due to adverse events</b> data were available from 43 studies (35,410 participants). Alemtuzumab probably results in a slight reduction of treatment discontinuation due to adverse events (OR 0.39, 95% CI 0.19 to 0.79; moderate‐certainty evidence). Daclizumab (OR 2.55, 95% CI 1.40 to 4.63; moderate‐certainty evidence), fingolimod (OR 1.84, 95% CI 1.31 to 2.57; moderate‐certainty evidence), teriflunomide (OR 1.82, 95% CI 1.19 to 2.79; moderate‐certainty evidence), interferon beta‐1a (OR 1.48, 95% CI 0.99 to 2.20; moderate‐certainty evidence), laquinimod (OR 1.49, 95 % CI 1.00 to 2.15; moderate‐certainty evidence), natalizumab (OR 1.57, 95% CI 0.81 to 3.05), and glatiramer acetate (OR 1.48, 95% CI 1.01 to 2.14; moderate‐certainty evidence) probably result in a slight increase in the number of people who discontinue treatment due to adverse events. </p> <p><b>Serious adverse events (SAEs)</b> were reported in 35 studies (33,998 participants). There was probably a trivial reduction in SAEs amongst people with RRMS treated with interferon beta‐1b as compared to placebo (OR 0.92, 95% CI 0.55 to 1.54; moderate‐certainty evidence). </p> </section> <section id="CD011381-sec-0007"> <h3 class="title" id="CD011381-sec-0007">Authors' conclusions</h3> <p>We are highly confident that, compared to placebo, two‐year treatment with natalizumab, cladribine, or alemtuzumab decreases relapses more than with other DMTs. We are moderately confident that a two‐year treatment with natalizumab may slow disability progression. Compared to those on placebo, people with RRMS treated with most of the assessed DMTs showed a higher frequency of treatment discontinuation due to AEs: we are moderately confident that this could happen with fingolimod, teriflunomide, interferon beta‐1a, laquinimod, natalizumab and daclizumab, while our certainty with other DMTs is lower. We are also moderately certain that treatment with alemtuzumab is associated with fewer discontinuations due to adverse events than placebo, and moderately certain that interferon beta‐1b probably results in a slight reduction in people who experience serious adverse events, but our certainty with regard to other DMTs is lower. </p> <p>Insufficient evidence is available to evaluate the efficacy and safety of DMTs in a longer term than two years, and this is a relevant issue for a chronic condition like MS that develops over decades. More than half of the included studies were sponsored by pharmaceutical companies and this may have influenced their results. Further studies should focus on direct comparison between active agents, with follow‐up of at least three years, and assess other patient‐relevant outcomes, such as quality of life and cognitive status, with particular focus on the impact of sex/gender on treatment effects. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011381-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011381-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011381-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011381-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011381-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011381-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011381-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD011381-abs-0017">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011381-abs-0016">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011381-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011381-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011381-abs-0020">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011381-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011381-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011381-abs-0015">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011381-abs-0002" lang="en"> <h3>What are the benefits and risks of drugs acting on the immune system to treat relapsing‐remitting multiple sclerosis ? </h3> <p><b>Key messages</b> </p> <p>‐ After two years of treatment, natalizumab, cladribine and alemtuzumab work best in reducing the frequency of relapses in relapsing‐remitting multiple sclerosis. Natalizumab is likely to be also effective in slowing the progression of disability after two years of treatment. </p> <p>‐ Longer studies are needed to assess the benefits and harms of drugs acting on the immune system for relapsing‐remitting multiple sclerosis. </p> <p>‐ Future research on these types of drugs should compare them against each other and focus on effects that are important to people with multiple sclerosis, such as their quality of life and their ability to think, learn, remember, use judgement, and make decisions. </p> <p><b>What is multiple sclerosis?</b> </p> <p>Multiple sclerosis is an uncommon condition affecting relevant functions of the body, caused by an inflammation of the brain and of the spinal cord with damage that in time impairs some important activities of daily living, such as walking and taking care of yourself. People with multiple sclerosis experience symptoms such as weakness, tiredness, painful cramps in their muscles, and reduction of sensitivity in parts of their body. Over the years, such symptoms may worsen and lead to the need for a wheelchair. The most common form of multiple sclerosis is called "relapsing‐remitting" as symptoms come and go over the years. The appearance of symptoms is called "relapse". In time, relapses become more and more frequent, with more troublesome symptoms and with shorter periods of well‐being in between. Although uncommon, multiple sclerosis is a particularly burdensome condition in that it typically affects young people, mainly women, in the most active stage of their life, between the age of 20 and 40 years. </p> <p><b>How is multiple sclerosis treated?</b> </p> <p>Although currently there is no treatment that can cure multiple sclerosis, it is treated with drugs called "disease‐modifying", in that they are aimed at reducing the frequency of relapses and at slowing the progression of disability. Many such drugs are available to reduce inflammation in the brain or spinal cord. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out which "disease‐modifying" drugs work best to make people with multiple sclerosis feel better and, at the same time, are well tolerated and have the fewest unwanted effects. In particular, we wanted to find out if any drug is better than the others in reducing the frequency of relapses and the worsening of disability, and if any drug is better tolerated than the others or causes fewer unwanted events. </p> <p><b>What did we do?</b> </p> <p>We searched thoroughly for studies comparing any "disease‐modifying" drug with another drug or with no treatment in adults (≥ 18 years old) with relapsing‐remitting multiple sclerosis. </p> <p>We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and number of participants involved and precision of the results. </p> <p><b>What did we find?</b> </p> <p>We found 50 studies with 36,541 people with multiple sclerosis (68.6% female and 31.4% male) treated with a "disease‐modifying" drug for at least one year. The biggest study included 2,244 people; the smallest included 19 people. The studies were conducted all over the world, mostly in the USA and Europe. Most studies lasted 12 or 24 months; only eight studies lasted more than 24 months. Most studies were performed by pharmaceutical companies in order to obtain authorisation from regulatory authorities for marketing the studied drug. Twenty‐five studies compared a "disease‐modifying" drug with no treatment; the other studies compared two different types of "disease‐modifying" drugs. We are highly confident that natalizumab, cladribine and alemtuzumab are more effective than most drugs in reducing the frequency of relapses after two years of treatment. We are moderately confident that natalizumab is also likely to be effective in slowing the worsening of disability after two years of treatment. We are moderately confident that people taking fingolimod, teriflunomide, glatiramer acetate, interferon beta‐1a, laquinimod, natalizumab and daclizumab are more likely to discontinue the drug because of unwanted effects. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the desirable and undesirable effects of "disease‐modifying" drugs is limited, mainly because the evidence is based on few cases of relapses and worsening of disability, and because we were concerned that the interests of pharmaceutical companies may have influenced the reporting of the study results. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>The evidence is up‐to‐date until August 8, 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011381-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011381-sec-0108"></div> <h3 class="title" id="CD011381-sec-0109">Implications for practice</h3> <section id="CD011381-sec-0109"> <p>Conservative interpretation of these results is warranted, since most of the included treatments have been evaluated in few trials. Nevertheless, we used a comprehensive, transparent, and pragmatic approach for rating the certainty of the evidence (i.e. the GRADE approach), so the results of this review may provide guidance to clinicians and patients. According to the GRADE approach, implications for practice should be based on moderate to high certainty of evidence, since any estimate of effect based on low to very low certainty of evidence is very uncertain and further research is likely to change the estimate. The results of this updated review show that, for preventing clinical relapses in the short term (24 months), natalizumab, alemtuzumab, and cladribine may be preferable to several other treatments, based on high certainty of evidence. For preventing disability from worsening in the short term (24 months), natalizumab is superior to several other treatments based on moderate certainty of evidence. Moreover, alemtuzumab may also have a better treatment durability, being associated with less discontinuation due to AEs. The number of SAEs seems, from the available evidence, to be only slightly affected by treatment with DMTs amongst people with RRMS. </p> <p>In addition to the available evidence for benefit provided above, there are two major concerns that have to be considered. First, the efficacy of all of these treatments beyond two years is uncertain and this is a relevant issue for a disease with a duration of 30 to 40 years. Second, short‐term trials provide limited safety data and do not provide useful evidence to obtain a reliable risk profile of treatments. In order to provide information on the long‐term safety of the treatments included in this review, non‐randomised studies should be considered. </p> <p>Finally, more than 68% of the studies included in this review were sponsored by pharmaceutical companies and this may have influenced their results. </p> </section> <h3 class="title" id="CD011381-sec-0110">Implications for research</h3> <section id="CD011381-sec-0110"> <p>The research agenda on DMTs for MS should address the following needs: first, randomised trials of direct comparisons between active agents would be useful, avoiding further placebo‐controlled studies that in the current context do not comply with the principle of clinical equipoise for RRMS, given the broad availability of therapeutic alternatives. Second, follow‐up of at least 36 months should be mandatory for confirmatory RCTs on DMTs for MS. Third, more studies are needed to evaluate the medium and long‐term benefit and safety of immunotherapies and the comparative safety of the different agents. As the number of drugs, including biological agents, that are available for the treatment of RRMS increases, more options will become available to participants and clinicians. In the absence of comparative trials, national and international registries and other types of large non‐randomised studies might be relevant sources for providing complementary data regarding the long‐term benefit and safety of immunotherapies for RRMS. Fourth, future clinical research on MS may benefit from long‐term data on outcomes deemed as relevant by people with MS, such as cognitive status and quality of life, as well as definition and validation of health state utility values. Finally, methods of outcome assessment should be more consistent across studies. Although relapses and disability progression are commonly used in MS research as efficacy outcomes, comparison of the relative effectiveness and safety across DMTs is challenging due to the heterogeneity in the way such outcomes are measured (e.g. annualised relapse rate rather than number of people with relapse; mean EDSS scores rather than number of people with MS presenting disability progression). Therefore, consistency in the choice of recommended efficacy and safety outcome measures is highly desirable, particularly in industry‐initiated trials, in which the findings may inform regulatory approval of novel DMTs. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011381-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011381-sec-0008"></div> <div class="table" id="CD011381-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Relapses at 12 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Population:</b> Patients with RRMS </p> <p><b>Interventions:</b> Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b, interferon beta‐1b (Betaferon), interferon beta‐1a (Avonex, Rebif), pegylated interferon beta‐1a, mitoxantrone, natalizumab, teriflunomide </p> <p><b>Comparator (reference):</b> Placebo </p> <p><b>Outcome:</b> Relapses at 12 months </p> <p><b>Setting(s):</b> Outpatient </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Intervention (no. of studies/participants)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect**</b> </p> <p><b>(95% CrI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effect***(95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With placebo</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With intervention</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Azathioprine</b> </p> <p>(Direct evidence; 1 RCT; 59 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.91</b><br/>(0.58 to 1.43) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>375 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>37 fewer per 1000</b><br/>(from 173 fewer to 177 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Daclizumab</b> </p> <p>(Direct evidence; 1 RCT; 621 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.55</b><br/>(0.42 to 0.73) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>227 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>185 fewer per 1000</b><br/>(from 239 fewer to 111 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fingolimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.48</b><br/>(0.39 to 0.57) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>198 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>214 fewer per 1000</b><br/>(from 251 fewer to 177 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Glatiramer acetate</b> </p> <p>(Direct evidence; 2 RCTs; 1454 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.64</b><br/>(0.55 to 0.75) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>264 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>148 fewer per 1000</b><br/>(from 185 fewer to 103 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Immunoglobulins</b> </p> <p>(Direct evidence; 2 RCTs; 91 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.60</b><br/>(0.47 to 0.79) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>247 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>165 fewer per 1000</b><br/>(from 218 fewer to 87 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta 1a‐1b</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 1.42</b><br/>(0.78 to 2.60) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>585 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>173 more per 1000</b> </p> <p>(from 91 fewer to 659 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1b (Betaferon)</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.82</b><br/>(0.50 to 1.33) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>338 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>74 fewer per 1000</b><br/>(from 206 fewer to 136 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1a (Avonex, Rebif)</b> </p> <p>(Direct evidence; 1 RCT; 560 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.76</b><br/>(0.68 to 0.85) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>313 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>99 fewer per 1000</b> </p> <p>(from 132 fewer to 62 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pegylated interferon beta‐1a</b> </p> <p>(Direct evidence; 1 RCT; 1512 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.68</b><br/>(0.56 to 0.82) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>280 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>132 fewer per 1000</b><br/>(from 181 fewer to 74 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mitoxantrone</b> </p> <p>(Direct evidence; 1 RCT; 51 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.40</b><br/>(0.21 to 0.74) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>165 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>247 fewer per 1000</b><br/>(from 326 fewer to 107 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Natalizumab</b> </p> <p>(Direct evidence; 1 RCT; 942 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.52</b><br/>(0.43 to 0.63) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>214 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>198 fewer per 1000</b><br/>(from 235 fewer to 152 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>High<sup>9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Teriflunomide</b> </p> <p>(Direct evidence; 1 RCT; 1169 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.66</b><br/>(0.55 to 0.78) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>272 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>140 fewer per 1000</b><br/>(from 185 fewer to 91 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>NMA‐SoF table definitions</b> </p> <p>** Network Meta‐analysis estimates are reported as risk ratios. CI: confidence interval.</p> <p>*** Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group. </p> <p><b>GRADE Working Group grades of evidence (or certainty in the evidence)</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> <p>1 Absolute observed point estimate falls in the small positive effect, 95% CI range from large positive effect to large negative effect: downgraded three levels. </p> <p>2 Absolute observed point estimate falls in the large positive effect, 95% CI range from large positive effect to moderate positive effect: downgraded one level. </p> <p>3 Downgraded one level for risk of bias. Absolute observed point estimate falls in the large positive effect, 95% CIs contained within positive effect. </p> <p>4 Absolute observed point estimate falls in the large positive effect, 95% CI range from large positive effect to moderate positive effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>5 Absolute observed point estimate falls in the large negative effect, 95% CI range from moderate positive effect to large negative effect: downgraded three levels. Further downgraded one level for risk of bias </p> <p>6 Absolute observed point estimate falls in the moderate positive effect, 95% CI range from large positive effect to large negative effect: downgraded three levels. Further downgraded one level for risk of bias </p> <p>7 Absolute observed point estimate falls in the moderate positive effect, 95% CI range from large positive effect to small positive effect: downgraded two levels. </p> <p>8 Absolute observed point estimate falls in the large positive effect, 95% CI range from large positive effect to moderate positive effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>9 Absolute observed point estimate falls in the large positive effect, 95% CIs contained within positive effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011381-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Relapses at 24 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Population:</b> Patients with RRMS </p> <p><b>Interventions:</b> alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate, immunoglobulins, interferon beta 1a‐1b, interferon beta‐1b (Betaferon), interferon beta‐1a (Avonex, Rebif, laquinimod, mitoxantrone, natalizumab, ponesimod, teriflunomide </p> <p><b>Comparator (reference):</b> Placebo </p> <p><b>Outcome:</b> Relapses at 24 months </p> <p><b>Setting(s):</b> Outpatient </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Intervention (no. of studies/participants)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect**</b> </p> <p><b>(95% CrI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effect***(95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With placebo</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With</i> intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alemtuzumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.57</b><br/>(0.47 to 0.68) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>291 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>219 fewer per 1000</b><br/>(from 270 fewer to 163 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>High<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Azathioprine</b> </p> <p>(Direct evidence; 1 RCT; 59 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.77</b> </p> <p>(0.51 to 1.18)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>392 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>117 fewer per 1000</b><br/>(from 250 fewer to 92 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cladribine</b> </p> <p>(Direct evidence; 1 RCT; 1326 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.53</b><br/>(0.44 to 0.64) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>270 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>240 fewer per 1000</b><br/>(from 285 fewer to 183 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>High<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dimethylfumarate</b> </p> <p>(Direct evidence; 2 RCTs; 2307 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.62</b><br/>(0.55 to 0.70) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>316 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>194 fewer per 1000</b><br/>(from 229 fewer to 153 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fingolimod</b> </p> <p>(Direct evidence; 2 RCTs; 2355 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.54</b><br/>(0.48 to 0.60) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>275 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>234 fewer per 1000</b><br/>(from 265 fewer to 204 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Glatiramer acetate</b> </p> <p>(Direct evidence; 3 RCsT; 1014 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.84</b><br/>(0.76 to 0.93) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>428 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>82 fewer per 1000</b><br/>(from 122 fewer to 36 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Immunoglobulins</b> </p> <p>(Direct evidence; 2 RCTs; 192 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.73</b><br/>(0.59 to 0.90) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>372 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>138 fewer per 1000</b><br/>(from 209 fewer to 51 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta 1a‐1b</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 1.21</b><br/>(0.66 to 2.19) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>617 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>107 more per 1000</b><br/>(from 173 fewer to 607 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I<b>nterferon beta‐1b (Betaferon)</b> </p> <p>(Direct evidence; 1 RCT; 372 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.85</b><br/>(0.76 to 0.94) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>433 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>76 fewer per 1000</b><br/>(from 122 fewer to 31 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1a (Avonex, Rebif)</b> </p> <p>(Direct evidence; 3 RCTs; 1629 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.84</b><br/>(0.78 to 0.91) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>428 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>82 fewer per 1000</b><br/>(from 112 fewer to 46 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laquinimod</b> </p> <p>(Direct evidence; 3 RCTs; 3457 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.83</b><br/>(0.76 to 0.91) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>423 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>87 fewer per 1000</b><br/>(from 122 fewer to 46 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mitoxantrone</b> </p> <p>(Direct evidence; 1 RCT; 51 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.47</b><br/>(0.27 to 0.80) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>240 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>270 fewer per 1000</b><br/>(from 372 fewer to 102 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>10</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Natalizumab</b> </p> <p>(Direct evidence; 1 RCT; 942 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.56</b><br/>(0.48 to 0.65) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>285 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>224 fewer per 1000</b><br/>(from 265 fewer to 178 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>High<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ponesimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.58</b><br/>(0.48 to 0.70) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>214 fewer per 1000</b><br/>(from 265 fewer to 153 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Teriflunomide</b> </p> <p>(Direct evidence; 1 RCT; 1088 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.82</b><br/>(0.71 to 0.94) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>418 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>92 fewer per 1000</b><br/>(from 148 fewer to 31 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>11</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>NMA‐SoF table definitions</b> </p> <p>** Network Meta‐analysis estimates are reported as risk ratios. CI: confidence interval.</p> <p>*** Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group. </p> <p><b>GRADE Working Group grades of evidence (or certainty in the evidence)</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> <p><b>Explanatory Footnotes</b> </p> <p>1 Absolute observed point estimate falls in the large positive effect, 95% CIs contained within positive effect. </p> <p>2 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from large positive effect to moderate negative effect: downgraded three levels </p> <p>3 Downgraded one level for risk of bias. Absolute observed point estimate falls in the large positive effect, 95% CIs contained within positive effect. </p> <p>4 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to small positive effect: downgraded one level </p> <p>5 Absolute observed point estimate falls in the large positive effect, 95% CIs range from large positive effect to small positive effect: downgraded two levels </p> <p>6 Absolute observed point estimate falls in the moderate negative effect, 95% CIs range from large positive effect to large negative effect: downgraded three levels. Further downgraded one level for risk of bias </p> <p>7 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels </p> <p>8 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to small positive effect: downgraded one level </p> <p>9 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to small positive effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>10 Absolute observed point estimate falls in the large positive effect, 95% CIs range from large positive effect to moderate positive effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>11 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from large positive effect to trivial positive effect: downgraded three levels. Further downgraded one level for risk of bias </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011381-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Relapses at 36 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patients:</b> Patients with RRMS </p> <p><b>Interventions:</b> interferon beta‐1b (Betaferon) </p> <p><b>Comparator (reference):</b> Placebo </p> <p><b>Outcome:</b> Relapses at 36 months </p> <p><b>Setting(s):</b> Outpatient </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Intervention (no. of studies/participants)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect**</b> </p> <p><b>(95% CrI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effect***(95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With placebo</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With</i> <i>intervention</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1b (Betaferon)</b> </p> <p>(Direct evidence; 2 RCTs; 403 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.86</b><br/>(0.67 to 1.11) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>862 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>741 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>121 fewer per 1000</b><br/>(from 284 fewer to 95 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>NMA‐SoF table definitions</b> </p> <p>** Network Meta‐analysis estimates are reported as risk ratios. CI: confidence interval.</p> <p>*** Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group. </p> <p><b>GRADE Working Group grades of evidence (or certainty in the evidence)</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> <p><b>Explanatory Footnotes</b> </p> <p>1 Absolute observed point estimate falls in the moderate positive effect, 95% CI ranges from large positive effect to moderate negative effect: downgraded three levels </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011381-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Disability at 24 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Population:</b> Patients with RRMS </p> <p><b>Interventions:</b> Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate, immunoglobulins, interferon beta 1a‐1b, interferon beta‐1b (Betaferon), interferon beta‐1a (Avonex, Rebif), laquinimod, mitoxantrone, natalizumab, ocrelizumab, ofatumumab, ozanimod, ponesimod, teriflunomide </p> <p><b>Comparator (reference):</b> Placebo </p> <p><b>Outcome:</b> Disability at 24 months </p> <p><b>Setting(s):</b> Outpatient </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Intervention</b> </p> <p><b>(no. of studies and participants)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect**</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effect***(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With placebo</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With intervention</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alemtuzumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.67</b><br/>(0.46 to 0.99) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>126 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>62 fewer per 1000</b><br/>(from 101 fewer to 2 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Azathioprine</b> </p> <p>(Direct evidence; 1 RCT; 59 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.60</b><br/>(0.22 to 1.63) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>113 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>75 fewer per 1000</b><br/>(from 146 fewer to 118 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cladribine</b> </p> <p>(Direct evidence; 1 RCT; 1326 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.72</b><br/>(0.56 to 0.91) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>135 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>53 fewer per 1000</b><br/>(from 83 fewer to 17 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dimethylfumarate</b> </p> <p>(Direct evidence; 2 RCTs; 2307 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.65</b><br/>(0.55 to 0.77) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>122 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>66 fewer per 1000</b><br/>(from 84 fewer to 43 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fingolimod</b> </p> <p>(Direct evidence; 2 RCTs; 2355 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.68</b><br/>(0.56 to 0.83) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>128 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>60 fewer per 1000</b><br/>(from 83 fewer to 32 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Glatiramer acetate</b> </p> <p>(Direct evidence; 3 RCTs; 1014 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.74</b><br/>(0.61 to 0.89) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>139 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>49 fewer per 1000</b><br/>(from 73 fewer to 21 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Immunoglobulins</b> </p> <p>(Direct evidence; 2 RCTs; 190 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.75</b><br/>(0.41 to 1.37) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>141 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>47 fewer per 1000</b><br/>(from 111 fewer to 69 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta 1a‐1b</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 3.19</b><br/>(0.31 to 33.21) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>599 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>411 more per 1000</b> </p> <p>(from 130 fewer to 1000 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1b (Betaferon)</b> </p> <p>(Direct evidence; 1 RCT; 372 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.77</b><br/>(0.62 to 0.94) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>145 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>43 fewer per 1000</b><br/>(from 71 fewer to 11 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1a (Avonex, Rebif)</b> </p> <p>(Direct evidence; 2 RCTs; 1069 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b><br/>(0.73 to 1.16) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>173 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15 fewer per 1000</b><br/>(from 51 fewer to 30 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>10</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laquinimod</b> </p> <p>(Direct evidence; 3 RCTs; 3451 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.78</b><br/>(0.63 to 0.96) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>146 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41 fewer per 1000</b><br/>(from 69 fewer to 8 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>11</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mitoxantrone</b> </p> <p>(Direct evidence; 1 RCT; 51 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.20</b><br/>(0.05 to 0.83) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>38 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>150 fewer per 1000</b><br/>(from 178 fewer to 32 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>12</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Natalizumab</b> </p> <p>(Direct evidence; 1 RCT; 942 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.59</b><br/>(0.46 to 0.75) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>111 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>77 fewer per 1000</b><br/>(from 101 fewer to 47 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>13</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocrelizumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.61</b><br/>(0.41 to 0.90) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>115 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>73 fewer per 1000</b><br/>(from 111 fewer to 19 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>14</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ofatumumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.54</b><br/>(0.38 to 0.77) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>101 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>86 fewer per 1000</b><br/>(from 116 fewer to 43 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>15</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ozanimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 1.19</b><br/>(0.74 to 1.91) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>223 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6 more per 1000</b><br/>(from 49 fewer to 171 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>16</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ponesimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.63</b><br/>(0.41 to 0.96) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>118 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>69 fewer per 1000</b><br/>(from 111 fewer to 8 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>17</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Teriflunomide</b> </p> <p>(Direct evidence; 1 RCT; 1088 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.76</b><br/>(0.61 to 0.95) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>143 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>45 fewer per 1000</b><br/>(from 73 fewer to 9 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>18</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>NMA‐SoF table definitions</b> </p> <p>** Network Meta‐analysis estimates are reported as risk ratios. CI: confidence interval.</p> <p>*** Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group. </p> <p><b>GRADE Working Group grades of evidence (or certainty in the evidence)</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> <p><b>Explanatory footnotes</b> </p> <p>1 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to trivial positive: downgraded three levels </p> <p>2 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from large positive effect to large negative effect: downgraded two levels </p> <p>3 Absolute observed point estimate falls in the small positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels </p> <p>4 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to small positive effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>5 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to small positive effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>6 Absolute observed point estimate falls in the small positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels. Further downgraded one level for risk of bias </p> <p>7 Absolute observed point estimate falls in the small positive effect, 95% CIs range from moderate positive effect to moderate negative effect: downgraded three levels </p> <p>8 Absolute observed point estimate falls in the large negative effect, 95% CIs range from large positive effect to large negative effect: downgraded three levels. Further downgraded one level for risk of bias </p> <p>9 Absolute observed point estimate falls in the small positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels </p> <p>10 Absolute observed point estimate falls in the trivial positive effect, 95% CIs range from small positive effect to trivial negative effect: downgraded two levels </p> <p>11 Absolute observed point estimate falls in the small positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels. Further downgraded one level for risk of bias </p> <p>12 Absolute observed point estimate falls in the large positive effect, 95% CIs range from large positive effect to small positive effect: downgraded two levels. Further downgraded one level for risk of bias </p> <p>13 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to small positive effect: downgraded one level </p> <p>14 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels. Further downgraded one level for risk of bias </p> <p>15 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from large positive effect to small positive effect: downgraded two levels. Further downgraded one level for risk of bias </p> <p>16 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from small positive effect to large negative effect: downgraded three levels </p> <p>17 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels. Further downgraded one level for risk of bias </p> <p>18 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels. Further downgraded one level for risk of bias </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011381-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Discontinuation due to adverse effects</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Population:</b> Patients with RRMS </p> <p><b>Interventions:</b> Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, immunoglobulins, interferon beta 1a‐1b, interferon beta‐1b (Betaferon), interferon beta‐1a (Avonex, Rebif), laquinimod, pegylated interferon beta1a, natalizumab, ocrelizumab, ofatumumab, ozanimod, ponesimod, teriflunomide </p> <p><b>Comparator (reference):</b> Placebo </p> <p><b>Outcome:</b> Treatment discontinuation due to adverse events </p> <p><b>Setting(s):</b> Outpatient </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Intervention (no. of studies/participants)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect**</b> </p> <p><b>(95% CrI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effect***(95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With placebo</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With</i> <i>intervention</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alemtuzumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 0.39</b><br/>(0.19 to 0.79) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>30 fewer per 1000</b><br/>(from 40 fewer to 10 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Azathioprine</b> </p> <p>(Direct evidence; 1 RCT; 54 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 6.26</b><br/>(0.67 to 58.05) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>246 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>196 more per 1000</b><br/>(from 16 fewer to 702 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cladribine</b> </p> <p>(Direct evidence; 1 RCT; 1326 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.38</b><br/>(0.46 to 4.15) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>67 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18 more per 1000</b><br/>(from 26 fewer to 128 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Daclizumab</b> </p> <p>(Direct evidence; 1 RCT; 600 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 2.55</b><br/>(1.40 to 4.63) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>117 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>68 more per 1000</b><br/>(from 18 more to 145 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dimethylfumarate</b> </p> <p>(Direct evidence; 2 RCTs; 2300 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.35</b><br/>(0.94 to 1.95) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>66 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16 more per 1000</b><br/>(from 3 fewer to 43 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fingolimod</b> </p> <p>(Direct evidence; 2 RCTs; 2355 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.84</b><br/>(1.31 to 2.57) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>87 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>38 more per 1000</b><br/>(from 14 more to 69 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Glatiramer acetate</b> </p> <p>(Direct evidence; 4 RCTs; 2419 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.48</b><br/>(1.02 to 2.14) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>72 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22 more per 1000</b><br/>(from 1 more to 51 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Immunoglobulins</b> </p> <p>(Direct evidence; 3 RCTs; 243 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 2.49</b><br/>(0.37 to 16.50) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>115 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>65 more per 1000</b><br/>(from 31 fewer to 413 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta 1a‐1b</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 3.02</b><br/>(0.27 to 33.65) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>136 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>86 more per 1000</b><br/>(from 36 fewer to 587 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1b</b> </p> <p>(Direct evidence; 1 RCT; 372 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 2.27</b><br/>(1.05 to 4.91) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>106 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>56 more per 1000</b><br/>(from 2 more to 154 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1a</b> </p> <p>(Direct evidence; 2 RCTs; 1457 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.48</b><br/>(0.99 to 2.20) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>72 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22 more per 1000</b><br/>(from 0 fewer to 53 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laquinimod</b> </p> <p>(Direct evidence; 3 RCTs; 3457 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.46</b><br/>(1.00 to 2.15) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>71 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>21 more per 1000</b><br/>(from 0 fewer to 51 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pegylated interferon beta‐1a</b> </p> <p>(Direct evidence; 1 RCT; 1512 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 3.58</b><br/>(1.47 to 8.73) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>157 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>108 more per 1000</b><br/>(from 22 more to 263 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Natalizumab</b> </p> <p>(Direct evidence; 1 RCT; 939 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.57</b><br/>(0.81 to 3.05) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>76 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>26 more per 1000</b><br/>(from 9 fewer to 88 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>10</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocrelizumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 0.82</b><br/>(0.42 to 1.60) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9 fewer per 1000</b><br/>(from 28 fewer to 27 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>11</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ofatumumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 2.00</b><br/>(1.05 to 3.81) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>94 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>45 more per 1000</b><br/>(from 2 more to 116 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>12</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ozanimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.01</b><br/>(0.52 to 1.95) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 fewer per 1000</b><br/>(from 23 fewer to 43 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>13</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ponesimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 5.04</b> <br/><b>(2.15 to 11.82)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>208 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>158 more per 1000</b><br/>(from 51 more to 332 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>14</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Teriflunomide</b> </p> <p>(Direct evidence; 2 RCTs; 2253 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.82</b><br/>(1.19 to 2.79) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>87 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>37 more per 1000</b><br/>(from 9 more to 77 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>NMA‐SoF table definitions</b> </p> <p>** Network Metanalysis estimates are reported as risk ratios. CI: confidence interval.</p> <p>*** Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group. </p> <p><b>GRADE Working Group grades of evidence (or certainty in the evidence)</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> <p><b>Explanatory Footnotes</b> </p> <p>1 Downgraded one level for risk of bias. Absolute observed point estimate falls in the trivial positive effect; 95% CIs contained within positive effect. </p> <p>2 Absolute observed point estimate falls in the small negative effect, 95% CIs range from trivial positive effect to large negative effect: downgraded three levels </p> <p>3 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from trivial positive effect to small negative effect: downgraded two levels </p> <p>4 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from trivial negative effect to small negative effect: downgraded one level </p> <p>5 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from trivial positive effect to trivial negative effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>6 Downgraded one level for risk of bias. Absolute observed point estimate falls in the trivial negative effect; 95% CIs contained within negative effect. </p> <p>7 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from trivial positive effect to large negative effect: downgraded three levels </p> <p>8 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from trivial negative effect to small negative effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>9 Absolute observed point estimate falls in the small negative effect, 95% CIs range from trivial negative effect to large negative effect: downgraded two levels. Further downgraded one level for risk of bias </p> <p>10 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from trivial positive effect to trivial negative effect: downgraded one level </p> <p>11 Absolute observed point estimate falls in the trivial positive effect, 95% CIs range from trivial positive effect to trivial negative effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>12 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from trivial negative effect to small negative effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>13 Absolute observed point estimate falls in the null effect, 95% CIs range from trivial positive effect to trivial negative effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>14 Absolute observed point estimate falls in the small negative effect, 95% CIs range from trivial negative effect to moderate negative effect: downgraded two levels. Further downgraded one level for risk of bias </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011381-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Serious adverse events</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> Patients with RRMS </p> <p><b>Interventions:</b> Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon beta‐1b (Betaferon), interferon beta‐1a (Avonex, Rebif), laquinimod, pegylated interferon beta‐1a, mitoxantrone, natalizumab, ocrelizumab, ofatumumab, ozanimod, ponesimod, teriflunomide </p> <p><b>Comparator (reference):</b> Placebo </p> <p><b>Outcome:</b> Serious adverse events </p> <p><b>Setting(s):</b> Outpatient </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Intervention (no. of studies/participants)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect**</b> </p> <p><b>(95% CrI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effect***(95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With placebo</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With intervention</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alemtuzumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.52</b><br/>(0.94 to 2.48) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>120 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>36 more per 1000</b><br/>(from 4 fewer to 96 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cladribine</b> </p> <p>(Direct evidence; 1 RCT; 1326 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.39</b><br/>(0.80 to 2.40) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>106 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>27 more per 1000</b><br/>(from 15 fewer to 92 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Daclizumab</b> </p> <p>(Direct evidence; 1 RCT; 600 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.90</b><br/>(1.21 to 2.99) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>140 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>61 more per 1000</b><br/>(from 15 more to 125 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dimethylfumarate</b> </p> <p>(Direct evidence; 2 RCTs; 2300 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.04</b><br/>(0.71 to 1.52) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>82 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3 more per 1000</b><br/>(from 22 fewer to 36 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fingolimod</b> </p> <p>(Direct evidence; 2 RCTs; 2355 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 0.86</b><br/>(0.64 to 1.13) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>69 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10 fewer per 1000</b><br/>(from 27 fewer to 9 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Glatiramer acetate</b> </p> <p>(Direct evidence; 3 RCTs; 2371 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 0.94</b><br/>(0.68 to 1.28) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>75 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4 fewer per 1000</b><br/>(from 24 fewer to 20 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1b (Betaferon)</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 0.92</b><br/>(0.55 to 1.54) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>73 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6 fewer per 1000</b><br/>(from 34 fewer to 38 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1a (Rebif, Avonex)</b> </p> <p>(Direct evidence; 1 RCT; 897 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.21</b><br/>(0.88 to 1.67) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>94 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15 more per 1000</b><br/>(from 9 fewer to 46 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laquinimod</b> </p> <p>(Direct evidence; 3 RCTs; 3457 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.25</b><br/>(0.92 to 1.70) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>97 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18 more per 1000</b><br/>(from 6 fewer to 48 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pegylated interferon beta‐1a</b> </p> <p>(Direct evidence; 1 RCT; 1512 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.08</b><br/>(0.59 to 1.96) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>85 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6 more per 1000</b><br/>(from 31 fewer to 65 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mitoxantrone</b> </p> <p>(Direct evidence; 1 RCT; 53 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 0.89</b><br/>(0.02 to 47.22) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>71 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8 fewer per 1000</b><br/>(from 77 fewer to 723 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>10</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Natalizumab</b> </p> <p>(Direct evidence; 1 RCT; 939 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.24</b><br/>(0.73 to 2.09) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>96 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>17 more per 1000</b><br/>(from 20 fewer to 73 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>11</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocrelizumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.00</b><br/>(0.58 to 1.72) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 fewer per 1000</b><br/>(from 32 fewer to 50 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>12</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ofatumumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.52</b><br/>(0.89 to 2.57) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>115 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>36 more per 1000</b><br/>(from 8 fewer to 102 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>13</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ozanimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.50</b><br/>(0.85 to 2.64) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>114 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>35 more per 1000</b><br/>(from 11 fewer to 106 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>14</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ponesimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.24</b><br/>(0.66 to 2.35) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>96 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>17 more per 1000</b><br/>(from 25 fewer to 89 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>15</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Teriflunomide</b> </p> <p>(Direct evidence; 2 RCTs; 2253 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.16</b><br/>(0.81 to 1.64) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>90 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>11 more per 1000</b><br/>(from 14 fewer to 44 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>16</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>NMA‐SoF table definitions</b> </p> <p>** Network Metanalysis estimates are reported as risk ratio. CI: confidence interval.</p> <p>*** Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group. </p> <p><b>GRADE Working Group grades of evidence (or certainty in the evidence)</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> <p><b>Explanatory Footnotes</b> </p> <p>1 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to moderate negative effect: downgraded three levels. Further downgraded one level for risk of bias. </p> <p>2 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to moderate negative effect: downgraded three levels. </p> <p>3 Absolute observed point estimate falls in the small negative effect, 95% CI range from trivial negative effect to moderate negative effect: downgraded two levels. </p> <p>4 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to trivial negative effect: downgraded one level. Further downgraded one level for risk of bias. </p> <p>5 Absolute observed point estimate falls in the trivial positive effect: (below small effect threshold), 95% CI range from trivial positive effect to trivial negative effect: downgraded one level. Further downgraded one level for risk of bias. </p> <p>6 Absolute observed point estimate falls in the trivial positive effect: (below small effect threshold), 95% CI range from trivial positive effect to trivial negative effect: downgraded one level. </p> <p>7 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to small negative effect: downgraded two levels. Further downgraded one level for risk of bias. </p> <p>8 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to small negative effect: downgraded two levels. Further downgraded one level for risk of bias. </p> <p>9 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to small negative effect: downgraded two levels. Further downgraded one level for risk of bias. </p> <p>10 Absolute observed point estimate falls in the trivial positive effect: (below small effect threshold), 95% CI range from moderate positive effect to large negative effect: downgraded three levels. Further downgraded one level for risk of bias. </p> <p>11 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to small negative effect: downgraded two levels. </p> <p>12 Absolute observed point estimate falls in the null effect, 95% CI range from trivial positive effect to small negative effect: downgraded two levels. Further downgraded one level for risk of bias. </p> <p>13 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to moderate negative effect: downgraded three levels. Further downgraded one level for risk of bias. </p> <p>14 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to moderate negative effect: downgraded three levels. </p> <p>15 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to moderate negative effect: downgraded three levels. Further downgraded one level for risk of bias. </p> <p>16 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to small negative effect: downgraded two levels. Further downgraded one level for risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011381-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011381-sec-0009"></div> <section id="CD011381-sec-0010"> <h3 class="title" id="CD011381-sec-0010">Description of the condition</h3> <p>Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the brain and spinal cord resulting from a complex interaction between genetic background and environmental factors. Its pathophysiology encompasses several pathological processes, including immune system dysregulation, demyelination, remyelination, microglial activation, and chronic neuroaxonal loss (<a href="./references#CD011381-bbs2-0189" title="FilippiM , Bar-OrA , PiehlF , PreziosaP , SolariA , VukusicS , et al. Multiple sclerosis. Nat Rev Dis Primers2018;4:43. [DOI: 10.1038/s41572-018-0041-4]">Filippi 2018</a>). In most patients, the clinical course is initially characterised by attacks of neurological dysfunction, with or without residual deficits. MS has been traditionally viewed as a two‐stage disease with early inflammation responsible for the initial relapsing‐remitting (RR) course and delayed neurodegeneration causing secondary disability progression. However, more recent evidence has pointed out a pathological continuum between the relapsing and progressive phases, with active ongoing inflammation and demyelination which can also be seen in end‐stage MS (<a href="./references#CD011381-bbs2-0225" title="LuchettiS , FransenNL , vanEdenCG , RamagliaV , MasonM , HuitingaI . Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis. Acta Neuropathol2018;135:511-28. [DOI: 10.1007/s00401-018-1818-y]">Lucchetti 2018</a>). On the other hand, neurodegeneration and neuronal loss leading to brain atrophy have also been observed in the earlier stages of the disease, at least in some cases, as demonstrated by the high prevalence of a certain degree of cognitive impairment even at disease onset (<a href="./references#CD011381-bbs2-0200" title="HaiderL , PradosF , ChungK , GoodkinO , KanberB , SudreC , et al. Cortical involvement determines impairment 30 years after a clinically isolated syndrome. Brain2021;144:1384-95. [DOI: 10.1093/brain/awab033]">Haider 2021</a>). </p> <p>MS is amongst the most common causes of neurological disability in young people and currently affects about 2.8 million people worldwide (Atlas of MS [https://www.atlasofms.org/map/global/epidemiology/number‐of‐people‐with‐ms, last accessed on 01/13/23]). Since the 1950s, MS incidence has gradually increased and currently ranges from 2 to 10 per 100,000 persons per year with a latitudinal gradient and a lower incidence closer to the equator (<a href="./references#CD011381-bbs2-0213" title="Koch-HenriksenN , MagyariM . Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Rev Neurol2021;17:676-688. [DOI: 10.1038/s41582-021-00556-y]">Koch‐Henriksen 2021</a>). Similarly, the female to male ratio has enlarged over time, settling at over 3:1 during the 2000s (<a href="./references#CD011381-bbs2-0127" title="AlonsoA , Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review.. Neurology.2008;71:129-35. [DOI: 10.1212/01.wnl.0000316802.35974.34]">Alonso 2008</a>). </p> <p>RRMS has a typical onset between 20 and 40 years of age, with a heterogeneous clinical presentation depending on the involvement of various regions of the central nervous system (CNS) (e.g. optic nerve, brainstem‐cerebellum, cerebral hemispheres, and spinal cord). The chronic course of MS typically evolves over 30 to 40 years, involving distinct clinical phenotypes. RRMS accounts for ~85% of patients and ~2–3% of patients per year will develop secondary progressive (SP) MS which is characterised by increasing and irreversible disability that occurs independently of the presence of relapses (<a href="./references#CD011381-bbs2-0222" title="LublinFD , ReingoldSC . Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology1996;46:907-11. [DOI: 10.1212/wnl.46.4.907]">Lublin 1996</a>). Male sex, older age at onset and high early relapse frequency predict higher risk of unremitting disability worsening (<a href="./references#CD011381-bbs2-0242" title="ScalfariA , NeuhausA , DaumerM , MuraroPA , EbersGC . Onset of secondary progressive phase and long-term evolution of multiple sclerosis. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85:67-75.">Scalfari 2014</a>). A minority of patients (~10‐15%) have a progressive disease course from onset, which is referred to as primary progressive MS (PPMS). These phenotypes have been subsequently revised based on the presence of inflammatory activity related to the disease which could be potentially targeted by disease‐modifying treatments (DMTs) (<a href="./references#CD011381-bbs2-0223" title="LublinFD , ReingoldSC , CohenJA , CutterGR , SørensenPS , ThompsonAJ , et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology2014;83:278-86. [DOI: 10.1212/WNL.0000000000000560]">Lublin 2014</a>). Such classification includes the "clinically isolated syndrome" (CIS), when the first clinical attack does not completely fulfil MS diagnostic criteria. Furthermore, within each subtype, MS can be classified as active or not active, depending on the occurrence of relapses and/or new, enlarging or contrast‐enhancing, lesions detected with magnetic resonance imaging (MRI). </p> <p>The diagnosis of MS relies on the demonstration of two subsequent clinical attacks (dissemination in time ‐ DIT) with the involvement of at least two different CNS areas (dissemination in space ‐ DIS) (<a href="./references#CD011381-bbs2-0214" title="KortewegT , TintoréM , UitdehaagB , RoviraA , FrederiksenJ , MillerD , et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol2006;5:221-7. [DOI: 10.1016/S1474-4422(06)70353-2]">Korteweg 2006</a>). Although MS diagnosis remains primarily based on clinical criteria, the 2001 McDonald criteria and their 2005 and 2010 revisions have incorporated criteria for DIT and DIS, thus allowing diagnosis at the time of its first symptoms (<a href="./references#CD011381-bbs2-0228" title="McDonaldW , CompstonA , EdanG , GoodkinD , HartungH , LublinF . Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Annals of Neurology2001;50:121-7.">McDonald 2001</a>; <a href="./references#CD011381-bbs2-0235" title="PolmanC , ReingoldS , EdanG , FilippiM , HartungH , KapposL , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Annals of Neurology2005;58:840-6.">Polman 2005</a>; <a href="./references#CD011381-bbs2-0236" title="PolmanCH , ReingoldSC , BanwellB , ClanetM , CohenJA , FilippiM , et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology2011;69:292–302.">Polman 2011</a>). Specifically, DIS can be demonstrated by greater than or equal to one MRI lesion in at least two CNS regions including: periventricular, juxtacortical, infratentorial and spinal cord. DIT is demonstrated by: (i) simultaneous asymptomatic contrast‐enhancing and non‐enhancing MRI lesions at any time; or (ii) a new lesion and/or contrast‐enhancing lesion(s) on follow‐up MRI, irrespective of its timing. Additionally, a more recent revision of the McDonald criteria (<a href="./references#CD011381-bbs2-0248" title="ThompsonAJ , BanwellBL , BarkhofF , CarrollWM , CoetzeeT , ComiG , et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018;17(2):30470-2. [DOI: 10.1016/S1474-4422(17)30470-2]">Thompson 2018</a>) allows diagnosing MS when DIS criteria are fulfilled and cerebrospinal fluid‐specific oligoclonal bands are detected, without detection in the serum. Other possible diagnoses must be excluded before confirming MS, as "no better explanation" should be demonstrated according to diagnostic criteria. </p> <p>Pharmacological therapies for MS include MS‐specific DMTs and symptomatic treatments, the latter aimed at relieving symptoms resulting from neurological impairment. As the number of effective DMTs has constantly increased during the last decades, interest in early MS treatment has grown in order to prevent long‐term disability. Additionally, growing evidence suggests that early intervention with high‐efficacy DMTs is associated with a significantly greater reduction of either inflammatory activity and long‐term disease progression compared to escalating from lower efficacy drugs (<a href="./references#CD011381-bbs2-0148" title="DaruwallaC , ShaygannejadV , OzakbasS , HavrdovaEK , HorakovaD , AlroughaniR , et al. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Mult Scler 2023;13524585231151951:Epub ahead of print. [DOI: 10.1177/13524585231151951]">Daruwalla 2023</a>; <a href="./references#CD011381-bbs2-0203" title="HeA , MerkelB , BrownJWL , Zhovits RyersonL , KisterI , MalpasCB , et al, MSBase study group. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol2020;19(4):307-316. [DOI: 10.1016/S1474-4422(20)30067-3]">He 2020</a>). Whilst historically DMTs have been mostly immunosuppressant or immunomodulatory, requiring ongoing administration to keep disease activity suppressed, immune reconstitution therapies that can be given as short courses have recently emerged. This enlarged treatment scenario raises the question whether a DMT should be initiated early, or even in pre‐symptomatic MS (e.g. when only MRI lesions are accidentally detected, in absence of clinical manifestations, a condition described as "radiologically isolated syndrome") and there are demands for an updated network meta‐analysis of randomised clinical trials (RCTs) assessing the efficacy and safety profile of the available DMTs. </p> </section> <section id="CD011381-sec-0011"> <h3 class="title" id="CD011381-sec-0011">Description of the intervention</h3> <p>Several DMTs are available for people with RRMS. Given the broad range of DMTs currently available, many factors related to context and to patients' preferences, expectations and values are usually taken into account when clinicians and patients make shared treatment decisions. For this review update, we considered all immunomodulators and immunosuppressants that, up to September 2021, have been studied in people with RRMS in randomised clinical trials (RCTs) with at least 12 months' follow‐up. </p> <p>Interferon beta‐1b (<a href="./references#CD011381-bbs2-0169" title="European Agency for the Evaluation of Medicinal Products. Committee for proprietary medicinal products European public assessment report: Betaferon. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000081/human_med_000673.jsp&amp;mid=WC0b01ac058001d124 (accessed June 2014).">EMEA 2002</a>; <a href="./references#CD011381-bbs2-0170" title="US Food and Drug Administration. Betaseron interferon beta-1b subcutaneous. Drug Approval Package - Licensing Action 1993. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103471s5063s5067s5079s5088s5120s5124s5136s5138lbl.pdf (accessed June 2014).">FDA 1993</a>), interferon beta‐1a (Rebif) (<a href="./references#CD011381-bbs2-0168" title="European Agency for the Evaluation of Medicinal Products. Committee for proprietary medicinal products European public assessment report: Rebif. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000136/WC500122183.pdf (accessed June 2014).">EMEA 1998</a>; <a href="./references#CD011381-bbs2-0173" title="US Food and Drug Administration. Interferon beta-1a (Rebif) Product Approval Information - Licensing Action 2002. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080737.htm (accessed June 2014).">FDA 2002</a>), interferon beta‐1a (Avonex) (<a href="./references#CD011381-bbs2-0167" title="European Agency for the Evaluation of Medicinal Products. Committee for proprietary medicinal products European public assessment report: Avonex. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000102/WC500029423.pdf (accessed June 2015).">EMEA 1997</a>; <a href="./references#CD011381-bbs2-0174" title="US Food and Drug Administration. Interferon beta-1a (Avonex) Product Approval Information - Licensing Action 2003. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/103628s5021TOC.cfm (accessed June 2014).">FDA 2003</a>), and glatiramer acetate (<a href="./references#CD011381-bbs2-0171" title="US Food and Drug Administration. Glatiramer acetate (Capoxane) Product Approval Information - Licensing Action 1996. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist (accessed June 2014).">FDA 1996</a>) were the first agents approved by national regulatory agencies. Interferon beta‐1b, interferon beta‐1a (Rebif), and glatiramer acetate are administered by subcutaneous injection; interferon beta‐1a (Avonex) by intramuscular injection. The main adverse effects of interferon beta are local injection site reactions and flu‐like symptoms with hyperthermia. </p> <p>Natalizumab was initially approved by the US Food and Drug Administration (FDA) in November 2004 (<a href="./references#CD011381-bbs2-0175" title="US Food and Drug Administration. Tysabri (Natalizumab) Product Approval Information 2004. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/125104s000_Natalizumab.cfm (accessed June 2014).">FDA 2004</a>), but was withdrawn by the manufacturer in February 2005, after three participants in the drug's clinical trials developed progressive multifocal leukoencephalopathy (PML), a rare and serious viral infection of the brain. Two of the participants died. Following a re‐examination of the participants in the previous clinical trials, the FDA allowed a clinical trial of natalizumab to proceed in February 2006. No additional cases of PML were reported and marketing of the drug for severe RRMS resumed (<a href="./references#CD011381-bbs2-0151" title="European Agency for the Evaluation of Medicinal Products. Committee for proprietary medicinal products European public assessment report: Tysabri. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000603/wapp/Post-authorisation/human_wapp_000166.jsp&amp;mid=WC0b01ac058001d128 (accessed June 2014).">EMA 2006</a>; <a href="./references#CD011381-bbs2-0176" title="US Food and Drug Administration. FDA Approves Resumed Marketing of Tysabri Under a Special Distribution Program. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108662.htm (accessed June 2014).">FDA 2006</a>; <a href="./references#CD011381-bbs2-0260" title="YousryT , MajorE , RyschkewitschC , FahleG , FischerS , HouJ , et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. New England Journal of Medicine2006;354(9):924-33. [PMID: 16510746]">Yousry 2006</a>). Natalizumab is administered by intravenous infusion, as a dose of 300 mg every four weeks. </p> <p>Mitoxantrone was approved in 2000 under the indication "for reducing neurological disability and/or the frequency of clinical relapses in people with worsening RRMS, SPMS or PRMS" (<a href="./references#CD011381-bbs2-0172" title="US Food and Drug Administration. Mitoxantrone (Novantrone) Product Approval Information - Licensing Action 2000. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&amp;DrugName=NOVANTRONE&amp;CFID=17505855&amp;CFTOKEN=fca8add70180e2b1-F1C49694-F504-892A-3B263F68EAFF59DC (accessed June 2014).">FDA 2000</a>). Safety issues of concern for people treated with mitoxantrone are cardiotoxicity and acute leukaemia. </p> <p>Fingolimod was the first oral treatment approved for people with RRMS to reduce the frequency of relapses and delay the accumulation of physical disability (<a href="./references#CD011381-bbs2-0152" title="European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Gilenya. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002202/human_med_001433.jsp&amp;mid=WC0b01ac058001d124 (accessed June 2014).">EMA 2011</a>; <a href="./references#CD011381-bbs2-0177" title="US Food and Drug Administration. Gilenya (Fingolimod) Product Approval Information 2010. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&amp;ApplNo=022527&amp;DrugName=GILENYA&amp;ActiveIngred=FINGOLIMOD&amp;SponsorApplicant=NOVARTIS&amp;ProductMktStatus=1&amp;goto=Search.DrugDetails (accessed June 2014).">FDA 2010</a>). Even at the recommended low dose of 0.5 mg once daily, the FDA and European Medicines Agency (EMA) warned about decrease in heart rate following initiation of fingolimod treatment, recommending that all patients be monitored for at least six hours for signs and symptoms of bradycardia, considering that, in some patients, the nadir of heart rate can be observed up to 24 hours after the first dose. </p> <p>Teriflunomide was the second oral agent approved for people with RRMS (<a href="./references#CD011381-bbs2-0153" title="European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Aubagio. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002514/human_med_001645.jsp&amp;mid=WC0b01ac058001d124 (accessed June 2014).">EMA 2013a</a>; <a href="./references#CD011381-bbs2-0178" title="US Food and Drug Administration. Aubagio (Teriflunomide) Product Approval Information 2012. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&amp;ApplNo=202992&amp;DrugName=AUBAGIO&amp;ActiveIngred=TERIFLUNOMIDE&amp;SponsorApplicant=SANOFI%20AVENTIS%20US&amp;ProductMktStatus=1&amp;goto=Search.DrugDetails (accessed June 2014).">FDA 2012</a>). It is taken orally as a 7 mg or 14 mg tablet once daily. Warnings issued about this drug were hepatotoxicity and risk of teratogenicity. </p> <p>Two other oral drugs, both with a mainly immunomodulatory mode of action, are available for the treatment of RRMS: teriflunomide is the active metabolite of leflunomide (<a href="./references#CD011381-bbs2-0233" title="OhJ , CalabresiPA . Emerging injectable therapies for multiple sclerosis. Lancet Neurology2013;12:1115–26.">Oh 2013</a>), inhibiting pyrimidine de novo synthesis, and dimethyl fumarate (<a href="./references#CD011381-bbs2-0219" title="LinkerRA , LeeDH , RyanS , Van DamAM , ConradR , BistaP , et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain2011;134(3):678-92.">Linker 2011</a>), the methyl ester of fumaric acid, is converted after administration into the active metabolite monomethyl fumarate. They were both approved for RRMS in the US in 2012 and in 2013, respectively. </p> <p>Dimethyl fumarate has been approved as a first‐line oral treatment for people with RRMS (<a href="./references#CD011381-bbs2-0155" title="European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Tecfidera. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002601/WC500162069.pdf (accessed June 2014).">EMA 2014a</a>; <a href="./references#CD011381-bbs2-0179" title="US Food and Drug Administration. Tecfidera (Dimethyl fumarate) Product Approval Information 2013. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&amp;ApplNo=204063&amp;DrugName=TECFIDERA&amp;ActiveIngred=DIMETHYL%20FUMARATE&amp;SponsorApplicant=BIOGEN%20IDEC%20INC&amp;ProductMktStatus=1&amp;goto=Search.DrugDetails (accessed June 2014).">FDA 2013</a>). The recommended dose is 240 mg twice a day. The most commonly reported adverse events leading to discontinuation in clinical trials were flushing and gastrointestinal events. </p> <p>Alemtuzumab has been approved for treatment of people with RRMS who have had an inadequate response to two or more drugs indicated for the treatment of MS (<a href="./references#CD011381-bbs2-0154" title="European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Lemtrada. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf (accessed June 2014).">EMA 2013b</a>; <a href="./references#CD011381-bbs2-0180" title="US Food and Drug Administration. Alemtuzumab (Lemtrada) Product Approval Information. Licensing Action 2014. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/103948Orig1s5139ltr.pdf (accessed Sept 2014).">FDA 2014a</a>). The drug is administered by intravenous infusion, as a dose of 12 mg/day for five consecutive days (60 mg total dose) followed by 12 mg/day for three consecutive days (36 mg total dose) administered 12 months after the initial treatment course. Particular warnings and precautions have to be taken into account for the treatment with alemtuzumab, since serious and sometimes fatal autoimmune conditions, life‐threatening infusion reactions, and increased risk of malignancies were observed in people treated with alemtuzumab. </p> <p>Peg‐interferon beta‐1a, which has been designed to maintain the effects of interferon beta in the body for a longer period of time, was approved by the FDA and EMA for people with RRMS (<a href="./references#CD011381-bbs2-0156" title="European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Plegridy. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002827/WC500170305.pdf (accessed June 2015).">EMA 2014b</a>; <a href="./references#CD011381-bbs2-0181" title="US Food and Drug Administration. Peginterferon beta-1a (Plegridy) Product Approval Information. Licensing Action 2014. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/biologics/2004/125083ltr.pdf (accessed September 2014).">FDA 2014b</a>). It is administered by subcutaneous injection at a dose of 125 µg every 14 days. The most common adverse reactions are injection site erythema, influenza‐like illness, pyrexia, headache, myalgia, chills, injection site pain, asthenia, injection site pruritus, and arthralgia. </p> <p>Daclizumab is a monoclonal antibody licenced in 2016 for the treatment of RRMS but, due to safety concerns, it was withdrawn worldwide from the market by its manufacturer in 2018 (<a href="./references#CD011381-bbs2-0160" title="European Medicines Agency. EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta. www.ema.europa.eu/en/news/ema-recommends-immediate-suspension-recall-multiple-sclerosis-medicine-zinbryta.">EMA 2018a</a>;<a href="./references#CD011381-bbs2-0159" title="European Medicines Agency. EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta. EMA Press Release2018.">EMA 2018</a>; <a href="./references#CD011381-bbs2-0184" title="US Food and Drug Administration. FDA working with manufacturers to withdraw Zinbryta from the market in the United States. www.fda.gov/drugs/drug-safety-and-availability/fda-working-manufacturers-withdraw-zinbryta-market-united-states (accessed March 2018).">FDA 2018</a>) </p> <p>Ocrelizumab was approved as a treatment for relapsing MS and PPMS (<a href="./references#CD011381-bbs2-0161" title="European Medicines Agency. Ocrevus. www.ema.europa.eu/en/medicines/human/EPAR/ocrevus.">EMA 2018b</a>; <a href="./references#CD011381-bbs2-0183" title="US Food and Drug Administration. FDA approves new drug to treat multiple sclerosis. www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-multiple-sclerosis (accessed March 2017).">FDA 2017</a>). It is administered by intravenous injection. </p> <p>Laquinimod is an oral immunomodulator investigated in two phase 3 trials for the treatment of people with RRMS. It is taken orally as a 0.6 mg tablet once daily. Its use in treating people with RRMS was approved in Russia but not in the EU, since in 2014 EMA refused authorisation. The EMA recommended refusal of the marketing authorisation for laquinimod as a treatment for RRMS due to concerns about potentially increased risks of cancer and teratogenicity in humans, especially given that the drug's mechanism of action is unclear (<a href="./references#CD011381-bbs2-0157" title="European Medicines Agency. Refusal of the marketing authorisation for Nerventra (laquinimod). http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002546/WC500160120.pdf (accessed June 2014).">EMA 2014c</a>). </p> <p>Azathioprine is a purine analogue exerting its immunosuppressive action by affecting DNA replication through inhibition of the synthesis of nucleic acids. It has been used for the treatment of people with MS in many countries on the basis of favourable results reported by placebo‐controlled RCTs (<a href="./references#CD011381-bbs2-0216" title="Laurson-DoubeJ , RijkeN , HelmeA , BanekeP , BanwellB , ViswanathanS , et al. Ethical use of off-label disease-modifying therapies for multiple sclerosis. Multiple Sclerosis2021;27(9):1403-10.">Laurson‐Doube 2021</a>). It is taken orally as a 2 mg/kg or 3 mg/kg tablet daily. It was reported that chronic immunosuppression with azathioprine increases the risk of malignancy in humans (<a href="./references#CD011381-bbs2-0182" title="US Food and Drug Administration. Imuran Product Information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/016324s037,017391s016lbl.pdf (accessed June 2015).">FDA 2014c</a>). </p> <p>Intravenous immunoglobulins may have a role for people with severe and frequent relapses for whom other treatments are contraindicated (<a href="./references#CD011381-bbs2-0130" title="Association of British Neurologists 2005. Guidelines for the use of intravenous immunoglobulin in neurological diseases. www.theabn.org/documents/IVIg-Guidelines (accessed October 2013).">Association of British Neurologists 2005</a>). Severe adverse events, including thrombosis of the jugular vein and allergic reaction leading to treatment discontinuation, were noted in 4% of 84 treatment courses with a total of 341 infusions under routine clinical conditions (<a href="./references#CD011381-bbs2-0150" title="ElovaaraI , ApostolskiS , vanDoornP , GilhusN , HietaharjuA , HonkaniemiJ , et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. European Journal of Neurology2008;15(9):893-908.">Elovaara 2008</a>). </p> <p>The current update includes the following additional interventions compared to the previous version of the review. Compounds with similar mechanism of action to fingolimod have been developed, in order to increase efficacy and improve safety, such as siponimod (<a href="./references#CD011381-bbs2-0162" title="European Medicines Agency. Mayzent. www.ema.europa.eu/en/medicines/human/EPAR/mayzent.">EMA 2020</a>; <a href="./references#CD011381-bbs2-0186" title="US Food and Drug Administration. FDA approves new oral drug to treat multiple sclerosis. www.fda.gov/news-events/press-announcements/fda-approves-new-oral-drug-treat-multiple-sclerosis (accessed April 2019).">FDA 2019b</a>), as well as ozanimod and ponesimod, licenced in 2020 and 2021, respectively (<a href="./references#CD011381-bbs2-0163" title="European Medicines Agency. Zeposia. www.ema.europa.eu/en/medicines/human/EPAR/zeposia.">EMA 2021a</a>; <a href="./references#CD011381-bbs2-0164" title="European Medicines Agency. Ponvory. www.ema.europa.eu/en/medicines/human/EPAR/ponvory.">EMA 2021b</a>; <a href="./references#CD011381-bbs2-0187" title="US Food and Drug Administration. Novel drug approvals for 2020. www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020 (accessed Jan 2021).">FDA 2020</a>; <a href="./references#CD011381-bbs2-0188" title="US Food and Drug Administration. Novel Drug Approvals for 2021. www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021;(accessed May 2023).">FDA 2021</a>). Cladribine is a synthetic chlorinated deoxyadenosine analog approved for the treatment of RRMS in Russia and Australia in 2010, while in the EU and the US it was licenced in 2017 and 2019, respectively, for highly active RRMS and active SPMS (<a href="./references#CD011381-bbs2-0158" title="European Medicines Agency. Mavenclad. www.ema.europa.eu/en/medicines/human/EPAR/mavenclad.">EMA 2017</a>; <a href="./references#CD011381-bbs2-0185" title="US Food and Drug Administration. FDA approves new oral treatment for multiple sclerosis. www.fda.gov/news-events/press-announcements/fda-approves-new-oral-treatment-multiple-sclerosis (accessed April 2019).">FDA 2019a</a>; <a href="./references#CD011381-bbs2-0217" title="LeistTP , WeissertR . Cladribine: mode of action and implications for treatment of multiple sclerosis. Clinical Neuropharmacology2011;34(1):28-35. [PMID: 21242742]">Leist 2011</a>). Recently, diroximel fumarate, a compound similar to dimethyl fumarate, was approved in 2019 in the US and EU for the treatment of RRMS (<a href="./references#CD011381-bbs2-0165" title="European Medicines Agency. Vumerity. www.ema.europa.eu/en/medicines/human/EPAR/vumerity.">EMA 2021c</a>). The anti‐CD20 monoclonal antibody ofatumumab was approved as a treatment for relapsing MS (<a href="./references#CD011381-bbs2-0166" title="European Medicines Agency. Kesimpta. www.ema.europa.eu/en/medicines/human/EPAR/kesimpta.">EMA 2021d</a>). </p> <p>Given the limited efficacy of currently available DMTs in delaying the progression of RRMS, many clinicians commonly prescribe immunosuppressant drugs with registered indications for conditions other than MS (mainly in rheumatological or autoimmune diseases, or in people undergoing transplant). As such, in addition to those included previously (azathioprine, intravenous immunoglobulins), we decided to include in our review the following interventions used in MS as off‐label treatments: rituximab, methotrexate, cyclophosphamide and long‐term corticosteroids. Rituximab is an anti‐CD20 monoclonal antibody similar to ocrelizumab and ofatumumab, commonly used to treat malignant blood cell neoplasms and several autoimmune diseases, such as rheumatoid arthritis, idiopathic thrombocytopenic purpura, and pemphigus vulgaris. Its efficacy and safety have also been studied in MS and in several countries, since rituximab is frequently prescribed off‐label (<a href="./references#CD011381-bbs2-0135" title="BerntssonSG , KristofferssonA , BoströmI , FeresiadouA , BurmanJ , LandtblomAM . Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?Acta Neurologica Scandinavica2018;138(4):327-31.">Berntsson 2018</a>; <a href="./references#CD011381-bbs2-0137" title="BrancatiS , GozzoL , LongoL , VitaleDC , DragoF . Rituximab in multiple sclerosis: are we ready for regulatory approval?Frontiers in Immunology2021;12:661882.">Brancati 2021</a>; <a href="./references#CD011381-bbs2-0216" title="Laurson-DoubeJ , RijkeN , HelmeA , BanekeP , BanwellB , ViswanathanS , et al. Ethical use of off-label disease-modifying therapies for multiple sclerosis. Multiple Sclerosis2021;27(9):1403-10.">Laurson‐Doube 2021</a>). Methotrexate, cyclophosphamide, and long‐term corticosteroids are systemic immunosuppressors. Methotrexate is a common treatment for autoimmune diseases. Cyclophosphamide, a DNA‐alkylating agent used for the treatment of people with autoimmune disorders, has also been administered to people with MS (<a href="./references#CD011381-bbs2-0131" title="AwaA , StuveO . Cyclophosphamide in multiple sclerosis:scientific rationale, history and novel treatment paradigms. Therapeutic Advances in Neurological Disorders2009;2:50-61.">Awad 2009</a>). Long‐term corticosteroids, given their anti‐inflammatory properties, have been proposed for the treatment of patients with MS since 1961 with mixed results. They have been administered by different schedules as pulsed periodic high‐dose methylprednisolone or oral continuous low‐dose prednisolone (<a href="./references#CD011381-bbs2-0144" title="CicconeA , BerettaS , BrusaferriF , GaleaI , ProttiA , SpreaficoC . Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database of Systematic Reviews2008, Issue 1. Art. No: CD006264. [DOI: 10.1002/14651858.CD006264.pub2]">Ciccone 2008</a>). Fludarabine is a cytotoxic agent effectively used as a treatment for patients with lymphoproliferative disorders and haematologic malignancies. It has also been used as an add‐on treatment in patients with MS experiencing breakthrough disease with an increase in the frequency of relapses and active MRI disease during treatment with other DMTs (<a href="./references#CD011381-bbs2-0196" title="GreenbergSJ , ZivadinovR , Lee-KwenP , SharmaJ , PlanterM , UmhauerM , et al. Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease. Ther Adv Neurol Disord2016;9:105-17. [DOI: 10.1177/1756285615626049]">Greenberg 2016</a>). The antibiotic minocycline has been studied as a potential treatment for MS due to its anti‐inflammatory properties (<a href="./references#CD011381-bbs2-0221" title="LoveR . Potential antibiotic treatment for multiple sclerosis?Lancet2002;359:50. [DOI: 10.1016/S0140-6736(02)07248-3]">Love 2002</a>; <a href="./references#CD011381-bbs2-0230" title="MetzLM , EliasziwM . Trial of Minocycline in Clinically Isolated Syndrome of Multiple Sclerosis. N Engl J Med2017;377:789. [DOI: 10.1056/NEJMc1708486]">Metz 2017</a>). Mycophenolate mofetil is an immunosuppressor mainly used as an anti‐rejection therapy in organ transplant recipients, that has also been considered as a potential treatment for MS (<a href="./references#CD011381-bbs2-0193" title="FrohmanEM , BrannonK , RackeMK , HawkerK . Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol2004;27:80-3. [DOI: 10.1097/00002826-200403000-00006]">Frohman 2004</a>). </p> </section> <section id="CD011381-sec-0012"> <h3 class="title" id="CD011381-sec-0012">How the intervention might work</h3> <p>Immunosuppressive or immunomodulatory effects are common to all treatments included in the review. Although they all target the immune system, their effects vary as follows: </p> <section id="CD011381-sec-0013"> <h4 class="title">1. Immunomodulation (IFNβ‐1b, IFNβ‐1a, glatiramer acetate, pegylated IFNβ‐1a, immunoglobulins, dimethyl fumarate and diroximel fumarate, laquinimod) </h4> <p>The mechanism of action of interferons beta in MS is incompletely understood. Interferons beta are naturally occurring cytokines possessing antiviral activity and a wide range of anti‐inflammatory properties. Recombinant forms of interferons beta are believed to directly increase expression and concentration of anti‐inflammatory agents, while down‐regulating the expression of pro‐inflammatory cytokines (<a href="./references#CD011381-bbs2-0212" title="KieseierBC . The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs2011;25:491-502.">Kieseier 2011</a>). Glatiramer acetate has an immunomodulatory action by inducing tolerance or anergy of myelin‐reactive lymphocytes (<a href="./references#CD011381-bbs2-0243" title="SchmiedM , DudaPW , KriegerJI , TrollmoC , HaflerDA . In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis. Clinical Immunology2003;106:163-74.">Schmied 2003</a>). It is furthermore believed to promote neuroprotective repair processes (<a href="./references#CD011381-bbs2-0126" title="AharoniR . Immunomodulation neuroprotection and remyelination. The fundamental therapeutic effects of glatiramer acetate: a critical review. Journal of Autoimmunity2014;54:81-92. [DOI: 10.1016/j.jaut.2014.05.005]">Aharoni 2014</a>). Pegylated interferon beta‐1a has a polyethylene glycol group attached to the α‐amino group of the N terminus of interferon beta‐1a (Avonex). Pegylation of interferon beta‐1a may improve its pharmacokinetic and pharmacodynamic properties, allowing for reduced dosing frequency, while maintaining the clinical effectiveness and safety of intramuscular interferon beta‐1a (<a href="./references#CD011381-bbs2-0208" title="HuX , MillerL , RichmanS , HitchmanS , GlickG , LiuS , et al. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. Journal of Clinical Pharmacology2012;52:798–808.">Hu 2012</a>). The mechanism of action of intravenous immunoglobulins in MS remains unclear, although remyelination of demyelinated axons may occur through the mediation of the effects of cytokines (<a href="./references#CD011381-bbs2-0247" title="StangelM , ToykaK , GoldR . Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Archives of Neurology1999;56(6):661-3.">Stangel 1999</a>). Dimethyl fumarate is a derivative of fumaric acid. It acts primarily by triggering the activation of a nuclear factor (Nrf2) transcriptional pathway, the primary cellular defence against the cytotoxic effects of oxidative stress. It promotes anti‐inflammatory activity and can inhibit expression of pro‐inflammatory cytokines and adhesion molecules (<a href="./references#CD011381-bbs2-0257" title="WilmsH , SieversJ , RickertU , Rostami-YazdiM , MrowietzU , LuciusR . Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. Journal of Neuroinflammation2010;7:30.">Wilms 2010</a>). Exactly how laquinimod works is unknown, but it is believed to have an immunomodulatory effect on the peripheral and central nervous systems. Data from animal studies indicate that laquinimod has a primary effect on innate immunity. The drug modulates the function of various myeloid antigen‐presenting cell populations, which then down regulate pro‐inflammatory T‐cell responses. Furthermore, data indicate that laquinimod acts directly on resident cells within the central nervous system to reduce demyelination and axonal damage (<a href="./references#CD011381-bbs2-0253" title="Varrin-DoyerM , ZamvilSS , Schulze-TopphoffU . Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Experimental Neurology2014;262:66-71.">Varrin‐Doyer 2014</a>). Minocycline is a tetracycline antibiotic agent with immune‐modulating properties. </p> </section> <section id="CD011381-sec-0014"> <h4 class="title">2. Systemic immunosuppression, inducing a reduction in the activation or efficacy of the immune system through cytostatic or cytotoxic effects (mitoxantrone, methotrexate, cyclophosphamide, long‐term corticosteroids, cladribine, azathioprine, teriflunomide, and leflunomide) </h4> <p>Mitoxantrone is a cytotoxic drug that intercalates with DNA and inhibits both DNA and RNA synthesis, thus reducing the number of lymphocytes (<a href="./references#CD011381-bbs2-0192" title="FoxE . Mechanism of action of mitoxantrone. Neurology2004;12:15-8.">Fox 2004</a>). Methotrexate is commonly used in autoimmune diseases and, since 1996, has been used in the treatment of MS. By acting as an antagonist to folic acid, it interferes with DNA synthesis, repair, and cellular replication, limiting cellular reproduction. Cyclophosphamide, a DNA‐alkylating agent used for the treatment of people with autoimmune disorders, has also been administered to people with MS (<a href="./references#CD011381-bbs2-0131" title="AwaA , StuveO . Cyclophosphamide in multiple sclerosis:scientific rationale, history and novel treatment paradigms. Therapeutic Advances in Neurological Disorders2009;2:50-61.">Awad 2009</a>). Long‐term corticosteroids have been proposed (such as pulsed periodic high‐dose methylprednisolone or oral continuous low‐dose prednisolone) for the treatment of patients with MS with mixed results (<a href="./references#CD011381-bbs2-0144" title="CicconeA , BerettaS , BrusaferriF , GaleaI , ProttiA , SpreaficoC . Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database of Systematic Reviews2008, Issue 1. Art. No: CD006264. [DOI: 10.1002/14651858.CD006264.pub2]">Ciccone 2008</a>). Cladribine is a purine antimetabolite, generally recommended for patients who are unresponsive or intolerant to an alternate drug indicated for the treatment of MS and administered orally divided into two treatment courses separated by one year. It provides a reduction of circulating T (CD4+ and CD8+) and B lymphocytes with relative sparing of other immune cells (<a href="./references#CD011381-bbs2-0136" title="BeutlerE . Cladribine (2-chlorodeoxyadenosine). Lancet1992;340:952-6. [DOI: 10.1016/0140-6736(92)92826-2]">Beutler 1992</a>). Azathioprine is a classical cytotoxic immunosuppressive drug that acts as a prodrug for mercaptopurine, inhibiting an enzyme that is required for DNA synthesis. Thus, it most strongly affects proliferating cells, such as the T‐cells and B‐cells of the immune system (<a href="./references#CD011381-bbs2-0249" title="TiedeI , FritzG , StrandS , PoppeD , DvorskyR , StrandD , et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. Journal of Clinical Investigation2003;111:1133-45. [PMID: 12697733]">Tiede 2003</a>). Fludarabine is a purine nucleoside analog prodrug determining systemic immunosuppression through a cytotoxic action by interfering with DNA synthesis of dividing lymphocytes and monocytes (<a href="./references#CD011381-bbs2-0262" title="ZinzaniPL , BuzziM , FarabegoliP , MartinelliG , TosiP , ZuffaE , VisaniG , TestoniN , SalvucciM , BendandiM , et al. Apoptosis induction with fludarabine on freshly isolated chronic myeloid leukemia cells. Haematologica1994;79:127-31.">Zinzani 1994</a>). Mycophenolate mofetil is an inhibitor of purine synthesis with anti‐inflammatory properties exerted on T and B lymphocytes and macrophages (<a href="./references#CD011381-bbs2-0132" title="BartenMJ , vanGelderT , GummertJF , ShorthouseR , MorrisRE . Novel assays of multiplelymphocyte functions in whole blood measure: new mechanisms of actionof mycophenolate mofetil in vivo. Transpl Immunol 2002 Jun;10(1):1–14.">Barten 2002</a>). </p> <p>Teriflunomide, the active metabolite of leflunomide, is an inhibitor of new pyrimidine synthesis for DNA replication. Consequently, the drug reduces T‐ and B‐lymphocyte activation, proliferation, and function in response to autoantigens. The exact mechanism of action in MS is not fully understood. The drug is thought to reduce the number of activated lymphocytes, which would cause inflammation and damage myelin in the central nervous system (<a href="./references#CD011381-bbs2-0145" title="ClaussenMC , KornT . Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clinical Immunology2012;142:49-56.">Claussen 2012</a>). </p> </section> <section id="CD011381-sec-0015"> <h4 class="title">3. Selective immunosuppression, as with monoclonal antibodies or biological agents directed towards specific antigenic targets (natalizumab, fingolimod, siponimod, ozanimod, ponesimod, alemtuzumab, ofatumumab, daclizumab, rituximab and ocrelizumab) </h4> <p>Natalizumab is a monoclonal antibody against the alfa4 integrin on the surface of lymphocytes. This integrin is essential in the process by which lymphocytes gain access to the brain by allowing the cells to penetrate the blood brain barrier. Natalizumab blocks the action of the alfa4 integrin so that lymphocytes are unable to enter the brain and attack myelin protein (<a href="./references#CD011381-bbs2-0259" title="YednockTA , CannonC , FritzLC , Sanchez-MadridF , SteinmanL , KarinN . Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature1992;356:63-6.">Yednock 1992</a>). Fingolimod acts as a functional antagonist of sphingosine‐1‐phosphate (S1P) receptor on lymphocytes, resulting in a reduced egress of lymphocytes from the lymph nodes. In particular, auto‐aggressive T‐cells are prevented from recirculating to the central nervous system (<a href="./references#CD011381-bbs2-0226" title="MandalaS , HajduR , BergstromJ , QuackenbushE , XieJ , MilliganJ , et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science2002;296:346-9.">Mandala 2002</a>). Siponimod is a sphingosine‐1‐phosphate (S1P) receptor modulator acting as a functional antagonist on S1P1 receptors on lymphocytes. By preventing egress of T cells from lymph nodes, it reduces their recirculation into the central nervous system, limiting inflammation (<a href="./references#CD011381-bbs2-0133" title="BehrangiN , FischbachF , KippM . Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action. Cells2019;8:24. [DOI: 10.3390/cells8010024]">Behrangi 2019</a>). The mechanisms of action of ozanimod and ponesimod is similar to that of siponimod, with higher receptor selectivity for the latter and short half life, facilitating faster reversibility of its effects on the immune system after discontinuation (<a href="./references#CD011381-bbs2-0246" title="ScottFL , ClemonsB , BrooksJ , BrahmacharyE , PowellR , DedmanH , et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br J Pharmacol2016;173(11):1778-92. [DOI: 10.1111/bph.13476]">Scott 2016</a>; <a href="./references#CD011381-bbs2-0238" title="RuggieriS , QuartuccioME , ProsperiniL . Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data. Degener Neurol Neuromuscul Dis2022;12:61-73. [DOI: 10.2147/DNND.S313825]">Ruggieri 2022</a>). Alemtuzumab is a monoclonal antibody against the CD52 antigen expressed on lymphocytes and monocytes. Its effects in MS are thought to be mediated by an extended lymphocyte depletion and change in the composition of lymphocytes that accompanies lymphocyte reconstitution (<a href="./references#CD011381-bbs2-0207" title="Hill-CawthorneGA , ButtonT , TuohyO , JonesJL , MayK , SomerfieldJ , et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83:298-304.">Hill‐Cawthorne 2012</a>). Ofatumumab is a CD20+ B‐cell‐targeting recombinant human monoclonal antibody. It was initially approved for the treatment of chronic lymphocytic leukaemia and is now approved in several countries as a subcutaneous injection for the treatment of RRMS (<a href="./references#CD011381-bbs2-0211" title="KangC , BlairHA . Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis. Drugs2022;82:55-62. [DOI: 10.1007/s40265-021-01650-7]">Kang 2021</a>). Daclizumab is a monoclonal antibody against the CD25 antigen (interleukin 2 receptor) expressed on immune cells. The mechanisms by which the drug exerts effects in MS are not clear. Daclizumab leads to expansion of regulatory CD56 natural killer T lymphocytes, which may be an important mechanism of action in MS. Furthermore, daclizumab modulates the function of dendritic cells, resulting in decreased T‐cell activation (<a href="./references#CD011381-bbs2-0258" title="WuestSC , EdwanJH , MartinJF , HanS , PerryJS , CartagenaCM , et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nature Medicine2011;17:604–9.">Wuest 2011</a>). Rituximab is a chimeric monoclonal B‐cell‐depleting anti‐CD20 antibody similar to ocrelizumab and ofatumumab, administered intravenously, commonly used in the treatment of malignant blood cell neoplasms and several autoimmune diseases, such as rheumatoid arthritis, idiopathic thrombocytopenic purpura, and pemphigus vulgaris. It has been used off‐label in the treatment of MS for more than two decades (<a href="./references#CD011381-bbs2-0241" title="SalzerJ , SvenningssonR , AlpingP , NovakovaL , BjörckA , FinkK , et al. Rituximab inmultiple sclerosis: A retrospective observational study on safety and efficacy. Neurology2016;87:2074–81.">Salzer 2016</a>; <a href="./references#CD011381-bbs2-0216" title="Laurson-DoubeJ , RijkeN , HelmeA , BanekeP , BanwellB , ViswanathanS , et al. Ethical use of off-label disease-modifying therapies for multiple sclerosis. Multiple Sclerosis2021;27(9):1403-10.">Laurson‐Doube 2021</a>). </p> <p>Ocrelizumab is a monoclonal antibody against the CD20 antigen expressed on B‐lymphocytes. The antibody depletes circulating B‐lymphocytes predominately through antibody‐mediated cytotoxicity (<a href="./references#CD011381-bbs2-0233" title="OhJ , CalabresiPA . Emerging injectable therapies for multiple sclerosis. Lancet Neurology2013;12:1115–26.">Oh 2013</a>). </p> <p>Mechanisms of action must be considered while assessing the risk of adverse events associated with the use of a drug, since safety is usually a consequence of the drug's main pharmacological effect (<a href="./references#CD011381-bbs2-0146" title="CompstonA , ColesA . Multiple sclerosis. Lancet2008;372:1502-17.">Compston 2008</a>; <a href="./references#CD011381-bbs2-0201" title="HauserSL , CreeBA . Treatment of multiple sclerosis: a review. American Journal of Medicine2020;133(12):1380-90.e2.">Hauser 2020</a>; <a href="./references#CD011381-bbs2-0227" title="MassacesiL . Compartmentalization of the immune response in the central nervous system and natural history of multiple sclerosis. Implications for therapy. Clinical Neurology and Neurosurgery2002;104(3):177-81.">Massacesi 2002</a>; <a href="./references#CD011381-bbs2-0229" title="MeinlE , KrumbholzM , DerfussT , JunkerA , HohlfeldR . Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. Journal of the Neurological Sciences2008;274(1-2):42-4.">Meinl 2008</a>). </p> </section> </section> <section id="CD011381-sec-0016"> <h3 class="title" id="CD011381-sec-0016">Why it is important to do this review</h3> <p>Although there is consensus that immunotherapies reduce the frequency of relapses in MS, their relative benefit in delaying new relapses or disability worsening remains unclear. This uncertainty is due to the limited number of direct comparison trials, which provide the most rigorous and valid research evidence on the relative efficacy and safety of different, competing treatments. Since the previous version of the review (<a href="./references#CD011381-bbs2-0264" title="TramacereI , Del GiovaneC , SalantiG , D'AmicoR , FilippiniG . Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD011381. [DOI: 10.1002/14651858.CD011381.pub2]">Tramacere 2015</a>), new DMTs have been approved by regulatory agencies, offering a broader spectrum of treatment options for people with MS. Evidence of efficacy in chronic autoimmune conditions, relatively good tolerability and reasonable cost has prompted the off‐label use of several immunosuppressants and immunomodulators for the treatment of MS in many countries, particularly in settings with budget constraints (<a href="./references#CD011381-bbs2-0261" title="ZeineddineMM , YamoutBI . Treatment of multiple sclerosis in special populations: the case of refugees. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(1):2055217319848466. [DOI: 10.1177/2055217319848466]">Zeineddine 2020</a>). A summary of the results, including both direct and indirect comparisons, may help to clarify the stated uncertainty (<a href="./references#CD011381-bbs2-0139" title="CaldwellD , AdesA , HigginsJ . Simultaneous comparison of multiple treatments: combining direct and indirect evidence as well. BMJ2005;331(7521):897-900.">Caldwell 2005</a>; <a href="./references#CD011381-bbs2-0194" title="GlennyA , AltmanD , SongF , SakarovitchC , DeeksJ , D'AmicoR , et al. Indirect comparisons of competing interventions. Health Technology Assessment2005;9:1-34.">Glenny 2005</a>). </p> <p>The data underlying the present review and NMA served as the evidence base for the development of a separate clinical practice guideline on the treatment of RRMS and PMS by an international, highly representative multi‐stakeholder panel (Multiple Sclerosis Essential Medicines Panel, MEMP) appointed by the Multiple Sclerosis International Federation (MSIF). The panel included people with MS and advocacy group representatives, clinicians from different speciality areas involved in the management of MS, pharmaco‐epidemiologists and health economists. The guidelines were developed with methodological guidance by the Department of Health Research Methods, Evidence and Impact (HEI), McMaster University, Hamilton, Ontario, Canada, according to the GRADE Working Group method for guideline development (<a href="./references#CD011381-bbs2-0128" title="Alonso-CoelloP , SchünemannHJ , MobergJ , Brignardello-PetersenR , AklEA , DavoliM , et al, GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ2016;353:i2016. [DOI: 10.1136/bmj.i2016] [PMID: 27353417]">Alonso‐Coello 2016</a>; <a href="./references#CD011381-bbs2-0129" title="Alonso-CoelloP , OxmanAD , MobergJ , Brignardello-PetersenR , AklEA , DavoliM , et al, GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ 2016;353:i2089. [DOI: 10.1136/bmj.i2089]">Alonso‐Coello 2016b</a>). The MEMP recommendations were used as the evidence base for an application for the inclusion of disease‐modifying treatments in the 23rd WHO Model List of Essential Medicines. The nine critical outcomes identified by MEMP were differentiated into primary and secondary outcomes in this review (see <a href="#CD011381-sec-0018">Methods</a>). </p> <p>This is an update of a Cochrane review published in 2015 (<a href="./references#CD011381-bbs2-0264" title="TramacereI , Del GiovaneC , SalantiG , D'AmicoR , FilippiniG . Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD011381. [DOI: 10.1002/14651858.CD011381.pub2]">Tramacere 2015</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011381-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011381-sec-0017"></div> <p>To compare, through network meta‐analysis, the efficacy and safety of interferon beta‐1b, interferon beta‐1a (Avonex, Rebif), glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, pegylated interferon beta‐1a, daclizumab, laquinimod, azathioprine, immunoglobulins, cladribine, cyclophosphamide, diroximel fumarate, fludarabine, interferon beta 1‐a and beta 1‐b, leflunomide, methotrexate, minocycline, mycophenolate mofetil, ofatumumab, ozanimod, ponesimod, rituximab, siponimod and steroids for the treatment of people with RRMS. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011381-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011381-sec-0018"></div> <section id="CD011381-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011381-sec-0020"> <h4 class="title">Types of studies</h4> <p>We included individually randomised parallel controlled clinical trials (RCTs). We considered studies published in abstracts whenever sufficient information was available on study design, characteristics of participants, interventions, and outcomes. Only studies with a follow‐up of 12 months or longer were included. </p> </section> <section id="CD011381-sec-0021"> <h4 class="title">Types of participants</h4> <p>We included adult participants aged 18 years or older with a diagnosis of RRMS according to Poser (<a href="./references#CD011381-bbs2-0237" title="PoserC , PatyD , ScheinbergL , McDonaldW , DavisF , EbersG , et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology1983;13:227-31.">Poser 1983</a>) or McDonald (<a href="./references#CD011381-bbs2-0228" title="McDonaldW , CompstonA , EdanG , GoodkinD , HartungH , LublinF . Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Annals of Neurology2001;50:121-7.">McDonald 2001</a>; <a href="./references#CD011381-bbs2-0235" title="PolmanC , ReingoldS , EdanG , FilippiM , HartungH , KapposL , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Annals of Neurology2005;58:840-6.">Polman 2005</a>; <a href="./references#CD011381-bbs2-0236" title="PolmanCH , ReingoldSC , BanwellB , ClanetM , CohenJA , FilippiM , et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology2011;69:292–302.">Polman 2011</a>) diagnostic criteria. We included all participants regardless of sex, degree of disability, and disease duration. </p> <p>We included studies primarily focused on RRMS but also including a subgroup of people with PMS only if the proportion of people with RRMS was ≥ 80%. Evidence from studies including 80% to 99% of people with RRMS were considered for downgrading because of indirectness while assessing the certainty of the evidence, according to GRADE methodology (<a href="./references#CD011381-bbs2-0198" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol2011;64:395-400. [DOI: 10.1016/j.jclinepi.2010.09.012]">Guyatt 2011</a>). </p> </section> <section id="CD011381-sec-0022"> <h4 class="title">Types of interventions</h4> <p>We included all immunomodulators or immunosuppressants (even if they were not licenced in any country). We excluded: (i) combination treatments; (ii) trials in which a drug regimen was compared with a different regimen of the same drug without another active agent or placebo as a control arm; (iii) all non‐pharmacological treatments; and (iv) interventions with over‐the‐counter drugs. </p> <p>We included RCTs that evaluated one or more of the following pharmacological interventions as monotherapy, compared to placebo or to another active agent: </p> <p> <ul id="CD011381-list-0001"> <li> <p>interferon beta‐1b</p> </li> <li> <p>interferon beta‐1a (Avonex, Rebif)</p> </li> <li> <p>glatiramer acetate</p> </li> <li> <p>natalizumab</p> </li> <li> <p>mitoxantrone</p> </li> <li> <p>fingolimod</p> </li> <li> <p>teriflunomide</p> </li> <li> <p>dimethyl fumarate</p> </li> <li> <p>alemtuzumab</p> </li> <li> <p>pegylated interferon beta‐1a</p> </li> <li> <p>daclizumab</p> </li> <li> <p>ocrelizumab</p> </li> <li> <p>laquinimod</p> </li> <li> <p>azathioprine</p> </li> <li> <p>immunoglobulins</p> </li> </ul> </p> <p>In this update, we also considered the following additional interventions for inclusion:</p> <p> <ul id="CD011381-list-0002"> <li> <p>cladribine</p> </li> <li> <p>cyclophosphamide</p> </li> <li> <p>diroximel fumarate</p> </li> <li> <p>fludarabine</p> </li> <li> <p>interferon beta 1‐a and beta 1‐b (when both are used in the same experimental arm as ‘interferon beta products’). </p> </li> <li> <p>leflunomide</p> </li> <li> <p>methotrexate</p> </li> <li> <p>minocycline</p> </li> <li> <p>mycophenolate mofetil</p> </li> <li> <p>ofatumumab</p> </li> <li> <p>ozanimod</p> </li> <li> <p>ponesimod</p> </li> <li> <p>rituximab</p> </li> <li> <p>siponimod</p> </li> <li> <p>steroids</p> </li> </ul> </p> <p>We included regimens as defined in primary studies, irrespective of their dose.</p> </section> <section id="CD011381-sec-0023"> <h4 class="title">Types of outcome measures</h4> <section id="CD011381-sec-0024"> <h5 class="title">Primary outcomes</h5> <p>We estimated the relative effects of the competing interventions according to the following primary outcomes: </p> <section id="CD011381-sec-0025"> <h6 class="title">Efficacy</h6> <p> <ul id="CD011381-list-0003"> <li> <p>Relapses: proportion of participants who experienced new relapses over 12, 24, or 36 months after randomisation or at the end of the study. A relapse is defined as newly developed or recently worsened symptoms of neurologic dysfunction that last for at least 24 hours, occurring in the absence of fever or other acute diseases and separated in time from any previous episode by more than 30 days (<a href="./references#CD011381-bbs2-0228" title="McDonaldW , CompstonA , EdanG , GoodkinD , HartungH , LublinF . Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Annals of Neurology2001;50:121-7.">McDonald 2001</a>; <a href="./references#CD011381-bbs2-0235" title="PolmanC , ReingoldS , EdanG , FilippiM , HartungH , KapposL , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Annals of Neurology2005;58:840-6.">Polman 2005</a>). A more stringent 48‐hour criterion has been used in some RCTs. A relapse can resolve either partially or completely. </p> </li> <li> <p>Disability worsening: proportion of participants who experienced disability worsening over 24 or 36 months after randomisation or at the end of the study. Worsening is defined as at least a 1‐point Expanded Disability Status Scale (EDSS) increase or a 0.5‐point increase if the baseline EDSS was greater than or equal to 5.5, confirmed during two subsequent neurological examinations separated by at least a six‐month interval free of attacks (<a href="./references#CD011381-bbs2-0215" title="KurtzkeJ . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983;33:1444-52.">Kurtzke 1983</a>). Disability worsening confirmed after only three months of follow‐up is considered a surrogate marker for unremitting disability. EDSS is a common measure of MS disability (where 0 is normal, 3 mild disability, 6 care requirement, 7 wheelchair use, and 10 is death from MS) and is used to measure disability worsening in clinical trials for MS. </p> </li> </ul> </p> </section> <section id="CD011381-sec-0026"> <h6 class="title">Safety</h6> <p> <ul id="CD011381-list-0004"> <li> <p>Discontinuation due to adverse events: measured by the number of participants who withdrew due to any adverse event at the end of the study </p> </li> <li> <p>Serious adverse events (SAEs): number of participants with any (one or more) SAEs, defined according to the authors of the study </p> </li> </ul> </p> </section> </section> <section id="CD011381-sec-0027"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011381-list-0005"> <li> <p>Cognitive decline: assessed as a continuous outcome considering the variation in the score of the Symbol Digit Modalities Test (SDMT) (<a href="./references#CD011381-bbs2-0134" title="BenedictRH , DeLucaJ , PhillipsG , LaRoccaN , HudsonLD , RudickR . Multiple Sclerosis Outcome Assessments Consortium. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.. Mult Scler.2017;23:721-733. [DOI: 10.1177/1352458517690821]">Benedict 2017</a>) when available or, alternatively, the Paced Auditory Serial Addition Test (PASAT) (<a href="./references#CD011381-bbs2-0197" title="Gronwall DM. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills1977;44:367-73. [DOI: 10.2466/pms.1977.44.2.367]">Gronwall 1977</a>); </p> </li> <li> <p>Quality‐of‐life impairment: assessed as a continuous outcome considering the variation in the score of scales reporting quality‐of‐life impairment. Any available scale was considered; </p> </li> <li> <p>New or enlarging T2‐weighted magnetic resonance imaging (MRI) lesions: measured by the number of participants with new or enlarging T2‐weighted MRI lesions at 12, 24, and 36 months after randomisation; </p> </li> <li> <p>New gadolinium‐enhancing positive T1‐weighted MRI lesions: measured by the number of participants with new gadolinium‐enhancing T1‐weighted MRI lesions at 12, 24, and 36 months after randomisation; </p> </li> <li> <p>Mortality: overall number of MS‐related deaths.</p> </li> </ul> </p> </section> </section> </section> <section id="CD011381-sec-0028"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011381-sec-0029"> <h4 class="title">Electronic searches</h4> <p>The previous version of this review searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Trials Register (on 30 September 2014). As this was not possible for this version of the review, a bespoke search was created by the Information Specialist of the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group. Searches were run in September 2021, then topped up on 8 August 2022: </p> <p> <ul id="CD011381-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (Issue 8 2022)(<a href="./appendices#CD011381-sec-0114">Appendix 1</a>); </p> </li> <li> <p>MEDLINE (PubMed) (January 2012 to 8 August 2022) (<a href="./appendices#CD011381-sec-0115">Appendix 2</a>); </p> </li> <li> <p>Embase (<a href="http://Embase.com" target="_blank">Embase.com</a>) (January 2012 to 2022 week 32) (<a href="./appendices#CD011381-sec-0116">Appendix 3</a>). </p> </li> </ul> </p> <p>We did not apply any search limitation with respect to study outcomes, methods of analysis, or language. </p> </section> <section id="CD011381-sec-0030"> <h4 class="title">Searching other resources</h4> <p>In addition to considering all studies from <a href="./references#CD011381-bbs2-0264" title="TramacereI , Del GiovaneC , SalantiG , D'AmicoR , FilippiniG . Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD011381. [DOI: 10.1002/14651858.CD011381.pub2]">Tramacere 2015</a>, to identify eligible studies prior to 2012, we consulted the identified studies in <a href="./references#CD011381-bbs2-0190" title="FilippiniG , Del GiovaneC , VacchiL , D’AmicoR , Di PietrantonjC , BeecherD , et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD008933. [DOI: 10.1002/14651858.CD008933]">Filippini 2013</a>, a prior Cochrane NMA review concerning immunomodulators and immunosuppressants for multiple sclerosis, where the search was performed until February 2012. </p> <p>We searched for ongoing studies on the following databases (see <a href="./appendices#CD011381-sec-0117">Appendix 4</a> for search strings):<br/>• World Health Organisation (WHO) International Clinical Trials Registry Platform (ICTRP) (apps.who.int/trialsearch). Search terms: relapsing multiple sclerosis, filtered for "Phase 2" "Phase 3" trials;<br/>• US National Institutes of Health clinical trial register (www.clinicaltrials.gov). Search term: "relapsing multiple sclerosis". </p> <p>We checked reference lists of all included studies and any relevant systematic reviews identified for additional references to studies. We examined any relevant retraction statements and errata for included studies. </p> </section> </section> <section id="CD011381-sec-0031"> <h3 class="title" id="CD011381-sec-0031">Data collection and analysis</h3> <section id="CD011381-sec-0032"> <h4 class="title">Selection of studies</h4> <p>For this version of the review, study selection was conducted with the Rayyan platform (https://rayyan.ai/) in accordance with the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011381-bbs2-0206" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2021</a>). Six review authors in pairs (BR, EB, FN, GP, IT, MF) independently screened the titles and abstracts. Potentially relevant articles were acquired in full text and assessed for eligibility by the same six authors in pairs. </p> </section> <section id="CD011381-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (SM, MGL) independently extracted data from the studies using a predefined data extraction form in an Excel spreadsheet and piloting the data extraction form on at least five studies in the review. We resolved disagreements by discussion with a third author (FN). Whenever data were available from both peer‐reviewed journals as full publications as well as from trials registries (such as ClinicalTrials.gov or WHO ICTRP), we extracted them from the former. We extracted results from trials registers when these were the only available data. </p> <p>We extracted from each included study data the following information:</p> <p> <ul id="CD011381-list-0007"> <li> <p>Study: first author or acronym, number of centres, year of publication, years that the study was conducted (recruitment and follow‐up), publication (full‐text publication, abstract publication, unpublished data); </p> </li> <li> <p>Study design: inclusion criteria, number of randomised participants, duration of follow‐up (12, 24, or 36 months); </p> </li> <li> <p>Population: baseline mean age, gender, definition of relapse;</p> </li> <li> <p>Potential effect modifiers: diagnostic criteria (Poser or McDonald criteria), previous treatments with DMTs, by structuring four categories: “no previous treatment with DMTs”, “previous treatment with DMTs”, “uncertain information on previous treatment with DMTs” and “mixed population of patients, previously treated and previously untreated with DMTs”; </p> </li> <li> <p>Intervention: active agent, dose, frequency, or duration of treatment;</p> </li> <li> <p>Funding source.</p> </li> </ul> </p> <section id="CD011381-sec-0034"> <h5 class="title">Outcome data</h5> <p>For dichotomous outcomes, we extracted the number of participants experiencing the event of interest over the number of randomised participants. </p> <p>For continuous outcomes relative to the outcomes 'cognitive decline' and 'quality‐of‐life impairment', we extracted the mean and standard deviation of the comparison groups, where possible. We extracted data at baseline and end point, as well as change scores. We used change scores in case end point scores were not reported (<a href="./references#CD011381-bbs2-0147" title="Da CostaBR , NueschE , RutjesAW , JohnstonBC , ReichenbachS , TrelleS , et al. Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study. Journal of Clinical Epidemiology2013;66:847-55.">Da Costa 2013</a>). We extracted data at the authors' defined timing points. </p> <p>When outcomes were not reported at our predefined time points, we extracted data as close as possible to that time point. We extracted the authors' definition of relapses and disability worsening. We extracted arm‐level data, when available. </p> <p>We further extracted the characteristics associated with the monitoring and reporting of adverse events, considering specific factors that may have a large influence on adverse event data. We evaluated methods of monitoring and detecting adverse events in each primary study: Did the researchers actively monitor for adverse events, or did they simply provide spontaneous reporting of adverse events that arose? Did the authors define adverse events according to an accepted international classification and report the number of SAEs? We reported this information in an additional table called 'Assessment of Adverse Events Monitoring' (<a href="#CD011381-tbl-0007">Table 1</a>). </p> <div class="table" id="CD011381-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Assessment of adverse events/serious adverse events in included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Did the researchers actively monitor for adverse events (AEs) or did they simply provide spontaneous reporting of AEs that arose?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Did the authors define serious AEs (SAEs) according to an accepted international classification and report the number of SAEs?</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0001" title="AchironA , GabbayU , GiladR , HassinB , BarakY , GornishM , et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology1998;50(2):398-402. ">Achiron 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0002" title="CalabresiPA , KieseierBC , ArnoldDL , BalcerLJ , BoykoA , PelletierJ , et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurology2014;13:657-65. HuX , CuiY , WhiteJ , ZhuY , DeykinA , NestorovI , HungS . Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. British Journal of Clinical Pharmacology2015;79(3):514-22. [DOI: 10.1111/bcp.12521] [PMID: 25265472]ScottTF , KieseierBC , NewsomeSD , ArnoldDL , YouX , HungS , Sperling B. Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis.. Mult Scler J Exp Transl Clin. 2016 ;2:2055217316676644. [DOI: 10.1177/2055217316676644] [PMID: 28607743]">ADVANCE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0003" title="BalcerLJ , GalettaSL , PolmanCH , EggenbergerE , CalabresiPA , ZhangA , et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.. J Neurol Sci2012;318(1-2):119-24. [DOI: 10.1016/j.jns.2012.03.009] [PMID: 22521274]LublinFD , CutterG , GiovannoniG , PaceA , CampbellNR , BelachewS . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.. Mult Scler Relat Disord2014;3(6):705-11. [DOI: 10.1016/j.msard.2014.08.005] [PMID: 25891549]PolmanCH , O'ConnorPW , HavrdovaE , HutchinsonM , KapposL , MillerDH , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):899-910. Weinstock-GuttmanB , GalettaSL , GiovannoniG , HavrdovaE , HutchinsonM , KapposL , et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology2012;259((5)):898-905. [DOI: 10.1007/s00415-011-6275-7] [PMID: 22008873]">AFFIRM 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Treating neurologists were responsible for all aspects of patient care, including the management of adverse events".</i> Participants <i>"visited the clinic every 12 weeks for ... blood chemical and hematologic analyses, evaluation of adverse events...</i>" (page 901). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0004" title="ComiG , JefferyD , KapposL , MontalbanX , BoykoA , RoccaMA , et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. New England Journal of Medicine2012;366(11):1000-9. FilippiM , RoccaMA , PaganiE , De StefanoN , JefferyD , KapposL , et al, ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry2014;85(8):851-8. [DOI: 10.1136/jnnp-2013-306132] [PMID: 24029546]">ALLEGRO 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Safety assessments were performed at screening, at baseline, and every 3 months until month 24</i>" (page 1002). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0005" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS I 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"<i>Adverse events were recorded at all visits and graded according to the Common Terminology</i> <br/><i>Criteria for Adverse Events (CTCAE)."</i> (page 548)<i>. "Additional safety assessments included laboratory tests, physical examination (including examination of skin), vital sign measures, ECG evaluations and assessment of suicidality"</i> (page 21, Appendix). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>A serious adverse event (SAE) was defined as any adverse event [appearance of (or worsening of any pre‐existing)] undesirable sign(s), symptom(s) or medical conditions(s)which met any one of the following criteria:</i> <br/><i>• was fatal or life‐threatening</i> <br/><i>• resulted in persistent or significant disability/incapacity</i> <br/><i>• constituted a congenital anomaly/birth defect</i> <br/><i>• required in‐patient hospitalisation or prolongation of existing hospitalisation, unless hospitalisation was for:</i> <br/><i>‐ routine treatment or monitoring of the studied indication, not associated with any deterioration in condition (e.g. hospitalisation for multiple sclerosis relapse treatment)</i> <br/><i>‐ elective or pre‐planned treatment for a pre‐existing condition that was unrelated to the indication under trial and had not worsened since signing the informed consent to treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospital admission</i> <br/><i>‐ social reasons and respite care in the absence of any deterioration in the patient’s general condition</i> <br/><i>• was medically significant, e.g. defined as an event that jeopardised the patient or may require medical or surgical intervention."</i> (Appendix, page 22). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0006" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS II 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"Adverse events were recorded at all visits and graded according to the Common Terminology Criteria for Adverse Events (CTCAE)"</i> (page 548)<i>. "Additional safety assessments included laboratory tests, physical examination (including examination of skin), vital sign measures, ECG evaluations and assessment of suicidality"</i> (page 21, Appendix). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"A serious adverse event (SAE) was defined as any adverse event [appearance of (or</i> <br/><i>worsening of any pre‐existing)] undesirable sign(s), symptom(s) or medical conditions(s)</i> <br/><i>which met any one of the following criteria:</i> <br/><i>• was fatal or life‐threatening</i> <br/><i>• resulted in persistent or significant disability/incapacity</i> <br/><i>• constituted a congenital anomaly/birth defect</i> <br/><i>• required in‐patient hospitalisation or prolongation of existing hospitalisation, unless</i> <br/><i>hospitalisation was for:</i> <br/><i>‐ routine treatment or monitoring of the studied indication, not associated with</i> <br/><i>any deterioration in condition (e.g. hospitalisation for multiple sclerosis</i> <br/><i>relapse treatment)</i> <br/><i>‐ elective or pre‐planned treatment for a pre‐existing condition that was</i> <br/><i>unrelated to the indication under trial and had not worsened since signing the informed consent</i> <br/><i>‐ treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospital admission</i> <br/><i>‐ social reasons and respite care in the absence of any deterioration in the patient’s general condition</i> <br/><i>• was medically significant, e.g. defined as an event that jeopardised the patient or may require medical or surgical intervention."</i> (Appendix, page 22). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0007" title="CreeBAC , GoldmanMD , CorboyJR , SingerBA , FoxEJ , ArnoldDL , et al, ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020 ;78(1):1–13. [DOI: 10.1001/jamaneurol.2020.2950] [PMID: 32852530]">ASSESS 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0008" title="BrownRA , NarayananS , StikovN , CookS , CadavidD , WolanskyL , et al. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. Neurology2016;87(9):905-11. [DOI: 10.1212/WNL.0000000000003043] [PMID: 27473139]CadavidD , WolanskyLJ , SkurnickJ , LincolnJ , CheriyanJ , SzczepanowskiK , et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology2009;72(23):1976-83. CheriyanJ , KimS , WolanskyLJ , CookSD , CadavidD . Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol2012;69(1):82-8. [DOI: 10.1001/archneurol.2011.674]">BECOME 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>After the initial interim analysis failed to raise any safety concerns with the use of monthly triple dose gadolinium, all patients still in the study were offered the option of obtaining additional monthly MRI scans for a second year of treatment</i>" (page 1977). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0009" title="O'ConnorP , FilippiM , ArnasonB , ComiG , CookS , GoodinD , et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology2009;8(10):889-97. SchipplingS , O'ConnorP , KnappertzV , PohlC , BogumilT , SuarezG , et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol2016;263(7):1418-26. [DOI: 10.1007/s00415-016-8146-8]">BEYOND 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Clinic visits were scheduled every 3 months to assess ... safety, and tolerability. The occurrence of new neurological symptoms and adverse events was assessed by telephone, 6 weeks after each visit</i>" (page 891). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0010" title="BornsteinMB , MillerA , SlagleS , WeitzmanM , Crystal, DrexlerE , et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New England Journal of Medicine1987;317(7):408-14. ">Bornstein 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Self‐evaluation reported to a clinical assistant</i>" (page 409) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0011" title="VollmerTL , SorensenPS , SelmajK , ZippF , HavrdovaE , CohenJA , et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology2014;261(4):773-83. ">BRAVO 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Patients were evaluated at 12 scheduled visits: months ‐1 (screening), 0 (baseline), 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24. Safety assessments (laboratory measures, vital signs) were performed at all visits, and electrocardiograms (ECGs) were performed at months ‐1, 0, 1, 2, 3, 6, 12, 18, and 24/early termination</i>" (page 775). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0012" title="CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786-801. FoxEJ , WynnD , ColesAJ , PalmerJ , MargolinDH , CAMMS223 Investigators. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. J Neurol Sci2016;363:188-94. [DOI: 10.1016/j.jns.2016.02.025]">CAMMS223 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Safety was assessed quarterly by the treating neurologist, who was aware of study‐group assignment</i> " (page 1787); "<i>Thyroid function and levels of antithyrotropin receptor antibodies and lymphocyte subpopulations were measured quarterly at a central laboratory</i> "; and "<i>All adverse events with an onset up to 36 months are reported. In addition, all serious adverse events and autoimmune‐associated disorders occurring before March 1, 2008, are listed</i>" (page 1788). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>To assess safety, we undertook monthly questionnaire follow‐up of patients, and did complete blood counts, serum creatinine, urinalysis, and microscopy monthly (every three months in patients in the interferon beta 1a group), and thyroid function tests every 3 months</i> "; "<i>Circulating lymphocyte subsets were assessed every 3 months in all patients and 1 month after alemtuzumab administration. We screened for anti‐alemtuzumab antibodies with a bridging ELISA before and at 1 month, 3 months, and 12 months after each dosing</i> "; and "<i>We measured interferon beta 1a‐neutralising antibodies at baseline and at 24 months with a cytopathic effect inhibition assay</i>" (page 1821). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>To assess safety, we undertook monthly questionnaire follow‐up of patients, and did complete blood counts, serum creatinine, and urinalysis with microscopy monthly (every 3 months in patients in the interferon beta 1a group), and thyroid function tests every 3 months</i> "; "<i>We assessed circulating lymphocyte subsets every 3 months in all patients and 1 month after every course of alemtuzumab. We screened for anti‐alemtuzumab antibodies with ELISA before and at 1 month, 3 months and 12 months after each dosing</i> "; and "<i>We measured interferon beta 1a‐neutralising antibodies at baseline and at 24 months with a cytopathic effect inhibition assay</i>" (page 1832). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0015" title="AfolabiD , AlborC , ZalewskiL , AltmannDR , BakerD , SchmiererK . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler2018 ;24(11):1461-1468. [DOI: 10.1177/1352458517726380] [PMID: 28817997]ComiG , CookSD , GiovannoniG , RammohanK , RieckmannP , SørensenPS , et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol2013;260(4):1136-46. [DOI: 10.1007/s00415-012-6775-0] [PMID: 23263473]De StefanoN , GiorgioA , BattagliniM , De LeucioA , HickingC , DangondF , et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018;24(2):222-226. [DOI: 10.1177/1352458517690269] [PMID: 28140753]GiovannoniG , ComiG , CookS , RammohanK , RieckmannP , Soelberg SørensenP , et al, CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):416-26. [DOI: 10.1056/NEJMoa0902533] [PMID: 20089960]GiovannoniG , Soelberg SorensenP , CookS , RammohanKW , RieckmannP , ComiG , et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler2019;25(6):819-827. [DOI: 10.1177/1352458518771875] [PMID: 29716436]HermannR , LitwinJS , FribergLE , DangondF , MunafoA . Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Br J Clin Pharmacol2019 ;85(7):1484-1494. [DOI: 10.1111/bcp.13919] [PMID: 30883839]VermerschP , GalazkaA , DangondF , DamianD , WongSL , JackD , et al. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Curr Med Res Opin2021;37(3):459-464. [DOI: 10.1080/03007995.2020.1865888] [PMID: 33331183]">CLARITY 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0016" title="LublinFD , CofieldSS , CutterGR , ConwitR , NarayanaPA , NelsonF , et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology2013;73(3):327-40. ">CombiRx 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Safety was assessed by recording all adverse events, serious and nonserious</i>" (page 329). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information on SAE definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0017" title="ComiG , DadonY , SassonN , SteinermanJR , KnappertzV , VollmerTL , et al. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler2022;28(4):608-619. [DOI: 10.1177/13524585211032803] [PMID: 34378456]NCT01707992. The Efficacy, Safety, and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). https://clinicaltrials.gov/show/NCT017079922012. ">CONCERTO 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Safety endpoints included assessment of adverse events (AEs) throughout the study, and vital signs, electrocardiograms (ECGs), and clinical laboratory<br/>parameters at specific scheduled site visits. ECG findings<br/>assessed as “abnormal, clinically significant” were evaluated by the data monitoring committee<br/>(DMC) cardiologist. Assessment of tolerability included evaluation of the proportion of patients who prematurely discontinued treatment, including those with ETD due to AEs" (page 2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Throughout the course of the study, every effort was made to remain alert to possible adverse events (AEs)</i> " and "<i>Any AE or SAE experienced by the subject was recorded on the CRF, regardless of the severity of the event or its relationship to study treatment</i>" (pages 66‐7 of Protocol) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0019" title="BenedictRH , CohanS , LynchSG , RiesterK , WangP , Castro-BorreroW , et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler2018 ;24(6):795-804. [DOI: 0.1177/1352458517707345]KapposL , HavrdovaE , GiovannoniG , KhatriBO , GauthierSA , GreenbergSJ , et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler2017;23(13):1736-1747. [DOI: 10.1177/1352458516683266]KapposL , WiendlH , SelmajK , ArnoldDL , HavrdovaE , BoykoA , et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2015;373(15):1418-28. [DOI: 10.1056/NEJMoa1501481]KruegerJG , KircikL , HougeirF , FriedmanA , YouX , LucasN , et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther2016;33(7):231-45. [DOI: 10.1007/s12325-016-0353-2]LiuY , VollmerT , HavrdovaE , RiesterK , LeeA , PhillipsG , et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;11:18-24. [DOI: 10.1016/j.msard.2016.11.005]NCT01064401. Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01064401 (accessed 30 September 2014). RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40.. [DOI: 10.1016/j.msard.2017.06.006]">DECIDE 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"A serious adverse event (SAE) is any untoward medical occurrence that at any dose:<br/>• results in death<br/>• in the view of the Investigator, places the subject at immediate risk of death (a life‐threatening event); however, this does not include an event that, had it occurred in a more severe form, might have caused death<br/>• requires inpatient hospitalisation or prolongation of existing hospitalisation<br/>• results in persistent or significant disability/incapacity, or<br/>• results in a congenital anomaly/birth defect.<br/>An SAE may also be any other medically important event that, in the opinion of the Investigator, may jeopardise the subject or may require intervention to prevent one of the other outcomes listed in the definition above" (Protocol). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0020" title="ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014;261(9):1794-802. [DOI: 10.1007/s00415-014-7412-x] [PMID: 24989666]ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol2014;261(12):2429-37. [DOI: 10.1007/s00415-014-7504-7] [PMID: 25270680]Bar-OrA , GoldR , KapposL , ArnoldDL , GiovannoniG , SelmajK , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol2013 ;260(9):2297-305. [DOI: 10.1007/s00415-013-6954-7] [PMID: 23797999]Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012] [PMID: 28751099]GoldR , KapposL , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine2012;367(12):1098-107. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272] [PMID: 28328179]KapposL , GoldR , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler2014;20(2):243-52. [DOI: 10.1177/1352458513507817] [PMID: 24150779]">DEFINE 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Study visits were scheduled every 4 weeks for safety assessments, including the monitoring of laboratory values</i>" (page 1100). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0021" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica2006;113(5):283-7. ">Etemadifar 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0022" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. Journal of Neurology2007;254(12):1723-8. ">Etemadifar 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Adverse events, vital signs and blood tests were monitored monthly</i>" (page 1724). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0023" title="FazekasF , DeisenhammerF , Strasser-FuchsS , NahlerG , MamoliB . Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet1997;349(9052):589-93. ">Fazekas 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants "<i>asked about safety monthly...</i>" (page 590). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>An independent data and safety monitoring board evaluated the safety</i> " and "S<i>tudy visits, including safety assessments, were scheduled at 2 weeks and 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24 months after randomization</i>" (page 389). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0025" title="CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(6):545-56. VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , Freedman MS A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017 3;3:2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS II 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"...<i>safety assessments, were scheduled at 2 weeks and 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24 months after randomization</i>" (Appendix, page 2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0026" title='DavisMD , AshtamkerN , SteinermanJR , KnappertzV . Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study. 2017 Neurol Neuroimmunol Neuroinflamm;4(2):e327. [DOI: 10.1212/NXI.0000000000000327] [PMID: 28210662]KhanO , RieckmannP , BoykoA , SelmajK , ZivadinovR , GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Annals of Neurology2013;73(6):705-13. ZivadinovR , DwyerM , BarkayH , SteinermanJR , KnappertzV , Khan O. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis. J Neurol2015;262(3):648-53. [DOI: 10.1007/s00415-014-7616-0] [PMID: 25542295]ZivadinovR , DwyerMG , RamasamyDP , DavisMD , SteinermanJR , KhanO . The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. J Neuroimaging2015;25(6):989-95. [DOI: 10.1111/jon.12293] [PMID: 26394270]'>GALA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Safety assessments included adverse events (AEs), standard clinical laboratory tests, vital signs, and electrocardiographic (ECG) measurements</i>" (page 707). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information on SAE definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0027" title="GobbiC , MeierDS , CottonF , SintzelM , LeppertD , GuttmannCR , ZeccaC . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol2013;13:101. [DOI: 10.1186/1471-2377-13-101] [PMID: 23915113]ZeccaC , RiccitelliGC , CalabreseP , PravatàE , CandrianU , GuttmannCR , Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol2014;14:38. [DOI: 10.1186/1471-2377-14-38] [PMID: 24576156]">Gobbi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0028" title="ComiG , PattiF , RoccaMA , MattioliFC , AmatoMP , GalloP , CentonzeD , PozzilliC , SaccàF , BerghFT , BartezaghiM , TurriniR , FilippiM , Golden Study Group. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol2017;264(12):2436-2449. [DOI: 10.1007/s00415-017-8642-5] [PMID: 29063244]">GOLDEN 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"AEs, SAEs and vital signs were assessed at each study visit"</i> (page 18). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information on SAE definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0029" title="GoodkinD , BaillyR , TeetzenM , HertsgaardD , BeattyW . The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology1991;41:20-5. ">Goodkin 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Side effects were reported to the treating neurologist every 6 months</i>" (page 21). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0030" title="IFNBMSG . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology1993;43(4):655-61. ">IFNB MS Group 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Treating neurologist reviewed side effects, laboratory findings for toxicity ...</i>" (page 656). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0031" title="DurelliL , VerdunE , BarberoP , BerguiM , VersinoE , GhezziA , et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002;359:1453-60. ">INCOMIN 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Safety assessments included adverse events, vital signs, physical examination, and concomitant medications. Patients underwent haematology and biochemical tests, including liver‐function tests, every 2 weeks for the first 8 weeks, and then every 3 months</i>" (page 1455). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0032" title="JohnsonK , BrooksB , CohenJ , FordC , GoldsteinJ , LisakR , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology1995;45(7):1268-76. ">Johnson 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>The evaluating physician monitored safety every 3 months..."</i> (page 1270). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0033" title="KnoblerRL , GreensteinJI , JohnsonKP , LublinFD , PanitchHS , ConwayK , et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. Journal of Interferon Research1993;13(5):333-40. ">Knobler 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"At each patient visit, a nurse coordinator collected patient diaries of daily events and documented adverse events noted in these records."</i> (page 335). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0034" title="Koch-HenriksenN , SørensenP , ChristensenT , FrederiksenJ , RavnborgM , JensenK , et al. A randomised study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology2006;66(7):1056-60. ">Koch‐Henriksen 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Patients were interviewed about side effects and had routine blood tests including hematology and liver function tests every 3 months and thyroid tests and neutralizing antibodies every 6 months</i>" (page 1057). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0035" title="LewanskaM , Siger-ZajdelM , SelmajK . No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. European Journal of Neurology2002;9(6):565-72. ">Lewanska 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Laboratory safety examinations were made at the beginning and at the end of the study period</i>" (page 566). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0036" title="MassacesiL , TramacereI , AmorosoS , BattagliaMA , BenedettiMD , FilippiniG , et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One2014;9(11):e113371. ">MAIN 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>At scheduled (quarterly) and unscheduled (i.e. at the onset of new symptoms or complications) follow‐up visits the treating neurologist recorded symptoms, blood test results, clinical AEs and their management</i>". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0037" title="MillefioriniE , GasperiniC , PozzilliC , D'AndreaF , BastianelloS , TrojanoM , et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology1997;244(3):153-9. ">Millefiorini 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>The safety of the treatment was assessed on the basis of adverse events volunteered by the patient either spontaneously or on questioning and monitoring of the main laboratory parameters</i>" (page 155). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0038" title="MokhberN , AzarpazhoohA , OroujiE , KhorramB , Modares GharaviM , KakhiS , KhallaghiH , AzarpazhoohMR . Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis. Psychiatry Clin Neurosci.2015;69(10):649-57. [DOI: 10.1111/pcn.12308] [PMID: 25907350]MokhberN , AzarpazhoohA , OroujiE , RaoSM , KhorramB , SahraianMA , ForoghipoorM , GharaviMM , KakhiS , NikkhahK , AzarpazhoohMR . Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. J Neurol Sci2014;342(1-2):16-20. [DOI: 10.1016/j.jns.2014.01.038] [PMID: 24841321]">Mokhber 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0039" title="JacobsL , CookfairD , RudickR , HerndonR , RichertJ , SalazarA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology1996;39:285-94. ">MSCRG 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Study visits were scheduled at baseline and every 6 months. Treating physicians reviewed toxicity test results, examined patients, and made all medical decisions</i>" (page 286). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0040" title="A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01247324 (accessed 30 September 2014). HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , JulianL , KöndgenH , LiC , NapieralskiJ , ZhengH , WolinskyJS . Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , BuffelsR , FioreD , GarrenH , HanJ , HauserSL . Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA I 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A serious adverse event is defined as any adverse event that, at any dose, fulfils at least one of the<br/>following criteria:<br/> Is fatal; (results in death*; please note: death is an outcome, not an event)<br/> Is life‐threatening (please note: the term “life‐threatening” refers to an event in which the patient was at immediate risk of death at the time of the event; it does not refer to an event which could hypothetically have caused a death had it been more severe)<br/> Requires in‐patient hospitalisation or prolongation of existing hospitalisation<br/> Results in persistent or significant disability/incapacity<br/> Is a congenital anomaly/birth defect<br/> Is medically significant or requires intervention to prevent one or other of the outcomes listed above (Appendix) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A serious adverse event is defined as any adverse event that, at any dose, fulfils at least one of the<br/>following criteria:<br/> Is fatal; (results in death*; please note: death is an outcome, not an event)<br/> Is life‐threatening (please note: the term “life‐threatening” refers to an event in which the patient was at immediate risk of death at the time of the event; it does not refer to an event which could hypothetically have caused a death had it been more severe)<br/> Requires in‐patient hospitalisation or prolongation of existing hospitalisation<br/> Results in persistent or significant disability/incapacity<br/> Is a congenital anomaly/birth defect<br/> Is medically significant or requires intervention to prevent one or other of the outcomes listed above (Appendix) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0042" title="KapposL , FoxRJ , BurcklenM , FreedmanMS , HavrdováEK , HennessyB , et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol 2021 May 1;;78(5):558-567. [DOI: 10.1001/jamaneurol.2021.0405] [PMID: 33779698]">OPTIMUM 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"Safety assessments included adverse events recorded</i> <br/><i>verbatim and later coded in accordance with MedDRA version 21 (International Council for Harmonisation) and predefined adverse events of special interest (AESIs)"</i> (page 560). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An SAE is defined by the ICH guidelines as any AE fulfilling at least one of the following criteria: </p> <p> <ul id="CD011381-list-0008"> <li> <p>Fatal;</p> </li> <li> <p>Life‐threatening: refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event that hypothetically might have caused death had it been more severe; </p> </li> <li> <p>Requiring inpatient hospitalisation or prolongation of existing hospitalisation;</p> </li> <li> <p>Resulting in persistent or significant disability or incapacity;</p> </li> <li> <p>Congenital anomaly or birth defect;</p> </li> <li> <p>Medically significant: refers to important medical events that may not immediately result in death, be life‐threatening, or require hospitalisation but may be considered to be SAEs when, based upon appropriate medical judgement, they may jeopardise the subject and may require medical or surgical intervention to prevent one of the outcomes listed in the definitions above (Protocol). </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0043" title="EbersGC . Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet1998;352(9139):1498-1504. [DOI: 10.1016/S0140-6736(98)03334-0]TraboulseeA , LiDKB , CascioneM , FangJ , DangondF , MillerA . Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. BMC Neurol2018;18(1):143. [DOI: 10.1186/s12883-018-1145-x] [PMID: 30217172]">PRISMS 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>A “treating” neurologist was responsible for overall medical management of the patient, including treatment of any side‐effects</i>" (page 1499). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0044" title="CohenJA , ComiG , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019;18(11):1021-1033. [DOI: 10.1016/S1474-4422(19)30238-8] [PMID: 31492652]NCT01628393. Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study). https://clinicaltrials.gov/show/NCT016283932012. ">RADIANCE 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"Adverse events were assessed at each visit"</i> (page 123). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0045" title="MikolD , BarkhofF , ChangP , CoyleP , JefferyD , SchwidS , et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology2008;7(10):903-14. ">REGARD 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Adverse events (including pregnancy), withdrawals owing to adverse events, serious adverse events, and laboratory results were obtained for safety comparisons</i>" (page 905). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Safety parameters were assessed at all visits</i>" (page 2168). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information on SAE definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0047" title="ComiG , KapposL , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology2019 ;18(11):1009-1020. [DOI: 10.1016/S1474-4422(19)30239-X]DeLucaJ , SchipplingS , MontalbanX , KapposL , CreeBAC , ComiG , et al. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Mult Scler Relat Disord2021;48:102673. [DOI: 10.1016/j.msard.2020.102673]NCT02294058. Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS). https://ClinicalTrials.gov/show/NCT022940582014. ">SUNBEAM 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"Adverse events were assessed at each visit"</i> (page 1012). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information on SAE definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0048" title="MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al, Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler2012;18(11):1625-32. [DOI: 10.1177/1352458512450354] [PMID: 22723573]O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293-303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol2013;260(10):2472-80. [DOI: 10.1007/s00415-013-6979-y] [PMID: 23852658]RadueEW , SprengerT , GaetanoL , Mueller-LenkeN , CavalierS , ThangaveluK , et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm2017;4(5):e390. [DOI: 10.1212/NXI.0000000000000390] [PMID: 28828394]WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013 ;19(10):1310-9. [DOI: 10.1177/1352458513475723] [PMID: 23447359]">TEMSO 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>A treating neurologist at each site was responsible for recording and managing adverse events and monitoring safety assessments</i> " and "<i>Safety was evaluated on the basis of adverse events reported by study participants or investigators. Laboratory tests were performed at the time of screening, at baseline, every 2 weeks for the first 24 weeks, and then every 6 weeks until study completion. Physical and neurologic examinations were performed at week 12 and then every 24 weeks. An abdominal ultrasonographic examination to assess for pancreatic abnormalities was performed before the study and then every 24 weeks, because of previous infrequent reports of pancreatitis associated with leflunomide use</i>" (pages 1294‐5). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0049" title="ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(3):247-56. FreedmanMS , MorawskiJ , ThangaveluK . Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. Mult Scler J Exp Transl Clin2018;4(2):2055217318775236. [DOI: 10.1177/2055217318775236] [PMID: 29796289]MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MäurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol2014;261(9):1781-8. [DOI: 10.1007/s00415-014-7395-7] [PMID: 24972678]MillerAE , XuX , MacdonellR , VucicS , TruffinetP , BenamorM , et al. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. J Clin Neurosci2019;59:229-231. [DOI: 10.1016/j.jocn.2018.09.012] [PMID: 30348586]QiuW , HuangDH , HouSF , ZhangMN , JinT , DongHQ , et al, TOWER Trial Chinese Group. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study. Chin Med J (Engl)2018;131(23):2776-2784. [DOI: 10.4103/0366-6999.246067] [PMID: 30511679]">TOWER 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Safety was assessed through adverse event reporting (upon occurrence), clinical laboratory tests (every 2 weeks until week 24, then every 6 weeks while still on treatment), vital signs (at weeks 2 and 6, then every 6 weeks until week 24, then every 12 weeks while still on treatment), abdominal ultrasonography (at week 24, then every 24 weeks), and electrocardiography (at baseline and end of treatment)</i>" (page 248). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0050" title="BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler2014;20(13):1704-13. [DOI: 10.1177/1352458514532317] [PMID: 24812043]CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402-15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol2013;260(8):2023-32. [DOI: 10.1007/s00415-013-6932-0] [PMID: 23632946]KhatriBO , PelletierJ , KapposL , HartungHP , ComiG , BarkhofF , et al, TRANSFORMS Study Group. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord2014;3(3):355-63. [DOI: 10.1016/j.msard.2013.11.006] [PMID: 25876473]MengX , ChinPS , HashmonayR , Zahur IslamM , CutterG . Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemp Clin Trials2015;41:69-74. [DOI: 10.1016/j.cct.2014.12.011] [PMID: 25545026]">TRANSFORMS 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>An independent data and safety monitoring board evaluated overall safety in the fingolimod phase 3 program</i> " and <i>"Safety assessments were conducted during screening, at baseline, and at months 1, 2, 3, 6, 9, and 12</i>" (page 404). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AE: adverse events<br/>CRF:<br/>CTCAE:<br/>DMC:<br/>ECG:<br/>ELISA:<br/>ETD:<br/>ICH:<br/>SAE: serious adverse events </p> </div> </div> </section> </section> <section id="CD011381-sec-0035"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias of each included study using the Cochrane Collaboration’s tool for assessing the risk of bias (<a href="./references#CD011381-bbs2-0204" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>). These include: random sequence generation, allocation concealment, blinding of participants and providers, blinding of outcome assessor(s), incomplete outcome data, and selective outcome reporting. Other potential risks of bias included the role of the sponsor: we judged a study as being at high risk of bias if it was funded by industry, and it was stated that the funder was involved in data management, analysis and interpretation, in writing of the study report, or where it was reported that the funders approved the final version of the paper; we judged studies as being at high risk of bias also if the first or last author and authors who performed the statistical analysis were employed by industry. We explicitly judged the risk of bias of each study on each criterion and classified it as being at 'low', 'high', or 'unclear' risk of bias. We judged incomplete outcome data as at low risk of bias when numbers and causes of dropouts were balanced (i.e. absence of a significant difference) between arms and appeared to be unrelated to the studied outcomes. We assessed selective outcome reporting bias by comparing outcomes reported in the study protocol along with published outcome results. If a study protocol was not available, we assigned a judgement of unclear risk of bias. </p> <p>Two authors (SM, MGL) assessed the risk of bias of each study independently and resolved any disagreement by discussion to reach consensus. </p> </section> <section id="CD011381-sec-0036"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011381-sec-0037"> <h5 class="title">Relative treatment effects</h5> <p>For dichotomous outcomes (i.e. disability and relapses), we reported risk ratios (RRs) and 95% confidence intervals (CIs). If the number of observed events had been small (less than 5% of the sample per group), and if studies had balanced treatment groups, we reported the Peto odds ratios (ORs) with 95% CIs.<br/>For continuous outcomes, we calculated the mean difference (MD) or standardised mean difference (SMD) if the same continuous outcome was measured with different metrics. To interpret SMD, we used the guiding principles (<a href="./references#CD011381-bbs2-0199" title="GuyattGH , ThorlundK , OxmanAD , WalterSD , PatrickD , FurukawaTA , et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. Journal of Clinical Epidemiology2013;66(2):173-83. [DOI: 10.1016/j.jclinepi.2012.08.001]">Guyatt 2013</a>) of thresholds for small (SMD = ±0.2), moderate (SMD = ±0.5), and large effects (SMD = ±0.8). We presented results from network meta‐analysis as summary relative effect sizes (RR, MD, or SMD) for each possible pair of treatments. </p> </section> <section id="CD011381-sec-0038"> <h5 class="title">Relative treatment ranking</h5> <p>We estimated the ranking probabilities for all treatments at each possible rank for each intervention. We obtained a treatment hierarchy using the surface under the cumulative ranking curve (SUCRA) and mean ranks. SUCRA was expressed as the percentage representing the relative probability of a treatment being amongst the best options without uncertainty (<a href="./references#CD011381-bbs2-0239" title="SalantiG , AdesA , IoannidisJ . Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology2011;64:163-71.">Salanti 2011</a>). </p> </section> </section> <section id="CD011381-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <section id="CD011381-sec-0040"> <h5 class="title">Studies with multiple treatment groups</h5> <p>For pairwise meta‐analysis, we considered the multi‐arm studies as multiple independent two‐arm studies. For network meta‐analysis (NMA), we accounted for the correlation between the effect sizes from multi‐arm studies (<a href="./references#CD011381-bbs2-0240" title="SalantiG . Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods2012;3(2):80-97.">Salanti 2012</a>). For studies with multi‐arm trials involving the same agent at different doses compared to a control treatment, we converted the treatment arms into a single arm by merging the different doses, summing the number of events, and calculating the sample size. </p> </section> <section id="CD011381-sec-0041"> <h5 class="title">Studies with multiple outcome scales</h5> <p>MS‐specific scales (e.g. MSQOL‐54, MSIS 29) were not combined with non‐MS‐specific scales (e.g. SF‐36 or EQ‐5D index). Where several scales were used in one RCT, we selected the scale that provided lower heterogeneity in combination (via SMD) with the others across studies. </p> </section> </section> <section id="CD011381-sec-0042"> <h4 class="title">Dealing with missing data</h4> <p>We used data that reflected the intention‐to‐treat (ITT) analysis for each included outcome. Primary analysis was performed considering the number of patients with the event in relation to the number of randomised individuals. In the case of participants with missing data, primary analysis was performed without any imputation. For adverse events, we used data from participants who received at least one dose of the study medication. Where standard deviations were missing for continuous outcomes, we calculated them according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011381-bbs2-0206" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> </section> <section id="CD011381-sec-0043"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD011381-sec-0044"> <h5 class="title">Assessment of clinical heterogeneity within treatment comparisons</h5> <p>To evaluate the presence of heterogeneity deriving from different characteristics of study participants, we assessed differences in age, disease duration, and baseline EDSS scores across the trials using information reported in the table '<a href="./references#CD011381-sec-0141" title="">Characteristics of included studies</a>'. </p> </section> <section id="CD011381-sec-0045"> <h5 class="title">Assessment of transitivity across treatment comparisons</h5> <p>We expected that the transitivity assumption held, assuming that all pairwise comparisons did not differ with respect to the distribution of effect modifiers. We evaluated the assumption of transitivity by comparing potential effect modifiers, which are reported in the '<a href="#CD011381-sec-0033">Data extraction and management</a>' section, across the different pairwise comparisons. </p> </section> </section> <section id="CD011381-sec-0046"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to evaluate the possibility of reporting bias by means of contour‐enhanced funnel plots (<a href="./references#CD011381-bbs2-0234" title="PetersJ , SuttonA , JonesD , AbramsK , RushtonL . Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology2008;61(10):991-6.">Peters 2008</a>). Contour‐enhanced funnel plots show areas of statistical significance, and they can help in distinguishing reporting bias from other possible reasons for asymmetry. In a network of interventions, each study estimates the relative effect of different interventions, so asymmetry in the funnel plot cannot be judged. To account for this, we used an adaptation of the funnel plot by subtracting from each study‐specific effect size the mean of meta‐analysis of the study‐specific comparison and plotted it against the study's standard error (<a href="./references#CD011381-bbs2-0141" title="ChaimaniA , SalantiG . Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Research Synthesis Methods2012;3(2):161-76.">Chaimani 2012</a>; <a href="./references#CD011381-bbs2-0142" title="ChaimaniA , HigginsJP , MavridisD , SpyridonosP , SalantiG . Graphical tools for network meta-analysis in Stata. PLoS One2013;8(10):e76654.">Chaimani 2013</a>). We employed the comparison‐adjusted funnel plot for all placebo‐controlled trials. Note that any asymmetry in the plot indicates the presence of small study effects and not necessarily reporting bias. </p> </section> <section id="CD011381-sec-0047"> <h4 class="title">Data synthesis</h4> <section id="CD011381-sec-0048"> <h5 class="title">Methods for direct treatment comparisons</h5> <p>We performed conventional pairwise meta‐analyses for each primary outcome using a random‐effects model for each treatment comparison with at least two studies (<a href="./references#CD011381-bbs2-0149" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7:177-88.">DerSimonian 1986</a>). </p> </section> <section id="CD011381-sec-0049"> <h5 class="title">Methods for indirect and mixed comparisons</h5> <p>We performed network meta‐analysis using a random‐effects model within a frequentist setting assuming equal heterogeneity across all comparisons, and we accounted for correlations induced by multi‐arm studies (<a href="./references#CD011381-bbs2-0231" title="MiladinovicB , HozoI , ChaimaniA , DjulbegovicB . Indirect treatment comparison. Stata Journal2014;14(1):76-86.">Miladinovic 2014</a>; <a href="./references#CD011381-bbs2-0240" title="SalantiG . Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods2012;3(2):80-97.">Salanti 2012</a>). The models enabled us to estimate the probability of each intervention being at each possible rank for each outcome, given the relative effect sizes as estimated in network meta‐analysis. We summarised the probabilities of a treatment being at each possible rank using SUCRAs and mean rank. We performed network meta‐analysis in Stata 13 using the 'mvmeta' command and self‐programmed Stata routines available at <a href="http://www.mtm.uoi.gr" target="_blank">http://www.mtm.uoi.gr</a> (<a href="./references#CD011381-bbs2-0142" title="ChaimaniA , HigginsJP , MavridisD , SpyridonosP , SalantiG . Graphical tools for network meta-analysis in Stata. PLoS One2013;8(10):e76654.">Chaimani 2013</a>; <a href="./references#CD011381-bbs2-0255" title="WhiteIR . Multivariate random-effects meta-regression: updates to mvmeta. Stata Journal2011;11:255-70.">White 2011</a>; <a href="./references#CD011381-bbs2-0256" title="WhiteIR , BarrettJK , JacksonD , HigginsJPT . Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Research Synthesis Methods2012;3(2):111-25.">White 2012</a>). </p> </section> </section> <section id="CD011381-sec-0050"> <h4 class="title">Assessment of statistical heterogeneity</h4> <p>We statistically assessed the presence of heterogeneity for all direct pairwise comparisons using the common τ<sup>2</sup> and I<sup>2</sup> statistics. The assessment of statistical heterogeneity in the entire network was based on the magnitude of the heterogeneity variance parameter (τ<sup>2</sup>) estimated from the network meta‐analysis models (<a href="./references#CD011381-bbs2-0210" title="JacksonD , BarrettJK , RiceS , WhiteIR , HigginsJP . A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. Statistics in Medicine2014;33(21):3639-54.">Jackson 2014</a>). </p> </section> <section id="CD011381-sec-0051"> <h4 class="title">Assessment of statistical inconsistency</h4> <p>Consistency in a network of treatments refers to the agreement between direct and indirect estimates. Joint analysis of treatments can be misleading if the network is substantially inconsistent. Inconsistency can be present if the trials in the network have different protocols and their inclusion/exclusion criteria are not comparable or may result in an uneven distribution of the effect modifiers across groups of trials that compare different treatments. To evaluate the presence of inconsistency locally, we used both the loop‐specific approach and the node splitting approach by using the software STATA (<a href="./references#CD011381-bbs2-0142" title="ChaimaniA , HigginsJP , MavridisD , SpyridonosP , SalantiG . Graphical tools for network meta-analysis in Stata. PLoS One2013;8(10):e76654.">Chaimani 2013</a>; <a href="./references#CD011381-bbs2-0254" title="VeronikiAA , VasiliadisHS , HigginsJP , SalantiG . Evaluation of inconsistency in networks of interventions. Internal Journal Epidemiology2013;42(1):332-45.">Veroniki 2013</a>). We used the 'design‐by‐treatment' model to evaluate the assumption of consistency in the entire network (<a href="./references#CD011381-bbs2-0205" title="HigginsJPT , JacksonD , BarrettJK , LuG , AdesAE , WhiteIR . Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Research Synthesis Methods2012;3:98-110.">Higgins 2012</a>). This method accounts for different sources of inconsistency that can occur when studies with different designs (two‐arm trials versus three‐arm trials) give different results, as well as disagreement between direct and indirect evidence. Using this approach, we inferred the presence of inconsistencies from any source in the entire network based on a Chi<sup>2</sup> test. We performed the design‐by‐treatment model in Stata using the 'mvmeta' command. </p> </section> <section id="CD011381-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform subgroup analyses for efficacy outcomes at 12, 24, and 36 months' follow‐up by using the following effect modifiers as possible sources of inconsistency or heterogeneity, or both: </p> <p> <ul id="CD011381-list-0009"> <li> <p>Diagnostic criteria (Poser or McDonald criteria);</p> </li> <li> <p>Previous treatment with immunomodulators or immunosuppressants (no or yes), i.e. first‐ or second‐line treatments. </p> </li> </ul> </p> </section> <section id="CD011381-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform the following sensitivity analyses:</p> <p> <ul id="CD011381-list-0010"> <li> <p>Including only trials with low risk of selection bias and attrition bias;</p> </li> <li> <p>Excluding trials with a total sample size of fewer than 50 randomised participants to detect potential small study effects. </p> </li> </ul> </p> </section> <section id="CD011381-sec-0054"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main results of the review in a Summary of findings (SoF) table, according to recommendations described in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011381-bbs2-0244" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , GuyattGH . Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022a</a>). We assessed the certainty of the NMA estimates for the outcomes below using the GRADE approach (<a href="./references#CD011381-bbs2-0138" title="Brignardello-PetersenR , BonnerA , AlexanderPE , SiemieniukRA , FurukawaTA , RochwergB , et al, GRADE Working Group. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. Journal of Clinical Epidemiology2018;93:36-44.">Brignardello‐Petersen 2018</a>): </p> <p> <ul id="CD011381-list-0011"> <li> <p>Proportion of people who experienced new relapses over 12, 24 and 36 months;</p> </li> <li> <p>Proportion of people who experienced disability worsening over 24 months;</p> </li> <li> <p>Proportion of people who withdrew due to any adverse event;</p> </li> <li> <p>Number of participants with any (one or more) SAEs.</p> </li> </ul> </p> <p>Since the results of this review and NMA will serve as the evidence base for guidance on the use of DMTs in people with RRMS, the certainty of the evidence for this review was assessed using a fully contextualised approach. A fully contextualised approach is important in NMAs to incorporate the value of individual outcomes in the overall interpretation of the results (<a href="./references#CD011381-bbs2-0245" title="SchünemannHJ , NeumannI , HultcrantzM , Brignardello-PetersenR , ZengL , MuradMH , et al. GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions. Journal of Clinical Epidemiology2022;150:225-42.">Schünemann 2022b</a>). This involved predefining quantitative thresholds to determine the magnitude of each health effect (desirable or undesirable) measured by means of each outcome. The magnitudes of desirable and undesirable health effects were defined according to the GRADE wording as 'trivial', 'small', 'moderate', and 'large'. </p> <p>For this NMA, we used outcomes assessed by the MSIF Essential Medicines Panel – which was convened to make recommendations on essential medicines for MS. The value of the outcomes was assessed by the guideline panel to judge both the priority of outcomes (not important/important/critical) and a health state utility value (HSUV) corresponding to the outcome in question. The panel identified nine critical outcomes. In this review, the authors further differentiated and reported those outcomes as four primary and five secondary outcomes. The HSUV was derived from a review of reviews or panel judgement if not identified from the literature. The HSUV is utilised to calculate thresholds for the magnitude of effects. The thresholds between trivial/small (T1), small/moderate (T2), and moderate/large (T3) were predefined through calculation informed by the health state utility value (HSUV) of each outcome (<a href="./appendices#CD011381-sec-0118">Appendix 5</a>). </p> <p>Thresholds were based on absolute anticipated effects of each intervention's outcome estimate using the formula: Threshold = (threshold coefficient/(1 ‐ utility) x 1000). The threshold coefficient was derived from an interim analysis of an ongoing global survey on decision thresholds by assessing respondent judgements across varied disease category examples (<a href="./references#CD011381-bbs2-0232" title="MorganoGP , MbuagbawL , SantessoN , XieF , BrozekJL , SiebertU , et al. Defining decision thresholds for judgments on health benefits and harms using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision (EtD) frameworks: a protocol for a randomised methodological study (GRADE-THRESHOLD). BMJ Open2022;12(3):e053246.">Morgano 2022</a>). </p> <p>We followed GRADE guidance for assessing imprecision using a fully contextualised approach (<a href="./references#CD011381-bbs2-0245" title="SchünemannHJ , NeumannI , HultcrantzM , Brignardello-PetersenR , ZengL , MuradMH , et al. GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions. Journal of Clinical Epidemiology2022;150:225-42.">Schünemann 2022b</a>). We graded the certainty of evidence for each outcome considering study limitations, indirectness, inconsistency, imprecision of effect estimates, and risk of reporting bias. According to the software <a href="./references#CD011381-bbs2-0195" title="GRADEpro. Version 3.2 for Windows. Brozek J, Oxman A, Schünemann H, 2008.">GRADEpro 2008</a>, we assigned four levels of certainty of evidence: high, moderate, low, and very low. </p> <p>In order to determine the imprecision of estimates, and therefore make imprecision judgements including downgrading by 1, 2, or 3 levels for certainty, point estimates of observed effects and their 95% CIs were contextualised in relation to the predefined thresholds (<a href="./references#CD011381-bbs2-0209" title="HultcrantzM , RindD , AklEA , TreweekS , MustafaRA , IorioA , et al. The GRADE Working Group clarifies the construct of certainty of evidence. J Clin Epidemiol2017;87:4-13. [DOI: 10.1016/j.jclinepi.2017.05.006]">Hultcrantz 2017</a>). In accordance with the GRADE guidance on imprecision, the overall imprecision of interventions was assessed across all outcomes with guideline panel input. If most outcomes were not downgraded for imprecision, the overall certainty was not necessarily downgraded to the lowest certainty (<a href="./references#CD011381-bbs2-0245" title="SchünemannHJ , NeumannI , HultcrantzM , Brignardello-PetersenR , ZengL , MuradMH , et al. GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions. Journal of Clinical Epidemiology2022;150:225-42.">Schünemann 2022b</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011381-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011381-sec-0055"></div> <section id="CD011381-sec-0056"> <h3 class="title">Description of studies</h3> <section id="CD011381-sec-0057"> <h4 class="title">Results of the search</h4> <p>We identified 16,926 reports through an electronic database search on 21 September 2021. A top‐up search conducted on 8 August 2022 identified a further 842 records (See <a href="#CD011381-fig-0001">Figure 1</a>). A total of 59 reports were carried over from the previous version of this review (<a href="./references#CD011381-bbs2-0264" title="TramacereI , Del GiovaneC , SalantiG , D'AmicoR , FilippiniG . Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD011381. [DOI: 10.1002/14651858.CD011381.pub2]">Tramacere 2015</a>), and 44 reports from another relevant NMA review which included studies with people with both RRMS and PMS (<a href="./references#CD011381-bbs2-0190" title="FilippiniG , Del GiovaneC , VacchiL , D’AmicoR , Di PietrantonjC , BeecherD , et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD008933. [DOI: 10.1002/14651858.CD008933]">Filippini 2013</a>). We screened a total of 12,507 de‐duplicated records, of which 12,328 were excluded based on the titles and abstracts. We evaluated 179 full texts as potentially meeting inclusion criteria. We excluded 41 studies with reasons (<a href="./references#CD011381-sec-0142" title="">Characteristics of excluded studies</a>), and identified 21 ongoing studies (<a href="./references#CD011381-sec-0144" title="">Characteristics of ongoing studies</a>). After full‐text review, we included 50 studies. A total of 13 studies were identified as potentially meeting inclusion criteria. These studies are summarised in <a href="./references#CD011381-sec-0143" title="">Characteristics of studies awaiting classification</a> and will undergo full‐text review in a future update of this review. </p> <div class="figure" id="CD011381-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow chart* Several of the studies were reported in the same reports: ASCLEPIOS I 2020; ASCLEPIOS II 2020 (reported in Hauser 2020); CARE‐MS I 2012; CARE‐MS II 2012 (reported in Arroyo 2017); OPERA I 2017; OPERA II 2017 (reported in the same four reports); CONFIRM 2012; DEFINE 2012 (reported in Fernandez 2017 and Havrdova 2017); FREEDOMS 2010; FREEDOMS II 2014 (reported in Vermersch 2017); DECIDE 2015; SELECT 2013 (reported in Giovannoni 2016 and Rose 2017)." data-id="CD011381-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow chart</p> <p>* Several of the studies were reported in the same reports: <a href="./references#CD011381-bbs2-0005" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS I 2020</a>; <a href="./references#CD011381-bbs2-0006" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS II 2020</a> (reported in Hauser 2020); <a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a>; <a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a> (reported in Arroyo 2017); <a href="./references#CD011381-bbs2-0040" title="A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01247324 (accessed 30 September 2014). HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , JulianL , KöndgenH , LiC , NapieralskiJ , ZhengH , WolinskyJS . Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , BuffelsR , FioreD , GarrenH , HanJ , HauserSL . Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA I 2017</a>; <a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a> (reported in the same four reports); <a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a>; <a href="./references#CD011381-bbs2-0020" title="ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014;261(9):1794-802. [DOI: 10.1007/s00415-014-7412-x] [PMID: 24989666]ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol2014;261(12):2429-37. [DOI: 10.1007/s00415-014-7504-7] [PMID: 25270680]Bar-OrA , GoldR , KapposL , ArnoldDL , GiovannoniG , SelmajK , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol2013 ;260(9):2297-305. [DOI: 10.1007/s00415-013-6954-7] [PMID: 23797999]Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012] [PMID: 28751099]GoldR , KapposL , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine2012;367(12):1098-107. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272] [PMID: 28328179]KapposL , GoldR , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler2014;20(2):243-52. [DOI: 10.1177/1352458513507817] [PMID: 24150779]">DEFINE 2012</a> (reported in Fernandez 2017 and Havrdova 2017); <a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a>; <a href="./references#CD011381-bbs2-0025" title="CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(6):545-56. VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , Freedman MS A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017 3;3:2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS II 2014</a> (reported in Vermersch 2017); <a href="./references#CD011381-bbs2-0019" title="BenedictRH , CohanS , LynchSG , RiesterK , WangP , Castro-BorreroW , et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler2018 ;24(6):795-804. [DOI: 0.1177/1352458517707345]KapposL , HavrdovaE , GiovannoniG , KhatriBO , GauthierSA , GreenbergSJ , et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler2017;23(13):1736-1747. [DOI: 10.1177/1352458516683266]KapposL , WiendlH , SelmajK , ArnoldDL , HavrdovaE , BoykoA , et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2015;373(15):1418-28. [DOI: 10.1056/NEJMoa1501481]KruegerJG , KircikL , HougeirF , FriedmanA , YouX , LucasN , et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther2016;33(7):231-45. [DOI: 10.1007/s12325-016-0353-2]LiuY , VollmerT , HavrdovaE , RiesterK , LeeA , PhillipsG , et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;11:18-24. [DOI: 10.1016/j.msard.2016.11.005]NCT01064401. Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01064401 (accessed 30 September 2014). RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40.. [DOI: 10.1016/j.msard.2017.06.006]">DECIDE 2015</a>; <a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a> (reported in Giovannoni 2016 and Rose 2017). </p> </div> </div> </div> <p>On the following DMTs, we found no studies satisfying our inclusion criteria: cyclophosphamide, diroximel fumarate, fludarabine, leflunomide, methotrexate, minocycline, mycophenolate mofetil, rituximab, siponimod, and steroids. </p> </section> <section id="CD011381-sec-0058"> <h4 class="title">Included studies</h4> <p>We included 50 studies involving 36,541 participants (68.6% female and 31.4% male) and published between 1987 and 2021 in this review. </p> <p>We included 34 studies already included in previous reviews (<a href="./references#CD011381-bbs2-0001" title="AchironA , GabbayU , GiladR , HassinB , BarakY , GornishM , et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology1998;50(2):398-402. ">Achiron 1998</a>; <a href="./references#CD011381-bbs2-0002" title="CalabresiPA , KieseierBC , ArnoldDL , BalcerLJ , BoykoA , PelletierJ , et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurology2014;13:657-65. HuX , CuiY , WhiteJ , ZhuY , DeykinA , NestorovI , HungS . Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. British Journal of Clinical Pharmacology2015;79(3):514-22. [DOI: 10.1111/bcp.12521] [PMID: 25265472]ScottTF , KieseierBC , NewsomeSD , ArnoldDL , YouX , HungS , Sperling B. Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis.. Mult Scler J Exp Transl Clin. 2016 ;2:2055217316676644. [DOI: 10.1177/2055217316676644] [PMID: 28607743]">ADVANCE 2014</a>; <a href="./references#CD011381-bbs2-0003" title="BalcerLJ , GalettaSL , PolmanCH , EggenbergerE , CalabresiPA , ZhangA , et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.. J Neurol Sci2012;318(1-2):119-24. [DOI: 10.1016/j.jns.2012.03.009] [PMID: 22521274]LublinFD , CutterG , GiovannoniG , PaceA , CampbellNR , BelachewS . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.. Mult Scler Relat Disord2014;3(6):705-11. [DOI: 10.1016/j.msard.2014.08.005] [PMID: 25891549]PolmanCH , O'ConnorPW , HavrdovaE , HutchinsonM , KapposL , MillerDH , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):899-910. Weinstock-GuttmanB , GalettaSL , GiovannoniG , HavrdovaE , HutchinsonM , KapposL , et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology2012;259((5)):898-905. [DOI: 10.1007/s00415-011-6275-7] [PMID: 22008873]">AFFIRM 2006</a>; <a href="./references#CD011381-bbs2-0004" title="ComiG , JefferyD , KapposL , MontalbanX , BoykoA , RoccaMA , et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. New England Journal of Medicine2012;366(11):1000-9. FilippiM , RoccaMA , PaganiE , De StefanoN , JefferyD , KapposL , et al, ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry2014;85(8):851-8. [DOI: 10.1136/jnnp-2013-306132] [PMID: 24029546]">ALLEGRO 2012</a>; <a href="./references#CD011381-bbs2-0008" title="BrownRA , NarayananS , StikovN , CookS , CadavidD , WolanskyL , et al. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. Neurology2016;87(9):905-11. [DOI: 10.1212/WNL.0000000000003043] [PMID: 27473139]CadavidD , WolanskyLJ , SkurnickJ , LincolnJ , CheriyanJ , SzczepanowskiK , et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology2009;72(23):1976-83. CheriyanJ , KimS , WolanskyLJ , CookSD , CadavidD . Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol2012;69(1):82-8. [DOI: 10.1001/archneurol.2011.674]">BECOME 2009</a>; <a href="./references#CD011381-bbs2-0009" title="O'ConnorP , FilippiM , ArnasonB , ComiG , CookS , GoodinD , et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology2009;8(10):889-97. SchipplingS , O'ConnorP , KnappertzV , PohlC , BogumilT , SuarezG , et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol2016;263(7):1418-26. [DOI: 10.1007/s00415-016-8146-8]">BEYOND 2009</a>; <a href="./references#CD011381-bbs2-0010" title="BornsteinMB , MillerA , SlagleS , WeitzmanM , Crystal, DrexlerE , et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New England Journal of Medicine1987;317(7):408-14. ">Bornstein 1987</a>; <a href="./references#CD011381-bbs2-0011" title="VollmerTL , SorensenPS , SelmajK , ZippF , HavrdovaE , CohenJA , et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology2014;261(4):773-83. ">BRAVO 2014</a>; <a href="./references#CD011381-bbs2-0012" title="CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786-801. FoxEJ , WynnD , ColesAJ , PalmerJ , MargolinDH , CAMMS223 Investigators. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. J Neurol Sci2016;363:188-94. [DOI: 10.1016/j.jns.2016.02.025]">CAMMS223 2008</a>; <a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a>; <a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a>; <a href="./references#CD011381-bbs2-0016" title="LublinFD , CofieldSS , CutterGR , ConwitR , NarayanaPA , NelsonF , et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology2013;73(3):327-40. ">CombiRx 2013</a>; <a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a>; <a href="./references#CD011381-bbs2-0020" title="ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014;261(9):1794-802. [DOI: 10.1007/s00415-014-7412-x] [PMID: 24989666]ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol2014;261(12):2429-37. [DOI: 10.1007/s00415-014-7504-7] [PMID: 25270680]Bar-OrA , GoldR , KapposL , ArnoldDL , GiovannoniG , SelmajK , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol2013 ;260(9):2297-305. [DOI: 10.1007/s00415-013-6954-7] [PMID: 23797999]Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012] [PMID: 28751099]GoldR , KapposL , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine2012;367(12):1098-107. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272] [PMID: 28328179]KapposL , GoldR , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler2014;20(2):243-52. [DOI: 10.1177/1352458513507817] [PMID: 24150779]">DEFINE 2012</a>; <a href="./references#CD011381-bbs2-0022" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. Journal of Neurology2007;254(12):1723-8. ">Etemadifar 2007</a>; <a href="./references#CD011381-bbs2-0023" title="FazekasF , DeisenhammerF , Strasser-FuchsS , NahlerG , MamoliB . Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet1997;349(9052):589-93. ">Fazekas 1997</a>; <a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a>; <a href="./references#CD011381-bbs2-0025" title="CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(6):545-56. VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , Freedman MS A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017 3;3:2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS II 2014</a>; <a href="./references#CD011381-bbs2-0026" title='DavisMD , AshtamkerN , SteinermanJR , KnappertzV . Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study. 2017 Neurol Neuroimmunol Neuroinflamm;4(2):e327. [DOI: 10.1212/NXI.0000000000000327] [PMID: 28210662]KhanO , RieckmannP , BoykoA , SelmajK , ZivadinovR , GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Annals of Neurology2013;73(6):705-13. ZivadinovR , DwyerM , BarkayH , SteinermanJR , KnappertzV , Khan O. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis. J Neurol2015;262(3):648-53. [DOI: 10.1007/s00415-014-7616-0] [PMID: 25542295]ZivadinovR , DwyerMG , RamasamyDP , DavisMD , SteinermanJR , KhanO . The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. J Neuroimaging2015;25(6):989-95. [DOI: 10.1111/jon.12293] [PMID: 26394270]'>GALA 2013</a>; <a href="./references#CD011381-bbs2-0029" title="GoodkinD , BaillyR , TeetzenM , HertsgaardD , BeattyW . The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology1991;41:20-5. ">Goodkin 1991</a>; <a href="./references#CD011381-bbs2-0030" title="IFNBMSG . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology1993;43(4):655-61. ">IFNB MS Group 1993</a>; <a href="./references#CD011381-bbs2-0031" title="DurelliL , VerdunE , BarberoP , BerguiM , VersinoE , GhezziA , et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002;359:1453-60. ">INCOMIN 2002</a>; <a href="./references#CD011381-bbs2-0032" title="JohnsonK , BrooksB , CohenJ , FordC , GoldsteinJ , LisakR , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology1995;45(7):1268-76. ">Johnson 1995</a>; <a href="./references#CD011381-bbs2-0034" title="Koch-HenriksenN , SørensenP , ChristensenT , FrederiksenJ , RavnborgM , JensenK , et al. A randomised study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology2006;66(7):1056-60. ">Koch‐Henriksen 2006</a>; <a href="./references#CD011381-bbs2-0035" title="LewanskaM , Siger-ZajdelM , SelmajK . No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. European Journal of Neurology2002;9(6):565-72. ">Lewanska 2002</a>; <a href="./references#CD011381-bbs2-0036" title="MassacesiL , TramacereI , AmorosoS , BattagliaMA , BenedettiMD , FilippiniG , et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One2014;9(11):e113371. ">MAIN 2014</a>; <a href="./references#CD011381-bbs2-0037" title="MillefioriniE , GasperiniC , PozzilliC , D'AndreaF , BastianelloS , TrojanoM , et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology1997;244(3):153-9. ">Millefiorini 1997</a>; <a href="./references#CD011381-bbs2-0039" title="JacobsL , CookfairD , RudickR , HerndonR , RichertJ , SalazarA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology1996;39:285-94. ">MSCRG 1996</a>; <a href="./references#CD011381-bbs2-0043" title="EbersGC . Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet1998;352(9139):1498-1504. [DOI: 10.1016/S0140-6736(98)03334-0]TraboulseeA , LiDKB , CascioneM , FangJ , DangondF , MillerA . Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. BMC Neurol2018;18(1):143. [DOI: 10.1186/s12883-018-1145-x] [PMID: 30217172]">PRISMS 1998</a>; <a href="./references#CD011381-bbs2-0045" title="MikolD , BarkhofF , ChangP , CoyleP , JefferyD , SchwidS , et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology2008;7(10):903-14. ">REGARD 2008</a>; <a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a>; <a href="./references#CD011381-bbs2-0048" title="MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al, Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler2012;18(11):1625-32. [DOI: 10.1177/1352458512450354] [PMID: 22723573]O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293-303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol2013;260(10):2472-80. [DOI: 10.1007/s00415-013-6979-y] [PMID: 23852658]RadueEW , SprengerT , GaetanoL , Mueller-LenkeN , CavalierS , ThangaveluK , et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm2017;4(5):e390. [DOI: 10.1212/NXI.0000000000000390] [PMID: 28828394]WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013 ;19(10):1310-9. [DOI: 10.1177/1352458513475723] [PMID: 23447359]">TEMSO 2011</a>; <a href="./references#CD011381-bbs2-0049" title="ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(3):247-56. FreedmanMS , MorawskiJ , ThangaveluK . Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. Mult Scler J Exp Transl Clin2018;4(2):2055217318775236. [DOI: 10.1177/2055217318775236] [PMID: 29796289]MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MäurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol2014;261(9):1781-8. [DOI: 10.1007/s00415-014-7395-7] [PMID: 24972678]MillerAE , XuX , MacdonellR , VucicS , TruffinetP , BenamorM , et al. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. J Clin Neurosci2019;59:229-231. [DOI: 10.1016/j.jocn.2018.09.012] [PMID: 30348586]QiuW , HuangDH , HouSF , ZhangMN , JinT , DongHQ , et al, TOWER Trial Chinese Group. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study. Chin Med J (Engl)2018;131(23):2776-2784. [DOI: 10.4103/0366-6999.246067] [PMID: 30511679]">TOWER 2014</a>; <a href="./references#CD011381-bbs2-0050" title="BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler2014;20(13):1704-13. [DOI: 10.1177/1352458514532317] [PMID: 24812043]CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402-15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol2013;260(8):2023-32. [DOI: 10.1007/s00415-013-6932-0] [PMID: 23632946]KhatriBO , PelletierJ , KapposL , HartungHP , ComiG , BarkhofF , et al, TRANSFORMS Study Group. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord2014;3(3):355-63. [DOI: 10.1016/j.msard.2013.11.006] [PMID: 25876473]MengX , ChinPS , HashmonayR , Zahur IslamM , CutterG . Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemp Clin Trials2015;41:69-74. [DOI: 10.1016/j.cct.2014.12.011] [PMID: 25545026]">TRANSFORMS 2010</a>). Three studies that were previously identified as ongoing in <a href="./references#CD011381-bbs2-0264" title="TramacereI , Del GiovaneC , SalantiG , D'AmicoR , FilippiniG . Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD011381. [DOI: 10.1002/14651858.CD011381.pub2]">Tramacere 2015</a> were also included: <a href="./references#CD011381-bbs2-0019" title="BenedictRH , CohanS , LynchSG , RiesterK , WangP , Castro-BorreroW , et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler2018 ;24(6):795-804. [DOI: 0.1177/1352458517707345]KapposL , HavrdovaE , GiovannoniG , KhatriBO , GauthierSA , GreenbergSJ , et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler2017;23(13):1736-1747. [DOI: 10.1177/1352458516683266]KapposL , WiendlH , SelmajK , ArnoldDL , HavrdovaE , BoykoA , et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2015;373(15):1418-28. [DOI: 10.1056/NEJMoa1501481]KruegerJG , KircikL , HougeirF , FriedmanA , YouX , LucasN , et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther2016;33(7):231-45. [DOI: 10.1007/s12325-016-0353-2]LiuY , VollmerT , HavrdovaE , RiesterK , LeeA , PhillipsG , et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;11:18-24. [DOI: 10.1016/j.msard.2016.11.005]NCT01064401. Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01064401 (accessed 30 September 2014). RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40.. [DOI: 10.1016/j.msard.2017.06.006]">DECIDE 2015</a>; <a href="./references#CD011381-bbs2-0040" title="A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01247324 (accessed 30 September 2014). HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , JulianL , KöndgenH , LiC , NapieralskiJ , ZhengH , WolinskyJS . Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , BuffelsR , FioreD , GarrenH , HanJ , HauserSL . Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA I 2017</a>; <a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a>. We also included two studies that were previously excluded in <a href="./references#CD011381-bbs2-0264" title="TramacereI , Del GiovaneC , SalantiG , D'AmicoR , FilippiniG . Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD011381. [DOI: 10.1002/14651858.CD011381.pub2]">Tramacere 2015</a> as we obtained further information and found that they met our pre‐defined inclusion criteria (<a href="./references#CD011381-bbs2-0021" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica2006;113(5):283-7. ">Etemadifar 2006</a>; <a href="./references#CD011381-bbs2-0033" title="KnoblerRL , GreensteinJI , JohnsonKP , LublinFD , PanitchHS , ConwayK , et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. Journal of Interferon Research1993;13(5):333-40. ">Knobler 1993</a>). </p> <p>The updated search identified an additional 11 new studies meeting our inclusion criteria, which were not previously included (<a href="./references#CD011381-bbs2-0005" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS I 2020</a>; <a href="./references#CD011381-bbs2-0006" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS II 2020</a>; <a href="./references#CD011381-bbs2-0007" title="CreeBAC , GoldmanMD , CorboyJR , SingerBA , FoxEJ , ArnoldDL , et al, ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020 ;78(1):1–13. [DOI: 10.1001/jamaneurol.2020.2950] [PMID: 32852530]">ASSESS 2020</a>; <a href="./references#CD011381-bbs2-0015" title="AfolabiD , AlborC , ZalewskiL , AltmannDR , BakerD , SchmiererK . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler2018 ;24(11):1461-1468. [DOI: 10.1177/1352458517726380] [PMID: 28817997]ComiG , CookSD , GiovannoniG , RammohanK , RieckmannP , SørensenPS , et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol2013;260(4):1136-46. [DOI: 10.1007/s00415-012-6775-0] [PMID: 23263473]De StefanoN , GiorgioA , BattagliniM , De LeucioA , HickingC , DangondF , et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018;24(2):222-226. [DOI: 10.1177/1352458517690269] [PMID: 28140753]GiovannoniG , ComiG , CookS , RammohanK , RieckmannP , Soelberg SørensenP , et al, CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):416-26. [DOI: 10.1056/NEJMoa0902533] [PMID: 20089960]GiovannoniG , Soelberg SorensenP , CookS , RammohanKW , RieckmannP , ComiG , et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler2019;25(6):819-827. [DOI: 10.1177/1352458518771875] [PMID: 29716436]HermannR , LitwinJS , FribergLE , DangondF , MunafoA . Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Br J Clin Pharmacol2019 ;85(7):1484-1494. [DOI: 10.1111/bcp.13919] [PMID: 30883839]VermerschP , GalazkaA , DangondF , DamianD , WongSL , JackD , et al. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Curr Med Res Opin2021;37(3):459-464. [DOI: 10.1080/03007995.2020.1865888] [PMID: 33331183]">CLARITY 2010</a>; <a href="./references#CD011381-bbs2-0017" title="ComiG , DadonY , SassonN , SteinermanJR , KnappertzV , VollmerTL , et al. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler2022;28(4):608-619. [DOI: 10.1177/13524585211032803] [PMID: 34378456]NCT01707992. The Efficacy, Safety, and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). https://clinicaltrials.gov/show/NCT017079922012. ">CONCERTO 2021</a>; <a href="./references#CD011381-bbs2-0027" title="GobbiC , MeierDS , CottonF , SintzelM , LeppertD , GuttmannCR , ZeccaC . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol2013;13:101. [DOI: 10.1186/1471-2377-13-101] [PMID: 23915113]ZeccaC , RiccitelliGC , CalabreseP , PravatàE , CandrianU , GuttmannCR , Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol2014;14:38. [DOI: 10.1186/1471-2377-14-38] [PMID: 24576156]">Gobbi 2013</a>; <a href="./references#CD011381-bbs2-0028" title="ComiG , PattiF , RoccaMA , MattioliFC , AmatoMP , GalloP , CentonzeD , PozzilliC , SaccàF , BerghFT , BartezaghiM , TurriniR , FilippiM , Golden Study Group. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol2017;264(12):2436-2449. [DOI: 10.1007/s00415-017-8642-5] [PMID: 29063244]">GOLDEN 2017</a>; <a href="./references#CD011381-bbs2-0038" title="MokhberN , AzarpazhoohA , OroujiE , KhorramB , Modares GharaviM , KakhiS , KhallaghiH , AzarpazhoohMR . Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis. Psychiatry Clin Neurosci.2015;69(10):649-57. [DOI: 10.1111/pcn.12308] [PMID: 25907350]MokhberN , AzarpazhoohA , OroujiE , RaoSM , KhorramB , SahraianMA , ForoghipoorM , GharaviMM , KakhiS , NikkhahK , AzarpazhoohMR . Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. J Neurol Sci2014;342(1-2):16-20. [DOI: 10.1016/j.jns.2014.01.038] [PMID: 24841321]">Mokhber 2014</a>; <a href="./references#CD011381-bbs2-0042" title="KapposL , FoxRJ , BurcklenM , FreedmanMS , HavrdováEK , HennessyB , et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol 2021 May 1;;78(5):558-567. [DOI: 10.1001/jamaneurol.2021.0405] [PMID: 33779698]">OPTIMUM 2021</a>; <a href="./references#CD011381-bbs2-0044" title="CohenJA , ComiG , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019;18(11):1021-1033. [DOI: 10.1016/S1474-4422(19)30238-8] [PMID: 31492652]NCT01628393. Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study). https://clinicaltrials.gov/show/NCT016283932012. ">RADIANCE 2019</a>; <a href="./references#CD011381-bbs2-0047" title="ComiG , KapposL , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology2019 ;18(11):1009-1020. [DOI: 10.1016/S1474-4422(19)30239-X]DeLucaJ , SchipplingS , MontalbanX , KapposL , CreeBAC , ComiG , et al. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Mult Scler Relat Disord2021;48:102673. [DOI: 10.1016/j.msard.2020.102673]NCT02294058. Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS). https://ClinicalTrials.gov/show/NCT022940582014. ">SUNBEAM 2019</a>). </p> <p>Of the 50 included studies, seven studies (<a href="./references#CD011381-bbs2-0005" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS I 2020</a>; <a href="./references#CD011381-bbs2-0006" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS II 2020</a>; <a href="./references#CD011381-bbs2-0008" title="BrownRA , NarayananS , StikovN , CookS , CadavidD , WolanskyL , et al. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. Neurology2016;87(9):905-11. [DOI: 10.1212/WNL.0000000000003043] [PMID: 27473139]CadavidD , WolanskyLJ , SkurnickJ , LincolnJ , CheriyanJ , SzczepanowskiK , et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology2009;72(23):1976-83. CheriyanJ , KimS , WolanskyLJ , CookSD , CadavidD . Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol2012;69(1):82-8. [DOI: 10.1001/archneurol.2011.674]">BECOME 2009</a>; <a href="./references#CD011381-bbs2-0044" title="CohenJA , ComiG , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019;18(11):1021-1033. [DOI: 10.1016/S1474-4422(19)30238-8] [PMID: 31492652]NCT01628393. Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study). https://clinicaltrials.gov/show/NCT016283932012. ">RADIANCE 2019</a>; <a href="./references#CD011381-bbs2-0047" title="ComiG , KapposL , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology2019 ;18(11):1009-1020. [DOI: 10.1016/S1474-4422(19)30239-X]DeLucaJ , SchipplingS , MontalbanX , KapposL , CreeBAC , ComiG , et al. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Mult Scler Relat Disord2021;48:102673. [DOI: 10.1016/j.msard.2020.102673]NCT02294058. Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS). https://ClinicalTrials.gov/show/NCT022940582014. ">SUNBEAM 2019</a>; <a href="./references#CD011381-bbs2-0048" title="MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al, Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler2012;18(11):1625-32. [DOI: 10.1177/1352458512450354] [PMID: 22723573]O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293-303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol2013;260(10):2472-80. [DOI: 10.1007/s00415-013-6979-y] [PMID: 23852658]RadueEW , SprengerT , GaetanoL , Mueller-LenkeN , CavalierS , ThangaveluK , et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm2017;4(5):e390. [DOI: 10.1212/NXI.0000000000000390] [PMID: 28828394]WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013 ;19(10):1310-9. [DOI: 10.1177/1352458513475723] [PMID: 23447359]">TEMSO 2011</a>; <a href="./references#CD011381-bbs2-0049" title="ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(3):247-56. FreedmanMS , MorawskiJ , ThangaveluK . Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. Mult Scler J Exp Transl Clin2018;4(2):2055217318775236. [DOI: 10.1177/2055217318775236] [PMID: 29796289]MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MäurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol2014;261(9):1781-8. [DOI: 10.1007/s00415-014-7395-7] [PMID: 24972678]MillerAE , XuX , MacdonellR , VucicS , TruffinetP , BenamorM , et al. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. J Clin Neurosci2019;59:229-231. [DOI: 10.1016/j.jocn.2018.09.012] [PMID: 30348586]QiuW , HuangDH , HouSF , ZhangMN , JinT , DongHQ , et al, TOWER Trial Chinese Group. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study. Chin Med J (Engl)2018;131(23):2776-2784. [DOI: 10.4103/0366-6999.246067] [PMID: 30511679]">TOWER 2014</a>) included a mixed sample of participants with not only relapsing but also other forms of MS. As per the methods, only those with more than 80% of the sampled population affected by relapsing forms were included in analyses. </p> <p>Median follow‐up was 24 months (including 12‐month follow‐up (11 studies); 18 months (1); 24 months (32), 25 months (1); 30 months (2) and 36 months (4)). Twenty‐five studies were placebo‐controlled and 25 were head‐to‐head studies. Funding came from industry in 40 studies, from public sources in six cases (<a href="./references#CD011381-bbs2-0010" title="BornsteinMB , MillerA , SlagleS , WeitzmanM , Crystal, DrexlerE , et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New England Journal of Medicine1987;317(7):408-14. ">Bornstein 1987</a>; <a href="./references#CD011381-bbs2-0016" title="LublinFD , CofieldSS , CutterGR , ConwitR , NarayanaPA , NelsonF , et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology2013;73(3):327-40. ">CombiRx 2013</a>; <a href="./references#CD011381-bbs2-0027" title="GobbiC , MeierDS , CottonF , SintzelM , LeppertD , GuttmannCR , ZeccaC . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol2013;13:101. [DOI: 10.1186/1471-2377-13-101] [PMID: 23915113]ZeccaC , RiccitelliGC , CalabreseP , PravatàE , CandrianU , GuttmannCR , Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol2014;14:38. [DOI: 10.1186/1471-2377-14-38] [PMID: 24576156]">Gobbi 2013</a>; <a href="./references#CD011381-bbs2-0031" title="DurelliL , VerdunE , BarberoP , BerguiM , VersinoE , GhezziA , et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002;359:1453-60. ">INCOMIN 2002</a>; <a href="./references#CD011381-bbs2-0035" title="LewanskaM , Siger-ZajdelM , SelmajK . No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. European Journal of Neurology2002;9(6):565-72. ">Lewanska 2002</a>; <a href="./references#CD011381-bbs2-0036" title="MassacesiL , TramacereI , AmorosoS , BattagliaMA , BenedettiMD , FilippiniG , et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One2014;9(11):e113371. ">MAIN 2014</a>) and funding sources were not reported in four cases (<a href="./references#CD011381-bbs2-0021" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica2006;113(5):283-7. ">Etemadifar 2006</a>; <a href="./references#CD011381-bbs2-0022" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. Journal of Neurology2007;254(12):1723-8. ">Etemadifar 2007</a>; <a href="./references#CD011381-bbs2-0037" title="MillefioriniE , GasperiniC , PozzilliC , D'AndreaF , BastianelloS , TrojanoM , et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology1997;244(3):153-9. ">Millefiorini 1997</a>; <a href="./references#CD011381-bbs2-0038" title="MokhberN , AzarpazhoohA , OroujiE , KhorramB , Modares GharaviM , KakhiS , KhallaghiH , AzarpazhoohMR . Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis. Psychiatry Clin Neurosci.2015;69(10):649-57. [DOI: 10.1111/pcn.12308] [PMID: 25907350]MokhberN , AzarpazhoohA , OroujiE , RaoSM , KhorramB , SahraianMA , ForoghipoorM , GharaviMM , KakhiS , NikkhahK , AzarpazhoohMR . Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. J Neurol Sci2014;342(1-2):16-20. [DOI: 10.1016/j.jns.2014.01.038] [PMID: 24841321]">Mokhber 2014</a>). </p> <p>Of the 50 included studies, one (<a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a>) included only people with MS previously treated with DMTs; five (<a href="./references#CD011381-bbs2-0009" title="O'ConnorP , FilippiM , ArnasonB , ComiG , CookS , GoodinD , et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology2009;8(10):889-97. SchipplingS , O'ConnorP , KnappertzV , PohlC , BogumilT , SuarezG , et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol2016;263(7):1418-26. [DOI: 10.1007/s00415-016-8146-8]">BEYOND 2009</a>; <a href="./references#CD011381-bbs2-0012" title="CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786-801. FoxEJ , WynnD , ColesAJ , PalmerJ , MargolinDH , CAMMS223 Investigators. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. J Neurol Sci2016;363:188-94. [DOI: 10.1016/j.jns.2016.02.025]">CAMMS223 2008</a>; <a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a>; <a href="./references#CD011381-bbs2-0031" title="DurelliL , VerdunE , BarberoP , BerguiM , VersinoE , GhezziA , et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002;359:1453-60. ">INCOMIN 2002</a>; <a href="./references#CD011381-bbs2-0038" title="MokhberN , AzarpazhoohA , OroujiE , KhorramB , Modares GharaviM , KakhiS , KhallaghiH , AzarpazhoohMR . Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis. Psychiatry Clin Neurosci.2015;69(10):649-57. [DOI: 10.1111/pcn.12308] [PMID: 25907350]MokhberN , AzarpazhoohA , OroujiE , RaoSM , KhorramB , SahraianMA , ForoghipoorM , GharaviMM , KakhiS , NikkhahK , AzarpazhoohMR . Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. J Neurol Sci2014;342(1-2):16-20. [DOI: 10.1016/j.jns.2014.01.038] [PMID: 24841321]">Mokhber 2014</a>) included only people with MS previously untreated with DMTs, 17 (<a href="./references#CD011381-bbs2-0001" title="AchironA , GabbayU , GiladR , HassinB , BarakY , GornishM , et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology1998;50(2):398-402. ">Achiron 1998</a>; <a href="./references#CD011381-bbs2-0003" title="BalcerLJ , GalettaSL , PolmanCH , EggenbergerE , CalabresiPA , ZhangA , et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.. J Neurol Sci2012;318(1-2):119-24. [DOI: 10.1016/j.jns.2012.03.009] [PMID: 22521274]LublinFD , CutterG , GiovannoniG , PaceA , CampbellNR , BelachewS . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.. Mult Scler Relat Disord2014;3(6):705-11. [DOI: 10.1016/j.msard.2014.08.005] [PMID: 25891549]PolmanCH , O'ConnorPW , HavrdovaE , HutchinsonM , KapposL , MillerDH , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):899-910. Weinstock-GuttmanB , GalettaSL , GiovannoniG , HavrdovaE , HutchinsonM , KapposL , et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology2012;259((5)):898-905. [DOI: 10.1007/s00415-011-6275-7] [PMID: 22008873]">AFFIRM 2006</a>; <a href="./references#CD011381-bbs2-0008" title="BrownRA , NarayananS , StikovN , CookS , CadavidD , WolanskyL , et al. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. Neurology2016;87(9):905-11. [DOI: 10.1212/WNL.0000000000003043] [PMID: 27473139]CadavidD , WolanskyLJ , SkurnickJ , LincolnJ , CheriyanJ , SzczepanowskiK , et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology2009;72(23):1976-83. CheriyanJ , KimS , WolanskyLJ , CookSD , CadavidD . Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol2012;69(1):82-8. [DOI: 10.1001/archneurol.2011.674]">BECOME 2009</a>; <a href="./references#CD011381-bbs2-0010" title="BornsteinMB , MillerA , SlagleS , WeitzmanM , Crystal, DrexlerE , et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New England Journal of Medicine1987;317(7):408-14. ">Bornstein 1987</a>; <a href="./references#CD011381-bbs2-0016" title="LublinFD , CofieldSS , CutterGR , ConwitR , NarayanaPA , NelsonF , et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology2013;73(3):327-40. ">CombiRx 2013</a>; <a href="./references#CD011381-bbs2-0021" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica2006;113(5):283-7. ">Etemadifar 2006</a>; <a href="./references#CD011381-bbs2-0022" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. Journal of Neurology2007;254(12):1723-8. ">Etemadifar 2007</a>; <a href="./references#CD011381-bbs2-0023" title="FazekasF , DeisenhammerF , Strasser-FuchsS , NahlerG , MamoliB . Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet1997;349(9052):589-93. ">Fazekas 1997</a>; <a href="./references#CD011381-bbs2-0029" title="GoodkinD , BaillyR , TeetzenM , HertsgaardD , BeattyW . The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology1991;41:20-5. ">Goodkin 1991</a>; <a href="./references#CD011381-bbs2-0030" title="IFNBMSG . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology1993;43(4):655-61. ">IFNB MS Group 1993</a>; <a href="./references#CD011381-bbs2-0032" title="JohnsonK , BrooksB , CohenJ , FordC , GoldsteinJ , LisakR , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology1995;45(7):1268-76. ">Johnson 1995</a>; <a href="./references#CD011381-bbs2-0033" title="KnoblerRL , GreensteinJI , JohnsonKP , LublinFD , PanitchHS , ConwayK , et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. Journal of Interferon Research1993;13(5):333-40. ">Knobler 1993</a>; <a href="./references#CD011381-bbs2-0034" title="Koch-HenriksenN , SørensenP , ChristensenT , FrederiksenJ , RavnborgM , JensenK , et al. A randomised study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology2006;66(7):1056-60. ">Koch‐Henriksen 2006</a>; <a href="./references#CD011381-bbs2-0035" title="LewanskaM , Siger-ZajdelM , SelmajK . No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. European Journal of Neurology2002;9(6):565-72. ">Lewanska 2002</a>; <a href="./references#CD011381-bbs2-0037" title="MillefioriniE , GasperiniC , PozzilliC , D'AndreaF , BastianelloS , TrojanoM , et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology1997;244(3):153-9. ">Millefiorini 1997</a>; <a href="./references#CD011381-bbs2-0039" title="JacobsL , CookfairD , RudickR , HerndonR , RichertJ , SalazarA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology1996;39:285-94. ">MSCRG 1996</a>; <a href="./references#CD011381-bbs2-0045" title="MikolD , BarkhofF , ChangP , CoyleP , JefferyD , SchwidS , et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology2008;7(10):903-14. ">REGARD 2008</a>) did not report data about previous treatments with DMTs, and 27 (<a href="./references#CD011381-bbs2-0002" title="CalabresiPA , KieseierBC , ArnoldDL , BalcerLJ , BoykoA , PelletierJ , et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurology2014;13:657-65. HuX , CuiY , WhiteJ , ZhuY , DeykinA , NestorovI , HungS . Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. British Journal of Clinical Pharmacology2015;79(3):514-22. [DOI: 10.1111/bcp.12521] [PMID: 25265472]ScottTF , KieseierBC , NewsomeSD , ArnoldDL , YouX , HungS , Sperling B. Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis.. Mult Scler J Exp Transl Clin. 2016 ;2:2055217316676644. [DOI: 10.1177/2055217316676644] [PMID: 28607743]">ADVANCE 2014</a>; <a href="./references#CD011381-bbs2-0004" title="ComiG , JefferyD , KapposL , MontalbanX , BoykoA , RoccaMA , et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. New England Journal of Medicine2012;366(11):1000-9. FilippiM , RoccaMA , PaganiE , De StefanoN , JefferyD , KapposL , et al, ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry2014;85(8):851-8. [DOI: 10.1136/jnnp-2013-306132] [PMID: 24029546]">ALLEGRO 2012</a>; <a href="./references#CD011381-bbs2-0005" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS I 2020</a>; <a href="./references#CD011381-bbs2-0006" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS II 2020</a>; <a href="./references#CD011381-bbs2-0007" title="CreeBAC , GoldmanMD , CorboyJR , SingerBA , FoxEJ , ArnoldDL , et al, ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020 ;78(1):1–13. [DOI: 10.1001/jamaneurol.2020.2950] [PMID: 32852530]">ASSESS 2020</a>; <a href="./references#CD011381-bbs2-0011" title="VollmerTL , SorensenPS , SelmajK , ZippF , HavrdovaE , CohenJA , et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology2014;261(4):773-83. ">BRAVO 2014</a>; <a href="./references#CD011381-bbs2-0015" title="AfolabiD , AlborC , ZalewskiL , AltmannDR , BakerD , SchmiererK . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler2018 ;24(11):1461-1468. [DOI: 10.1177/1352458517726380] [PMID: 28817997]ComiG , CookSD , GiovannoniG , RammohanK , RieckmannP , SørensenPS , et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol2013;260(4):1136-46. [DOI: 10.1007/s00415-012-6775-0] [PMID: 23263473]De StefanoN , GiorgioA , BattagliniM , De LeucioA , HickingC , DangondF , et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018;24(2):222-226. [DOI: 10.1177/1352458517690269] [PMID: 28140753]GiovannoniG , ComiG , CookS , RammohanK , RieckmannP , Soelberg SørensenP , et al, CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):416-26. [DOI: 10.1056/NEJMoa0902533] [PMID: 20089960]GiovannoniG , Soelberg SorensenP , CookS , RammohanKW , RieckmannP , ComiG , et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler2019;25(6):819-827. [DOI: 10.1177/1352458518771875] [PMID: 29716436]HermannR , LitwinJS , FribergLE , DangondF , MunafoA . Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Br J Clin Pharmacol2019 ;85(7):1484-1494. [DOI: 10.1111/bcp.13919] [PMID: 30883839]VermerschP , GalazkaA , DangondF , DamianD , WongSL , JackD , et al. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Curr Med Res Opin2021;37(3):459-464. [DOI: 10.1080/03007995.2020.1865888] [PMID: 33331183]">CLARITY 2010</a>; <a href="./references#CD011381-bbs2-0017" title="ComiG , DadonY , SassonN , SteinermanJR , KnappertzV , VollmerTL , et al. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler2022;28(4):608-619. [DOI: 10.1177/13524585211032803] [PMID: 34378456]NCT01707992. The Efficacy, Safety, and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). https://clinicaltrials.gov/show/NCT017079922012. ">CONCERTO 2021</a>; <a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a>; <a href="./references#CD011381-bbs2-0019" title="BenedictRH , CohanS , LynchSG , RiesterK , WangP , Castro-BorreroW , et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler2018 ;24(6):795-804. [DOI: 0.1177/1352458517707345]KapposL , HavrdovaE , GiovannoniG , KhatriBO , GauthierSA , GreenbergSJ , et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler2017;23(13):1736-1747. [DOI: 10.1177/1352458516683266]KapposL , WiendlH , SelmajK , ArnoldDL , HavrdovaE , BoykoA , et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2015;373(15):1418-28. [DOI: 10.1056/NEJMoa1501481]KruegerJG , KircikL , HougeirF , FriedmanA , YouX , LucasN , et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther2016;33(7):231-45. [DOI: 10.1007/s12325-016-0353-2]LiuY , VollmerT , HavrdovaE , RiesterK , LeeA , PhillipsG , et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;11:18-24. [DOI: 10.1016/j.msard.2016.11.005]NCT01064401. Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01064401 (accessed 30 September 2014). RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40.. [DOI: 10.1016/j.msard.2017.06.006]">DECIDE 2015</a>; <a href="./references#CD011381-bbs2-0020" title="ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014;261(9):1794-802. [DOI: 10.1007/s00415-014-7412-x] [PMID: 24989666]ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol2014;261(12):2429-37. [DOI: 10.1007/s00415-014-7504-7] [PMID: 25270680]Bar-OrA , GoldR , KapposL , ArnoldDL , GiovannoniG , SelmajK , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol2013 ;260(9):2297-305. [DOI: 10.1007/s00415-013-6954-7] [PMID: 23797999]Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012] [PMID: 28751099]GoldR , KapposL , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine2012;367(12):1098-107. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272] [PMID: 28328179]KapposL , GoldR , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler2014;20(2):243-52. [DOI: 10.1177/1352458513507817] [PMID: 24150779]">DEFINE 2012</a>; <a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a>; <a href="./references#CD011381-bbs2-0025" title="CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(6):545-56. VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , Freedman MS A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017 3;3:2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS II 2014</a>; <a href="./references#CD011381-bbs2-0026" title='DavisMD , AshtamkerN , SteinermanJR , KnappertzV . Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study. 2017 Neurol Neuroimmunol Neuroinflamm;4(2):e327. [DOI: 10.1212/NXI.0000000000000327] [PMID: 28210662]KhanO , RieckmannP , BoykoA , SelmajK , ZivadinovR , GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Annals of Neurology2013;73(6):705-13. ZivadinovR , DwyerM , BarkayH , SteinermanJR , KnappertzV , Khan O. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis. J Neurol2015;262(3):648-53. [DOI: 10.1007/s00415-014-7616-0] [PMID: 25542295]ZivadinovR , DwyerMG , RamasamyDP , DavisMD , SteinermanJR , KhanO . The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. J Neuroimaging2015;25(6):989-95. [DOI: 10.1111/jon.12293] [PMID: 26394270]'>GALA 2013</a>; <a href="./references#CD011381-bbs2-0027" title="GobbiC , MeierDS , CottonF , SintzelM , LeppertD , GuttmannCR , ZeccaC . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol2013;13:101. [DOI: 10.1186/1471-2377-13-101] [PMID: 23915113]ZeccaC , RiccitelliGC , CalabreseP , PravatàE , CandrianU , GuttmannCR , Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol2014;14:38. [DOI: 10.1186/1471-2377-14-38] [PMID: 24576156]">Gobbi 2013</a>; <a href="./references#CD011381-bbs2-0028" title="ComiG , PattiF , RoccaMA , MattioliFC , AmatoMP , GalloP , CentonzeD , PozzilliC , SaccàF , BerghFT , BartezaghiM , TurriniR , FilippiM , Golden Study Group. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol2017;264(12):2436-2449. [DOI: 10.1007/s00415-017-8642-5] [PMID: 29063244]">GOLDEN 2017</a>; <a href="./references#CD011381-bbs2-0036" title="MassacesiL , TramacereI , AmorosoS , BattagliaMA , BenedettiMD , FilippiniG , et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One2014;9(11):e113371. ">MAIN 2014</a>; <a href="./references#CD011381-bbs2-0040" title="A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01247324 (accessed 30 September 2014). HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , JulianL , KöndgenH , LiC , NapieralskiJ , ZhengH , WolinskyJS . Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , BuffelsR , FioreD , GarrenH , HanJ , HauserSL . Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA I 2017</a>; <a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a>; <a href="./references#CD011381-bbs2-0042" title="KapposL , FoxRJ , BurcklenM , FreedmanMS , HavrdováEK , HennessyB , et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol 2021 May 1;;78(5):558-567. [DOI: 10.1001/jamaneurol.2021.0405] [PMID: 33779698]">OPTIMUM 2021</a>; <a href="./references#CD011381-bbs2-0043" title="EbersGC . Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet1998;352(9139):1498-1504. [DOI: 10.1016/S0140-6736(98)03334-0]TraboulseeA , LiDKB , CascioneM , FangJ , DangondF , MillerA . Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. BMC Neurol2018;18(1):143. [DOI: 10.1186/s12883-018-1145-x] [PMID: 30217172]">PRISMS 1998</a>; <a href="./references#CD011381-bbs2-0044" title="CohenJA , ComiG , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019;18(11):1021-1033. [DOI: 10.1016/S1474-4422(19)30238-8] [PMID: 31492652]NCT01628393. Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study). https://clinicaltrials.gov/show/NCT016283932012. ">RADIANCE 2019</a>; <a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a>; <a href="./references#CD011381-bbs2-0047" title="ComiG , KapposL , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology2019 ;18(11):1009-1020. [DOI: 10.1016/S1474-4422(19)30239-X]DeLucaJ , SchipplingS , MontalbanX , KapposL , CreeBAC , ComiG , et al. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Mult Scler Relat Disord2021;48:102673. [DOI: 10.1016/j.msard.2020.102673]NCT02294058. Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS). https://ClinicalTrials.gov/show/NCT022940582014. ">SUNBEAM 2019</a>; <a href="./references#CD011381-bbs2-0048" title="MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al, Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler2012;18(11):1625-32. [DOI: 10.1177/1352458512450354] [PMID: 22723573]O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293-303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol2013;260(10):2472-80. [DOI: 10.1007/s00415-013-6979-y] [PMID: 23852658]RadueEW , SprengerT , GaetanoL , Mueller-LenkeN , CavalierS , ThangaveluK , et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm2017;4(5):e390. [DOI: 10.1212/NXI.0000000000000390] [PMID: 28828394]WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013 ;19(10):1310-9. [DOI: 10.1177/1352458513475723] [PMID: 23447359]">TEMSO 2011</a>; <a href="./references#CD011381-bbs2-0049" title="ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(3):247-56. FreedmanMS , MorawskiJ , ThangaveluK . Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. Mult Scler J Exp Transl Clin2018;4(2):2055217318775236. [DOI: 10.1177/2055217318775236] [PMID: 29796289]MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MäurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol2014;261(9):1781-8. [DOI: 10.1007/s00415-014-7395-7] [PMID: 24972678]MillerAE , XuX , MacdonellR , VucicS , TruffinetP , BenamorM , et al. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. J Clin Neurosci2019;59:229-231. [DOI: 10.1016/j.jocn.2018.09.012] [PMID: 30348586]QiuW , HuangDH , HouSF , ZhangMN , JinT , DongHQ , et al, TOWER Trial Chinese Group. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study. Chin Med J (Engl)2018;131(23):2776-2784. [DOI: 10.4103/0366-6999.246067] [PMID: 30511679]">TOWER 2014</a>; <a href="./references#CD011381-bbs2-0050" title="BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler2014;20(13):1704-13. [DOI: 10.1177/1352458514532317] [PMID: 24812043]CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402-15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol2013;260(8):2023-32. [DOI: 10.1007/s00415-013-6932-0] [PMID: 23632946]KhatriBO , PelletierJ , KapposL , HartungHP , ComiG , BarkhofF , et al, TRANSFORMS Study Group. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord2014;3(3):355-63. [DOI: 10.1016/j.msard.2013.11.006] [PMID: 25876473]MengX , ChinPS , HashmonayR , Zahur IslamM , CutterG . Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemp Clin Trials2015;41:69-74. [DOI: 10.1016/j.cct.2014.12.011] [PMID: 25545026]">TRANSFORMS 2010</a>) included a mixed population of patients with and without previous treatment with DMTs, but did not report separate outcome data for the two subgroups. </p> <p>The table, <a href="./references#CD011381-sec-0141" title="">Characteristics of included studies</a>, provides details of the included studies. <a href="#CD011381-tbl-0007">Table 1</a> provides the characteristics associated with the monitoring and reporting of adverse events, considering specific factors. </p> <p>We identified 21 ongoing trials (<a href="./references#CD011381-bbs2-0108" title="EUCTR2013-003884-71-BE, Genzyme Corporation Yes. Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409. https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-003884-71-BE2014. ">EUCTR2013‐003884‐71‐BE</a>; <a href="./references#CD011381-bbs2-0106" title="Euctr SK . A clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: first part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug). http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012-003647-30-SK2014. ">EUCTR2012‐003647‐30‐SK</a>; <a href="./references#CD011381-bbs2-0109" title="EUCTR2014-001012-19-NL, Yes V U University Medical Center. Effects of fingolimod on advanced brain measures and clinical measures in multiple sclerosis. https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2014-001012-19-NL2014. ">EUCTR2014‐001012‐19‐NL</a>; <a href="./references#CD011381-bbs2-0105" title="Euctr PL . International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012-000540-10-PL2015. ">EUCTR2012‐000540‐10‐PL</a>;<a href="./references#CD011381-bbs2-0110" title="EUCTR2018-000284-93-BG, Mapi Pharma Ltd Yes. A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000284-932019. ">EUCTR2018‐000284‐93‐BG</a>; <a href="./references#CD011381-bbs2-0112" title="Euctr NO . A Clinical Study Comparing Rituximab and Cladribine for Relapsing Multiple Sclerosis. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2019-001505-24-NO2019. ">EUCTR2019‐001505‐24‐NO</a>; <a href="./references#CD011381-bbs2-0113" title="Euctr DK . Non-inferiority study of ocrelizumab and rituximab in active multiple sclerosis. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-002981-15-DK2020. ">EUCTR2020‐002981‐15‐DK</a>; <a href="./references#CD011381-bbs2-0111" title="Euctr GB . A phase 2b study of Cladribine to halt deterioration in people with advanced multiple sclerosis. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-005038-39-GB2020. ">EUCTR2018‐005038‐39‐GB</a>; <a href="./references#CD011381-bbs2-0114" title="Irct20130812014333N. Comparison of effectiveness and complication of rituximab and fingolimod in improvement disability motion. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20130812014333N1252019. ">IRCT20130812014333N</a>; <a href="./references#CD011381-bbs2-0115" title="Irct201404195280N. The therapeutic effect of Avonex, Rebif and Betaferon on disability and quality of life in multiple sclerosis: a Randomized Clinical Trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201404195280N162014. ">IRCT201404195280N</a>; <a href="./references#CD011381-bbs2-0120" title="Nct. A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS. https://clinicaltrials.gov/show/NCT041212212019. ">NCT04121221</a>; <a href="./references#CD011381-bbs2-0119" title="Nct. Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis. https://clinicaltrials.gov/show/NCT040568972019. ">NCT04056897</a>; <a href="./references#CD011381-bbs2-0121" title="Nct. Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS). https://clinicaltrials.gov/show/NCT041214032019. ">NCT04121403</a>; <a href="./references#CD011381-bbs2-0123" title="Nct. Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis. https://clinicaltrials.gov/show/NCT046887882020. ">NCT04688788</a>; <a href="./references#CD011381-bbs2-0122" title="Nct. Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease. https://clinicaltrials.gov/show/NCT045786392020. ">NCT04578639</a>; <a href="./references#CD011381-bbs2-0124" title="Study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/03/0025192012. ">WHO‐ICTRP 002519</a>; <a href="./references#CD011381-bbs2-0125" title="Per. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of ocrelizumab in comparison to interferon beta-1a (rebif®) in patients with relapsing multiple sclerosis. http://www.who.int/trialsearch/Trial2.aspx?TrialID=PER-024-142014. ">WHO‐ICTRP PER‐024‐14</a>). Of these, four studies have been withdrawn, and results are unlikely to be available (<a href="./references#CD011381-bbs2-0107" title="Euctr SE . A clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared to Interferon ß-1a (Avonex, authorised drug) administered once weekly. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-002082-19-SE2013. ">EUCTR2013‐002082‐19‐SE</a>; <a href="./references#CD011381-bbs2-0116" title="Industries Teva Pharmaceutical. A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability. https://ClinicalTrials.gov/show/NCT014041172012. ">NCT01404117</a>; <a href="./references#CD011381-bbs2-0118" title="NCT01975298. A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS). https://clinicaltrials.gov/show/NCT019752982013. ">NCT01975298</a>; <a href="./references#CD011381-bbs2-0117" title="Nct. Safety and Efficacy of Fingolimod in MS Patients in China. https://clinicaltrials.gov/show/NCT019410042013. ">NCT01941004</a>). The remaining 17 studies will be assessed and included, where appropriate, in a future update of this review. Please see <a href="./references#CD011381-sec-0144" title="">Characteristics of ongoing studies</a> for further details. </p> </section> <section id="CD011381-sec-0059"> <h4 class="title">Excluded studies</h4> <p>After full‐text review, we excluded 41 studies with reasons (see <a href="./references#CD011381-sec-0142" title="">Characteristics of excluded studies</a>): </p> <p>Fifteen were excluded where the randomised, blinded portion of the trial was less than one year (<a href="./references#CD011381-bbs2-0055" title="Bar-OrA , GroveRA , AustinDJ , TolsonJM , VanMeterSA , LewisEW , DerosierFJ , LopezMC , KavanaghST , MillerAE , Sorensen PS. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.. Neurology.2018 ;90(20):e1805-e1814. [DOI: 10.1212/WNL.0000000000005516]">Bar‐Or 2017</a>; <a href="./references#CD011381-bbs2-0057" title="BoykoAN , LashchNY , SharanovaSN , ZakharovaMN , TrifonovaOV , SimanivTO , LysogorskayaEV , GuryanovaOE , KotovSV , IakushinaTI , LizhdvoyVY , BelovaYA , KhabirovFA , BabichevaNN , KhaibullinTI , GranatovEV , AveryanovaLA , SazonovDV , OdinakMM , TrinitatskyYV , TsukurovaLA , SergeevaAI , IvanovRA , Shustova MS. [Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study] [Sravnitel'noe platsebo-kontroliruemoe klinicheskoe issledovanie effektivnosti i bezopasnosti preparatov glatiramera atsetata 20 mg u patsientov s remittiruyushchim rasseyannym sklerozom: rezul'taty pervogo goda nablyudeniya]. Zh Nevrol Psikhiatr Im S S Korsakova.2016;116(10 Pt 2):61-67. [DOI: 10.17116/jnevro201611610261-67]">Boyko 2016</a>; <a href="./references#CD011381-bbs2-0062" title="CohenJ , BelovaA , SelmajK , WolfC , SormaniMP , OberyéJ , vanden TweelE , MulderR , KoperN , VoortmanG , BarkhofF , Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE) Study Group. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.. JAMA Neurol2015;72(12):1433-41. [DOI: 10.1001/jamaneurol.2015.2154]">Cohen 2015</a>; <a href="./references#CD011381-bbs2-0063" title="CohenJA , ArnoldDL , ComiG , Bar-OrA , GujrathiS , HartungJP , CravetsM , OlsonA , FrohnaPA , SelmajKW , RADIANCE Study Group. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.. Lancet Neurol.2016 ;15(4):373-81. [DOI: 10.1016/S1474-4422(16)00018-1]">Cohen 2016</a>; <a href="./references#CD011381-bbs2-0064" title="ComiG , FilippiM , WolinskyJS . European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Annals of Neurology2001;49(3):290-7. [PMID: 11261502]">Comi 2001</a>; <a href="./references#CD011381-bbs2-0068" title="FazekasF , LublinF , LiD , FreedmanM , HartungH , RieckmannP , et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology2008;71(4):265-71. ">Fazekas 2008</a>; <a href="./references#CD011381-bbs2-0074" title="De StefanoN , CurtinF , StubinskiB , et al. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing—remitting multiple sclerosis.. Multiple Sclerosis Journal. 2010;16(7):888-892. [DOI: 10.1177/1352458510362442]De StefanoN , SormaniMP , StubinskiB , BlevinsG , DrulovicJS , IssardD , ShotekovP , Gasperini C. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.. J Neurol Sci. 2012;312((1-2)):97-101. [DOI: 10.1016/j.jns.2011.08.013] [PMID: 21880336]GiorgioA , BattagliniM , GentileG , StromilloML , GasperiniC , ViscontiA , Paolillo A and De Stefano N. Mapping the ProgressiveTreatment-Related Reduction ofActive MRI Lesions in MultipleSclerosis.. Front. Neurol2020;11:585296. [DOI: 10.3389/fneur.2020.585296]">IMPROVE 2010</a>; <a href="./references#CD011381-bbs2-0080" title="Le PageE , VeillardD , LaplaudDA , HamonicS , WardiR , LebrunC , ZagnoliF , WiertlewskiS , DeburghgraeveV , CoustansM , EdanG , COPOUSEP investigators, West Network for Excellence in Neuroscience. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.. Lancet.2015;386(9997):974-81. [DOI: 10.1016/S0140-6736(15)61137-0]">Le Page 2015</a>; <a href="./references#CD011381-bbs2-0082" title="NewsomeSD , GuoS , AltincatalA , ProskorovskyI , KinterE , PhillipsG , YouX , Sabatella G. Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis. Mult Scler Relat Disord.2015;4(4):446-51. [DOI: 10.1111/cns.12235]">Newsome 2015</a>; <a href="./references#CD011381-bbs2-0083" title="OchiH , NiinoM , OnizukaY , HiramatsuK , HaseM , YunJ , MattaA , Torii S. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.. Adv Ther.2018 ;35(10):1598-1611. [DOI: 10.1007/s12325-018-0788-8]">Ochi 2018</a>; <a href="./references#CD011381-bbs2-0084" title="OWIMS. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology1999;53(4):679-86. ">OWIMS 1999</a>; <a href="./references#CD011381-bbs2-0086" title="SaidaT , KiraJI , KishidaS , YamamuraT , OhtsukaN , DongQ , Tibung JT. Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis.. Neurol Ther.2017;6(1):153-159. [DOI: 10.1007/s40120-016-0062-4]">Saida 2017</a>; <a href="./references#CD011381-bbs2-0088" title="Simaniv, TO , Zakharova, MN , Boyko, AN , Lashch, NYu, Kotov, SV , Khabirov, FA , Khaibullin, TI , Sazonov, DV , Yarmoschuk, AV , Babenko, LA , et al. SAFETY ASPECTS WITHOUT LOSS OF EFFECTIVENESS IN THE SWITCH OF PATIENTS WITH MULTIPLE SCLEROSIS FROM THE ORIGINAL DRUG GLATIRAMER ACETATE COPAXONE-TEVA ON THE BIOSIMILAR TIMEXON. Russian neurological Journal2019;0(4):44-51. [DOI: http://dx.doi.org/10.30629/2658-7947-2019-24-4-44-51]">Simaniv 2019</a>; <a href="./references#CD011381-bbs2-0090" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2014;20(6):705-16. ">TENERE 2014</a>; <a href="./references#CD011381-bbs2-0091" title="ZiemssenT , TumaniH , SehrT , ThomasK , PaulF , RichterN , SamaraE , SpiegelsteinO , SoraniE , Bar-IlanO , MimrodD , HayardenyL . Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. J Neuroinflammation.2017 ;31(14(1)):172. [DOI: 10.1186/s12974-017-0945-z]">Ziemssen 2017</a>); one study was non‐randomised (<a href="./references#CD011381-bbs2-0056" title="BoikoAN , BosenkoLP , VasilovskiiVV , VolkovaLI , ZakharovaMN , KotovSV , LekomtsevaEV , NegrichTI , ParshinaEV , PatrushevaOP , ProkopenkoSV , SazonovDV , TimchenkoPV , TrinitatskiiYV , KhabirovFA , KhavunkaMY , ChichanovskayaLV , ShermanMA , Lin'kovaYN , Zinkina‐OrikhanAV , TursunovaKB . A Comparative Placebo-Controlled Clinical Trial of the Efficacy and Safety of Interferon β-1a Formulations for S.C. Administration in Patients with Remitting Multiple Sclerosis: first-Year Results. Neuroscience and behavioral physiology2018;48(7):883‐889. ">Boiko 2018</a>); one was a pooled post hoc analysis (<a href="./references#CD011381-bbs2-0052" title="AgiusM , MengX , ChinP , GrinspanA , Hashmonay R. Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom.. CNS Neurosci Ther2014;20(5):446-51. [DOI: 10.1111/cns.12235] [PMID: 24684973]">Agius 2014</a>) and five used a comparator that was not admissible under our inclusion criteria (<a href="./references#CD011381-bbs2-0060" title="CascioneM , TenenbaumN , WendtJ , MengX , SchofieldL , CreeBAC , PREFERMS investigators. Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.. Mult Scler Relat Disord.2018 ;25:50-56. [DOI: 10.1016/j.msard.2018.07.014]">Cascione 2018</a>; <a href="./references#CD011381-bbs2-0065" title="Patricia K Coyle, Anthony T Reder, Mark S Freedman, Juanzhi Fang, Fernando Dangond. Early MRI results and odds of attaining ‘no evidence of disease activity’ status in MS patients treated with interferon β-1a in the EVIDENCE study. Journal of the Neurological Sciences2017;379:151-156. [DOI: 10.1016/j.jns.2017.05.052]">Coyle 2017</a>; <a href="./references#CD011381-bbs2-0066" title="CreeBAC , ArnoldDL , CascioneM , FoxEJ , WilliamsIM , MengX , SchofieldL , Tenenbaum N. Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial.. Ther Adv Neurol Disord.2018;11:756286418774338. [DOI: 10.1177/1756286418774338]">Cree 2018</a>; <a href="./references#CD011381-bbs2-0070" title="FoxE , EdwardsK , BurchG , WynnDR , LaGankeC , CraytonH , HunterSF , HuffmanC , KimE , PestreichL , McCagueK , BarbatoL , EPOC study investigators. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple sclerosis and related disorders2014;3(5):607‐619. ">Fox 2014</a>; <a href="./references#CD011381-bbs2-0079" title="LamplC , NaglS , ArnasonB , ComiG , O ConnorP , CookS , JefferyD , KapposL , FilippiM , BeckmannK , BogumilT , PohlC , SandbrinkR , HartungHP . Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study. J Neurol2013;260(7):1838-45. [DOI: 10.1007/s00415-013-6888-0]">Lampl 2013</a>). </p> <p>Studies excluded at full‐text review included five that were previously included in <a href="./references#CD011381-bbs2-0264" title="TramacereI , Del GiovaneC , SalantiG , D'AmicoR , FilippiniG . Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD011381. [DOI: 10.1002/14651858.CD011381.pub2]">Tramacere 2015</a> for insufficient follow‐up duration (<a href="./references#CD011381-bbs2-0064" title="ComiG , FilippiM , WolinskyJS . European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Annals of Neurology2001;49(3):290-7. [PMID: 11261502]">Comi 2001</a>; <a href="./references#CD011381-bbs2-0068" title="FazekasF , LublinF , LiD , FreedmanM , HartungH , RieckmannP , et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology2008;71(4):265-71. ">Fazekas 2008</a>; <a href="./references#CD011381-bbs2-0084" title="OWIMS. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology1999;53(4):679-86. ">OWIMS 1999</a>; <a href="./references#CD011381-bbs2-0090" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2014;20(6):705-16. ">TENERE 2014</a>) and incorrect comparator (<a href="./references#CD011381-bbs2-0067" title="SchwidS , PanitchH . Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clinical Therapeutics2007;29(9):2031-48. ">EVIDENCE 2007</a>), as well as four included in <a href="./references#CD011381-bbs2-0190" title="FilippiniG , Del GiovaneC , VacchiL , D’AmicoR , Di PietrantonjC , BeecherD , et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD008933. [DOI: 10.1002/14651858.CD008933]">Filippini 2013</a> for wrong intervention (<a href="./references#CD011381-bbs2-0087" title="RudickRA , StuartWH , CalabresiPA , ConfavreuxC , GalettaSL , RadueEW , et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):911-23. ">SENTINEL 2006</a>), wrong publication type (<a href="./references#CD011381-bbs2-0072" title="GhezziA , Di FalcoM , Locatelli C In: Consette RE, Delmotte P editor(s). Clinical controlled randomized trial of azathioprine in multiple sclerosis. Elsevier1989. ">Ghezzi 1989</a>) and mixed populations where &lt; 80% were people with relapsing MS (<a href="./references#CD011381-bbs2-0058" title="The British, Dutch MSATG. Double-masked trial of azathioprine in multiple sclerosis. Lancet1988;Vol. 2(8604):179–83. ">British and Dutch 1988</a>; <a href="./references#CD011381-bbs2-0081" title="MilaneseC , La MantiaL , SalmaggiA , Eoli M. A double blind study on azathioprine efficacy in multiple sclerosis: final report.. Journal of Neurology1993;240(5):295–8. ">Milanese 1993</a>). </p> <p>The previous version of this review excluded the following studies: six studies for insufficient duration (<a href="./references#CD011381-bbs2-0061" title="WynnD , KaufmanM , MontalbanX , VollmerT , SimonJ , ElkinsJ , et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurology2010;9(4):381-90. ">CHOICE 2010</a>; <a href="./references#CD011381-bbs2-0075" title="KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New Egyptian Journal of Medicine2006;355(11):1124-40. ">Kappos 2006</a>; <a href="./references#CD011381-bbs2-0076" title="KapposL , GoldR , MillerDH , MacmanusDG , HavrdovaE , LimmrothV , et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet2008;372(9648):1463-72. ">Kappos 2008</a>; <a href="./references#CD011381-bbs2-0077" title="KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ">Kappos 2011</a>; <a href="./references#CD011381-bbs2-0085" title="SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(9):1269-77. ">Saida 2012</a>; <a href="./references#CD011381-bbs2-0089" title="SorensenPS , LisbyS , GroveR , DerosierF , ShackelfordS , HavrdovaE , et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology2014;82(7):573-81. ">Sorensen 2014</a>), five studies evaluating combination therapies (<a href="./references#CD011381-bbs2-0051" title="CohenJA , ImreyPB , CalabresiPA , EdwardsKR , EickenhorstT , Felton WL 3rd, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology2009;72(6):535-41. ">ACT 2009</a>; <a href="./references#CD011381-bbs2-0071" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Neurology2012;78(23):1877-85. ">Freedman 2012</a>; <a href="./references#CD011381-bbs2-0073" title="HavrdovaE , ZivadinovR , KrasenskyJ , DwyerMG , NovakovaI , DolezalO , et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England)2009;15(8):965-76. ">Havrdova 2009</a>; <a href="./references#CD011381-bbs2-0078" title="KhourySJ , HealyBC , KivisäkkP , VigliettaV , EgorovaS , GuttmannCR , et al. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Archives of Neurology2010;67(9):1055-61. ">Khoury 2010</a>; <a href="./references#CD011381-bbs2-0087" title="RudickRA , StuartWH , CalabresiPA , ConfavreuxC , GalettaSL , RadueEW , et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):911-23. ">SENTINEL 2006</a>), two studies evaluating treatments that are not included in this review (<a href="./references#CD011381-bbs2-0053" title="AshtariF , SavojMR . Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: a randomized controlled trial. Journal of Research in Medical Sciences2011;16(4):457-62. ">Ashtari 2011</a>; <a href="./references#CD011381-bbs2-0054" title="KapposL , HartungHP , FreedmanMS , BoykoA , RadüEW , MikolDD , et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurology2014;13(4):353-63. ">ATAMS 2014</a>), a study that was non‐randomised (<a href="./references#CD011381-bbs2-0059" title="CalabreseM , BernardiV , AtzoriM , MattisiI , FavarettoA , RinaldiF , et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(4):418-24. ">Calabrese 2012</a>), and one dose‐finding study without a control group (<a href="./references#CD011381-bbs2-0069" title="ComiG , CohenJA , ArnoldDL , WynnD , FilippiM , FORTE Study Group. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Annals of Neurology2011;69(1):75-82. ">FORTE 2011</a>). <a href="./references#CD011381-bbs2-0021" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica2006;113(5):283-7. ">Etemadifar 2006</a> and <a href="./references#CD011381-bbs2-0033" title="KnoblerRL , GreensteinJI , JohnsonKP , LublinFD , PanitchHS , ConwayK , et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. Journal of Interferon Research1993;13(5):333-40. ">Knobler 1993</a> were included in this version of the review, though they were excluded in the previous version. </p> </section> </section> <section id="CD011381-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>The risks of bias in the included studies for individual domains are summarised in <a href="#CD011381-fig-0002">Figure 2</a> and <a href="#CD011381-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD011381-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011381-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011381-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011381-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011381-sec-0061"> <h4 class="title">Allocation</h4> <section id="CD011381-sec-0062"> <h5 class="title">Sequence generation</h5> <p>Ten studies (20%) did not provide enough information to assess sequence generation (unclear risk) (<a href="./references#CD011381-bbs2-0010" title="BornsteinMB , MillerA , SlagleS , WeitzmanM , Crystal, DrexlerE , et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New England Journal of Medicine1987;317(7):408-14. ">Bornstein 1987</a>; <a href="./references#CD011381-bbs2-0017" title="ComiG , DadonY , SassonN , SteinermanJR , KnappertzV , VollmerTL , et al. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler2022;28(4):608-619. [DOI: 10.1177/13524585211032803] [PMID: 34378456]NCT01707992. The Efficacy, Safety, and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). https://clinicaltrials.gov/show/NCT017079922012. ">CONCERTO 2021</a>; <a href="./references#CD011381-bbs2-0021" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica2006;113(5):283-7. ">Etemadifar 2006</a>; <a href="./references#CD011381-bbs2-0027" title="GobbiC , MeierDS , CottonF , SintzelM , LeppertD , GuttmannCR , ZeccaC . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol2013;13:101. [DOI: 10.1186/1471-2377-13-101] [PMID: 23915113]ZeccaC , RiccitelliGC , CalabreseP , PravatàE , CandrianU , GuttmannCR , Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol2014;14:38. [DOI: 10.1186/1471-2377-14-38] [PMID: 24576156]">Gobbi 2013</a>; <a href="./references#CD011381-bbs2-0028" title="ComiG , PattiF , RoccaMA , MattioliFC , AmatoMP , GalloP , CentonzeD , PozzilliC , SaccàF , BerghFT , BartezaghiM , TurriniR , FilippiM , Golden Study Group. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol2017;264(12):2436-2449. [DOI: 10.1007/s00415-017-8642-5] [PMID: 29063244]">GOLDEN 2017</a>; <a href="./references#CD011381-bbs2-0030" title="IFNBMSG . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology1993;43(4):655-61. ">IFNB MS Group 1993</a>; <a href="./references#CD011381-bbs2-0032" title="JohnsonK , BrooksB , CohenJ , FordC , GoldsteinJ , LisakR , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology1995;45(7):1268-76. ">Johnson 1995</a>; <a href="./references#CD011381-bbs2-0033" title="KnoblerRL , GreensteinJI , JohnsonKP , LublinFD , PanitchHS , ConwayK , et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. Journal of Interferon Research1993;13(5):333-40. ">Knobler 1993</a>; <a href="./references#CD011381-bbs2-0039" title="JacobsL , CookfairD , RudickR , HerndonR , RichertJ , SalazarA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology1996;39:285-94. ">MSCRG 1996</a>; <a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a>), and the remaining 40 (80%) reported adequate methods (low risk). </p> </section> <section id="CD011381-sec-0063"> <h5 class="title">Allocation concealment</h5> <p>One trial (2%) used an unconcealed procedure (high risk) (<a href="./references#CD011381-bbs2-0010" title="BornsteinMB , MillerA , SlagleS , WeitzmanM , Crystal, DrexlerE , et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New England Journal of Medicine1987;317(7):408-14. ">Bornstein 1987</a>). Twenty‐one (42%) did not provide sufficient information to enable a risk of bias judgement (unclear risk) (<a href="./references#CD011381-bbs2-0001" title="AchironA , GabbayU , GiladR , HassinB , BarakY , GornishM , et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology1998;50(2):398-402. ">Achiron 1998</a>; <a href="./references#CD011381-bbs2-0008" title="BrownRA , NarayananS , StikovN , CookS , CadavidD , WolanskyL , et al. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. Neurology2016;87(9):905-11. [DOI: 10.1212/WNL.0000000000003043] [PMID: 27473139]CadavidD , WolanskyLJ , SkurnickJ , LincolnJ , CheriyanJ , SzczepanowskiK , et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology2009;72(23):1976-83. CheriyanJ , KimS , WolanskyLJ , CookSD , CadavidD . Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol2012;69(1):82-8. [DOI: 10.1001/archneurol.2011.674]">BECOME 2009</a>; <a href="./references#CD011381-bbs2-0009" title="O'ConnorP , FilippiM , ArnasonB , ComiG , CookS , GoodinD , et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology2009;8(10):889-97. SchipplingS , O'ConnorP , KnappertzV , PohlC , BogumilT , SuarezG , et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol2016;263(7):1418-26. [DOI: 10.1007/s00415-016-8146-8]">BEYOND 2009</a>; <a href="./references#CD011381-bbs2-0011" title="VollmerTL , SorensenPS , SelmajK , ZippF , HavrdovaE , CohenJA , et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology2014;261(4):773-83. ">BRAVO 2014</a>; <a href="./references#CD011381-bbs2-0015" title="AfolabiD , AlborC , ZalewskiL , AltmannDR , BakerD , SchmiererK . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler2018 ;24(11):1461-1468. [DOI: 10.1177/1352458517726380] [PMID: 28817997]ComiG , CookSD , GiovannoniG , RammohanK , RieckmannP , SørensenPS , et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol2013;260(4):1136-46. [DOI: 10.1007/s00415-012-6775-0] [PMID: 23263473]De StefanoN , GiorgioA , BattagliniM , De LeucioA , HickingC , DangondF , et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018;24(2):222-226. [DOI: 10.1177/1352458517690269] [PMID: 28140753]GiovannoniG , ComiG , CookS , RammohanK , RieckmannP , Soelberg SørensenP , et al, CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):416-26. [DOI: 10.1056/NEJMoa0902533] [PMID: 20089960]GiovannoniG , Soelberg SorensenP , CookS , RammohanKW , RieckmannP , ComiG , et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler2019;25(6):819-827. [DOI: 10.1177/1352458518771875] [PMID: 29716436]HermannR , LitwinJS , FribergLE , DangondF , MunafoA . Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Br J Clin Pharmacol2019 ;85(7):1484-1494. [DOI: 10.1111/bcp.13919] [PMID: 30883839]VermerschP , GalazkaA , DangondF , DamianD , WongSL , JackD , et al. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Curr Med Res Opin2021;37(3):459-464. [DOI: 10.1080/03007995.2020.1865888] [PMID: 33331183]">CLARITY 2010</a>; <a href="./references#CD011381-bbs2-0017" title="ComiG , DadonY , SassonN , SteinermanJR , KnappertzV , VollmerTL , et al. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler2022;28(4):608-619. [DOI: 10.1177/13524585211032803] [PMID: 34378456]NCT01707992. The Efficacy, Safety, and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). https://clinicaltrials.gov/show/NCT017079922012. ">CONCERTO 2021</a>; <a href="./references#CD011381-bbs2-0021" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica2006;113(5):283-7. ">Etemadifar 2006</a>; <a href="./references#CD011381-bbs2-0022" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. Journal of Neurology2007;254(12):1723-8. ">Etemadifar 2007</a>; <a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a>; <a href="./references#CD011381-bbs2-0025" title="CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(6):545-56. VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , Freedman MS A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017 3;3:2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS II 2014</a>; <a href="./references#CD011381-bbs2-0026" title='DavisMD , AshtamkerN , SteinermanJR , KnappertzV . Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study. 2017 Neurol Neuroimmunol Neuroinflamm;4(2):e327. [DOI: 10.1212/NXI.0000000000000327] [PMID: 28210662]KhanO , RieckmannP , BoykoA , SelmajK , ZivadinovR , GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Annals of Neurology2013;73(6):705-13. ZivadinovR , DwyerM , BarkayH , SteinermanJR , KnappertzV , Khan O. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis. J Neurol2015;262(3):648-53. [DOI: 10.1007/s00415-014-7616-0] [PMID: 25542295]ZivadinovR , DwyerMG , RamasamyDP , DavisMD , SteinermanJR , KhanO . The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. J Neuroimaging2015;25(6):989-95. [DOI: 10.1111/jon.12293] [PMID: 26394270]'>GALA 2013</a>; <a href="./references#CD011381-bbs2-0027" title="GobbiC , MeierDS , CottonF , SintzelM , LeppertD , GuttmannCR , ZeccaC . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol2013;13:101. [DOI: 10.1186/1471-2377-13-101] [PMID: 23915113]ZeccaC , RiccitelliGC , CalabreseP , PravatàE , CandrianU , GuttmannCR , Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol2014;14:38. [DOI: 10.1186/1471-2377-14-38] [PMID: 24576156]">Gobbi 2013</a>; <a href="./references#CD011381-bbs2-0028" title="ComiG , PattiF , RoccaMA , MattioliFC , AmatoMP , GalloP , CentonzeD , PozzilliC , SaccàF , BerghFT , BartezaghiM , TurriniR , FilippiM , Golden Study Group. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol2017;264(12):2436-2449. [DOI: 10.1007/s00415-017-8642-5] [PMID: 29063244]">GOLDEN 2017</a>; <a href="./references#CD011381-bbs2-0029" title="GoodkinD , BaillyR , TeetzenM , HertsgaardD , BeattyW . The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology1991;41:20-5. ">Goodkin 1991</a>; <a href="./references#CD011381-bbs2-0030" title="IFNBMSG . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology1993;43(4):655-61. ">IFNB MS Group 1993</a>; <a href="./references#CD011381-bbs2-0032" title="JohnsonK , BrooksB , CohenJ , FordC , GoldsteinJ , LisakR , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology1995;45(7):1268-76. ">Johnson 1995</a>; <a href="./references#CD011381-bbs2-0033" title="KnoblerRL , GreensteinJI , JohnsonKP , LublinFD , PanitchHS , ConwayK , et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. Journal of Interferon Research1993;13(5):333-40. ">Knobler 1993</a>; <a href="./references#CD011381-bbs2-0035" title="LewanskaM , Siger-ZajdelM , SelmajK . No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. European Journal of Neurology2002;9(6):565-72. ">Lewanska 2002</a>; <a href="./references#CD011381-bbs2-0038" title="MokhberN , AzarpazhoohA , OroujiE , KhorramB , Modares GharaviM , KakhiS , KhallaghiH , AzarpazhoohMR . Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis. Psychiatry Clin Neurosci.2015;69(10):649-57. [DOI: 10.1111/pcn.12308] [PMID: 25907350]MokhberN , AzarpazhoohA , OroujiE , RaoSM , KhorramB , SahraianMA , ForoghipoorM , GharaviMM , KakhiS , NikkhahK , AzarpazhoohMR . Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. J Neurol Sci2014;342(1-2):16-20. [DOI: 10.1016/j.jns.2014.01.038] [PMID: 24841321]">Mokhber 2014</a>; <a href="./references#CD011381-bbs2-0039" title="JacobsL , CookfairD , RudickR , HerndonR , RichertJ , SalazarA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology1996;39:285-94. ">MSCRG 1996</a>; <a href="./references#CD011381-bbs2-0045" title="MikolD , BarkhofF , ChangP , CoyleP , JefferyD , SchwidS , et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology2008;7(10):903-14. ">REGARD 2008</a>). The remaining 38 (76%) studies reported adequate methods of allocation concealment (low risk). </p> </section> </section> <section id="CD011381-sec-0064"> <h4 class="title">Blinding</h4> <section id="CD011381-sec-0065"> <h5 class="title">Blinding of participants and personnel (performance bias )</h5> <p>Seventeen (34%) studies were not blinded (high risk)(<a href="./references#CD011381-bbs2-0007" title="CreeBAC , GoldmanMD , CorboyJR , SingerBA , FoxEJ , ArnoldDL , et al, ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020 ;78(1):1–13. [DOI: 10.1001/jamaneurol.2020.2950] [PMID: 32852530]">ASSESS 2020</a>; <a href="./references#CD011381-bbs2-0008" title="BrownRA , NarayananS , StikovN , CookS , CadavidD , WolanskyL , et al. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. Neurology2016;87(9):905-11. [DOI: 10.1212/WNL.0000000000003043] [PMID: 27473139]CadavidD , WolanskyLJ , SkurnickJ , LincolnJ , CheriyanJ , SzczepanowskiK , et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology2009;72(23):1976-83. CheriyanJ , KimS , WolanskyLJ , CookSD , CadavidD . Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol2012;69(1):82-8. [DOI: 10.1001/archneurol.2011.674]">BECOME 2009</a>; <a href="./references#CD011381-bbs2-0009" title="O'ConnorP , FilippiM , ArnasonB , ComiG , CookS , GoodinD , et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology2009;8(10):889-97. SchipplingS , O'ConnorP , KnappertzV , PohlC , BogumilT , SuarezG , et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol2016;263(7):1418-26. [DOI: 10.1007/s00415-016-8146-8]">BEYOND 2009</a>; <a href="./references#CD011381-bbs2-0010" title="BornsteinMB , MillerA , SlagleS , WeitzmanM , Crystal, DrexlerE , et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New England Journal of Medicine1987;317(7):408-14. ">Bornstein 1987</a>; <a href="./references#CD011381-bbs2-0011" title="VollmerTL , SorensenPS , SelmajK , ZippF , HavrdovaE , CohenJA , et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology2014;261(4):773-83. ">BRAVO 2014</a>; <a href="./references#CD011381-bbs2-0012" title="CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786-801. FoxEJ , WynnD , ColesAJ , PalmerJ , MargolinDH , CAMMS223 Investigators. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. J Neurol Sci2016;363:188-94. [DOI: 10.1016/j.jns.2016.02.025]">CAMMS223 2008</a>; <a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a>; <a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a>; <a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a>; <a href="./references#CD011381-bbs2-0021" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica2006;113(5):283-7. ">Etemadifar 2006</a>; <a href="./references#CD011381-bbs2-0022" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. Journal of Neurology2007;254(12):1723-8. ">Etemadifar 2007</a>; <a href="./references#CD011381-bbs2-0027" title="GobbiC , MeierDS , CottonF , SintzelM , LeppertD , GuttmannCR , ZeccaC . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol2013;13:101. [DOI: 10.1186/1471-2377-13-101] [PMID: 23915113]ZeccaC , RiccitelliGC , CalabreseP , PravatàE , CandrianU , GuttmannCR , Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol2014;14:38. [DOI: 10.1186/1471-2377-14-38] [PMID: 24576156]">Gobbi 2013</a>; <a href="./references#CD011381-bbs2-0028" title="ComiG , PattiF , RoccaMA , MattioliFC , AmatoMP , GalloP , CentonzeD , PozzilliC , SaccàF , BerghFT , BartezaghiM , TurriniR , FilippiM , Golden Study Group. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol2017;264(12):2436-2449. [DOI: 10.1007/s00415-017-8642-5] [PMID: 29063244]">GOLDEN 2017</a>; <a href="./references#CD011381-bbs2-0031" title="DurelliL , VerdunE , BarberoP , BerguiM , VersinoE , GhezziA , et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002;359:1453-60. ">INCOMIN 2002</a>; <a href="./references#CD011381-bbs2-0034" title="Koch-HenriksenN , SørensenP , ChristensenT , FrederiksenJ , RavnborgM , JensenK , et al. A randomised study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology2006;66(7):1056-60. ">Koch‐Henriksen 2006</a>; <a href="./references#CD011381-bbs2-0036" title="MassacesiL , TramacereI , AmorosoS , BattagliaMA , BenedettiMD , FilippiniG , et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One2014;9(11):e113371. ">MAIN 2014</a>; <a href="./references#CD011381-bbs2-0045" title="MikolD , BarkhofF , ChangP , CoyleP , JefferyD , SchwidS , et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology2008;7(10):903-14. ">REGARD 2008</a>); nine (18%) studies did not provide sufficient information to enable assessment (unclear risk) (<a href="./references#CD011381-bbs2-0020" title="ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014;261(9):1794-802. [DOI: 10.1007/s00415-014-7412-x] [PMID: 24989666]ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol2014;261(12):2429-37. [DOI: 10.1007/s00415-014-7504-7] [PMID: 25270680]Bar-OrA , GoldR , KapposL , ArnoldDL , GiovannoniG , SelmajK , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol2013 ;260(9):2297-305. [DOI: 10.1007/s00415-013-6954-7] [PMID: 23797999]Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012] [PMID: 28751099]GoldR , KapposL , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine2012;367(12):1098-107. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272] [PMID: 28328179]KapposL , GoldR , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler2014;20(2):243-52. [DOI: 10.1177/1352458513507817] [PMID: 24150779]">DEFINE 2012</a>; <a href="./references#CD011381-bbs2-0023" title="FazekasF , DeisenhammerF , Strasser-FuchsS , NahlerG , MamoliB . Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet1997;349(9052):589-93. ">Fazekas 1997</a>; <a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a>; <a href="./references#CD011381-bbs2-0030" title="IFNBMSG . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology1993;43(4):655-61. ">IFNB MS Group 1993</a>; <a href="./references#CD011381-bbs2-0032" title="JohnsonK , BrooksB , CohenJ , FordC , GoldsteinJ , LisakR , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology1995;45(7):1268-76. ">Johnson 1995</a>; <a href="./references#CD011381-bbs2-0035" title="LewanskaM , Siger-ZajdelM , SelmajK . No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. European Journal of Neurology2002;9(6):565-72. ">Lewanska 2002</a>; <a href="./references#CD011381-bbs2-0037" title="MillefioriniE , GasperiniC , PozzilliC , D'AndreaF , BastianelloS , TrojanoM , et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology1997;244(3):153-9. ">Millefiorini 1997</a>; <a href="./references#CD011381-bbs2-0039" title="JacobsL , CookfairD , RudickR , HerndonR , RichertJ , SalazarA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology1996;39:285-94. ">MSCRG 1996</a>; <a href="./references#CD011381-bbs2-0043" title="EbersGC . Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet1998;352(9139):1498-1504. [DOI: 10.1016/S0140-6736(98)03334-0]TraboulseeA , LiDKB , CascioneM , FangJ , DangondF , MillerA . Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. BMC Neurol2018;18(1):143. [DOI: 10.1186/s12883-018-1145-x] [PMID: 30217172]">PRISMS 1998</a>); the remaining 24 (48%) studies reported that participants and investigators were blinded (low risk). </p> </section> <section id="CD011381-sec-0066"> <h5 class="title">Blinding of outcome assessor (detection bias)</h5> <p>Six studies (12%) were at high risk (<a href="./references#CD011381-bbs2-0031" title="DurelliL , VerdunE , BarberoP , BerguiM , VersinoE , GhezziA , et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002;359:1453-60. ">INCOMIN 2002</a>; <a href="./references#CD011381-bbs2-0034" title="Koch-HenriksenN , SørensenP , ChristensenT , FrederiksenJ , RavnborgM , JensenK , et al. A randomised study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology2006;66(7):1056-60. ">Koch‐Henriksen 2006</a>; <a href="./references#CD011381-bbs2-0036" title="MassacesiL , TramacereI , AmorosoS , BattagliaMA , BenedettiMD , FilippiniG , et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One2014;9(11):e113371. ">MAIN 2014</a>; <a href="./references#CD011381-bbs2-0037" title="MillefioriniE , GasperiniC , PozzilliC , D'AndreaF , BastianelloS , TrojanoM , et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology1997;244(3):153-9. ">Millefiorini 1997</a>; <a href="./references#CD011381-bbs2-0048" title="MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al, Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler2012;18(11):1625-32. [DOI: 10.1177/1352458512450354] [PMID: 22723573]O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293-303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol2013;260(10):2472-80. [DOI: 10.1007/s00415-013-6979-y] [PMID: 23852658]RadueEW , SprengerT , GaetanoL , Mueller-LenkeN , CavalierS , ThangaveluK , et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm2017;4(5):e390. [DOI: 10.1212/NXI.0000000000000390] [PMID: 28828394]WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013 ;19(10):1310-9. [DOI: 10.1177/1352458513475723] [PMID: 23447359]">TEMSO 2011</a>; <a href="./references#CD011381-bbs2-0050" title="BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler2014;20(13):1704-13. [DOI: 10.1177/1352458514532317] [PMID: 24812043]CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402-15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol2013;260(8):2023-32. [DOI: 10.1007/s00415-013-6932-0] [PMID: 23632946]KhatriBO , PelletierJ , KapposL , HartungHP , ComiG , BarkhofF , et al, TRANSFORMS Study Group. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord2014;3(3):355-63. [DOI: 10.1016/j.msard.2013.11.006] [PMID: 25876473]MengX , ChinPS , HashmonayR , Zahur IslamM , CutterG . Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemp Clin Trials2015;41:69-74. [DOI: 10.1016/j.cct.2014.12.011] [PMID: 25545026]">TRANSFORMS 2010</a>), eleven studies (22%) did not provide sufficient information to enable assessment (unclear risk), and the remaining 33 studies (66%) were at low risk of detection bias (i.e. they reported that outcome assessors were blinded). </p> </section> </section> <section id="CD011381-sec-0067"> <h4 class="title">Incomplete outcome data</h4> <p>We judged 16 of 50 (32%) included studies as meeting the criteria for high risk of bias due to incomplete outcome data (balanced numbers across intervention groups with similar reasons for loss to follow‐up) (<a href="./references#CD011381-bbs2-0002" title="CalabresiPA , KieseierBC , ArnoldDL , BalcerLJ , BoykoA , PelletierJ , et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurology2014;13:657-65. HuX , CuiY , WhiteJ , ZhuY , DeykinA , NestorovI , HungS . Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. British Journal of Clinical Pharmacology2015;79(3):514-22. [DOI: 10.1111/bcp.12521] [PMID: 25265472]ScottTF , KieseierBC , NewsomeSD , ArnoldDL , YouX , HungS , Sperling B. Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis.. Mult Scler J Exp Transl Clin. 2016 ;2:2055217316676644. [DOI: 10.1177/2055217316676644] [PMID: 28607743]">ADVANCE 2014</a>; <a href="./references#CD011381-bbs2-0004" title="ComiG , JefferyD , KapposL , MontalbanX , BoykoA , RoccaMA , et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. New England Journal of Medicine2012;366(11):1000-9. FilippiM , RoccaMA , PaganiE , De StefanoN , JefferyD , KapposL , et al, ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry2014;85(8):851-8. [DOI: 10.1136/jnnp-2013-306132] [PMID: 24029546]">ALLEGRO 2012</a>; <a href="./references#CD011381-bbs2-0012" title="CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786-801. FoxEJ , WynnD , ColesAJ , PalmerJ , MargolinDH , CAMMS223 Investigators. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. J Neurol Sci2016;363:188-94. [DOI: 10.1016/j.jns.2016.02.025]">CAMMS223 2008</a>; <a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a>; <a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a>; <a href="./references#CD011381-bbs2-0016" title="LublinFD , CofieldSS , CutterGR , ConwitR , NarayanaPA , NelsonF , et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology2013;73(3):327-40. ">CombiRx 2013</a>; <a href="./references#CD011381-bbs2-0017" title="ComiG , DadonY , SassonN , SteinermanJR , KnappertzV , VollmerTL , et al. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler2022;28(4):608-619. [DOI: 10.1177/13524585211032803] [PMID: 34378456]NCT01707992. The Efficacy, Safety, and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). https://clinicaltrials.gov/show/NCT017079922012. ">CONCERTO 2021</a>; <a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a>; <a href="./references#CD011381-bbs2-0020" title="ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014;261(9):1794-802. [DOI: 10.1007/s00415-014-7412-x] [PMID: 24989666]ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol2014;261(12):2429-37. [DOI: 10.1007/s00415-014-7504-7] [PMID: 25270680]Bar-OrA , GoldR , KapposL , ArnoldDL , GiovannoniG , SelmajK , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol2013 ;260(9):2297-305. [DOI: 10.1007/s00415-013-6954-7] [PMID: 23797999]Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012] [PMID: 28751099]GoldR , KapposL , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine2012;367(12):1098-107. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272] [PMID: 28328179]KapposL , GoldR , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler2014;20(2):243-52. [DOI: 10.1177/1352458513507817] [PMID: 24150779]">DEFINE 2012</a>; <a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a>; <a href="./references#CD011381-bbs2-0025" title="CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(6):545-56. VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , Freedman MS A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017 3;3:2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS II 2014</a>; <a href="./references#CD011381-bbs2-0028" title="ComiG , PattiF , RoccaMA , MattioliFC , AmatoMP , GalloP , CentonzeD , PozzilliC , SaccàF , BerghFT , BartezaghiM , TurriniR , FilippiM , Golden Study Group. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol2017;264(12):2436-2449. [DOI: 10.1007/s00415-017-8642-5] [PMID: 29063244]">GOLDEN 2017</a>; <a href="./references#CD011381-bbs2-0034" title="Koch-HenriksenN , SørensenP , ChristensenT , FrederiksenJ , RavnborgM , JensenK , et al. A randomised study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology2006;66(7):1056-60. ">Koch‐Henriksen 2006</a>; <a href="./references#CD011381-bbs2-0040" title="A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01247324 (accessed 30 September 2014). HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , JulianL , KöndgenH , LiC , NapieralskiJ , ZhengH , WolinskyJS . Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , BuffelsR , FioreD , GarrenH , HanJ , HauserSL . Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA I 2017</a>; <a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a>; <a href="./references#CD011381-bbs2-0049" title="ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(3):247-56. FreedmanMS , MorawskiJ , ThangaveluK . Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. Mult Scler J Exp Transl Clin2018;4(2):2055217318775236. [DOI: 10.1177/2055217318775236] [PMID: 29796289]MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MäurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol2014;261(9):1781-8. [DOI: 10.1007/s00415-014-7395-7] [PMID: 24972678]MillerAE , XuX , MacdonellR , VucicS , TruffinetP , BenamorM , et al. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. J Clin Neurosci2019;59:229-231. [DOI: 10.1016/j.jocn.2018.09.012] [PMID: 30348586]QiuW , HuangDH , HouSF , ZhangMN , JinT , DongHQ , et al, TOWER Trial Chinese Group. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study. Chin Med J (Engl)2018;131(23):2776-2784. [DOI: 10.4103/0366-6999.246067] [PMID: 30511679]">TOWER 2014</a>) and seven (14%) (<a href="./references#CD011381-bbs2-0021" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica2006;113(5):283-7. ">Etemadifar 2006</a>; <a href="./references#CD011381-bbs2-0030" title="IFNBMSG . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology1993;43(4):655-61. ">IFNB MS Group 1993</a>; <a href="./references#CD011381-bbs2-0031" title="DurelliL , VerdunE , BarberoP , BerguiM , VersinoE , GhezziA , et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002;359:1453-60. ">INCOMIN 2002</a>; <a href="./references#CD011381-bbs2-0033" title="KnoblerRL , GreensteinJI , JohnsonKP , LublinFD , PanitchHS , ConwayK , et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. Journal of Interferon Research1993;13(5):333-40. ">Knobler 1993</a>; <a href="./references#CD011381-bbs2-0045" title="MikolD , BarkhofF , ChangP , CoyleP , JefferyD , SchwidS , et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology2008;7(10):903-14. ">REGARD 2008</a>; <a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a>; <a href="./references#CD011381-bbs2-0048" title="MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al, Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler2012;18(11):1625-32. [DOI: 10.1177/1352458512450354] [PMID: 22723573]O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293-303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol2013;260(10):2472-80. [DOI: 10.1007/s00415-013-6979-y] [PMID: 23852658]RadueEW , SprengerT , GaetanoL , Mueller-LenkeN , CavalierS , ThangaveluK , et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm2017;4(5):e390. [DOI: 10.1212/NXI.0000000000000390] [PMID: 28828394]WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013 ;19(10):1310-9. [DOI: 10.1177/1352458513475723] [PMID: 23447359]">TEMSO 2011</a>) did not provide sufficient information to assess risk of incomplete outcome data (unclear risk). The remaining 27 (54%) studies were judged to be low risk. </p> </section> <section id="CD011381-sec-0068"> <h4 class="title">Selective reporting</h4> <p>Five studies (10%) were judged as being at high risk of bias for selective reporting because of non‐reporting all prespecified primary benefit outcomes (<a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a>; <a href="./references#CD011381-bbs2-0020" title="ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014;261(9):1794-802. [DOI: 10.1007/s00415-014-7412-x] [PMID: 24989666]ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol2014;261(12):2429-37. [DOI: 10.1007/s00415-014-7504-7] [PMID: 25270680]Bar-OrA , GoldR , KapposL , ArnoldDL , GiovannoniG , SelmajK , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol2013 ;260(9):2297-305. [DOI: 10.1007/s00415-013-6954-7] [PMID: 23797999]Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012] [PMID: 28751099]GoldR , KapposL , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine2012;367(12):1098-107. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272] [PMID: 28328179]KapposL , GoldR , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler2014;20(2):243-52. [DOI: 10.1177/1352458513507817] [PMID: 24150779]">DEFINE 2012</a>; <a href="./references#CD011381-bbs2-0027" title="GobbiC , MeierDS , CottonF , SintzelM , LeppertD , GuttmannCR , ZeccaC . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol2013;13:101. [DOI: 10.1186/1471-2377-13-101] [PMID: 23915113]ZeccaC , RiccitelliGC , CalabreseP , PravatàE , CandrianU , GuttmannCR , Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol2014;14:38. [DOI: 10.1186/1471-2377-14-38] [PMID: 24576156]">Gobbi 2013</a>; <a href="./references#CD011381-bbs2-0033" title="KnoblerRL , GreensteinJI , JohnsonKP , LublinFD , PanitchHS , ConwayK , et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. Journal of Interferon Research1993;13(5):333-40. ">Knobler 1993</a>; <a href="./references#CD011381-bbs2-0048" title="MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al, Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler2012;18(11):1625-32. [DOI: 10.1177/1352458512450354] [PMID: 22723573]O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293-303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol2013;260(10):2472-80. [DOI: 10.1007/s00415-013-6979-y] [PMID: 23852658]RadueEW , SprengerT , GaetanoL , Mueller-LenkeN , CavalierS , ThangaveluK , et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm2017;4(5):e390. [DOI: 10.1212/NXI.0000000000000390] [PMID: 28828394]WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013 ;19(10):1310-9. [DOI: 10.1177/1352458513475723] [PMID: 23447359]">TEMSO 2011</a>). Two studies (4%) were judged as being at unclear risk of bias in this domain because of the lack of a protocol (<a href="./references#CD011381-bbs2-0021" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica2006;113(5):283-7. ">Etemadifar 2006</a>) or because primary and secondary outcomes were submitted to Clinical Trials.gov after study completion (<a href="./references#CD011381-bbs2-0015" title="AfolabiD , AlborC , ZalewskiL , AltmannDR , BakerD , SchmiererK . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler2018 ;24(11):1461-1468. [DOI: 10.1177/1352458517726380] [PMID: 28817997]ComiG , CookSD , GiovannoniG , RammohanK , RieckmannP , SørensenPS , et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol2013;260(4):1136-46. [DOI: 10.1007/s00415-012-6775-0] [PMID: 23263473]De StefanoN , GiorgioA , BattagliniM , De LeucioA , HickingC , DangondF , et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018;24(2):222-226. [DOI: 10.1177/1352458517690269] [PMID: 28140753]GiovannoniG , ComiG , CookS , RammohanK , RieckmannP , Soelberg SørensenP , et al, CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):416-26. [DOI: 10.1056/NEJMoa0902533] [PMID: 20089960]GiovannoniG , Soelberg SorensenP , CookS , RammohanKW , RieckmannP , ComiG , et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler2019;25(6):819-827. [DOI: 10.1177/1352458518771875] [PMID: 29716436]HermannR , LitwinJS , FribergLE , DangondF , MunafoA . Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Br J Clin Pharmacol2019 ;85(7):1484-1494. [DOI: 10.1111/bcp.13919] [PMID: 30883839]VermerschP , GalazkaA , DangondF , DamianD , WongSL , JackD , et al. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Curr Med Res Opin2021;37(3):459-464. [DOI: 10.1080/03007995.2020.1865888] [PMID: 33331183]">CLARITY 2010</a>). The remaining 43 (86%) reported all prespecified primary benefit outcomes and were judged as having low risk of bias. </p> </section> <section id="CD011381-sec-0069"> <h4 class="title">Other potential sources of bias</h4> <p>We judged 34 studies (68%) as being at high risk of other bias; this includes the role of the sponsor in authorship of the study report or in data management or analysis (<a href="./references#CD011381-bbs2-0002" title="CalabresiPA , KieseierBC , ArnoldDL , BalcerLJ , BoykoA , PelletierJ , et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurology2014;13:657-65. HuX , CuiY , WhiteJ , ZhuY , DeykinA , NestorovI , HungS . Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. British Journal of Clinical Pharmacology2015;79(3):514-22. [DOI: 10.1111/bcp.12521] [PMID: 25265472]ScottTF , KieseierBC , NewsomeSD , ArnoldDL , YouX , HungS , Sperling B. Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis.. Mult Scler J Exp Transl Clin. 2016 ;2:2055217316676644. [DOI: 10.1177/2055217316676644] [PMID: 28607743]">ADVANCE 2014</a>; <a href="./references#CD011381-bbs2-0003" title="BalcerLJ , GalettaSL , PolmanCH , EggenbergerE , CalabresiPA , ZhangA , et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.. J Neurol Sci2012;318(1-2):119-24. [DOI: 10.1016/j.jns.2012.03.009] [PMID: 22521274]LublinFD , CutterG , GiovannoniG , PaceA , CampbellNR , BelachewS . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.. Mult Scler Relat Disord2014;3(6):705-11. [DOI: 10.1016/j.msard.2014.08.005] [PMID: 25891549]PolmanCH , O'ConnorPW , HavrdovaE , HutchinsonM , KapposL , MillerDH , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):899-910. Weinstock-GuttmanB , GalettaSL , GiovannoniG , HavrdovaE , HutchinsonM , KapposL , et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology2012;259((5)):898-905. [DOI: 10.1007/s00415-011-6275-7] [PMID: 22008873]">AFFIRM 2006</a>; <a href="./references#CD011381-bbs2-0004" title="ComiG , JefferyD , KapposL , MontalbanX , BoykoA , RoccaMA , et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. New England Journal of Medicine2012;366(11):1000-9. FilippiM , RoccaMA , PaganiE , De StefanoN , JefferyD , KapposL , et al, ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry2014;85(8):851-8. [DOI: 10.1136/jnnp-2013-306132] [PMID: 24029546]">ALLEGRO 2012</a>; <a href="./references#CD011381-bbs2-0005" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS I 2020</a>; <a href="./references#CD011381-bbs2-0006" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS II 2020</a>; <a href="./references#CD011381-bbs2-0007" title="CreeBAC , GoldmanMD , CorboyJR , SingerBA , FoxEJ , ArnoldDL , et al, ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020 ;78(1):1–13. [DOI: 10.1001/jamaneurol.2020.2950] [PMID: 32852530]">ASSESS 2020</a>; <a href="./references#CD011381-bbs2-0008" title="BrownRA , NarayananS , StikovN , CookS , CadavidD , WolanskyL , et al. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. Neurology2016;87(9):905-11. [DOI: 10.1212/WNL.0000000000003043] [PMID: 27473139]CadavidD , WolanskyLJ , SkurnickJ , LincolnJ , CheriyanJ , SzczepanowskiK , et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology2009;72(23):1976-83. CheriyanJ , KimS , WolanskyLJ , CookSD , CadavidD . Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol2012;69(1):82-8. [DOI: 10.1001/archneurol.2011.674]">BECOME 2009</a>; <a href="./references#CD011381-bbs2-0009" title="O'ConnorP , FilippiM , ArnasonB , ComiG , CookS , GoodinD , et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology2009;8(10):889-97. SchipplingS , O'ConnorP , KnappertzV , PohlC , BogumilT , SuarezG , et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol2016;263(7):1418-26. [DOI: 10.1007/s00415-016-8146-8]">BEYOND 2009</a>; <a href="./references#CD011381-bbs2-0011" title="VollmerTL , SorensenPS , SelmajK , ZippF , HavrdovaE , CohenJA , et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology2014;261(4):773-83. ">BRAVO 2014</a>; <a href="./references#CD011381-bbs2-0012" title="CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786-801. FoxEJ , WynnD , ColesAJ , PalmerJ , MargolinDH , CAMMS223 Investigators. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. J Neurol Sci2016;363:188-94. [DOI: 10.1016/j.jns.2016.02.025]">CAMMS223 2008</a>; <a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a>; <a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a>; <a href="./references#CD011381-bbs2-0015" title="AfolabiD , AlborC , ZalewskiL , AltmannDR , BakerD , SchmiererK . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler2018 ;24(11):1461-1468. [DOI: 10.1177/1352458517726380] [PMID: 28817997]ComiG , CookSD , GiovannoniG , RammohanK , RieckmannP , SørensenPS , et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol2013;260(4):1136-46. [DOI: 10.1007/s00415-012-6775-0] [PMID: 23263473]De StefanoN , GiorgioA , BattagliniM , De LeucioA , HickingC , DangondF , et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018;24(2):222-226. [DOI: 10.1177/1352458517690269] [PMID: 28140753]GiovannoniG , ComiG , CookS , RammohanK , RieckmannP , Soelberg SørensenP , et al, CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):416-26. [DOI: 10.1056/NEJMoa0902533] [PMID: 20089960]GiovannoniG , Soelberg SorensenP , CookS , RammohanKW , RieckmannP , ComiG , et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler2019;25(6):819-827. [DOI: 10.1177/1352458518771875] [PMID: 29716436]HermannR , LitwinJS , FribergLE , DangondF , MunafoA . Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Br J Clin Pharmacol2019 ;85(7):1484-1494. [DOI: 10.1111/bcp.13919] [PMID: 30883839]VermerschP , GalazkaA , DangondF , DamianD , WongSL , JackD , et al. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Curr Med Res Opin2021;37(3):459-464. [DOI: 10.1080/03007995.2020.1865888] [PMID: 33331183]">CLARITY 2010</a>; <a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a>; <a href="./references#CD011381-bbs2-0019" title="BenedictRH , CohanS , LynchSG , RiesterK , WangP , Castro-BorreroW , et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler2018 ;24(6):795-804. [DOI: 0.1177/1352458517707345]KapposL , HavrdovaE , GiovannoniG , KhatriBO , GauthierSA , GreenbergSJ , et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler2017;23(13):1736-1747. [DOI: 10.1177/1352458516683266]KapposL , WiendlH , SelmajK , ArnoldDL , HavrdovaE , BoykoA , et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2015;373(15):1418-28. [DOI: 10.1056/NEJMoa1501481]KruegerJG , KircikL , HougeirF , FriedmanA , YouX , LucasN , et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther2016;33(7):231-45. [DOI: 10.1007/s12325-016-0353-2]LiuY , VollmerT , HavrdovaE , RiesterK , LeeA , PhillipsG , et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;11:18-24. [DOI: 10.1016/j.msard.2016.11.005]NCT01064401. Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01064401 (accessed 30 September 2014). RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40.. [DOI: 10.1016/j.msard.2017.06.006]">DECIDE 2015</a>; <a href="./references#CD011381-bbs2-0020" title="ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014;261(9):1794-802. [DOI: 10.1007/s00415-014-7412-x] [PMID: 24989666]ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol2014;261(12):2429-37. [DOI: 10.1007/s00415-014-7504-7] [PMID: 25270680]Bar-OrA , GoldR , KapposL , ArnoldDL , GiovannoniG , SelmajK , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol2013 ;260(9):2297-305. [DOI: 10.1007/s00415-013-6954-7] [PMID: 23797999]Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012] [PMID: 28751099]GoldR , KapposL , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine2012;367(12):1098-107. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272] [PMID: 28328179]KapposL , GoldR , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler2014;20(2):243-52. [DOI: 10.1177/1352458513507817] [PMID: 24150779]">DEFINE 2012</a>; <a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a>; <a href="./references#CD011381-bbs2-0025" title="CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(6):545-56. VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , Freedman MS A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017 3;3:2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS II 2014</a>; <a href="./references#CD011381-bbs2-0026" title='DavisMD , AshtamkerN , SteinermanJR , KnappertzV . Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study. 2017 Neurol Neuroimmunol Neuroinflamm;4(2):e327. [DOI: 10.1212/NXI.0000000000000327] [PMID: 28210662]KhanO , RieckmannP , BoykoA , SelmajK , ZivadinovR , GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Annals of Neurology2013;73(6):705-13. ZivadinovR , DwyerM , BarkayH , SteinermanJR , KnappertzV , Khan O. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis. J Neurol2015;262(3):648-53. [DOI: 10.1007/s00415-014-7616-0] [PMID: 25542295]ZivadinovR , DwyerMG , RamasamyDP , DavisMD , SteinermanJR , KhanO . The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. J Neuroimaging2015;25(6):989-95. [DOI: 10.1111/jon.12293] [PMID: 26394270]'>GALA 2013</a>; <a href="./references#CD011381-bbs2-0028" title="ComiG , PattiF , RoccaMA , MattioliFC , AmatoMP , GalloP , CentonzeD , PozzilliC , SaccàF , BerghFT , BartezaghiM , TurriniR , FilippiM , Golden Study Group. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol2017;264(12):2436-2449. [DOI: 10.1007/s00415-017-8642-5] [PMID: 29063244]">GOLDEN 2017</a>; <a href="./references#CD011381-bbs2-0032" title="JohnsonK , BrooksB , CohenJ , FordC , GoldsteinJ , LisakR , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology1995;45(7):1268-76. ">Johnson 1995</a>; <a href="./references#CD011381-bbs2-0033" title="KnoblerRL , GreensteinJI , JohnsonKP , LublinFD , PanitchHS , ConwayK , et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. Journal of Interferon Research1993;13(5):333-40. ">Knobler 1993</a>; <a href="./references#CD011381-bbs2-0039" title="JacobsL , CookfairD , RudickR , HerndonR , RichertJ , SalazarA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology1996;39:285-94. ">MSCRG 1996</a>; <a href="./references#CD011381-bbs2-0040" title="A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01247324 (accessed 30 September 2014). HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , JulianL , KöndgenH , LiC , NapieralskiJ , ZhengH , WolinskyJS . Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , BuffelsR , FioreD , GarrenH , HanJ , HauserSL . Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA I 2017</a>; <a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a>; <a href="./references#CD011381-bbs2-0042" title="KapposL , FoxRJ , BurcklenM , FreedmanMS , HavrdováEK , HennessyB , et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol 2021 May 1;;78(5):558-567. [DOI: 10.1001/jamaneurol.2021.0405] [PMID: 33779698]">OPTIMUM 2021</a>; <a href="./references#CD011381-bbs2-0043" title="EbersGC . Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet1998;352(9139):1498-1504. [DOI: 10.1016/S0140-6736(98)03334-0]TraboulseeA , LiDKB , CascioneM , FangJ , DangondF , MillerA . Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. BMC Neurol2018;18(1):143. [DOI: 10.1186/s12883-018-1145-x] [PMID: 30217172]">PRISMS 1998</a>; <a href="./references#CD011381-bbs2-0044" title="CohenJA , ComiG , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019;18(11):1021-1033. [DOI: 10.1016/S1474-4422(19)30238-8] [PMID: 31492652]NCT01628393. Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study). https://clinicaltrials.gov/show/NCT016283932012. ">RADIANCE 2019</a>; <a href="./references#CD011381-bbs2-0045" title="MikolD , BarkhofF , ChangP , CoyleP , JefferyD , SchwidS , et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology2008;7(10):903-14. ">REGARD 2008</a>; <a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a>; <a href="./references#CD011381-bbs2-0047" title="ComiG , KapposL , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology2019 ;18(11):1009-1020. [DOI: 10.1016/S1474-4422(19)30239-X]DeLucaJ , SchipplingS , MontalbanX , KapposL , CreeBAC , ComiG , et al. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Mult Scler Relat Disord2021;48:102673. [DOI: 10.1016/j.msard.2020.102673]NCT02294058. Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS). https://ClinicalTrials.gov/show/NCT022940582014. ">SUNBEAM 2019</a>; <a href="./references#CD011381-bbs2-0048" title="MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al, Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler2012;18(11):1625-32. [DOI: 10.1177/1352458512450354] [PMID: 22723573]O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293-303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol2013;260(10):2472-80. [DOI: 10.1007/s00415-013-6979-y] [PMID: 23852658]RadueEW , SprengerT , GaetanoL , Mueller-LenkeN , CavalierS , ThangaveluK , et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm2017;4(5):e390. [DOI: 10.1212/NXI.0000000000000390] [PMID: 28828394]WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013 ;19(10):1310-9. [DOI: 10.1177/1352458513475723] [PMID: 23447359]">TEMSO 2011</a>; <a href="./references#CD011381-bbs2-0049" title="ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(3):247-56. FreedmanMS , MorawskiJ , ThangaveluK . Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. Mult Scler J Exp Transl Clin2018;4(2):2055217318775236. [DOI: 10.1177/2055217318775236] [PMID: 29796289]MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MäurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol2014;261(9):1781-8. [DOI: 10.1007/s00415-014-7395-7] [PMID: 24972678]MillerAE , XuX , MacdonellR , VucicS , TruffinetP , BenamorM , et al. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. J Clin Neurosci2019;59:229-231. [DOI: 10.1016/j.jocn.2018.09.012] [PMID: 30348586]QiuW , HuangDH , HouSF , ZhangMN , JinT , DongHQ , et al, TOWER Trial Chinese Group. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study. Chin Med J (Engl)2018;131(23):2776-2784. [DOI: 10.4103/0366-6999.246067] [PMID: 30511679]">TOWER 2014</a>; <a href="./references#CD011381-bbs2-0050" title="BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler2014;20(13):1704-13. [DOI: 10.1177/1352458514532317] [PMID: 24812043]CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402-15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol2013;260(8):2023-32. [DOI: 10.1007/s00415-013-6932-0] [PMID: 23632946]KhatriBO , PelletierJ , KapposL , HartungHP , ComiG , BarkhofF , et al, TRANSFORMS Study Group. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord2014;3(3):355-63. [DOI: 10.1016/j.msard.2013.11.006] [PMID: 25876473]MengX , ChinPS , HashmonayR , Zahur IslamM , CutterG . Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemp Clin Trials2015;41:69-74. [DOI: 10.1016/j.cct.2014.12.011] [PMID: 25545026]">TRANSFORMS 2010</a>); eight studies (16%) were judged as being at unclear risk of bias for this domain because the role of the study sponsor was unclear (<a href="./references#CD011381-bbs2-0001" title="AchironA , GabbayU , GiladR , HassinB , BarakY , GornishM , et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology1998;50(2):398-402. ">Achiron 1998</a>; <a href="./references#CD011381-bbs2-0021" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica2006;113(5):283-7. ">Etemadifar 2006</a>; <a href="./references#CD011381-bbs2-0022" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. Journal of Neurology2007;254(12):1723-8. ">Etemadifar 2007</a>; <a href="./references#CD011381-bbs2-0023" title="FazekasF , DeisenhammerF , Strasser-FuchsS , NahlerG , MamoliB . Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet1997;349(9052):589-93. ">Fazekas 1997</a>; <a href="./references#CD011381-bbs2-0029" title="GoodkinD , BaillyR , TeetzenM , HertsgaardD , BeattyW . The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology1991;41:20-5. ">Goodkin 1991</a>; <a href="./references#CD011381-bbs2-0030" title="IFNBMSG . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology1993;43(4):655-61. ">IFNB MS Group 1993</a>; <a href="./references#CD011381-bbs2-0034" title="Koch-HenriksenN , SørensenP , ChristensenT , FrederiksenJ , RavnborgM , JensenK , et al. A randomised study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology2006;66(7):1056-60. ">Koch‐Henriksen 2006</a>; <a href="./references#CD011381-bbs2-0037" title="MillefioriniE , GasperiniC , PozzilliC , D'AndreaF , BastianelloS , TrojanoM , et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology1997;244(3):153-9. ">Millefiorini 1997</a>). The remaining 8 (16%) were judged as being at low risk of bias. </p> </section> </section> <section id="CD011381-sec-0070"> <h3 class="title" id="CD011381-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD011381-tbl-0001"><b>Summary of findings 1</b> Relapses at 12 months</a>; <a href="./full#CD011381-tbl-0002"><b>Summary of findings 2</b> Relapses at 24 months</a>; <a href="./full#CD011381-tbl-0003"><b>Summary of findings 3</b> Relapses at 36 months</a>; <a href="./full#CD011381-tbl-0004"><b>Summary of findings 4</b> Disability at 24 months</a>; <a href="./full#CD011381-tbl-0005"><b>Summary of findings 5</b> Discontinuation due to adverse effects</a>; <a href="./full#CD011381-tbl-0006"><b>Summary of findings 6</b> Serious adverse events</a> </p> <p><a href="./full#CD011381-tbl-0001">summary of findings Table 1</a>, <a href="./full#CD011381-tbl-0002">summary of findings Table 2</a>, <a href="./full#CD011381-tbl-0003">summary of findings Table 3</a>, <a href="./full#CD011381-tbl-0004">summary of findings Table 4</a>, <a href="./full#CD011381-tbl-0005">summary of findings Table 5</a>, and <a href="./full#CD011381-tbl-0006">summary of findings Table 6</a> provide overall estimates of treatment effects compared with placebo and the certainty of the available evidence obtained through network meta‐analyses for the four efficacy outcomes (chance of experiencing one or more relapses over 12 months, chance of experiencing one or more relapses over 24 months, chance of experiencing one or more relapses over 36 months, chance of disability getting worse over 24 months), and for the two safety outcomes (discontinuation due to adverse events and SAEs). </p> <p><a href="#CD011381-fig-0004">Figure 4</a>, <a href="#CD011381-fig-0005">Figure 5</a>, and <a href="#CD011381-fig-0006">Figure 6</a> show the network geometries for the efficacy and safety outcomes of immunomodulators and immunosuppressants included in the review (<a href="#CD011381-sec-0024">Primary outcomes</a>; <a href="#CD011381-sec-0027">Secondary outcomes</a>). Each line links the treatments that have been directly compared in studies. The thickness of the line is proportional to the number of participants included in the comparison and the width of each circle is proportional to the number of studies included in the comparison. </p> <div class="figure" id="CD011381-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Network plots of treatment comparisons for primary efficacy and safety outcomes (Primary outcomes). The width of the lines is proportional to the precision of each pair of treatments, and the size of every circle is proportional to the number of trials comparing every pair of treatments.AE, adverse effects; SAE, serious adverse events." data-id="CD011381-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-04.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Network plots of treatment comparisons for primary efficacy and safety outcomes (<a href="#CD011381-sec-0024">Primary outcomes</a>). The width of the lines is proportional to the precision of each pair of treatments, and the size of every circle is proportional to the number of trials comparing every pair of treatments. </p> <p>AE, adverse effects; SAE, serious adverse events.</p> </div> </div> </div> <div class="figure" id="CD011381-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Network plots of treatment comparisons for secondary efficacy and safety outcomes (Secondary outcomes). The width of the lines is proportional to the precision of each pair of treatments, and the size of every circle is proportional to the number of trials comparing every pair of treatments.Gd, gadolinium; MRI, magnetic resonance imaging; w, weighted." data-id="CD011381-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-05.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Network plots of treatment comparisons for secondary efficacy and safety outcomes (<a href="#CD011381-sec-0027">Secondary outcomes</a>). The width of the lines is proportional to the precision of each pair of treatments, and the size of every circle is proportional to the number of trials comparing every pair of treatments. </p> <p>Gd, gadolinium; MRI, magnetic resonance imaging; w, weighted.</p> </div> </div> </div> <div class="figure" id="CD011381-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Network plots of treatment comparisons for cognitive decline and quality of life*. The width of the lines is proportional to the precision of each pair of treatments, and the size of every circle is proportional to the number of trials comparing every pair of treatments.* Please refer to Effects of interventions for further details on the quality‐of‐life scales used.Abbreviations: MH,; MSQOL,: PH,; SF‐36,." data-id="CD011381-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-06.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Network plots of treatment comparisons for cognitive decline and quality of life*. The width of the lines is proportional to the precision of each pair of treatments, and the size of every circle is proportional to the number of trials comparing every pair of treatments. </p> <p>* Please refer to <a href="#CD011381-sec-0070">Effects of interventions</a> for further details on the quality‐of‐life scales used. </p> <p>Abbreviations: MH,; MSQOL,: PH,; SF‐36,.</p> </div> </div> </div> <p><a href="#CD011381-fig-0007">Figure 7</a> shows network estimates of primary efficacy and safety outcomes of each treatment against placebo within the networks. </p> <div class="figure" id="CD011381-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Network meta‐analysis (NMA) estimates of primary efficacy and safety outcomes in comparisons against placebo.AE, adverse effects; CI, confidence interval; RR, risk ratio; SAE, serious adverse events." data-id="CD011381-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-07.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Network meta‐analysis (NMA) estimates of primary efficacy and safety outcomes in comparisons against placebo. </p> <p>AE, adverse effects; CI, confidence interval; RR, risk ratio; SAE, serious adverse events. </p> </div> </div> </div> <p><a href="#CD011381-tbl-0008">Table 2</a>, <a href="#CD011381-tbl-0009">Table 3</a>, <a href="#CD011381-tbl-0010">Table 4</a>, <a href="#CD011381-tbl-0011">Table 5</a>, <a href="#CD011381-tbl-0012">Table 6</a>, <a href="#CD011381-tbl-0013">Table 7</a>, and <a href="#CD011381-tbl-0014">Table 8</a> show network estimates of primary efficacy and safety outcomes of each treatment against placebo and against each other treatment included in the network. </p> <div class="table" id="CD011381-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Netleague: Relapse (12 months)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Teriflunomide</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.52 (1.28,1.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.80,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.61,1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.31,1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.16 (1.16,4.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.74,2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.94,1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.67,1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.78,1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.72 (0.56,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.61,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.38 (0.85,2.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.66 (0.55,0.78) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo/no treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.68 (0.56,0.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.52 (0.43,0.63 </b>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.40 (0.21,0.74) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 (0.78,2.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.50,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.76 (0.68,0.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.60 (0.47,0.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.55,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.48 (0.39,0.57) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55 (0.42,0.73) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.58,1.43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.75,1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.47 (1.22,1.78) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pegylated interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.58,1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.30,1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.10 (1.12,3.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.71,2.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.90,1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.65,1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.75,1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.70 (0.54,0.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.58,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.82,2.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.99,1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.93 (1.60,2.33) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.31 (1.00,1.71) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Natalizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.40,1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.75 (1.46,5.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.58 (0.94,2.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.47 (1.18,1.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.85,1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.98,1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.70,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.76,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76 (1.08,2.87)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67 (0.87,3.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.53 (1.35,4.73) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.72 (0.89,3.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.31 (0.68,2.52)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mitoxantrone</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.61 (1.51,8.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.07 (0.94,4.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.92 (1.02,3.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 (0.78,3.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.63 (0.86,3.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.20 (0.63,2.31) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.40 (0.71,2.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.30 (1.06,4.99) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.46 (0.25,0.87) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.38,1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.48 (0.25,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.36 (0.19,0.68) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.28 (0.12,0.66) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a and ‐1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.26,1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.53 (0.29,0.98) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42 (0.22,0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.45 (0.24,0.84) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.33 (0.18,0.63) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.39 (0.20,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.43,0.95) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.48,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.75,1.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.49,1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 (0.38,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.22,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.74 (0.80,3.78)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1b Betaferon</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.57,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.43,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.49,1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.58 (0.36,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.39,1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.57,2.17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.71,1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.32 (1.18,1.47) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.72,1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.68 (0.55,0.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.52 (0.28,0.98) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.88 (1.02,3.46) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.66,1.75)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.60,1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.71,1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.63 (0.53,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.73 (0.54,0.98) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.75,1.91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.80,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.65 (1.27,2.15) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.81,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.62,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.33,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.36 (1.22,4.54) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.78,2.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.94,1.67)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Immunoglobulins</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.79,1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.57,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.62,1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (0.89,2.54)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.81,1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.55 (1.33,1.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.83,1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.63,1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.32,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.21 (1.19,4.11) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.78,2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.99,1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.69,1.27)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glatiramer acetate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.74 (0.61,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.63,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.87,2.27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.39 (1.07,1.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.10 (1.74,2.54) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.43 (1.09,1.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.83,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.43,1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.00 (1.59,5.63) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.72 (1.07,2.76 </b>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.60 (1.34,1.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.92,1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.36 (1.11,1.65) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fingolimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.83,1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.91 (1.17,3.13) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.86,1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.81 (1.37,2.39) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.88,1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.67,1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.36,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.58 (1.33,5.00) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48 (0.84,2.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.37 (1.02,1.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.75,1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.85,1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.61,1.20)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Daclizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.65 (0.97,2.80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.45,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.70,1.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.46,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.57 (0.35,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.43 (0.20,0.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.57 (1.05,2.33) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.46,1.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.52,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.39,1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.44,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.52 (0.32,0.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.36,1.03)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Azathioprine</b> </p> </th> </tr> </tbody> </table> <div class="table-footnote"> <p>Significant results are bolded and underlined</p> </div> </div> <div class="table" id="CD011381-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Netleague: Relapse (24 months)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Teriflunomide</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.70 (0.62,0.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.22 (1.06,1.40) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.68 (0.55,0.84) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.57 (0.33,0.99) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.86,1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.47 (0.79,2.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.86,1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.87,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.68,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.86,1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.65 (0.55,0.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.75 (0.63,0.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.51,0.81) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.60,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.55,0.86)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.42 (1.25,1.63) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ponesimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.73 (1.43,2.10) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.76,1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.46,1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.44 (1.16,1.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.09 (1.11,3.92) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.47 (1.18,1.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.46 (1.19,1.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.94,1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.45 (1.17,1.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.74,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.86,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.70,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.84,2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.75,1.28)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.82 (0.71,0.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.58 (0.48,0.70) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo/no treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.56 (0.48,0.65) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.47 (0.27,0.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.83 (0.76,0.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.66,2.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.85 (0.76,0.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.84 (0.78,0.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.59,0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.84 (0.76,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.54 (0.48,0.60) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.62 (0.55,0.70) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.53 (0.44,0.64 </b>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.51,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.47,0.68)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.47 (1.19,1.81) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.80,1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.79 (1.53,2.09) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Natalizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.48,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.48 (1.24,1.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.16 (1.16,4.00) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.51 (1.25,1.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.51 (1.26,1.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30 (0.99,1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.50 (1.24,1.81) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.79,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.91,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.74,1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.38 (0.88,2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.79,1.29)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.76 (1.01,3.06) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.70,2.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.14 (1.25,3.66) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.68,2.09)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mitoxantrone</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.77 (1.03,3.05) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.58 (1.15,5.76) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.81 (1.05,3.13) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.80 (1.05,3.10) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55 (0.87,2.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.79 (1.04,3.09) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.66,1.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.76,2.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.64,1.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.65 (0.84,3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.69,2.13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.84,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.70 (0.56,0.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.21 (1.10,1.32) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.56,0.81) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.56 (0.33,0.97) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laquinimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.79,2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.89,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.91,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.69,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.88,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.65 (0.56,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.75 (0.64,0.87) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.52,0.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.61,1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.56,0.83)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.37,1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.48 (0.26,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.46,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.46 (0.25,0.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.39 (0.17,0.87) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.38,1.26)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta 1a and 1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.38,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.38,1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.32,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.38,1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.45 (0.24,0.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.51 (0.28,0.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.44 (0.23,0.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.42,0.98) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.47 (0.25,0.88) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.82,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.68 (0.55,0.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.18 (1.06,1.31) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.66 (0.55,0.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55 (0.32,0.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.85,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 (0.78,2.61)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.88,1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.68,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.89,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.54,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.73 (0.63,0.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.62 (0.50,0.77) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.91 (0.59,1.41) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.55,0.81) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.83,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.68 (0.56,0.84) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.19 (1.10,1.28) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.66 (0.56,0.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55 (0.32,0.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.88,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43 (0.78,2.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.89,1.13)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.69,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.88,1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.56,0.73) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.73 (0.64,0.84) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.63 (0.51,0.77) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.60,1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.57,0.79) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.88,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.60,1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.38 (1.11,1.71) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.59,1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.36,1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.91,1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66 (0.88,3.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.92,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.93,1.46)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Immunoglobulins</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.91,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.74 (0.58,0.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.67,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.73 (0.55,0.97) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.67,1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.59,1.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.83,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.69 (0.55,0.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.19 (1.08,1.32) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.55,0.81) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.56 (0.32,0.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.86,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (0.79,2.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.91,1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.90,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.68,1.10)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glatiramer acetate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.55,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.74 (0.64,0.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.63 (0.51,0.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.60,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.55,0.82) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.53 (1.28,1.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.86,1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.86 (1.66,2.09) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.85,1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.50,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.54 (1.33,1.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.24 (1.22,4.12) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.57 (1.34,1.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.57 (1.36,1.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.35 (1.06,1.72) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.56 (1.33,1.82) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fingolimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.98,1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.79,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (0.93,2.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.85,1.30)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.33 (1.10,1.59) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.74,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.61 (1.43,1.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.74,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.44,1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.34 (1.15,1.55) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.95 (1.06,3.58) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.37 (1.17,1.60) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.36 (1.18,1.57) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.92,1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.35 (1.17,1.56) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.74,1.02)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dimethyl fumarate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.68,1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.81,1.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.74,1.13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.55 (1.23,1.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.84,1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.89 (1.57,2.28) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.83,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.50,1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.57 (1.28,1.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.28 (1.22,4.26) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.60 (1.29,1.98) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.59 (1.30,1.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.37 (1.03,1.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.58 (1.28,1.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.82,1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.94,1.46)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cladribine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.46 (0.92,2.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.82,1.38)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.68,1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.47,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.85,1.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.46,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.31,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.70,1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.56 (1.02,2.39) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.71,1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.71,1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.59,1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.70,1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.45,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.52,1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.43,1.08)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Azathioprine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.46,1.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.45 (1.16,1.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.78,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.77 (1.48,2.12) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.78,1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.47,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.47 (1.20,1.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.13 (1.14,3.99) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.50 (1.23,1.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.49 (1.27,1.76) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28 (0.97,1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.48 (1.22,1.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.77,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.88,1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.72,1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 (0.87,2.16)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alemtuzumab</b> </p> </th> </tr> </tbody> </table> <div class="table-footnote"> <p>Significant results are bolded and underlined</p> </div> </div> <div class="table" id="CD011381-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Netleague: Relapse (36 months)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.57,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.60,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.45 (0.32,0.65) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.92,1.75<b>) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glatiramer acetate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.61,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.58 (0.36,0.93) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.49 (1.33,1.67) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.83,1.64)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Daclizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.46,0.98) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.20 (1.54,3.16) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.74 (1.07,2.81) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.48 (1.02,2.16) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alemtuzumab</b> </p> </th> </tr> </tbody> </table> <div class="table-footnote"> <p>Significant results are bolded and underlined</p> </div> </div> <div class="table" id="CD011381-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Netleague: Disability (24 months)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Teriflunomide</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.57,1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.31 (1.05,1.63) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.56 (0.92,2.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.71 (0.54,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.51,1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.56,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (0.06,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.76,1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.17 (0.40,43.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.74,1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.88,1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.51,1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.72,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.67,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.65,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.68,1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.29,2.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.57,1.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.84,1.77)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ponesimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.60 (1.04,2.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.90 (1.00,3.60) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.54,1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.54,1.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.57,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32 (0.07,1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.77,2.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.09 (0.47,55.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.76,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.47 (0.90,2.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.57,2.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.74,1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.68,1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.65,1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.70,1.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.33,2.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.60,1.91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.76 (0.61,0.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.63 (0.41,0.96) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo/no treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.74,1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54 (0.38,0.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.61 (0.41,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.59 (0.46,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.20 (0.05,0.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.78 (0.63,0.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.19 (0.31,33.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.62,0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.73,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.41,1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.74 (0.61,0.89) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.68 (0.56,0.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.65 (0.55,0.77) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.72 (0.56,0.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.22,1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.46,0.99) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.38,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53 (0.28,1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.52,1.35)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ozanimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.45 (0.25,0.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.51 (0.30,0.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.50 (0.29,0.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.17 (0.04,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.40,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.68 (0.25,29.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.40,1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.51,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 (0.29,1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.39,1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.58 (0.35,0.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55 (0.33,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.35,1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.17,1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.57 (0.34,0.95) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.41 (1.08,1.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.73,1.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.85 (1.30,2.63) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.20 (1.22,3.96) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ofatumumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.66,1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.71,1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.08,1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (0.96,2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.90 (0.55,63.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 (0.94,2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.71 (1.12,2.59) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.69,2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 (0.92,2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.85,1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.82,1.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.86,2.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.39,3.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.74,2.09)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.80,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.58,1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.65 (1.11,2.45) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.96 (1.16,3.31) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.53,1.51)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ocrelizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.61,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.07,1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.84,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.26 (0.49,56.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.85,1.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.52 (1.10,2.09 </b>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.60,2.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.82,1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.73,1.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.71,1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.74,1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.34,2.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.71,1.73)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.93,1.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.65,1.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.69 (1.33,2.16) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.01 (1.18,3.42) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.60,1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.65,1.63)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Natalizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.08,1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.96,1.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.39 (0.51,56.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30 (0.94,1.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.56 (1.12,2.18) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.66,2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.92,1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.85,1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.82,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.86,1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.37,2.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.72,1.79)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.87 (0.91,16.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.17 (0.71,14.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.06 (1.21,21.16) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6.01 (1.33,27.11) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.74 (0.63,11.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.07 (0.70,13.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.99 (0.70,12.76)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mitoxantrone</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.95 (0.93,16.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16.13 (1.04,251.30) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.87 (0.91,16.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.66 (1.10,19.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.79 (0.80,17.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.74 (0.88,15.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.46 (0.82,14.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.30 (0.78,13.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.62 (0.85,15.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.06 (0.54,17.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.40 (0.77,14.95)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.72,1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.50,1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28 (1.04,1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 (0.92,2.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.46,1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.50,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.55,1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25 (0.06,1.07)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laquinimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.08 (0.39,42.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.73,1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.88,1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.50,1.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.72,1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.66,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.64,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.67,1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.28,2.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.56,1.31)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24 (0.02,2.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (0.02,2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31 (0.03,3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.03,4.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17 (0.02,1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19 (0.02,2.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19 (0.02,1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.06 (0.00,0.97) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24 (0.02,2.58)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta 1a and 1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24 (0.02,2.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (0.03,3.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 (0.02,2.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 (0.02,2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 (0.02,2.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (0.02,2.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22 (0.02,2.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19 (0.02,1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 (0.02,2.27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.74,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.51,1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.31 (1.06,1.61) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55 (0.97,2.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.47,1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.53,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.56,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (0.06,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.76,1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.16 (0.40,43.81)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.95,1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.51,1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.81,1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.67,1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.66,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.68,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.29,2.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.60,1.29)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.60,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.42,1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.86,1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.85,1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.59 (0.39,0.89) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.66 (0.48,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.46,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.21 (0.05,0.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.63,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.46 (0.33,36.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.66,1.05)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.42,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.64,1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.55,1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.71 (0.54,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.56,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.24,1.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.73 (0.54,0.99) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.53,1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.40,1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.73,2.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.59 (0.73,3.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.36,1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.39,1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.41,1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (0.06,1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.55,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.26 (0.38,47.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.54,1.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.64,2.35)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Immunoglobulins</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.52,1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.48,1.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.46,1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.50,1.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.25,2.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.44,1.84)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.77,1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.53,1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.35 (1.12,1.64) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.61 (1.00,2.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.49,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.55,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.59,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27 (0.06,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.80,1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.31 (0.41,45.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.87,1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.99,1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.54,1.91)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glatiramer acetate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.70,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.71,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.71,1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.30,2.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.62,1.34)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.83,1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.57,1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.46 (1.20,1.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.74 (1.04,2.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.53,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.57,1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.63,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (0.07,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.86,1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.66 (0.44,48.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.84,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (1.00,1.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.58,2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.82,1.42)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fingolimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.73,1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.76,1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.32,2.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.64,1.51)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.89,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.60,1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.53 (1.29,1.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.82 (1.11,2.99) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.56,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.61,1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.67,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (0.07,1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.92,1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.88 (0.47,51.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.91,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.41 (1.08,1.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.61,2.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.91,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.81,1.36)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dimethyl fumarate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.82,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.34,2.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.68,1.55)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.77,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.53,1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.40 (1.10,1.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66 (0.98,2.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.49,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.53,1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.59,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 (0.06,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.79,1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.45 (0.42,47.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.78,1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.92,1.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.54,2.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.76,1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.70,1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.68,1.23)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cladribine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.30,2.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.60,1.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.46,3.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.35,3.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66 (0.61,4.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.97 (0.65,5.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.31,2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.34,2.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.35,2.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.06,1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.47,3.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.27 (0.63,44.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.46,3.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 (0.55,4.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.39,3.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.44,3.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.41,3.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.39,2.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.43,3.29)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Azathioprine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.38,3.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.73,1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.52,1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.49 (1.01,2.19) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.77 (1.06,2.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.48,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.58,1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.56,1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (0.07,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.76,1.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.74 (0.44,51.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.77,1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.37 (1.01,1.87) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.54,2.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.75,1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.66,1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.64,1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.68,1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.31,2.61)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alemtuzumab</b> </p> </th> </tr> </tbody> </table> <div class="table-footnote"> <p>Significant results are bolded and underlined</p> </div> </div> <div class="table" id="CD011381-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Netleague: Disability (36 months)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.82,1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.72 (0.58,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.37 (0.20,0.68) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.64,1.23)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glatiramer acetate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.43,0.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.33 (0.17,0.66) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.39 (1.12,1.73) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.57 (1.06,2.33) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Daclizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.52 (0.27,0.99) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.68 (1.47,4.88) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.03 (1.53,6.03) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.93 (1.01,3.68) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alemtuzumab</b> </p> </th> </tr> </tbody> </table> <div class="table-footnote"> <p>Significant results are bolded and underlined</p> </div> </div> <div class="table" id="CD011381-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Netleague: Discontinuation due to adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Teriflunomide</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.76 (1.32,5.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55 (0.36,0.84) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.96 (0.73,5.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.25,1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.67,1.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.45 (0.20,0.99) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.39,1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.45,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66 (0.14,19.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.52,3.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.45,1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36 (0.20,9.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.46,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.59,1.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.42,1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.40 (0.67,2.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.23,2.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.43 (0.36,33.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.21 (0.09,0.49) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.36 (0.17,0.76) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ponesimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.20 (0.08,0.47) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.21,2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.20 (0.07,0.59) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.40 (0.16,0.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.16 (0.05,0.48) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.31 (0.11,0.92) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.29 (0.11,0.74) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.05,7.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 (0.14,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.29 (0.11,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49 (0.06,3.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.29 (0.12,0.74) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.36 (0.15,0.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.27 (0.11,0.68) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.18,1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27 (0.07,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.11,13.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.08 (0.03,0.23) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.82 (1.19,2.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.04 (2.15,11.82) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo/ no treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.58 (1.47,8.73 </b>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.52,1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.00 (1.05,3.81) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.42,1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.57 (0.81,3.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.46 (1.00,2.15) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.02 (0.27,33.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.27 (1.05,4.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48 (0.99,2.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.49 (0.37,16.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.48 (1.02,2.14) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.84 (1.31,2.57) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.94,1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.55 (1.40,4.63) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.38 (0.46,4.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.26 (0.67,58.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.39 (0.19,0.79) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.19,1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.41,4.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.28 (0.11,0.68) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pegylated interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.28 (0.09,0.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.19,1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.23 (0.07,0.70) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.14,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 (0.15,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.06,11.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 (0.19,2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 (0.16,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.09,5.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 (0.16,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.20,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.38 (0.14,0.99) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.24,2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 (0.09,1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.75 (0.16,19.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.11 (0.03,0.34) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.81 (0.83,3.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.01 (1.70,14.73) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.51,1.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.56 (1.17,10.80) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ozanimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.99 (0.79,5.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.38,1.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.56 (0.61,3.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.71,3.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.25,36.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.25 (0.88,5.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.47 (0.87,2.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.47 (0.33,18.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.47 (0.76,2.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.83 (0.93,3.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.65,2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.53 (1.25,5.13) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 (0.38,4.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.22 (0.61,63.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.38 (0.17,0.86) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.56,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.52 (1.04,6.10) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.50 (0.26,0.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.79 (0.60,5.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50 (0.20,1.27)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ofatumumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 (0.16,1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.31,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.35,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.51 (0.12,18.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.42,3.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.35,1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.17,9.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.35,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.44,1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.32,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.53,3.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.19,2.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.13 (0.31,31.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.19 (0.07,0.51) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.23 (1.01,4.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6.16 (2.08,18.25) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.62,2.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.38 (1.43,13.37) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.58,2.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.44 (0.96,6.20)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ocrelizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.92 (0.75,4.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.79 (0.86,3.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.69 (0.30,45.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.77 (1.07,7.18) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.81 (1.05,3.11) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.04 (0.41,22.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.81 (0.92,3.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.24 (1.13,4.46) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.65 (0.79,3.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.11 (1.52,6.38) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.69 (0.47,6.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.65 (0.75,78.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47 (0.21,1.07)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.53,2.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.21 (1.09,9.43) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.33,1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.28 (0.75,6.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.25,1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.51,3.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.20,1.34)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Natalizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.43,2.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.92 (0.16,23.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (0.53,3.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.43,2.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.58 (0.21,11.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.44,2.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.56,2.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.40,1.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (0.66,3.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.24,3.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.98 (0.39,40.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.25 (0.09,0.65) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.70,2.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.45 (1.35,8.77) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.47,1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.45 (0.93,6.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.33,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 (0.65,2.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.27,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.50,2.31)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laquinimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.06 (0.18,23.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55 (0.66,3.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.62,1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.70 (0.25,11.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.61,1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.77,2.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.55,1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.74 (0.89,3.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.29,3.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.28 (0.45,40.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.26 (0.12,0.58) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.05,6.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67 (0.13,21.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.03,3.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.09,15.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.03,4.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.05,8.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27 (0.02,3.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.04,6.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.04,5.56)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta 1a and 1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.06,9.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49 (0.04,5.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.04,17.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49 (0.04,5.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.05,6.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 (0.04,5.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.07,10.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.03,6.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.07 (0.82,5.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13 (0.01,1.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.33,1.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.22 (0.70,7.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.44 (0.20,0.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.58 (0.49,5.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.17,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.32,2.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.36 (0.14,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.26,1.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.28,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 (0.11,16.69)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.30,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.14,8.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.32,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.37,1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.26,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.46,2.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.16,2.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.76 (0.26,29.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.17 (0.06,0.46) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.69,2.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.41 (1.33,8.73) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.45,1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.42 (0.91,6.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.40,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.63,2.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55 (0.32,0.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.49,2.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.60,1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.04 (0.18,23.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.54 (0.70,3.35)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.68 (0.24,11.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.67,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.82,1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.55,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.72 (1.08,2.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.29,3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.23 (0.44,40.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (0.14,0.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.11,5.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.03 (0.25,16.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.06,2.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (0.18,11.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.05,3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.11,5.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.04,2.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 (0.09,4.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 (0.09,4.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.06,26.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.12,7.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 (0.09,4.12)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Immunoglobulins</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 (0.09,4.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.11,5.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54 (0.08,3.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.14,7.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.06,4.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.52 (0.14,46.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 (0.02,1.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.70,2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.41 (1.35,8.64) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.68 (0.47,0.98) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.43 (0.92,6.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.35,1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.64,2.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.28,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.50,2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.59,1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.05 (0.18,23.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.54 (0.75,3.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.67,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.68 (0.24,11.58)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glatiramer acetate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.83,1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.59,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.72 (0.95,3.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.29,2.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.24 (0.44,40.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.26 (0.13,0.54) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.58,1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.74 (1.10,6.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.54 (0.39,0.76) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.95 (0.75,5.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.28,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.53,2.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.45 (0.22,0.89) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.41,1.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.49,1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64 (0.14,18.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.56,2.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.53,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.20,9.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.54,1.20)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fingolimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.46,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.75,2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.24,2.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.41 (0.36,32.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.21 (0.10,0.44) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.77,2.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.73 (1.48,9.42) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.51,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.65 (1.01,6.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.36,1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48 (0.71,3.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.29,1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.55,2.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.64,1.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.24 (0.20,25.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.68 (0.74,3.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.66,1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.84 (0.27,12.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.70,1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36 (0.85,2.18)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dimethyl fumarate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.88 (0.96,3.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.32,3.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.63 (0.48,44.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (0.13,0.63)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.34,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.98 (0.70,5.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.39 (0.22,0.71) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.48,4.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.39 (0.19,0.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.33,1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32 (0.16,0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.25,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.29,1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.10,14.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.36,2.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.58 (0.36,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.13,7.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.32,1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.39,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53 (0.27,1.04)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Daclizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54 (0.16,1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.46 (0.24,24.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.15 (0.07,0.33) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.41,4.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.65 (0.91,14.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.24,2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.59 (0.63,10.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.20,2.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.40,5.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.59 (0.16,2.15) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.32,4.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.33,3.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19 (0.15,30.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64 (0.43,6.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.33,3.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.80 (0.20,16.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.33,3.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 (0.42,4.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.31,3.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.84 (0.53,6.44)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cladribine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.53 (0.38,54.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 (0.08,1.04)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (0.03,2.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.07,8.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 (0.02,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.05,6.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 (0.02,1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32 (0.03,3.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13 (0.01,1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25 (0.02,2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 (0.02,2.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.19,1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 (0.03,3.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24 (0.02,2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.02,7.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24 (0.02,2.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (0.03,2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22 (0.02,2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 (0.04,4.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22 (0.02,2.65)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Azathioprine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06 (0.01,0.64)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.72 (2.05,10.89) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>13.04 (4.27,39.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.59 (1.26,5.32) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9.27 (2.95,29.14) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.60 (1.16,5.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.17 (1.97,13.60) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.12 (0.94,4.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.07 (1.53,10.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.79 (1.74,8.25) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.82 (0.63,96.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.87 (2.16,15.92) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.82 (2.08,7.03) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.43 (0.85,48.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.82 (1.84,7.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.75 (2.27,9.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.50 (1.59,7.68) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6.59 (3.05,14.27) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.58 (0.96,13.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16.19 (1.56,168.25) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alemtuzumab</b> </p> </th> </tr> </tbody> </table> <div class="table-footnote"> <p>Significant results are bolded and underlined</p> </div> </div> <div class="table" id="CD011381-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Netleague: Serious adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Teriflunomid</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.63,1.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.61,1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.47,1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30 (0.67,2.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.31 (0.88,1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.45,1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.57,2.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.01,41.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.68,1.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.43,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.65,1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.51,1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.47,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.53,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64 (0.93,2.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.62,2.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.72,2.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.55,1.58)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ponesimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.43,1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.36,2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.51,2.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.63,2.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.35,1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.44,2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.01,39.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.50,2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.33,1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.48,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.37,1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.34,1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.40,1.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 (0.70,3.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.48,2.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.55,2.73)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.81,1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.66,2.35)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo/ no treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.59,1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (0.85,2.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 (0.89,2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.58,1.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.73,2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.02,47.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.92,1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.55,1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.88,1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.68,1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.64,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.71,1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.90 (1.21,2.99) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.80,2.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 (0.94,2.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.54,2.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.48,2.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.51,1.69)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pegylated interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.61,3.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.63,3.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.41,2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.52,2.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.01,45.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.59,2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.39,1.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.57,2.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.44,1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.41,1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.47,1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76 (0.83,3.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.57,2.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.65,3.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.40,1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.35,1.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.38,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.32,1.64)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ozanimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.47,2.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.35,1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.38,1.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 (0.01,32.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.45,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.31,1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.50,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.35,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.32,1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.36,1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.69,2.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.42,2.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.56,1.85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.51,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.42,1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.39,1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.32,1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.46,2.14)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ofatumumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.31,1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.39,1.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 (0.01,32.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.45,1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.29,1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.43,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.33,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.31,1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.36,1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.63,2.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.43,1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.49,2.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.61,2.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.54,2.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.58,1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.48,2.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (0.79,2.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.51 (0.71,3.22)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ocrelizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.58,2.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.02,48.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.69,2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.47,1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.78,1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.54,1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.49,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.55,1.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.90 (1.07,3.39) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.38 (0.64,2.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 (0.86,2.69)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.50,1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.44,2.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.48,1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.39,1.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.56,2.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.58,2.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.38,1.72)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Natalizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.01,39.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.55,1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.36,1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.53,1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.41,1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.38,1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.44,1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.54 (0.77,3.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.52,2.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.60,2.52)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30 (0.02,69.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.03,77.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.02,59.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.02,67.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.68 (0.03,92.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.70 (0.03,93.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.02,61.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.03,76.26)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mitoxantrone</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.40 (0.03,75.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.02,56.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36 (0.03,72.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.02,56.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.02,51.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.02,62.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.13 (0.04,116.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55 (0.03,85.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.71 (0.03,93.46)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.58,1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.49,2.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.59,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.44,1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.64,2.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.66,2.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.44,1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.54,1.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.01,38.21)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laquinimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.41,1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.64,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.49,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.46,1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.51,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 (0.90,2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.59,2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.70,2.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.67,2.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.59,3.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.65,1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.53,2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (0.81,3.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64 (0.79,3.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.55,2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.65,2.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.02,52.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36 (0.75,2.44)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.31 (0.78,2.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.67,1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.55,1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.62,2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.06 (1.11,3.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (0.71,3.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.65 (0.88,3.12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.59,1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.50,2.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.60,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.45,1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.78,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.68,2.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.54,1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.55,1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.01,39.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.69,1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.46,1.28)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.56,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.71 (0.51,0.99) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.53,1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.57 (1.07,2.30) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.61,2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.87,1.82)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.77,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 (0.65,2.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.78,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.59,2.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.60 (0.91,2.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (0.88,2.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.62,1.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.72,2.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.02,51.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.87,2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.65,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.93,1.79)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glatiramer acetate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.65,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.71,1.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.03 (1.26,3.28) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48 (0.78,2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.63 (1.00,2.66) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.86,2.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.72,2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.88,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.65,2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.75 (0.99,3.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.77 (0.97,3.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.68,2.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.80,2.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.02,55.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.46 (0.97,2.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.63,1.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.41 (1.01,1.97) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.78,1.54)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fingolimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.77,1.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.22 (1.37,3.60) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (0.87,3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.78 (1.09,2.92) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.66,1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.57,2.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.66,1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.51,2.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.74,2.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.46 (0.76,2.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.51,1.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.62,2.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.02,46.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.74,1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.49,1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.73,1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.58,1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.52,1.30)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dimethyl fumarate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.83 (1.03,3.26) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.68,2.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.47 (0.81,2.67)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.34,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.30,1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.53 (0.33,0.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.27,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.43,1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.40,1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.53 (0.30,0.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.32,1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47 (0.01,25.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.39,1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49 (0.26,0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.43,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.49 (0.31,0.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.45 (0.28,0.73) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55 (0.31,0.97) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Daclizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.36,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.47,1.36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.43,1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.39,2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.42,1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.35,1.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.49,2.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.51,2.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.33,1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.42,1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.01,35.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.48,1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.31,1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.46,1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.36,1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.33,1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.38,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 (0.67,2.80)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cladribine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.53,2.30)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.42,1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.37,1.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.40,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.33,1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.54,1.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.48,2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.37,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.40,1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.01,31.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.47,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.32,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.55,1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.38,1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.56 (0.34,0.92) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.37,1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.73,2.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.44,1.89)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alemtuzumab</b> </p> </th> </tr> </tbody> </table> <div class="table-footnote"> <p>Significant results are bolded and underlined</p> </div> </div> <p><a href="./appendices#CD011381-sec-0119">Appendix 6</a>, <a href="./appendices#CD011381-sec-0120">Appendix 7</a>, <a href="./appendices#CD011381-sec-0121">Appendix 8</a>, <a href="./appendices#CD011381-sec-0122">Appendix 9</a>, <a href="./appendices#CD011381-sec-0123">Appendix 10</a>, <a href="./appendices#CD011381-sec-0124">Appendix 11</a>, <a href="./appendices#CD011381-sec-0125">Appendix 12</a>, and <a href="./appendices#CD011381-sec-0126">Appendix 13</a> show estimates of secondary efficacy and safety outcomes of each treatment against placebo and against each other treatment included in the network. </p> <section id="CD011381-sec-0071"> <h4 class="title">1. Primary outcomes</h4> <section id="CD011381-sec-0072"> <h5 class="title">1.1 Efficacy</h5> <section id="CD011381-sec-0073"> <h6 class="title">Relapses (over 12, 24 and 36 months) and disability worsening (over 24 and 36 months)</h6> <section id="CD011381-sec-0074"> <p><b>Pairwise meta‐analysis (direct comparisons)</b></p> <p>Treatment estimates from pairwise meta‐analyses for each efficacy outcome are reported in <a href="./references#CD011381-fig-0008" title="">Analysis 1.1</a>, <a href="./references#CD011381-fig-0009" title="">Analysis 1.2</a>, <a href="./references#CD011381-fig-0010" title="">Analysis 1.3</a>, <a href="./references#CD011381-fig-0011" title="">Analysis 1.4</a>, and <a href="./references#CD011381-fig-0012" title="">Analysis 1.5</a>. </p> </section> <section id="CD011381-sec-0075"> <p><b>Network meta‐analysis estimates (combination of direct and indirect comparisons) of treatment effects</b></p> <p>See: <a href="./full#CD011381-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD011381-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011381-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD011381-tbl-0004">summary of findings Table 4</a>. </p> <p>a) <b>Relapses over 12 months</b> were provided in 18 studies involving 9310 participants with RRMS (25.49% of the participants in this review) (<a href="./references#CD011381-bbs2-0001" title="AchironA , GabbayU , GiladR , HassinB , BarakY , GornishM , et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology1998;50(2):398-402. ">Achiron 1998</a>; <a href="./references#CD011381-bbs2-0002" title="CalabresiPA , KieseierBC , ArnoldDL , BalcerLJ , BoykoA , PelletierJ , et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurology2014;13:657-65. HuX , CuiY , WhiteJ , ZhuY , DeykinA , NestorovI , HungS . Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. British Journal of Clinical Pharmacology2015;79(3):514-22. [DOI: 10.1111/bcp.12521] [PMID: 25265472]ScottTF , KieseierBC , NewsomeSD , ArnoldDL , YouX , HungS , Sperling B. Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis.. Mult Scler J Exp Transl Clin. 2016 ;2:2055217316676644. [DOI: 10.1177/2055217316676644] [PMID: 28607743]">ADVANCE 2014</a>; <a href="./references#CD011381-bbs2-0003" title="BalcerLJ , GalettaSL , PolmanCH , EggenbergerE , CalabresiPA , ZhangA , et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.. J Neurol Sci2012;318(1-2):119-24. [DOI: 10.1016/j.jns.2012.03.009] [PMID: 22521274]LublinFD , CutterG , GiovannoniG , PaceA , CampbellNR , BelachewS . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.. Mult Scler Relat Disord2014;3(6):705-11. [DOI: 10.1016/j.msard.2014.08.005] [PMID: 25891549]PolmanCH , O'ConnorPW , HavrdovaE , HutchinsonM , KapposL , MillerDH , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):899-910. Weinstock-GuttmanB , GalettaSL , GiovannoniG , HavrdovaE , HutchinsonM , KapposL , et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology2012;259((5)):898-905. [DOI: 10.1007/s00415-011-6275-7] [PMID: 22008873]">AFFIRM 2006</a>; <a href="./references#CD011381-bbs2-0007" title="CreeBAC , GoldmanMD , CorboyJR , SingerBA , FoxEJ , ArnoldDL , et al, ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020 ;78(1):1–13. [DOI: 10.1001/jamaneurol.2020.2950] [PMID: 32852530]">ASSESS 2020</a>; <a href="./references#CD011381-bbs2-0008" title="BrownRA , NarayananS , StikovN , CookS , CadavidD , WolanskyL , et al. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. Neurology2016;87(9):905-11. [DOI: 10.1212/WNL.0000000000003043] [PMID: 27473139]CadavidD , WolanskyLJ , SkurnickJ , LincolnJ , CheriyanJ , SzczepanowskiK , et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology2009;72(23):1976-83. CheriyanJ , KimS , WolanskyLJ , CookSD , CadavidD . Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol2012;69(1):82-8. [DOI: 10.1001/archneurol.2011.674]">BECOME 2009</a>; <a href="./references#CD011381-bbs2-0010" title="BornsteinMB , MillerA , SlagleS , WeitzmanM , Crystal, DrexlerE , et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New England Journal of Medicine1987;317(7):408-14. ">Bornstein 1987</a>; <a href="./references#CD011381-bbs2-0022" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. Journal of Neurology2007;254(12):1723-8. ">Etemadifar 2007</a>; <a href="./references#CD011381-bbs2-0026" title='DavisMD , AshtamkerN , SteinermanJR , KnappertzV . Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study. 2017 Neurol Neuroimmunol Neuroinflamm;4(2):e327. [DOI: 10.1212/NXI.0000000000000327] [PMID: 28210662]KhanO , RieckmannP , BoykoA , SelmajK , ZivadinovR , GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Annals of Neurology2013;73(6):705-13. ZivadinovR , DwyerM , BarkayH , SteinermanJR , KnappertzV , Khan O. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis. J Neurol2015;262(3):648-53. [DOI: 10.1007/s00415-014-7616-0] [PMID: 25542295]ZivadinovR , DwyerMG , RamasamyDP , DavisMD , SteinermanJR , KhanO . The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. J Neuroimaging2015;25(6):989-95. [DOI: 10.1111/jon.12293] [PMID: 26394270]'>GALA 2013</a>; <a href="./references#CD011381-bbs2-0027" title="GobbiC , MeierDS , CottonF , SintzelM , LeppertD , GuttmannCR , ZeccaC . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol2013;13:101. [DOI: 10.1186/1471-2377-13-101] [PMID: 23915113]ZeccaC , RiccitelliGC , CalabreseP , PravatàE , CandrianU , GuttmannCR , Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol2014;14:38. [DOI: 10.1186/1471-2377-14-38] [PMID: 24576156]">Gobbi 2013</a>; <a href="./references#CD011381-bbs2-0028" title="ComiG , PattiF , RoccaMA , MattioliFC , AmatoMP , GalloP , CentonzeD , PozzilliC , SaccàF , BerghFT , BartezaghiM , TurriniR , FilippiM , Golden Study Group. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol2017;264(12):2436-2449. [DOI: 10.1007/s00415-017-8642-5] [PMID: 29063244]">GOLDEN 2017</a>; <a href="./references#CD011381-bbs2-0029" title="GoodkinD , BaillyR , TeetzenM , HertsgaardD , BeattyW . The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology1991;41:20-5. ">Goodkin 1991</a>; <a href="./references#CD011381-bbs2-0035" title="LewanskaM , Siger-ZajdelM , SelmajK . No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. European Journal of Neurology2002;9(6):565-72. ">Lewanska 2002</a>; <a href="./references#CD011381-bbs2-0036" title="MassacesiL , TramacereI , AmorosoS , BattagliaMA , BenedettiMD , FilippiniG , et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One2014;9(11):e113371. ">MAIN 2014</a>; <a href="./references#CD011381-bbs2-0037" title="MillefioriniE , GasperiniC , PozzilliC , D'AndreaF , BastianelloS , TrojanoM , et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology1997;244(3):153-9. ">Millefiorini 1997</a>; <a href="./references#CD011381-bbs2-0043" title="EbersGC . Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet1998;352(9139):1498-1504. [DOI: 10.1016/S0140-6736(98)03334-0]TraboulseeA , LiDKB , CascioneM , FangJ , DangondF , MillerA . Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. BMC Neurol2018;18(1):143. [DOI: 10.1186/s12883-018-1145-x] [PMID: 30217172]">PRISMS 1998</a>; <a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a>; <a href="./references#CD011381-bbs2-0049" title="ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(3):247-56. FreedmanMS , MorawskiJ , ThangaveluK . Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. Mult Scler J Exp Transl Clin2018;4(2):2055217318775236. [DOI: 10.1177/2055217318775236] [PMID: 29796289]MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MäurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol2014;261(9):1781-8. [DOI: 10.1007/s00415-014-7395-7] [PMID: 24972678]MillerAE , XuX , MacdonellR , VucicS , TruffinetP , BenamorM , et al. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. J Clin Neurosci2019;59:229-231. [DOI: 10.1016/j.jocn.2018.09.012] [PMID: 30348586]QiuW , HuangDH , HouSF , ZhangMN , JinT , DongHQ , et al, TOWER Trial Chinese Group. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study. Chin Med J (Engl)2018;131(23):2776-2784. [DOI: 10.4103/0366-6999.246067] [PMID: 30511679]">TOWER 2014</a>; <a href="./references#CD011381-bbs2-0050" title="BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler2014;20(13):1704-13. [DOI: 10.1177/1352458514532317] [PMID: 24812043]CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402-15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol2013;260(8):2023-32. [DOI: 10.1007/s00415-013-6932-0] [PMID: 23632946]KhatriBO , PelletierJ , KapposL , HartungHP , ComiG , BarkhofF , et al, TRANSFORMS Study Group. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord2014;3(3):355-63. [DOI: 10.1016/j.msard.2013.11.006] [PMID: 25876473]MengX , ChinPS , HashmonayR , Zahur IslamM , CutterG . Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemp Clin Trials2015;41:69-74. [DOI: 10.1016/j.cct.2014.12.011] [PMID: 25545026]">TRANSFORMS 2010</a>) and assessing 13 treatments. The network geometry for relapses over 12 months is shown in <a href="#CD011381-fig-0004">Figure 4</a>. </p> <p>Nine treatments assessed in 18 studies were compared to placebo, of which seven treatments were evaluated in head‐to‐head comparisons in seven studies. Using placebo as a common comparator (see <a href="#CD011381-fig-0007">Figure 7</a>), treatment with natalizumab results in a large reduction of people with relapses (RR 0.52, 95% CI 0.43 to 0.63; high‐certainty evidence). Treatment with fingolimod (RR 0.48, 95% CI 0.39 to 0.57; moderate‐certainty evidence), daclizumab (RR 0.55, 95% CI 0.42 to 0.73; moderate‐certainty evidence) or immunoglobulins (RR 0.60, 95% CI 0.47 to 0.79; moderate‐certainty evidence) probably results in a large reduction of people with relapses. Treatment with mitoxantrone (RR 0.40, 95% CI 0.21 to 0.74; low‐certainty evidence), teriflunomide (RR 0.66, 95% CI 0.55 to 0.78; low‐certainty evidence), pegylated interferon beta‐1a (RR 0.68, 95% CI 0.56 to 0.82; low‐certainty evidence) or glatiramer acetate (RR 0.64, 95% CI 0.55 to 0.75; low‐certainty evidence) may result in a large reduction of people with relapses. Treatment with interferon beta‐1a (Avonex, Rebif) (RR 0.76, 95% CI 0.68 to 0.85; low‐certainty evidence) may moderately reduce the number of people with relapses. Treatment with interferon beta‐1b (RR 0.82, 95% CI 0.50 to 1.33; very low‐certainty evidence) may moderately reduce the number of people with relapses, but the evidence is very uncertain. When interferon beta 1‐a and beta 1‐b (RR 1.42, 95% CI 0.78 to 2.60; very low‐certainty evidence) were both used in the same intervention, there may have been a large increase in the number of people with relapses, but the evidence is very uncertain. Differences across treatments were found and are shown in <a href="#CD011381-tbl-0008">Table 2</a>. </p> <p>b) <b>Relapses over 24 months</b> were provided in 28 studies involving 19,869 participants with RRMS (54.37% of those included in this review) (<a href="./references#CD011381-bbs2-0001" title="AchironA , GabbayU , GiladR , HassinB , BarakY , GornishM , et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology1998;50(2):398-402. ">Achiron 1998</a>; <a href="./references#CD011381-bbs2-0003" title="BalcerLJ , GalettaSL , PolmanCH , EggenbergerE , CalabresiPA , ZhangA , et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.. J Neurol Sci2012;318(1-2):119-24. [DOI: 10.1016/j.jns.2012.03.009] [PMID: 22521274]LublinFD , CutterG , GiovannoniG , PaceA , CampbellNR , BelachewS . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.. Mult Scler Relat Disord2014;3(6):705-11. [DOI: 10.1016/j.msard.2014.08.005] [PMID: 25891549]PolmanCH , O'ConnorPW , HavrdovaE , HutchinsonM , KapposL , MillerDH , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):899-910. Weinstock-GuttmanB , GalettaSL , GiovannoniG , HavrdovaE , HutchinsonM , KapposL , et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology2012;259((5)):898-905. [DOI: 10.1007/s00415-011-6275-7] [PMID: 22008873]">AFFIRM 2006</a>; <a href="./references#CD011381-bbs2-0004" title="ComiG , JefferyD , KapposL , MontalbanX , BoykoA , RoccaMA , et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. New England Journal of Medicine2012;366(11):1000-9. FilippiM , RoccaMA , PaganiE , De StefanoN , JefferyD , KapposL , et al, ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry2014;85(8):851-8. [DOI: 10.1136/jnnp-2013-306132] [PMID: 24029546]">ALLEGRO 2012</a>; <a href="./references#CD011381-bbs2-0008" title="BrownRA , NarayananS , StikovN , CookS , CadavidD , WolanskyL , et al. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. Neurology2016;87(9):905-11. [DOI: 10.1212/WNL.0000000000003043] [PMID: 27473139]CadavidD , WolanskyLJ , SkurnickJ , LincolnJ , CheriyanJ , SzczepanowskiK , et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology2009;72(23):1976-83. CheriyanJ , KimS , WolanskyLJ , CookSD , CadavidD . Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol2012;69(1):82-8. [DOI: 10.1001/archneurol.2011.674]">BECOME 2009</a>; <a href="./references#CD011381-bbs2-0009" title="O'ConnorP , FilippiM , ArnasonB , ComiG , CookS , GoodinD , et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology2009;8(10):889-97. SchipplingS , O'ConnorP , KnappertzV , PohlC , BogumilT , SuarezG , et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol2016;263(7):1418-26. [DOI: 10.1007/s00415-016-8146-8]">BEYOND 2009</a>; <a href="./references#CD011381-bbs2-0010" title="BornsteinMB , MillerA , SlagleS , WeitzmanM , Crystal, DrexlerE , et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New England Journal of Medicine1987;317(7):408-14. ">Bornstein 1987</a>; <a href="./references#CD011381-bbs2-0011" title="VollmerTL , SorensenPS , SelmajK , ZippF , HavrdovaE , CohenJA , et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology2014;261(4):773-83. ">BRAVO 2014</a>; <a href="./references#CD011381-bbs2-0012" title="CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786-801. FoxEJ , WynnD , ColesAJ , PalmerJ , MargolinDH , CAMMS223 Investigators. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. J Neurol Sci2016;363:188-94. [DOI: 10.1016/j.jns.2016.02.025]">CAMMS223 2008</a>; <a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a>; <a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a>; <a href="./references#CD011381-bbs2-0015" title="AfolabiD , AlborC , ZalewskiL , AltmannDR , BakerD , SchmiererK . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler2018 ;24(11):1461-1468. [DOI: 10.1177/1352458517726380] [PMID: 28817997]ComiG , CookSD , GiovannoniG , RammohanK , RieckmannP , SørensenPS , et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol2013;260(4):1136-46. [DOI: 10.1007/s00415-012-6775-0] [PMID: 23263473]De StefanoN , GiorgioA , BattagliniM , De LeucioA , HickingC , DangondF , et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018;24(2):222-226. [DOI: 10.1177/1352458517690269] [PMID: 28140753]GiovannoniG , ComiG , CookS , RammohanK , RieckmannP , Soelberg SørensenP , et al, CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):416-26. [DOI: 10.1056/NEJMoa0902533] [PMID: 20089960]GiovannoniG , Soelberg SorensenP , CookS , RammohanKW , RieckmannP , ComiG , et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler2019;25(6):819-827. [DOI: 10.1177/1352458518771875] [PMID: 29716436]HermannR , LitwinJS , FribergLE , DangondF , MunafoA . Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Br J Clin Pharmacol2019 ;85(7):1484-1494. [DOI: 10.1111/bcp.13919] [PMID: 30883839]VermerschP , GalazkaA , DangondF , DamianD , WongSL , JackD , et al. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Curr Med Res Opin2021;37(3):459-464. [DOI: 10.1080/03007995.2020.1865888] [PMID: 33331183]">CLARITY 2010</a>; <a href="./references#CD011381-bbs2-0017" title="ComiG , DadonY , SassonN , SteinermanJR , KnappertzV , VollmerTL , et al. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler2022;28(4):608-619. [DOI: 10.1177/13524585211032803] [PMID: 34378456]NCT01707992. The Efficacy, Safety, and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). https://clinicaltrials.gov/show/NCT017079922012. ">CONCERTO 2021</a>; <a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a>; <a href="./references#CD011381-bbs2-0020" title="ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014;261(9):1794-802. [DOI: 10.1007/s00415-014-7412-x] [PMID: 24989666]ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol2014;261(12):2429-37. [DOI: 10.1007/s00415-014-7504-7] [PMID: 25270680]Bar-OrA , GoldR , KapposL , ArnoldDL , GiovannoniG , SelmajK , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol2013 ;260(9):2297-305. [DOI: 10.1007/s00415-013-6954-7] [PMID: 23797999]Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012] [PMID: 28751099]GoldR , KapposL , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine2012;367(12):1098-107. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272] [PMID: 28328179]KapposL , GoldR , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler2014;20(2):243-52. [DOI: 10.1177/1352458513507817] [PMID: 24150779]">DEFINE 2012</a>; <a href="./references#CD011381-bbs2-0021" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica2006;113(5):283-7. ">Etemadifar 2006</a>; <a href="./references#CD011381-bbs2-0023" title="FazekasF , DeisenhammerF , Strasser-FuchsS , NahlerG , MamoliB . Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet1997;349(9052):589-93. ">Fazekas 1997</a>; <a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a>; <a href="./references#CD011381-bbs2-0025" title="CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(6):545-56. VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , Freedman MS A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017 3;3:2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS II 2014</a>; <a href="./references#CD011381-bbs2-0029" title="GoodkinD , BaillyR , TeetzenM , HertsgaardD , BeattyW . The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology1991;41:20-5. ">Goodkin 1991</a>; <a href="./references#CD011381-bbs2-0030" title="IFNBMSG . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology1993;43(4):655-61. ">IFNB MS Group 1993</a>; <a href="./references#CD011381-bbs2-0031" title="DurelliL , VerdunE , BarberoP , BerguiM , VersinoE , GhezziA , et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002;359:1453-60. ">INCOMIN 2002</a>; <a href="./references#CD011381-bbs2-0032" title="JohnsonK , BrooksB , CohenJ , FordC , GoldsteinJ , LisakR , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology1995;45(7):1268-76. ">Johnson 1995</a>; <a href="./references#CD011381-bbs2-0034" title="Koch-HenriksenN , SørensenP , ChristensenT , FrederiksenJ , RavnborgM , JensenK , et al. A randomised study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology2006;66(7):1056-60. ">Koch‐Henriksen 2006</a>; <a href="./references#CD011381-bbs2-0036" title="MassacesiL , TramacereI , AmorosoS , BattagliaMA , BenedettiMD , FilippiniG , et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One2014;9(11):e113371. ">MAIN 2014</a>; <a href="./references#CD011381-bbs2-0037" title="MillefioriniE , GasperiniC , PozzilliC , D'AndreaF , BastianelloS , TrojanoM , et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology1997;244(3):153-9. ">Millefiorini 1997</a>; <a href="./references#CD011381-bbs2-0039" title="JacobsL , CookfairD , RudickR , HerndonR , RichertJ , SalazarA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology1996;39:285-94. ">MSCRG 1996</a>; <a href="./references#CD011381-bbs2-0042" title="KapposL , FoxRJ , BurcklenM , FreedmanMS , HavrdováEK , HennessyB , et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol 2021 May 1;;78(5):558-567. [DOI: 10.1001/jamaneurol.2021.0405] [PMID: 33779698]">OPTIMUM 2021</a>; <a href="./references#CD011381-bbs2-0043" title="EbersGC . Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet1998;352(9139):1498-1504. [DOI: 10.1016/S0140-6736(98)03334-0]TraboulseeA , LiDKB , CascioneM , FangJ , DangondF , MillerA . Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. BMC Neurol2018;18(1):143. [DOI: 10.1186/s12883-018-1145-x] [PMID: 30217172]">PRISMS 1998</a>; <a href="./references#CD011381-bbs2-0045" title="MikolD , BarkhofF , ChangP , CoyleP , JefferyD , SchwidS , et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology2008;7(10):903-14. ">REGARD 2008</a>; <a href="./references#CD011381-bbs2-0048" title="MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al, Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler2012;18(11):1625-32. [DOI: 10.1177/1352458512450354] [PMID: 22723573]O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293-303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol2013;260(10):2472-80. [DOI: 10.1007/s00415-013-6979-y] [PMID: 23852658]RadueEW , SprengerT , GaetanoL , Mueller-LenkeN , CavalierS , ThangaveluK , et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm2017;4(5):e390. [DOI: 10.1212/NXI.0000000000000390] [PMID: 28828394]WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013 ;19(10):1310-9. [DOI: 10.1177/1352458513475723] [PMID: 23447359]">TEMSO 2011</a>) and assessing 15 treatments. The network geometry for relapses over 24 months is shown in <a href="#CD011381-fig-0004">Figure 4</a>. </p> <p>Twelve treatments, assessed in 21 studies, were compared to placebo, ten treatments were evaluated in head‐to‐head comparisons in 11 studies and two studies involving 2751 participants had both placebo and active treatment arms. Using placebo as a common comparator, treatment with cladribine (RR 0.53, 95% CI 0.44 to 0.64; high‐certainty evidence), alemtuzumab (RR 0.57, 95% CI 0.47 to 0.68; high‐certainty evidence) and natalizumab (RR 0.56, 95% CI 0.48 to 0.65; high‐certainty evidence) resulted in a large decrease in people with relapses. Treatment with fingolimod (RR 0.54, 95% CI 0.48 to 0.60; moderate‐certainty evidence), dimethyl fumarate (RR 0.62, 95% CI 0.55 to 0.70; moderate‐certainty evidence), and ponesimod (RR 0.58, 95% CI 0.48 to 0.70; moderate‐certainty evidence) probably results in a large decrease of people with relapses. Treatment with glatiramer acetate (RR 0.84, 95%, CI 0.76 to 0.93; moderate‐certainty evidence) and interferon beta‐1a (Avonex, Rebif) (RR 0.84, 95% CI 0.78 to 0.91; moderate‐certainty evidence) probably moderately decreases people with relapses. Treatment with mitoxantrone (RR 0.47, 95% CI 0.27 to 0.80; low‐certainty evidence) may result in a large decrease in people with relapses. Treatment with immunoglobulins (RR 0.73, 95% CI 0.59 to 0.90; low‐certainty evidence) may result in a large reduction of people with relapses. Treatment with interferon beta‐1b (Betaferon) (RR 0.85, 95% CI 0.76 to 0.94; low‐certainty evidence) and laquinimod (RR 0.83, 95% CI 0.76 to 0.91; low‐certainty evidence) may moderately decrease the number of people with relapses. Treatment with teriflunomide (RR 0.82, 95% CI 0.71 to 0.94; very low‐certainty evidence) and azathioprine (RR 0.77, 95% CI 0.51 to 1.18; very low‐certainty evidence) may moderately decrease people with relapses but the evidence is very uncertain. When interferon beta 1‐a and beta 1‐b (RR 1.21, 95% CI 0.66 to 2.19; very low‐certainty evidence) were both used in the same intervention arm, there may have been a moderate increase in the number of people with relapses, but the evidence is very uncertain. Differences across treatments were found and are shown in <a href="#CD011381-tbl-0009">Table 3</a>. </p> <p>c) <b>Relapses over 36 months</b> were provided in five studies involving 3087 participants with RRMS (8.44% of the participants in this review) (<a href="./references#CD011381-bbs2-0012" title="CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786-801. FoxEJ , WynnD , ColesAJ , PalmerJ , MargolinDH , CAMMS223 Investigators. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. J Neurol Sci2016;363:188-94. [DOI: 10.1016/j.jns.2016.02.025]">CAMMS223 2008</a>; <a href="./references#CD011381-bbs2-0016" title="LublinFD , CofieldSS , CutterGR , ConwitR , NarayanaPA , NelsonF , et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology2013;73(3):327-40. ">CombiRx 2013</a>; <a href="./references#CD011381-bbs2-0019" title="BenedictRH , CohanS , LynchSG , RiesterK , WangP , Castro-BorreroW , et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler2018 ;24(6):795-804. [DOI: 0.1177/1352458517707345]KapposL , HavrdovaE , GiovannoniG , KhatriBO , GauthierSA , GreenbergSJ , et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler2017;23(13):1736-1747. [DOI: 10.1177/1352458516683266]KapposL , WiendlH , SelmajK , ArnoldDL , HavrdovaE , BoykoA , et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2015;373(15):1418-28. [DOI: 10.1056/NEJMoa1501481]KruegerJG , KircikL , HougeirF , FriedmanA , YouX , LucasN , et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther2016;33(7):231-45. [DOI: 10.1007/s12325-016-0353-2]LiuY , VollmerT , HavrdovaE , RiesterK , LeeA , PhillipsG , et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;11:18-24. [DOI: 10.1016/j.msard.2016.11.005]NCT01064401. Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01064401 (accessed 30 September 2014). RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40.. [DOI: 10.1016/j.msard.2017.06.006]">DECIDE 2015</a>; <a href="./references#CD011381-bbs2-0030" title="IFNBMSG . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology1993;43(4):655-61. ">IFNB MS Group 1993</a>; <a href="./references#CD011381-bbs2-0033" title="KnoblerRL , GreensteinJI , JohnsonKP , LublinFD , PanitchHS , ConwayK , et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. Journal of Interferon Research1993;13(5):333-40. ">Knobler 1993</a>) and assessing five treatments. The network geometry for relapses over 36 months is shown in <a href="#CD011381-fig-0004">Figure 4</a>. </p> <p>Only one treatment, assessed in two studies, was compared to placebo. Three treatments were evaluated in head‐to‐head comparisons in three studies. Treatment with interferon beta‐1b (Betaferon) (RR 0.86, 95% CI 0.67 to 1.11; very low‐certainty evidence) may moderately decrease people with relapses, but the evidence is very uncertain. Differences across treatments were found and are shown in <a href="#CD011381-tbl-0010">Table 4</a>. </p> <p>d) <b>Disability worsening over 24 months</b> was available from 31 studies and 24,303 participants with RRMS (66.51% of those included in this review) (<a href="./references#CD011381-bbs2-0001" title="AchironA , GabbayU , GiladR , HassinB , BarakY , GornishM , et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology1998;50(2):398-402. ">Achiron 1998</a>; <a href="./references#CD011381-bbs2-0003" title="BalcerLJ , GalettaSL , PolmanCH , EggenbergerE , CalabresiPA , ZhangA , et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.. J Neurol Sci2012;318(1-2):119-24. [DOI: 10.1016/j.jns.2012.03.009] [PMID: 22521274]LublinFD , CutterG , GiovannoniG , PaceA , CampbellNR , BelachewS . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.. Mult Scler Relat Disord2014;3(6):705-11. [DOI: 10.1016/j.msard.2014.08.005] [PMID: 25891549]PolmanCH , O'ConnorPW , HavrdovaE , HutchinsonM , KapposL , MillerDH , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):899-910. Weinstock-GuttmanB , GalettaSL , GiovannoniG , HavrdovaE , HutchinsonM , KapposL , et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology2012;259((5)):898-905. [DOI: 10.1007/s00415-011-6275-7] [PMID: 22008873]">AFFIRM 2006</a>; <a href="./references#CD011381-bbs2-0004" title="ComiG , JefferyD , KapposL , MontalbanX , BoykoA , RoccaMA , et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. New England Journal of Medicine2012;366(11):1000-9. FilippiM , RoccaMA , PaganiE , De StefanoN , JefferyD , KapposL , et al, ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry2014;85(8):851-8. [DOI: 10.1136/jnnp-2013-306132] [PMID: 24029546]">ALLEGRO 2012</a>; <a href="./references#CD011381-bbs2-0005" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS I 2020</a>; <a href="./references#CD011381-bbs2-0006" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS II 2020</a>; <a href="./references#CD011381-bbs2-0008" title="BrownRA , NarayananS , StikovN , CookS , CadavidD , WolanskyL , et al. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. Neurology2016;87(9):905-11. [DOI: 10.1212/WNL.0000000000003043] [PMID: 27473139]CadavidD , WolanskyLJ , SkurnickJ , LincolnJ , CheriyanJ , SzczepanowskiK , et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology2009;72(23):1976-83. CheriyanJ , KimS , WolanskyLJ , CookSD , CadavidD . Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol2012;69(1):82-8. [DOI: 10.1001/archneurol.2011.674]">BECOME 2009</a>; <a href="./references#CD011381-bbs2-0009" title="O'ConnorP , FilippiM , ArnasonB , ComiG , CookS , GoodinD , et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology2009;8(10):889-97. SchipplingS , O'ConnorP , KnappertzV , PohlC , BogumilT , SuarezG , et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol2016;263(7):1418-26. [DOI: 10.1007/s00415-016-8146-8]">BEYOND 2009</a>; <a href="./references#CD011381-bbs2-0010" title="BornsteinMB , MillerA , SlagleS , WeitzmanM , Crystal, DrexlerE , et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New England Journal of Medicine1987;317(7):408-14. ">Bornstein 1987</a>; <a href="./references#CD011381-bbs2-0011" title="VollmerTL , SorensenPS , SelmajK , ZippF , HavrdovaE , CohenJA , et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology2014;261(4):773-83. ">BRAVO 2014</a>; <a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a>; <a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a>; <a href="./references#CD011381-bbs2-0015" title="AfolabiD , AlborC , ZalewskiL , AltmannDR , BakerD , SchmiererK . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler2018 ;24(11):1461-1468. [DOI: 10.1177/1352458517726380] [PMID: 28817997]ComiG , CookSD , GiovannoniG , RammohanK , RieckmannP , SørensenPS , et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol2013;260(4):1136-46. [DOI: 10.1007/s00415-012-6775-0] [PMID: 23263473]De StefanoN , GiorgioA , BattagliniM , De LeucioA , HickingC , DangondF , et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018;24(2):222-226. [DOI: 10.1177/1352458517690269] [PMID: 28140753]GiovannoniG , ComiG , CookS , RammohanK , RieckmannP , Soelberg SørensenP , et al, CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):416-26. [DOI: 10.1056/NEJMoa0902533] [PMID: 20089960]GiovannoniG , Soelberg SorensenP , CookS , RammohanKW , RieckmannP , ComiG , et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler2019;25(6):819-827. [DOI: 10.1177/1352458518771875] [PMID: 29716436]HermannR , LitwinJS , FribergLE , DangondF , MunafoA . Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Br J Clin Pharmacol2019 ;85(7):1484-1494. [DOI: 10.1111/bcp.13919] [PMID: 30883839]VermerschP , GalazkaA , DangondF , DamianD , WongSL , JackD , et al. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Curr Med Res Opin2021;37(3):459-464. [DOI: 10.1080/03007995.2020.1865888] [PMID: 33331183]">CLARITY 2010</a>; <a href="./references#CD011381-bbs2-0017" title="ComiG , DadonY , SassonN , SteinermanJR , KnappertzV , VollmerTL , et al. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler2022;28(4):608-619. [DOI: 10.1177/13524585211032803] [PMID: 34378456]NCT01707992. The Efficacy, Safety, and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). https://clinicaltrials.gov/show/NCT017079922012. ">CONCERTO 2021</a>; <a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a>; <a href="./references#CD011381-bbs2-0020" title="ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014;261(9):1794-802. [DOI: 10.1007/s00415-014-7412-x] [PMID: 24989666]ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol2014;261(12):2429-37. [DOI: 10.1007/s00415-014-7504-7] [PMID: 25270680]Bar-OrA , GoldR , KapposL , ArnoldDL , GiovannoniG , SelmajK , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol2013 ;260(9):2297-305. [DOI: 10.1007/s00415-013-6954-7] [PMID: 23797999]Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012] [PMID: 28751099]GoldR , KapposL , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine2012;367(12):1098-107. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272] [PMID: 28328179]KapposL , GoldR , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler2014;20(2):243-52. [DOI: 10.1177/1352458513507817] [PMID: 24150779]">DEFINE 2012</a>; <a href="./references#CD011381-bbs2-0023" title="FazekasF , DeisenhammerF , Strasser-FuchsS , NahlerG , MamoliB . Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet1997;349(9052):589-93. ">Fazekas 1997</a>; <a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a>; <a href="./references#CD011381-bbs2-0025" title="CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(6):545-56. VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , Freedman MS A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017 3;3:2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS II 2014</a>; <a href="./references#CD011381-bbs2-0029" title="GoodkinD , BaillyR , TeetzenM , HertsgaardD , BeattyW . The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology1991;41:20-5. ">Goodkin 1991</a>; <a href="./references#CD011381-bbs2-0030" title="IFNBMSG . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology1993;43(4):655-61. ">IFNB MS Group 1993</a>; <a href="./references#CD011381-bbs2-0031" title="DurelliL , VerdunE , BarberoP , BerguiM , VersinoE , GhezziA , et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002;359:1453-60. ">INCOMIN 2002</a>; <a href="./references#CD011381-bbs2-0032" title="JohnsonK , BrooksB , CohenJ , FordC , GoldsteinJ , LisakR , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology1995;45(7):1268-76. ">Johnson 1995</a>; <a href="./references#CD011381-bbs2-0034" title="Koch-HenriksenN , SørensenP , ChristensenT , FrederiksenJ , RavnborgM , JensenK , et al. A randomised study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology2006;66(7):1056-60. ">Koch‐Henriksen 2006</a>; <a href="./references#CD011381-bbs2-0036" title="MassacesiL , TramacereI , AmorosoS , BattagliaMA , BenedettiMD , FilippiniG , et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One2014;9(11):e113371. ">MAIN 2014</a>; <a href="./references#CD011381-bbs2-0037" title="MillefioriniE , GasperiniC , PozzilliC , D'AndreaF , BastianelloS , TrojanoM , et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology1997;244(3):153-9. ">Millefiorini 1997</a>; <a href="./references#CD011381-bbs2-0039" title="JacobsL , CookfairD , RudickR , HerndonR , RichertJ , SalazarA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology1996;39:285-94. ">MSCRG 1996</a>; <a href="./references#CD011381-bbs2-0040" title="A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01247324 (accessed 30 September 2014). HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , JulianL , KöndgenH , LiC , NapieralskiJ , ZhengH , WolinskyJS . Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , BuffelsR , FioreD , GarrenH , HanJ , HauserSL . Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA I 2017</a>; <a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a>; <a href="./references#CD011381-bbs2-0042" title="KapposL , FoxRJ , BurcklenM , FreedmanMS , HavrdováEK , HennessyB , et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol 2021 May 1;;78(5):558-567. [DOI: 10.1001/jamaneurol.2021.0405] [PMID: 33779698]">OPTIMUM 2021</a>; <a href="./references#CD011381-bbs2-0044" title="CohenJA , ComiG , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019;18(11):1021-1033. [DOI: 10.1016/S1474-4422(19)30238-8] [PMID: 31492652]NCT01628393. Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study). https://clinicaltrials.gov/show/NCT016283932012. ">RADIANCE 2019</a>; <a href="./references#CD011381-bbs2-0045" title="MikolD , BarkhofF , ChangP , CoyleP , JefferyD , SchwidS , et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology2008;7(10):903-14. ">REGARD 2008</a>; <a href="./references#CD011381-bbs2-0048" title="MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al, Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler2012;18(11):1625-32. [DOI: 10.1177/1352458512450354] [PMID: 22723573]O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293-303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol2013;260(10):2472-80. [DOI: 10.1007/s00415-013-6979-y] [PMID: 23852658]RadueEW , SprengerT , GaetanoL , Mueller-LenkeN , CavalierS , ThangaveluK , et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm2017;4(5):e390. [DOI: 10.1212/NXI.0000000000000390] [PMID: 28828394]WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013 ;19(10):1310-9. [DOI: 10.1177/1352458513475723] [PMID: 23447359]">TEMSO 2011</a>) and assessing 18 treatments. The network geometry for disability worsening over 24 months is shown in <a href="#CD011381-fig-0004">Figure 4</a>. </p> <p>Eleven treatments, assessed in 20 studies, were compared to placebo (see <a href="#CD011381-fig-0007">Figure 7</a>), thirteen treatments were evaluated in head‐to‐head comparisons in 15 studies and two studies involving 2751 participants had both placebo and active treatment arms. Using placebo as a common comparator, treatment with natalizumab (RR 0.59, 95% CI 0.46 to 0.75; moderate‐certainty evidence) probably results in a moderate reduction of people with disability worsening. Treatment with dimethylfumarate (RR 0.65, 95% CI 0.55 to 0.77; low‐certainty evidence), alemtuzumab (RR 0.67, 95% CI 0.46 to 0.99; low‐certainty evidence), and fingolimod (RR 0.68, 95% CI 0.56 to 0.83; low‐certainty evidence) may moderately reduce people with disability worsening. Treatment with cladribine (RR 0.72, 95% CI 0.56 to 0.91; low‐certainty evidence) and interferon beta‐1b (Betaferon) (RR 0.77 95% CI 0.62 to 0.94; low‐certainty evidence) may result in a small reduction of people with disability worsening. Treatment with mitoxantrone (RR 0.20, 95% CI 0.05 to 0.83; very low‐certainty evidence) may result in a large reduction of people who experience disability worsening, but the evidence is very uncertain. The evidence is very uncertain about the following effects on numbers of people experiencing disability worsening: moderate reductions with ofatumumab (RR 0.54, 95% CI 0.38 to 0.77; very low‐certainty evidence), ocrelizumab (RR 0.61, 95% CI 0.41 to 0.90; very low‐certainty evidence), azathioprine (RR 0.60, 95% CI 0.22 to 1.63; very low‐certainty evidence) and ponesimod (RR 0.63, 95% CI 0.41 to 0.96; very low‐certainty evidence). The evidence is very uncertain about the following effects on numbers of people experiencing disability worsening: small reductions with glatiramer acetate (RR 0.74, 95% CI 0.61 to 0.89; very low‐certainty evidence), teriflunomide (RR 0.76, 95% CI 0.61 to 0.95; very low‐certainty evidence) and laquinimod (RR 0.78, 95% CI 0.63 to 0.96; very low‐certainty evidence). Treatment with interferon beta‐1a (RR 0.92, 95% CI 0.73 to 1.16; low‐certainty evidence) may result in a trivial reduction in the number people who experience disability worsening. Treatment with immunoglobulins (RR 0.75, 95% CI 0.41 to 1.37; very low‐certainty evidence) may result in a small reduction in the number of people with disability worsening, but the evidence is very uncertain. When interferon beta 1‐a and beta 1‐b (RR 3.19, 95% CI 0.31 to 33.21; very low‐certainty evidence) were both used in the same intervention arm, there may have been a large increase in the number of people with disability progression, but the evidence is very uncertain. Treatment with ozanimod (RR 1.19, 95% CI 0.74 to 1.91; very low‐certainty evidence) may result in a trivial increase in the number of people with disability progression, but the evidence is very uncertain. Differences across treatments were found and are shown in <a href="#CD011381-tbl-0011">Table 5</a>. </p> <p>e) <b>Disability worsening over 36 months</b> was available from three studies and 2684 participants with RRMS (7.35% of those included in this review)(<a href="./references#CD011381-bbs2-0012" title="CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786-801. FoxEJ , WynnD , ColesAJ , PalmerJ , MargolinDH , CAMMS223 Investigators. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. J Neurol Sci2016;363:188-94. [DOI: 10.1016/j.jns.2016.02.025]">CAMMS223 2008</a>; <a href="./references#CD011381-bbs2-0016" title="LublinFD , CofieldSS , CutterGR , ConwitR , NarayanaPA , NelsonF , et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology2013;73(3):327-40. ">CombiRx 2013</a>; <a href="./references#CD011381-bbs2-0019" title="BenedictRH , CohanS , LynchSG , RiesterK , WangP , Castro-BorreroW , et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler2018 ;24(6):795-804. [DOI: 0.1177/1352458517707345]KapposL , HavrdovaE , GiovannoniG , KhatriBO , GauthierSA , GreenbergSJ , et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler2017;23(13):1736-1747. [DOI: 10.1177/1352458516683266]KapposL , WiendlH , SelmajK , ArnoldDL , HavrdovaE , BoykoA , et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2015;373(15):1418-28. [DOI: 10.1056/NEJMoa1501481]KruegerJG , KircikL , HougeirF , FriedmanA , YouX , LucasN , et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther2016;33(7):231-45. [DOI: 10.1007/s12325-016-0353-2]LiuY , VollmerT , HavrdovaE , RiesterK , LeeA , PhillipsG , et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;11:18-24. [DOI: 10.1016/j.msard.2016.11.005]NCT01064401. Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01064401 (accessed 30 September 2014). RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40.. [DOI: 10.1016/j.msard.2017.06.006]">DECIDE 2015</a>) and assessing four treatments. No studies were compared to placebo. Differences across treatments were found and are shown in <a href="#CD011381-tbl-0012">Table 6</a>. The network geometry for disability worsening over 36 months is shown in <a href="#CD011381-fig-0004">Figure 4</a>. </p> </section> </section> </section> <section id="CD011381-sec-0076"> <h5 class="title">1.2 Safety</h5> <section id="CD011381-sec-0077"> <h6 class="title">Treatment discontinuation due to adverse events and serious adverse events (SAEs)</h6> <section id="CD011381-sec-0078"> <p><b>Pairwise meta‐analysis (direct comparisons)</b></p> <p>Treatment estimates for pairwise meta‐analyses are reported in <a href="./references#CD011381-fig-0013" title="">Analysis 2.1</a>; <a href="./references#CD011381-fig-0014" title="">Analysis 2.2</a>. </p> </section> <section id="CD011381-sec-0079"> <p><b>Network meta‐analysis estimates (combination of direct and indirect comparisons) of treatment effects</b></p> <p>See: <a href="./full#CD011381-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD011381-tbl-0006">summary of findings Table 6</a>. </p> <p>a) <b>Treatment discontinuation due to adverse events</b> was available from 43 studies and 35,410 participants with RRMS (96.9% of those included in this review) (<a href="./references#CD011381-bbs2-0001" title="AchironA , GabbayU , GiladR , HassinB , BarakY , GornishM , et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology1998;50(2):398-402. ">Achiron 1998</a>; <a href="./references#CD011381-bbs2-0002" title="CalabresiPA , KieseierBC , ArnoldDL , BalcerLJ , BoykoA , PelletierJ , et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurology2014;13:657-65. HuX , CuiY , WhiteJ , ZhuY , DeykinA , NestorovI , HungS . Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. British Journal of Clinical Pharmacology2015;79(3):514-22. [DOI: 10.1111/bcp.12521] [PMID: 25265472]ScottTF , KieseierBC , NewsomeSD , ArnoldDL , YouX , HungS , Sperling B. Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis.. Mult Scler J Exp Transl Clin. 2016 ;2:2055217316676644. [DOI: 10.1177/2055217316676644] [PMID: 28607743]">ADVANCE 2014</a>; <a href="./references#CD011381-bbs2-0003" title="BalcerLJ , GalettaSL , PolmanCH , EggenbergerE , CalabresiPA , ZhangA , et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.. J Neurol Sci2012;318(1-2):119-24. [DOI: 10.1016/j.jns.2012.03.009] [PMID: 22521274]LublinFD , CutterG , GiovannoniG , PaceA , CampbellNR , BelachewS . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.. Mult Scler Relat Disord2014;3(6):705-11. [DOI: 10.1016/j.msard.2014.08.005] [PMID: 25891549]PolmanCH , O'ConnorPW , HavrdovaE , HutchinsonM , KapposL , MillerDH , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):899-910. Weinstock-GuttmanB , GalettaSL , GiovannoniG , HavrdovaE , HutchinsonM , KapposL , et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology2012;259((5)):898-905. [DOI: 10.1007/s00415-011-6275-7] [PMID: 22008873]">AFFIRM 2006</a>; <a href="./references#CD011381-bbs2-0004" title="ComiG , JefferyD , KapposL , MontalbanX , BoykoA , RoccaMA , et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. New England Journal of Medicine2012;366(11):1000-9. FilippiM , RoccaMA , PaganiE , De StefanoN , JefferyD , KapposL , et al, ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry2014;85(8):851-8. [DOI: 10.1136/jnnp-2013-306132] [PMID: 24029546]">ALLEGRO 2012</a>;<a href="./references#CD011381-bbs2-0005" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS I 2020</a>; <a href="./references#CD011381-bbs2-0006" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS II 2020</a>; <a href="./references#CD011381-bbs2-0007" title="CreeBAC , GoldmanMD , CorboyJR , SingerBA , FoxEJ , ArnoldDL , et al, ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020 ;78(1):1–13. [DOI: 10.1001/jamaneurol.2020.2950] [PMID: 32852530]">ASSESS 2020</a>; <a href="./references#CD011381-bbs2-0009" title="O'ConnorP , FilippiM , ArnasonB , ComiG , CookS , GoodinD , et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology2009;8(10):889-97. SchipplingS , O'ConnorP , KnappertzV , PohlC , BogumilT , SuarezG , et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol2016;263(7):1418-26. [DOI: 10.1007/s00415-016-8146-8]">BEYOND 2009</a>; <a href="./references#CD011381-bbs2-0010" title="BornsteinMB , MillerA , SlagleS , WeitzmanM , Crystal, DrexlerE , et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New England Journal of Medicine1987;317(7):408-14. ">Bornstein 1987</a>; <a href="./references#CD011381-bbs2-0011" title="VollmerTL , SorensenPS , SelmajK , ZippF , HavrdovaE , CohenJA , et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology2014;261(4):773-83. ">BRAVO 2014</a>; <a href="./references#CD011381-bbs2-0012" title="CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786-801. FoxEJ , WynnD , ColesAJ , PalmerJ , MargolinDH , CAMMS223 Investigators. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. J Neurol Sci2016;363:188-94. [DOI: 10.1016/j.jns.2016.02.025]">CAMMS223 2008</a>; <a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a>; <a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a>; <a href="./references#CD011381-bbs2-0015" title="AfolabiD , AlborC , ZalewskiL , AltmannDR , BakerD , SchmiererK . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler2018 ;24(11):1461-1468. [DOI: 10.1177/1352458517726380] [PMID: 28817997]ComiG , CookSD , GiovannoniG , RammohanK , RieckmannP , SørensenPS , et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol2013;260(4):1136-46. [DOI: 10.1007/s00415-012-6775-0] [PMID: 23263473]De StefanoN , GiorgioA , BattagliniM , De LeucioA , HickingC , DangondF , et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018;24(2):222-226. [DOI: 10.1177/1352458517690269] [PMID: 28140753]GiovannoniG , ComiG , CookS , RammohanK , RieckmannP , Soelberg SørensenP , et al, CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):416-26. [DOI: 10.1056/NEJMoa0902533] [PMID: 20089960]GiovannoniG , Soelberg SorensenP , CookS , RammohanKW , RieckmannP , ComiG , et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler2019;25(6):819-827. [DOI: 10.1177/1352458518771875] [PMID: 29716436]HermannR , LitwinJS , FribergLE , DangondF , MunafoA . Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Br J Clin Pharmacol2019 ;85(7):1484-1494. [DOI: 10.1111/bcp.13919] [PMID: 30883839]VermerschP , GalazkaA , DangondF , DamianD , WongSL , JackD , et al. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Curr Med Res Opin2021;37(3):459-464. [DOI: 10.1080/03007995.2020.1865888] [PMID: 33331183]">CLARITY 2010</a>; <a href="./references#CD011381-bbs2-0016" title="LublinFD , CofieldSS , CutterGR , ConwitR , NarayanaPA , NelsonF , et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology2013;73(3):327-40. ">CombiRx 2013</a>; <a href="./references#CD011381-bbs2-0017" title="ComiG , DadonY , SassonN , SteinermanJR , KnappertzV , VollmerTL , et al. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler2022;28(4):608-619. [DOI: 10.1177/13524585211032803] [PMID: 34378456]NCT01707992. The Efficacy, Safety, and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). https://clinicaltrials.gov/show/NCT017079922012. ">CONCERTO 2021</a>; <a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a>; <a href="./references#CD011381-bbs2-0020" title="ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014;261(9):1794-802. [DOI: 10.1007/s00415-014-7412-x] [PMID: 24989666]ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol2014;261(12):2429-37. [DOI: 10.1007/s00415-014-7504-7] [PMID: 25270680]Bar-OrA , GoldR , KapposL , ArnoldDL , GiovannoniG , SelmajK , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol2013 ;260(9):2297-305. [DOI: 10.1007/s00415-013-6954-7] [PMID: 23797999]Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012] [PMID: 28751099]GoldR , KapposL , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine2012;367(12):1098-107. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272] [PMID: 28328179]KapposL , GoldR , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler2014;20(2):243-52. [DOI: 10.1177/1352458513507817] [PMID: 24150779]">DEFINE 2012</a>; <a href="./references#CD011381-bbs2-0019" title="BenedictRH , CohanS , LynchSG , RiesterK , WangP , Castro-BorreroW , et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler2018 ;24(6):795-804. [DOI: 0.1177/1352458517707345]KapposL , HavrdovaE , GiovannoniG , KhatriBO , GauthierSA , GreenbergSJ , et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler2017;23(13):1736-1747. [DOI: 10.1177/1352458516683266]KapposL , WiendlH , SelmajK , ArnoldDL , HavrdovaE , BoykoA , et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2015;373(15):1418-28. [DOI: 10.1056/NEJMoa1501481]KruegerJG , KircikL , HougeirF , FriedmanA , YouX , LucasN , et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther2016;33(7):231-45. [DOI: 10.1007/s12325-016-0353-2]LiuY , VollmerT , HavrdovaE , RiesterK , LeeA , PhillipsG , et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;11:18-24. [DOI: 10.1016/j.msard.2016.11.005]NCT01064401. Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01064401 (accessed 30 September 2014). RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40.. [DOI: 10.1016/j.msard.2017.06.006]">DECIDE 2015</a>; <a href="./references#CD011381-bbs2-0022" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. Journal of Neurology2007;254(12):1723-8. ">Etemadifar 2007</a>; <a href="./references#CD011381-bbs2-0023" title="FazekasF , DeisenhammerF , Strasser-FuchsS , NahlerG , MamoliB . Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet1997;349(9052):589-93. ">Fazekas 1997</a>; <a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a>; <a href="./references#CD011381-bbs2-0025" title="CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(6):545-56. VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , Freedman MS A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017 3;3:2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS II 2014</a>; <a href="./references#CD011381-bbs2-0026" title='DavisMD , AshtamkerN , SteinermanJR , KnappertzV . Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study. 2017 Neurol Neuroimmunol Neuroinflamm;4(2):e327. [DOI: 10.1212/NXI.0000000000000327] [PMID: 28210662]KhanO , RieckmannP , BoykoA , SelmajK , ZivadinovR , GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Annals of Neurology2013;73(6):705-13. ZivadinovR , DwyerM , BarkayH , SteinermanJR , KnappertzV , Khan O. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis. J Neurol2015;262(3):648-53. [DOI: 10.1007/s00415-014-7616-0] [PMID: 25542295]ZivadinovR , DwyerMG , RamasamyDP , DavisMD , SteinermanJR , KhanO . The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. J Neuroimaging2015;25(6):989-95. [DOI: 10.1111/jon.12293] [PMID: 26394270]'>GALA 2013</a>; <a href="./references#CD011381-bbs2-0027" title="GobbiC , MeierDS , CottonF , SintzelM , LeppertD , GuttmannCR , ZeccaC . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol2013;13:101. [DOI: 10.1186/1471-2377-13-101] [PMID: 23915113]ZeccaC , RiccitelliGC , CalabreseP , PravatàE , CandrianU , GuttmannCR , Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol2014;14:38. [DOI: 10.1186/1471-2377-14-38] [PMID: 24576156]">Gobbi 2013</a>; <a href="./references#CD011381-bbs2-0028" title="ComiG , PattiF , RoccaMA , MattioliFC , AmatoMP , GalloP , CentonzeD , PozzilliC , SaccàF , BerghFT , BartezaghiM , TurriniR , FilippiM , Golden Study Group. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol2017;264(12):2436-2449. [DOI: 10.1007/s00415-017-8642-5] [PMID: 29063244]">GOLDEN 2017</a>; <a href="./references#CD011381-bbs2-0029" title="GoodkinD , BaillyR , TeetzenM , HertsgaardD , BeattyW . The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology1991;41:20-5. ">Goodkin 1991</a>; <a href="./references#CD011381-bbs2-0030" title="IFNBMSG . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology1993;43(4):655-61. ">IFNB MS Group 1993</a>; <a href="./references#CD011381-bbs2-0031" title="DurelliL , VerdunE , BarberoP , BerguiM , VersinoE , GhezziA , et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002;359:1453-60. ">INCOMIN 2002</a>; <a href="./references#CD011381-bbs2-0032" title="JohnsonK , BrooksB , CohenJ , FordC , GoldsteinJ , LisakR , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology1995;45(7):1268-76. ">Johnson 1995</a>; <a href="./references#CD011381-bbs2-0035" title="LewanskaM , Siger-ZajdelM , SelmajK . No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. European Journal of Neurology2002;9(6):565-72. ">Lewanska 2002</a>; <a href="./references#CD011381-bbs2-0036" title="MassacesiL , TramacereI , AmorosoS , BattagliaMA , BenedettiMD , FilippiniG , et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One2014;9(11):e113371. ">MAIN 2014</a>; <a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a>; <a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a>; <a href="./references#CD011381-bbs2-0042" title="KapposL , FoxRJ , BurcklenM , FreedmanMS , HavrdováEK , HennessyB , et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol 2021 May 1;;78(5):558-567. [DOI: 10.1001/jamaneurol.2021.0405] [PMID: 33779698]">OPTIMUM 2021</a>; <a href="./references#CD011381-bbs2-0043" title="EbersGC . Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet1998;352(9139):1498-1504. [DOI: 10.1016/S0140-6736(98)03334-0]TraboulseeA , LiDKB , CascioneM , FangJ , DangondF , MillerA . Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. BMC Neurol2018;18(1):143. [DOI: 10.1186/s12883-018-1145-x] [PMID: 30217172]">PRISMS 1998</a>; <a href="./references#CD011381-bbs2-0044" title="CohenJA , ComiG , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019;18(11):1021-1033. [DOI: 10.1016/S1474-4422(19)30238-8] [PMID: 31492652]NCT01628393. Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study). https://clinicaltrials.gov/show/NCT016283932012. ">RADIANCE 2019</a>; <a href="./references#CD011381-bbs2-0045" title="MikolD , BarkhofF , ChangP , CoyleP , JefferyD , SchwidS , et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology2008;7(10):903-14. ">REGARD 2008</a>; <a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a>; <a href="./references#CD011381-bbs2-0047" title="ComiG , KapposL , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology2019 ;18(11):1009-1020. [DOI: 10.1016/S1474-4422(19)30239-X]DeLucaJ , SchipplingS , MontalbanX , KapposL , CreeBAC , ComiG , et al. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Mult Scler Relat Disord2021;48:102673. [DOI: 10.1016/j.msard.2020.102673]NCT02294058. Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS). https://ClinicalTrials.gov/show/NCT022940582014. ">SUNBEAM 2019</a>; <a href="./references#CD011381-bbs2-0048" title="MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al, Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler2012;18(11):1625-32. [DOI: 10.1177/1352458512450354] [PMID: 22723573]O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293-303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol2013;260(10):2472-80. [DOI: 10.1007/s00415-013-6979-y] [PMID: 23852658]RadueEW , SprengerT , GaetanoL , Mueller-LenkeN , CavalierS , ThangaveluK , et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm2017;4(5):e390. [DOI: 10.1212/NXI.0000000000000390] [PMID: 28828394]WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013 ;19(10):1310-9. [DOI: 10.1177/1352458513475723] [PMID: 23447359]">TEMSO 2011</a>; <a href="./references#CD011381-bbs2-0049" title="ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(3):247-56. FreedmanMS , MorawskiJ , ThangaveluK . Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. Mult Scler J Exp Transl Clin2018;4(2):2055217318775236. [DOI: 10.1177/2055217318775236] [PMID: 29796289]MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MäurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol2014;261(9):1781-8. [DOI: 10.1007/s00415-014-7395-7] [PMID: 24972678]MillerAE , XuX , MacdonellR , VucicS , TruffinetP , BenamorM , et al. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. J Clin Neurosci2019;59:229-231. [DOI: 10.1016/j.jocn.2018.09.012] [PMID: 30348586]QiuW , HuangDH , HouSF , ZhangMN , JinT , DongHQ , et al, TOWER Trial Chinese Group. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study. Chin Med J (Engl)2018;131(23):2776-2784. [DOI: 10.4103/0366-6999.246067] [PMID: 30511679]">TOWER 2014</a>; <a href="./references#CD011381-bbs2-0050" title="BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler2014;20(13):1704-13. [DOI: 10.1177/1352458514532317] [PMID: 24812043]CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402-15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol2013;260(8):2023-32. [DOI: 10.1007/s00415-013-6932-0] [PMID: 23632946]KhatriBO , PelletierJ , KapposL , HartungHP , ComiG , BarkhofF , et al, TRANSFORMS Study Group. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord2014;3(3):355-63. [DOI: 10.1016/j.msard.2013.11.006] [PMID: 25876473]MengX , ChinPS , HashmonayR , Zahur IslamM , CutterG . Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemp Clin Trials2015;41:69-74. [DOI: 10.1016/j.cct.2014.12.011] [PMID: 25545026]">TRANSFORMS 2010</a>) and assessing 19 treatments. The network geometry for treatment discontinuation due to adverse events is shown in <a href="#CD011381-fig-0004">Figure 4</a>. </p> <p>Thirteen treatments, assessed in 24 studies, were compared to placebo, 16 treatments were evaluated in head‐to‐head comparisons in 21 studies and two studies involving 2751 participants had both placebo and active treatment arms. Using placebo as a common comparator, treatment with alemtuzumab probably results in a trivial reduction of people who discontinued due to adverse events (OR 0.39, 95% CI 0.19 to 0.79; moderate‐certainty evidence). Treatment with ocrelizumab may result in a trivial reduction in people who discontinue due to adverse events (OR 0.82, 95% CI 0.42 to 1.60; low‐certainty evidence). Treatment with daclizumab (OR 2.55, 95% CI 1.40 to 4.63; moderate‐certainty evidence), fingolimod (OR 1.84, 95% CI 1.31 to 2.57; moderate‐certainty evidence), teriflunomide (OR 1.82, 95% CI 1.19 to 2.79; moderate‐certainty evidence), interferon beta‐1a (OR 1.48, 95% CI 0.99 to 2.20; moderate‐certainty evidence), laquinimod (OR 1.49, 95 % CI 1.00 to 2.15; moderate‐certainty evidence), natalizumab (OR 1.57, 95% CI 0.81 to 3.05), and glatiramer acetate (OR 1.48, 95% CI 1.02 to 2.14; moderate‐certainty evidence) probably result in a trivial increase in people who discontinued due to adverse events. Treatment with interferon beta‐1b (Betaferon) (OR 2.27, 95% CI 1.05 to 4.91; low‐certainty evidence), ofatumumab (OR 2.00, 95% CI 1.05 to 23.81; low‐certainty evidence), cladribine (OR 1.38, 95% CI 0.46 to 4.15; low‐certainty evidence) and dimethyl fumerate (OR 1.35, 95% CI 0.94 to 1.95; low‐certainty evidence) may result in a trivial increase in people who discontinued due to adverse events. Treatment with ozanimod (OR 1.01, 95% CI 0.52 to 1.95; low‐certainty evidence) may have little to no effect on people who discontinued due to adverse effects. Treatment with pegylated interferon beta‐1a (OR 3.58, 95% CI 1.47 to 8.73; very low‐certainty evidence), azathioprine (OR 6.26, 95% CI 0.67 to 58.05) and ponesimod (OR 5.04, 95% CI 2.15 to 11.82; very low‐certainty evidence) may result in a small increase in people who discontinued due to adverse events, but the evidence is very uncertain (see <a href="#CD011381-fig-0007">Figure 7</a>). Treatment with immunoglobulins (OR 2.49, 95% CI 0.37 to 16.50; very low‐certainty evidence) and interferon beta 1a‐1b (OR 3.02, 95% Ci 0.27 to 33.65; very low‐certainty evidence) may result in a trivial increase in people who discontinued due to adverse effects, but the evidence is very uncertain. Differences across treatments were found and are shown in <a href="#CD011381-tbl-0013">Table 7</a>. </p> <p>b) <b>SAEs</b> were available from 35 studies and 33,998 participants with RRMS (93% of those included in this review) (<a href="./references#CD011381-bbs2-0002" title="CalabresiPA , KieseierBC , ArnoldDL , BalcerLJ , BoykoA , PelletierJ , et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurology2014;13:657-65. HuX , CuiY , WhiteJ , ZhuY , DeykinA , NestorovI , HungS . Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. British Journal of Clinical Pharmacology2015;79(3):514-22. [DOI: 10.1111/bcp.12521] [PMID: 25265472]ScottTF , KieseierBC , NewsomeSD , ArnoldDL , YouX , HungS , Sperling B. Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis.. Mult Scler J Exp Transl Clin. 2016 ;2:2055217316676644. [DOI: 10.1177/2055217316676644] [PMID: 28607743]">ADVANCE 2014</a>; <a href="./references#CD011381-bbs2-0003" title="BalcerLJ , GalettaSL , PolmanCH , EggenbergerE , CalabresiPA , ZhangA , et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.. J Neurol Sci2012;318(1-2):119-24. [DOI: 10.1016/j.jns.2012.03.009] [PMID: 22521274]LublinFD , CutterG , GiovannoniG , PaceA , CampbellNR , BelachewS . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.. Mult Scler Relat Disord2014;3(6):705-11. [DOI: 10.1016/j.msard.2014.08.005] [PMID: 25891549]PolmanCH , O'ConnorPW , HavrdovaE , HutchinsonM , KapposL , MillerDH , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):899-910. Weinstock-GuttmanB , GalettaSL , GiovannoniG , HavrdovaE , HutchinsonM , KapposL , et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology2012;259((5)):898-905. [DOI: 10.1007/s00415-011-6275-7] [PMID: 22008873]">AFFIRM 2006</a>; <a href="./references#CD011381-bbs2-0004" title="ComiG , JefferyD , KapposL , MontalbanX , BoykoA , RoccaMA , et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. New England Journal of Medicine2012;366(11):1000-9. FilippiM , RoccaMA , PaganiE , De StefanoN , JefferyD , KapposL , et al, ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry2014;85(8):851-8. [DOI: 10.1136/jnnp-2013-306132] [PMID: 24029546]">ALLEGRO 2012</a>; <a href="./references#CD011381-bbs2-0005" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS I 2020</a>; <a href="./references#CD011381-bbs2-0006" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS II 2020</a>; <a href="./references#CD011381-bbs2-0007" title="CreeBAC , GoldmanMD , CorboyJR , SingerBA , FoxEJ , ArnoldDL , et al, ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020 ;78(1):1–13. [DOI: 10.1001/jamaneurol.2020.2950] [PMID: 32852530]">ASSESS 2020</a>; <a href="./references#CD011381-bbs2-0009" title="O'ConnorP , FilippiM , ArnasonB , ComiG , CookS , GoodinD , et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology2009;8(10):889-97. SchipplingS , O'ConnorP , KnappertzV , PohlC , BogumilT , SuarezG , et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol2016;263(7):1418-26. [DOI: 10.1007/s00415-016-8146-8]">BEYOND 2009</a>; <a href="./references#CD011381-bbs2-0008" title="BrownRA , NarayananS , StikovN , CookS , CadavidD , WolanskyL , et al. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. Neurology2016;87(9):905-11. [DOI: 10.1212/WNL.0000000000003043] [PMID: 27473139]CadavidD , WolanskyLJ , SkurnickJ , LincolnJ , CheriyanJ , SzczepanowskiK , et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology2009;72(23):1976-83. CheriyanJ , KimS , WolanskyLJ , CookSD , CadavidD . Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol2012;69(1):82-8. [DOI: 10.1001/archneurol.2011.674]">BECOME 2009</a>; <a href="./references#CD011381-bbs2-0011" title="VollmerTL , SorensenPS , SelmajK , ZippF , HavrdovaE , CohenJA , et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology2014;261(4):773-83. ">BRAVO 2014</a>; <a href="./references#CD011381-bbs2-0012" title="CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786-801. FoxEJ , WynnD , ColesAJ , PalmerJ , MargolinDH , CAMMS223 Investigators. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. J Neurol Sci2016;363:188-94. [DOI: 10.1016/j.jns.2016.02.025]">CAMMS223 2008</a>; <a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a> ; <a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a>; <a href="./references#CD011381-bbs2-0015" title="AfolabiD , AlborC , ZalewskiL , AltmannDR , BakerD , SchmiererK . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler2018 ;24(11):1461-1468. [DOI: 10.1177/1352458517726380] [PMID: 28817997]ComiG , CookSD , GiovannoniG , RammohanK , RieckmannP , SørensenPS , et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol2013;260(4):1136-46. [DOI: 10.1007/s00415-012-6775-0] [PMID: 23263473]De StefanoN , GiorgioA , BattagliniM , De LeucioA , HickingC , DangondF , et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018;24(2):222-226. [DOI: 10.1177/1352458517690269] [PMID: 28140753]GiovannoniG , ComiG , CookS , RammohanK , RieckmannP , Soelberg SørensenP , et al, CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):416-26. [DOI: 10.1056/NEJMoa0902533] [PMID: 20089960]GiovannoniG , Soelberg SorensenP , CookS , RammohanKW , RieckmannP , ComiG , et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler2019;25(6):819-827. [DOI: 10.1177/1352458518771875] [PMID: 29716436]HermannR , LitwinJS , FribergLE , DangondF , MunafoA . Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Br J Clin Pharmacol2019 ;85(7):1484-1494. [DOI: 10.1111/bcp.13919] [PMID: 30883839]VermerschP , GalazkaA , DangondF , DamianD , WongSL , JackD , et al. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Curr Med Res Opin2021;37(3):459-464. [DOI: 10.1080/03007995.2020.1865888] [PMID: 33331183]">CLARITY 2010</a>; <a href="./references#CD011381-bbs2-0016" title="LublinFD , CofieldSS , CutterGR , ConwitR , NarayanaPA , NelsonF , et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology2013;73(3):327-40. ">CombiRx 2013</a>; <a href="./references#CD011381-bbs2-0017" title="ComiG , DadonY , SassonN , SteinermanJR , KnappertzV , VollmerTL , et al. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler2022;28(4):608-619. [DOI: 10.1177/13524585211032803] [PMID: 34378456]NCT01707992. The Efficacy, Safety, and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). https://clinicaltrials.gov/show/NCT017079922012. ">CONCERTO 2021</a>; <a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a>; <a href="./references#CD011381-bbs2-0020" title="ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014;261(9):1794-802. [DOI: 10.1007/s00415-014-7412-x] [PMID: 24989666]ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol2014;261(12):2429-37. [DOI: 10.1007/s00415-014-7504-7] [PMID: 25270680]Bar-OrA , GoldR , KapposL , ArnoldDL , GiovannoniG , SelmajK , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol2013 ;260(9):2297-305. [DOI: 10.1007/s00415-013-6954-7] [PMID: 23797999]Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012] [PMID: 28751099]GoldR , KapposL , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine2012;367(12):1098-107. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272] [PMID: 28328179]KapposL , GoldR , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler2014;20(2):243-52. [DOI: 10.1177/1352458513507817] [PMID: 24150779]">DEFINE 2012</a>; <a href="./references#CD011381-bbs2-0019" title="BenedictRH , CohanS , LynchSG , RiesterK , WangP , Castro-BorreroW , et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler2018 ;24(6):795-804. [DOI: 0.1177/1352458517707345]KapposL , HavrdovaE , GiovannoniG , KhatriBO , GauthierSA , GreenbergSJ , et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler2017;23(13):1736-1747. [DOI: 10.1177/1352458516683266]KapposL , WiendlH , SelmajK , ArnoldDL , HavrdovaE , BoykoA , et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2015;373(15):1418-28. [DOI: 10.1056/NEJMoa1501481]KruegerJG , KircikL , HougeirF , FriedmanA , YouX , LucasN , et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther2016;33(7):231-45. [DOI: 10.1007/s12325-016-0353-2]LiuY , VollmerT , HavrdovaE , RiesterK , LeeA , PhillipsG , et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;11:18-24. [DOI: 10.1016/j.msard.2016.11.005]NCT01064401. Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01064401 (accessed 30 September 2014). RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40.. [DOI: 10.1016/j.msard.2017.06.006]">DECIDE 2015</a>; <a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a>; <a href="./references#CD011381-bbs2-0025" title="CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(6):545-56. VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , Freedman MS A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017 3;3:2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS II 2014</a>; <a href="./references#CD011381-bbs2-0026" title='DavisMD , AshtamkerN , SteinermanJR , KnappertzV . Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study. 2017 Neurol Neuroimmunol Neuroinflamm;4(2):e327. [DOI: 10.1212/NXI.0000000000000327] [PMID: 28210662]KhanO , RieckmannP , BoykoA , SelmajK , ZivadinovR , GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Annals of Neurology2013;73(6):705-13. ZivadinovR , DwyerM , BarkayH , SteinermanJR , KnappertzV , Khan O. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis. J Neurol2015;262(3):648-53. [DOI: 10.1007/s00415-014-7616-0] [PMID: 25542295]ZivadinovR , DwyerMG , RamasamyDP , DavisMD , SteinermanJR , KhanO . The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. J Neuroimaging2015;25(6):989-95. [DOI: 10.1111/jon.12293] [PMID: 26394270]'>GALA 2013</a>; <a href="./references#CD011381-bbs2-0027" title="GobbiC , MeierDS , CottonF , SintzelM , LeppertD , GuttmannCR , ZeccaC . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol2013;13:101. [DOI: 10.1186/1471-2377-13-101] [PMID: 23915113]ZeccaC , RiccitelliGC , CalabreseP , PravatàE , CandrianU , GuttmannCR , Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol2014;14:38. [DOI: 10.1186/1471-2377-14-38] [PMID: 24576156]">Gobbi 2013</a>;<a href="./references#CD011381-bbs2-0028" title="ComiG , PattiF , RoccaMA , MattioliFC , AmatoMP , GalloP , CentonzeD , PozzilliC , SaccàF , BerghFT , BartezaghiM , TurriniR , FilippiM , Golden Study Group. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol2017;264(12):2436-2449. [DOI: 10.1007/s00415-017-8642-5] [PMID: 29063244]">GOLDEN 2017</a>; <a href="./references#CD011381-bbs2-0032" title="JohnsonK , BrooksB , CohenJ , FordC , GoldsteinJ , LisakR , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology1995;45(7):1268-76. ">Johnson 1995</a>; <a href="./references#CD011381-bbs2-0037" title="MillefioriniE , GasperiniC , PozzilliC , D'AndreaF , BastianelloS , TrojanoM , et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology1997;244(3):153-9. ">Millefiorini 1997</a>; <a href="./references#CD011381-bbs2-0040" title="A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01247324 (accessed 30 September 2014). HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , JulianL , KöndgenH , LiC , NapieralskiJ , ZhengH , WolinskyJS . Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , BuffelsR , FioreD , GarrenH , HanJ , HauserSL . Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA I 2017</a>; <a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a>; <a href="./references#CD011381-bbs2-0042" title="KapposL , FoxRJ , BurcklenM , FreedmanMS , HavrdováEK , HennessyB , et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol 2021 May 1;;78(5):558-567. [DOI: 10.1001/jamaneurol.2021.0405] [PMID: 33779698]">OPTIMUM 2021</a>; <a href="./references#CD011381-bbs2-0044" title="CohenJA , ComiG , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019;18(11):1021-1033. [DOI: 10.1016/S1474-4422(19)30238-8] [PMID: 31492652]NCT01628393. Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study). https://clinicaltrials.gov/show/NCT016283932012. ">RADIANCE 2019</a>; <a href="./references#CD011381-bbs2-0045" title="MikolD , BarkhofF , ChangP , CoyleP , JefferyD , SchwidS , et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology2008;7(10):903-14. ">REGARD 2008</a>; <a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a>; <a href="./references#CD011381-bbs2-0047" title="ComiG , KapposL , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology2019 ;18(11):1009-1020. [DOI: 10.1016/S1474-4422(19)30239-X]DeLucaJ , SchipplingS , MontalbanX , KapposL , CreeBAC , ComiG , et al. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Mult Scler Relat Disord2021;48:102673. [DOI: 10.1016/j.msard.2020.102673]NCT02294058. Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS). https://ClinicalTrials.gov/show/NCT022940582014. ">SUNBEAM 2019</a>; <a href="./references#CD011381-bbs2-0048" title="MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al, Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler2012;18(11):1625-32. [DOI: 10.1177/1352458512450354] [PMID: 22723573]O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293-303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol2013;260(10):2472-80. [DOI: 10.1007/s00415-013-6979-y] [PMID: 23852658]RadueEW , SprengerT , GaetanoL , Mueller-LenkeN , CavalierS , ThangaveluK , et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm2017;4(5):e390. [DOI: 10.1212/NXI.0000000000000390] [PMID: 28828394]WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013 ;19(10):1310-9. [DOI: 10.1177/1352458513475723] [PMID: 23447359]">TEMSO 2011</a>; <a href="./references#CD011381-bbs2-0049" title="ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(3):247-56. FreedmanMS , MorawskiJ , ThangaveluK . Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. Mult Scler J Exp Transl Clin2018;4(2):2055217318775236. [DOI: 10.1177/2055217318775236] [PMID: 29796289]MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MäurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol2014;261(9):1781-8. [DOI: 10.1007/s00415-014-7395-7] [PMID: 24972678]MillerAE , XuX , MacdonellR , VucicS , TruffinetP , BenamorM , et al. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. J Clin Neurosci2019;59:229-231. [DOI: 10.1016/j.jocn.2018.09.012] [PMID: 30348586]QiuW , HuangDH , HouSF , ZhangMN , JinT , DongHQ , et al, TOWER Trial Chinese Group. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study. Chin Med J (Engl)2018;131(23):2776-2784. [DOI: 10.4103/0366-6999.246067] [PMID: 30511679]">TOWER 2014</a>; <a href="./references#CD011381-bbs2-0050" title="BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler2014;20(13):1704-13. [DOI: 10.1177/1352458514532317] [PMID: 24812043]CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402-15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol2013;260(8):2023-32. [DOI: 10.1007/s00415-013-6932-0] [PMID: 23632946]KhatriBO , PelletierJ , KapposL , HartungHP , ComiG , BarkhofF , et al, TRANSFORMS Study Group. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord2014;3(3):355-63. [DOI: 10.1016/j.msard.2013.11.006] [PMID: 25876473]MengX , ChinPS , HashmonayR , Zahur IslamM , CutterG . Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemp Clin Trials2015;41:69-74. [DOI: 10.1016/j.cct.2014.12.011] [PMID: 25545026]">TRANSFORMS 2010</a>) and assessing 17 treatments. The network geometry for SAEs is shown in <a href="#CD011381-fig-0004">Figure 4</a>. </p> <p>Eleven treatments, assessed in 18 studies, were compared to placebo, 14 treatments were evaluated in head‐to‐head comparisons in 21 studies, and two studies involving 2751 participants had both placebo and active treatment arms. Compared to placebo (see <a href="#CD011381-fig-0007">Figure 7</a>), treatment with interferon beta‐1b (OR 0.92, 95% CI 0.55 to 1.54; moderate‐certainty evidence) probably results in a trivial reduction in people who experience SAEs. Treatment with fingolimod (OR 0.86, 95% CI 0.64 to 1.13; low‐certainty evidence) and glatiramer acetate (OR 0.94, 95% CI 0.68 to 1.28; low‐certainty evidence) may result in a trivial reduction in people who experience SAEs. Treatment with mitoxantrone (OR 0.89, 95% CI 0.02 to 47.22; very low‐certainty evidence) may result in a trivial reduction in people who experience SAEs, but the evidence is very uncertain. Treatment with daclizumab may result in a small increase in people with SAEs (OR 1.90, 95% CI 1.21 to 2.99; low‐certainty evidence). Treatment with dimethyl fumerate (OR 1.04, 95% CI 0.71 to 1.52; low‐certainty evidence) and natalizumab (OR 1.24, 95% CI 0.73 to 2.09; low‐certainty evidence) may result in a trivial increase in people who experience SAEs. Treatment with ocrelizumab (OR 1.00, 95% CIs 0.58 to 1.72; very low‐certainty evidence) may result in little or no effect on people who experince SAEs, but the evidence is very uncertain. Treatment with the remaining DMTS may result in a trivial increase in the people experiencing SAEs, but the evidence is very uncertain: alemtuzumab (OR 1.52, 95% CI 0.94 to 2.48; very low‐certainty evidence), cladribine (OR 1.39, 95% CI 0.80 to 2.40; very low‐certainty evidence), interferon beta‐1a (OR 1.21, 95% CI 0.88 to 1.67; very low‐certainty evidence), laquinimod (OR 1.25, 95% CI 0.92 to 1.70; very low‐certainty evidence), pegylated beta‐1a (OR 1.08, 95% CI 0.59 to 1.96; very low‐certainty evidence), ofatumumab (OR 1.52, 95% CI 0.89 to 2.57; very low‐certainty evidence), ozanimod (OR 1.50, 95% CI 0.85 to 2.64; very low‐certainty evidence), ponesimod (OR 1.24, 95% CI 0.66 to 2.35; very low‐certainty evidence) and teriflunomide (OR 1.16, 95% CI 0.81 to 1.64); very low‐certainty evidence). Differences across treatments were found and are shown in <a href="#CD011381-tbl-0014">Table 8</a>. </p> </section> </section> </section> </section> <section id="CD011381-sec-0080"> <h4 class="title">2. Secondary outcomes</h4> <section id="CD011381-sec-0081"> <h5 class="title">2.1 Efficacy</h5> <section id="CD011381-sec-0082"> <h6 class="title">Cognitive decline, quality‐of‐life impairment, new or enlarging T2‐weighted MRI lesions, new gadolinium‐enhancing positive T1‐weighted MRI lesions (at 12, 24, and 36 months) </h6> <section id="CD011381-sec-0083"> <p><b>Pairwise meta‐analysis (direct comparisons)</b></p> <p>Treatment estimates for pairwise meta‐analyses for each outcome are reported in <a href="./references#CD011381-fig-0015" title="">Analysis 3.1</a>; <a href="./references#CD011381-fig-0016" title="">Analysis 3.2</a>; <a href="./references#CD011381-fig-0017" title="">Analysis 3.3</a>; <a href="./references#CD011381-fig-0018" title="">Analysis 3.4</a>; <a href="./references#CD011381-fig-0019" title="">Analysis 3.5</a>; <a href="./references#CD011381-fig-0020" title="">Analysis 3.6</a>; <a href="./references#CD011381-fig-0021" title="">Analysis 3.7</a>; <a href="./references#CD011381-fig-0022" title="">Analysis 3.8</a>; <a href="./references#CD011381-fig-0023" title="">Analysis 3.9</a>; <a href="./references#CD011381-fig-0024" title="">Analysis 3.10</a>. </p> </section> <section id="CD011381-sec-0084"> <p><b>Network meta‐analysis estimates (combination of direct and indirect comparisons) of treatment effects</b></p> <p>The network geometry for each outcome is presented in <a href="#CD011381-fig-0005">Figure 5</a> and <a href="#CD011381-fig-0006">Figure 6</a>, and <a href="./appendices#CD011381-sec-0119">Appendix 6</a>; <a href="./appendices#CD011381-sec-0120">Appendix 7</a>; <a href="./appendices#CD011381-sec-0121">Appendix 8</a>; <a href="./appendices#CD011381-sec-0122">Appendix 9</a>; <a href="./appendices#CD011381-sec-0123">Appendix 10</a>; <a href="./appendices#CD011381-sec-0124">Appendix 11</a>; and <a href="./appendices#CD011381-sec-0125">Appendix 12</a> show the network estimates for each treatment against placebo or against another treatment within the network of each outcome. </p> <p>a) <b>New gadolinium‐enhancing positive T1‐weighted MRI lesions at 12 months</b> were reported in six studies involving 5212 participants with RRMS (14.3% of those included in this review) (<a href="./references#CD011381-bbs2-0003" title="BalcerLJ , GalettaSL , PolmanCH , EggenbergerE , CalabresiPA , ZhangA , et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.. J Neurol Sci2012;318(1-2):119-24. [DOI: 10.1016/j.jns.2012.03.009] [PMID: 22521274]LublinFD , CutterG , GiovannoniG , PaceA , CampbellNR , BelachewS . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.. Mult Scler Relat Disord2014;3(6):705-11. [DOI: 10.1016/j.msard.2014.08.005] [PMID: 25891549]PolmanCH , O'ConnorPW , HavrdovaE , HutchinsonM , KapposL , MillerDH , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):899-910. Weinstock-GuttmanB , GalettaSL , GiovannoniG , HavrdovaE , HutchinsonM , KapposL , et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology2012;259((5)):898-905. [DOI: 10.1007/s00415-011-6275-7] [PMID: 22008873]">AFFIRM 2006</a>; <a href="./references#CD011381-bbs2-0007" title="CreeBAC , GoldmanMD , CorboyJR , SingerBA , FoxEJ , ArnoldDL , et al, ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020 ;78(1):1–13. [DOI: 10.1001/jamaneurol.2020.2950] [PMID: 32852530]">ASSESS 2020</a>; <a href="./references#CD011381-bbs2-0031" title="DurelliL , VerdunE , BarberoP , BerguiM , VersinoE , GhezziA , et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002;359:1453-60. ">INCOMIN 2002</a>; <a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a>; <a href="./references#CD011381-bbs2-0047" title="ComiG , KapposL , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology2019 ;18(11):1009-1020. [DOI: 10.1016/S1474-4422(19)30239-X]DeLucaJ , SchipplingS , MontalbanX , KapposL , CreeBAC , ComiG , et al. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Mult Scler Relat Disord2021;48:102673. [DOI: 10.1016/j.msard.2020.102673]NCT02294058. Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS). https://ClinicalTrials.gov/show/NCT022940582014. ">SUNBEAM 2019</a>; <a href="./references#CD011381-bbs2-0050" title="BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler2014;20(13):1704-13. [DOI: 10.1177/1352458514532317] [PMID: 24812043]CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402-15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol2013;260(8):2023-32. [DOI: 10.1007/s00415-013-6932-0] [PMID: 23632946]KhatriBO , PelletierJ , KapposL , HartungHP , ComiG , BarkhofF , et al, TRANSFORMS Study Group. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord2014;3(3):355-63. [DOI: 10.1016/j.msard.2013.11.006] [PMID: 25876473]MengX , ChinPS , HashmonayR , Zahur IslamM , CutterG . Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemp Clin Trials2015;41:69-74. [DOI: 10.1016/j.cct.2014.12.011] [PMID: 25545026]">TRANSFORMS 2010</a>) and assessing seven treatments. Two treatments assessed in two studies were compared to placebo. Using placebo as a common comparator, treatment with natalizumab results in a large reduction of new gadolinium‐enhancing positive T1‐weighted MRI lesions (RR 0.11, 95% CI 0.07 to 0.17). A trivial increase in new gadolinium‐enhancing positive T1‐weighted MRI lesions probably resulted in people treated with daclizumab (RR 1.00, 95% CI 0.97 to 1.04). Differences across treatments were found and are shown in <a href="./appendices#CD011381-sec-0119">Appendix 6</a>. </p> <p>b) Data on <b>new gadolinium‐enhancing positive T1‐weighted MRI lesions at 24 months</b> was available from 11 studies involving 7935 participants with RRMS (21% of those included in this review) (<a href="./references#CD011381-bbs2-0003" title="BalcerLJ , GalettaSL , PolmanCH , EggenbergerE , CalabresiPA , ZhangA , et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.. J Neurol Sci2012;318(1-2):119-24. [DOI: 10.1016/j.jns.2012.03.009] [PMID: 22521274]LublinFD , CutterG , GiovannoniG , PaceA , CampbellNR , BelachewS . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.. Mult Scler Relat Disord2014;3(6):705-11. [DOI: 10.1016/j.msard.2014.08.005] [PMID: 25891549]PolmanCH , O'ConnorPW , HavrdovaE , HutchinsonM , KapposL , MillerDH , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):899-910. Weinstock-GuttmanB , GalettaSL , GiovannoniG , HavrdovaE , HutchinsonM , KapposL , et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology2012;259((5)):898-905. [DOI: 10.1007/s00415-011-6275-7] [PMID: 22008873]">AFFIRM 2006</a>; <a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a>; <a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a>; <a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a>; <a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a>; <a href="./references#CD011381-bbs2-0031" title="DurelliL , VerdunE , BarberoP , BerguiM , VersinoE , GhezziA , et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002;359:1453-60. ">INCOMIN 2002</a>; <a href="./references#CD011381-bbs2-0036" title="MassacesiL , TramacereI , AmorosoS , BattagliaMA , BenedettiMD , FilippiniG , et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One2014;9(11):e113371. ">MAIN 2014</a>; <a href="./references#CD011381-bbs2-0040" title="A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01247324 (accessed 30 September 2014). HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , JulianL , KöndgenH , LiC , NapieralskiJ , ZhengH , WolinskyJS . Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , BuffelsR , FioreD , GarrenH , HanJ , HauserSL . Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA I 2017</a>; <a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a>; <a href="./references#CD011381-bbs2-0044" title="CohenJA , ComiG , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019;18(11):1021-1033. [DOI: 10.1016/S1474-4422(19)30238-8] [PMID: 31492652]NCT01628393. Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study). https://clinicaltrials.gov/show/NCT016283932012. ">RADIANCE 2019</a>; <a href="./references#CD011381-bbs2-0045" title="MikolD , BarkhofF , ChangP , CoyleP , JefferyD , SchwidS , et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology2008;7(10):903-14. ">REGARD 2008</a>) and assessing eleven treatments. Four treatments assessed in three studies were compared to placebo, seven treatments were evaluated in head‐to‐head comparisons in nine studies and one study involving 1417 participants had both placebo and active treatment arms. </p> <p>Using placebo as a common comparator, natalizumab (RR 0.11, 95% CI 0.07 to 0.17) resulted in a large reduction in new gadolinium‐enhancing positive T1‐weighted MRI lesions. Treatment with ocrelizumab (RR 0.09, 95% CI 0.05 to 0.16) and alemtuzumab (RR 0.13, 95% CI 0.08 to 0.23) probably resulted in a large reduction in new gadolinium‐enhancing positive T1‐weighted MRI lesions. Treatment with interferon beta‐1b (Betaferon) (RR 0.16, 95% CI 0.08 to 0.31) may have resulted in a large reduction in new gadolinium‐enhancing positive T1‐weighted MRI lesions. Treatment with interferon beta‐1a (Avonex, Rebif) (RR 0.34, 95% CI 0.21 to 0.55), fingolimod (RR 0.29, 95% CI 0.23 to 0.38), dimethyl fumarate (RR 0.50, 95% CI 0.37 to 0.69), ozanimod (RR 0.30, 95% CI 0.18 to 0.49), and glatiramer acetate (RR 0.59, 95% CI 0.42 to 0.84) may have resulted in a moderate reduction in new gadolinium‐enhancing positive T1‐weighted MRI lesions. Differences across treatments were found and are shown in <a href="./appendices#CD011381-sec-0120">Appendix 7</a>. </p> <p>c) No studies assessed new gadolinium‐enhancing positive T1‐weighted MRI lesions at 36 months. </p> <p>d) <b>New or enlarging T2‐weighted MRI lesions at 12 months</b> was reported in seven studies involving 5234 participants with RRMS (14.32% of those included in this review) (<a href="./references#CD011381-bbs2-0003" title="BalcerLJ , GalettaSL , PolmanCH , EggenbergerE , CalabresiPA , ZhangA , et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.. J Neurol Sci2012;318(1-2):119-24. [DOI: 10.1016/j.jns.2012.03.009] [PMID: 22521274]LublinFD , CutterG , GiovannoniG , PaceA , CampbellNR , BelachewS . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.. Mult Scler Relat Disord2014;3(6):705-11. [DOI: 10.1016/j.msard.2014.08.005] [PMID: 25891549]PolmanCH , O'ConnorPW , HavrdovaE , HutchinsonM , KapposL , MillerDH , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):899-910. Weinstock-GuttmanB , GalettaSL , GiovannoniG , HavrdovaE , HutchinsonM , KapposL , et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology2012;259((5)):898-905. [DOI: 10.1007/s00415-011-6275-7] [PMID: 22008873]">AFFIRM 2006</a>; <a href="./references#CD011381-bbs2-0007" title="CreeBAC , GoldmanMD , CorboyJR , SingerBA , FoxEJ , ArnoldDL , et al, ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020 ;78(1):1–13. [DOI: 10.1001/jamaneurol.2020.2950] [PMID: 32852530]">ASSESS 2020</a>; <a href="./references#CD011381-bbs2-0027" title="GobbiC , MeierDS , CottonF , SintzelM , LeppertD , GuttmannCR , ZeccaC . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol2013;13:101. [DOI: 10.1186/1471-2377-13-101] [PMID: 23915113]ZeccaC , RiccitelliGC , CalabreseP , PravatàE , CandrianU , GuttmannCR , Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol2014;14:38. [DOI: 10.1186/1471-2377-14-38] [PMID: 24576156]">Gobbi 2013</a>; <a href="./references#CD011381-bbs2-0031" title="DurelliL , VerdunE , BarberoP , BerguiM , VersinoE , GhezziA , et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002;359:1453-60. ">INCOMIN 2002</a>; <a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a>; <a href="./references#CD011381-bbs2-0047" title="ComiG , KapposL , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology2019 ;18(11):1009-1020. [DOI: 10.1016/S1474-4422(19)30239-X]DeLucaJ , SchipplingS , MontalbanX , KapposL , CreeBAC , ComiG , et al. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Mult Scler Relat Disord2021;48:102673. [DOI: 10.1016/j.msard.2020.102673]NCT02294058. Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS). https://ClinicalTrials.gov/show/NCT022940582014. ">SUNBEAM 2019</a>; <a href="./references#CD011381-bbs2-0050" title="BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler2014;20(13):1704-13. [DOI: 10.1177/1352458514532317] [PMID: 24812043]CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402-15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol2013;260(8):2023-32. [DOI: 10.1007/s00415-013-6932-0] [PMID: 23632946]KhatriBO , PelletierJ , KapposL , HartungHP , ComiG , BarkhofF , et al, TRANSFORMS Study Group. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord2014;3(3):355-63. [DOI: 10.1016/j.msard.2013.11.006] [PMID: 25876473]MengX , ChinPS , HashmonayR , Zahur IslamM , CutterG . Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemp Clin Trials2015;41:69-74. [DOI: 10.1016/j.cct.2014.12.011] [PMID: 25545026]">TRANSFORMS 2010</a>) and assessing seven treatments. Two treatments, assessed in two studies, were compared to placebo, and six treatments were evaluated in head‐to‐head comparisons in five studies. Using placebo as a common comparator, treatment with interferon beta‐1a (Avonex, Rebif) resulted in a large reduction of new or enlarging T2‐weighted MRI lesions (RR 0.51, 95% CI 0.45 to 0.57). Treatment with immunoglobulins may have resulted in a trivial reduction in new or enlarging T2‐weighted MRI lesions (RR 0.98, 95% CI 0.30 to 3.28). There was probably little or no effect on new or enlarging T2‐weighted MRI lesions with daclizumab (RR 1.00, 95% CI 0.97 to 1.04). A large increase in new or enlarging T2‐weighted MRI lesions may have resulted in people treated with glatiramer acetate (RR 2.37, 95% CI 0.50 to 11.30), interferon beta‐1b (RR 2.12, 95% CI 0.45 to 9.97), natalizumab (RR 2.01, 95% CI 0.43 to 9.51) and fingolimod (RR 1.89, 95% CI 0.40 to 8.99). Differences across treatments were found and are shown in <a href="./appendices#CD011381-sec-0121">Appendix 8</a>. </p> <p>e) <b>New or enlarging T2‐weighted MRI lesions at 24 months</b> were reported in ten studies involving 6893 participants with RRMS (19% of those included in this review) (<a href="./references#CD011381-bbs2-0003" title="BalcerLJ , GalettaSL , PolmanCH , EggenbergerE , CalabresiPA , ZhangA , et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.. J Neurol Sci2012;318(1-2):119-24. [DOI: 10.1016/j.jns.2012.03.009] [PMID: 22521274]LublinFD , CutterG , GiovannoniG , PaceA , CampbellNR , BelachewS . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.. Mult Scler Relat Disord2014;3(6):705-11. [DOI: 10.1016/j.msard.2014.08.005] [PMID: 25891549]PolmanCH , O'ConnorPW , HavrdovaE , HutchinsonM , KapposL , MillerDH , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):899-910. Weinstock-GuttmanB , GalettaSL , GiovannoniG , HavrdovaE , HutchinsonM , KapposL , et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology2012;259((5)):898-905. [DOI: 10.1007/s00415-011-6275-7] [PMID: 22008873]">AFFIRM 2006</a>; <a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a>; <a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a>; <a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a>; <a href="./references#CD011381-bbs2-0031" title="DurelliL , VerdunE , BarberoP , BerguiM , VersinoE , GhezziA , et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002;359:1453-60. ">INCOMIN 2002</a>; <a href="./references#CD011381-bbs2-0036" title="MassacesiL , TramacereI , AmorosoS , BattagliaMA , BenedettiMD , FilippiniG , et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One2014;9(11):e113371. ">MAIN 2014</a>; <a href="./references#CD011381-bbs2-0040" title="A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01247324 (accessed 30 September 2014). HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , JulianL , KöndgenH , LiC , NapieralskiJ , ZhengH , WolinskyJS . Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , BuffelsR , FioreD , GarrenH , HanJ , HauserSL . Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA I 2017</a>; <a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a>; <a href="./references#CD011381-bbs2-0044" title="CohenJA , ComiG , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019;18(11):1021-1033. [DOI: 10.1016/S1474-4422(19)30238-8] [PMID: 31492652]NCT01628393. Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study). https://clinicaltrials.gov/show/NCT016283932012. ">RADIANCE 2019</a>; <a href="./references#CD011381-bbs2-0045" title="MikolD , BarkhofF , ChangP , CoyleP , JefferyD , SchwidS , et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology2008;7(10):903-14. ">REGARD 2008</a>) and assessing ten treatments. Two treatments, assessed in two studies, were compared to placebo. Using placebo as a common comparator, treatment with natalizumab (RR 0.50, 95% CI 0.45 to 0.55) resulted in a large reduction of new or enlarging T2‐weighted MRI lesions. Treatment with fingolimod (RR 0.62, 95% CI 0.56 to 0.68) may have resulted in a large reduction of new or enlarging T2‐weighted MRI lesions. Differences across treatments were found and are shown in <a href="./appendices#CD011381-sec-0122">Appendix 9</a>. </p> <p>f) No studies assessed new or enlarging T2‐weighted MRI at 36 months.</p> <p>g) <b>Cognitive decline</b> was available from six studies involving 4243 participants with RRMS (11.6% of those included in this review) (<a href="./references#CD011381-bbs2-0007" title="CreeBAC , GoldmanMD , CorboyJR , SingerBA , FoxEJ , ArnoldDL , et al, ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020 ;78(1):1–13. [DOI: 10.1001/jamaneurol.2020.2950] [PMID: 32852530]">ASSESS 2020</a>; <a href="./references#CD011381-bbs2-0016" title="LublinFD , CofieldSS , CutterGR , ConwitR , NarayanaPA , NelsonF , et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology2013;73(3):327-40. ">CombiRx 2013</a>; <a href="./references#CD011381-bbs2-0019" title="BenedictRH , CohanS , LynchSG , RiesterK , WangP , Castro-BorreroW , et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler2018 ;24(6):795-804. [DOI: 0.1177/1352458517707345]KapposL , HavrdovaE , GiovannoniG , KhatriBO , GauthierSA , GreenbergSJ , et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler2017;23(13):1736-1747. [DOI: 10.1177/1352458516683266]KapposL , WiendlH , SelmajK , ArnoldDL , HavrdovaE , BoykoA , et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2015;373(15):1418-28. [DOI: 10.1056/NEJMoa1501481]KruegerJG , KircikL , HougeirF , FriedmanA , YouX , LucasN , et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther2016;33(7):231-45. [DOI: 10.1007/s12325-016-0353-2]LiuY , VollmerT , HavrdovaE , RiesterK , LeeA , PhillipsG , et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;11:18-24. [DOI: 10.1016/j.msard.2016.11.005]NCT01064401. Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01064401 (accessed 30 September 2014). RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40.. [DOI: 10.1016/j.msard.2017.06.006]">DECIDE 2015</a>; <a href="./references#CD011381-bbs2-0027" title="GobbiC , MeierDS , CottonF , SintzelM , LeppertD , GuttmannCR , ZeccaC . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol2013;13:101. [DOI: 10.1186/1471-2377-13-101] [PMID: 23915113]ZeccaC , RiccitelliGC , CalabreseP , PravatàE , CandrianU , GuttmannCR , Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol2014;14:38. [DOI: 10.1186/1471-2377-14-38] [PMID: 24576156]">Gobbi 2013</a>; <a href="./references#CD011381-bbs2-0038" title="MokhberN , AzarpazhoohA , OroujiE , KhorramB , Modares GharaviM , KakhiS , KhallaghiH , AzarpazhoohMR . Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis. Psychiatry Clin Neurosci.2015;69(10):649-57. [DOI: 10.1111/pcn.12308] [PMID: 25907350]MokhberN , AzarpazhoohA , OroujiE , RaoSM , KhorramB , SahraianMA , ForoghipoorM , GharaviMM , KakhiS , NikkhahK , AzarpazhoohMR . Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. J Neurol Sci2014;342(1-2):16-20. [DOI: 10.1016/j.jns.2014.01.038] [PMID: 24841321]">Mokhber 2014</a>; <a href="./references#CD011381-bbs2-0047" title="ComiG , KapposL , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology2019 ;18(11):1009-1020. [DOI: 10.1016/S1474-4422(19)30239-X]DeLucaJ , SchipplingS , MontalbanX , KapposL , CreeBAC , ComiG , et al. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Mult Scler Relat Disord2021;48:102673. [DOI: 10.1016/j.msard.2020.102673]NCT02294058. Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS). https://ClinicalTrials.gov/show/NCT022940582014. ">SUNBEAM 2019</a>) and assessing seven treatments. No studies were compared to placebo, and six treatments were evaluated in head‐to‐head comparisons in seven studies. Differences across treatments were found and are shown in <a href="./appendices#CD011381-sec-0123">Appendix 10</a>. </p> <p>h) Data on <b>quality‐of‐life impairment</b> were reported in studies with different scales (non‐MS related quality of health questionnaires and MS related questionnaires) and subscales (physical and mental). </p> <p>Quality‐of‐life impairment (non‐MS related; total) was available from two studies involving 1061 participants with RRMS (3% of those included in this review) and assessing three treatments (<a href="./references#CD011381-bbs2-0015" title="AfolabiD , AlborC , ZalewskiL , AltmannDR , BakerD , SchmiererK . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler2018 ;24(11):1461-1468. [DOI: 10.1177/1352458517726380] [PMID: 28817997]ComiG , CookSD , GiovannoniG , RammohanK , RieckmannP , SørensenPS , et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol2013;260(4):1136-46. [DOI: 10.1007/s00415-012-6775-0] [PMID: 23263473]De StefanoN , GiorgioA , BattagliniM , De LeucioA , HickingC , DangondF , et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018;24(2):222-226. [DOI: 10.1177/1352458517690269] [PMID: 28140753]GiovannoniG , ComiG , CookS , RammohanK , RieckmannP , Soelberg SørensenP , et al, CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):416-26. [DOI: 10.1056/NEJMoa0902533] [PMID: 20089960]GiovannoniG , Soelberg SorensenP , CookS , RammohanKW , RieckmannP , ComiG , et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler2019;25(6):819-827. [DOI: 10.1177/1352458518771875] [PMID: 29716436]HermannR , LitwinJS , FribergLE , DangondF , MunafoA . Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Br J Clin Pharmacol2019 ;85(7):1484-1494. [DOI: 10.1111/bcp.13919] [PMID: 30883839]VermerschP , GalazkaA , DangondF , DamianD , WongSL , JackD , et al. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Curr Med Res Opin2021;37(3):459-464. [DOI: 10.1080/03007995.2020.1865888] [PMID: 33331183]">CLARITY 2010</a>; <a href="./references#CD011381-bbs2-0027" title="GobbiC , MeierDS , CottonF , SintzelM , LeppertD , GuttmannCR , ZeccaC . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol2013;13:101. [DOI: 10.1186/1471-2377-13-101] [PMID: 23915113]ZeccaC , RiccitelliGC , CalabreseP , PravatàE , CandrianU , GuttmannCR , Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol2014;14:38. [DOI: 10.1186/1471-2377-14-38] [PMID: 24576156]">Gobbi 2013</a>). One study was compared to placebo. Compared to placebo, cladribine (SMD 0.19 SD, 95% CI 0.06 to 0.32) probably resulted in a trivial improvement in quality of life. </p> <p>Quality of life impairment (non‐MS related; index) was available from one study involving 1042 participants with RRMS (3% of those included in this review) and assessing one treatment (<a href="./references#CD011381-bbs2-0015" title="AfolabiD , AlborC , ZalewskiL , AltmannDR , BakerD , SchmiererK . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler2018 ;24(11):1461-1468. [DOI: 10.1177/1352458517726380] [PMID: 28817997]ComiG , CookSD , GiovannoniG , RammohanK , RieckmannP , SørensenPS , et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol2013;260(4):1136-46. [DOI: 10.1007/s00415-012-6775-0] [PMID: 23263473]De StefanoN , GiorgioA , BattagliniM , De LeucioA , HickingC , DangondF , et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018;24(2):222-226. [DOI: 10.1177/1352458517690269] [PMID: 28140753]GiovannoniG , ComiG , CookS , RammohanK , RieckmannP , Soelberg SørensenP , et al, CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):416-26. [DOI: 10.1056/NEJMoa0902533] [PMID: 20089960]GiovannoniG , Soelberg SorensenP , CookS , RammohanKW , RieckmannP , ComiG , et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler2019;25(6):819-827. [DOI: 10.1177/1352458518771875] [PMID: 29716436]HermannR , LitwinJS , FribergLE , DangondF , MunafoA . Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Br J Clin Pharmacol2019 ;85(7):1484-1494. [DOI: 10.1111/bcp.13919] [PMID: 30883839]VermerschP , GalazkaA , DangondF , DamianD , WongSL , JackD , et al. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Curr Med Res Opin2021;37(3):459-464. [DOI: 10.1080/03007995.2020.1865888] [PMID: 33331183]">CLARITY 2010</a>). Compared to placebo, cladribine probably resulted in a trivial improvement in quality of life (SMD 0.24 SD, 95% CI 0.11 to 0.37). </p> <p>Quality‐of‐life impairment (non‐MS related; physical subscale) was available from five studies involving 4073 participants with RRMS (11% of those included in this review) and assessing four treatments (<a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a>; <a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a>; <a href="./references#CD011381-bbs2-0040" title="A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01247324 (accessed 30 September 2014). HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , JulianL , KöndgenH , LiC , NapieralskiJ , ZhengH , WolinskyJS . Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , BuffelsR , FioreD , GarrenH , HanJ , HauserSL . Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA I 2017</a>; <a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a>; <a href="./references#CD011381-bbs2-0049" title="ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(3):247-56. FreedmanMS , MorawskiJ , ThangaveluK . Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. Mult Scler J Exp Transl Clin2018;4(2):2055217318775236. [DOI: 10.1177/2055217318775236] [PMID: 29796289]MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MäurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol2014;261(9):1781-8. [DOI: 10.1007/s00415-014-7395-7] [PMID: 24972678]MillerAE , XuX , MacdonellR , VucicS , TruffinetP , BenamorM , et al. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. J Clin Neurosci2019;59:229-231. [DOI: 10.1016/j.jocn.2018.09.012] [PMID: 30348586]QiuW , HuangDH , HouSF , ZhangMN , JinT , DongHQ , et al, TOWER Trial Chinese Group. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study. Chin Med J (Engl)2018;131(23):2776-2784. [DOI: 10.4103/0366-6999.246067] [PMID: 30511679]">TOWER 2014</a>). Compared to placebo, teriflunomide may have resulted in a trivial improvement in quality of life (non‐MS related; physical subscale) (SMD 0.1 SD, 95% CI ‐0.02 to 0.22). </p> <p>Quality of life impairment (MS related; physical) was available from six studies involving 6261 participants with RRMS (17% of those included in this review) (<a href="./references#CD011381-bbs2-0007" title="CreeBAC , GoldmanMD , CorboyJR , SingerBA , FoxEJ , ArnoldDL , et al, ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020 ;78(1):1–13. [DOI: 10.1001/jamaneurol.2020.2950] [PMID: 32852530]">ASSESS 2020</a>; <a href="./references#CD011381-bbs2-0019" title="BenedictRH , CohanS , LynchSG , RiesterK , WangP , Castro-BorreroW , et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler2018 ;24(6):795-804. [DOI: 0.1177/1352458517707345]KapposL , HavrdovaE , GiovannoniG , KhatriBO , GauthierSA , GreenbergSJ , et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler2017;23(13):1736-1747. [DOI: 10.1177/1352458516683266]KapposL , WiendlH , SelmajK , ArnoldDL , HavrdovaE , BoykoA , et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2015;373(15):1418-28. [DOI: 10.1056/NEJMoa1501481]KruegerJG , KircikL , HougeirF , FriedmanA , YouX , LucasN , et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther2016;33(7):231-45. [DOI: 10.1007/s12325-016-0353-2]LiuY , VollmerT , HavrdovaE , RiesterK , LeeA , PhillipsG , et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;11:18-24. [DOI: 10.1016/j.msard.2016.11.005]NCT01064401. Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01064401 (accessed 30 September 2014). RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40.. [DOI: 10.1016/j.msard.2017.06.006]">DECIDE 2015</a>; <a href="./references#CD011381-bbs2-0038" title="MokhberN , AzarpazhoohA , OroujiE , KhorramB , Modares GharaviM , KakhiS , KhallaghiH , AzarpazhoohMR . Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis. Psychiatry Clin Neurosci.2015;69(10):649-57. [DOI: 10.1111/pcn.12308] [PMID: 25907350]MokhberN , AzarpazhoohA , OroujiE , RaoSM , KhorramB , SahraianMA , ForoghipoorM , GharaviMM , KakhiS , NikkhahK , AzarpazhoohMR . Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. J Neurol Sci2014;342(1-2):16-20. [DOI: 10.1016/j.jns.2014.01.038] [PMID: 24841321]">Mokhber 2014</a>; <a href="./references#CD011381-bbs2-0044" title="CohenJA , ComiG , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019;18(11):1021-1033. [DOI: 10.1016/S1474-4422(19)30238-8] [PMID: 31492652]NCT01628393. Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study). https://clinicaltrials.gov/show/NCT016283932012. ">RADIANCE 2019</a>; <a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a>; <a href="./references#CD011381-bbs2-0047" title="ComiG , KapposL , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology2019 ;18(11):1009-1020. [DOI: 10.1016/S1474-4422(19)30239-X]DeLucaJ , SchipplingS , MontalbanX , KapposL , CreeBAC , ComiG , et al. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Mult Scler Relat Disord2021;48:102673. [DOI: 10.1016/j.msard.2020.102673]NCT02294058. Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS). https://ClinicalTrials.gov/show/NCT022940582014. ">SUNBEAM 2019</a>) and assessing six treatments. One treatment, assessed in one study, was compared to placebo, and six treatments were evaluated in head‐to‐head comparisons in five studies. Using placebo as a common comparator, treatment with daclizumab (SMD 0.22 SD, 95% CI 0.05 to 0.38) probably resulted in a trivial improvement in quality of life on this scale. Ozanimod (SMD 0.5 SD, 95% CI 0.29 to 0.71), interferon beta‐1a (Avonex, Rebif) (SMD 0.36 SD, 95% CI 0.16 to 0.55) and interferon beta‐1b (SMD 0.41 SD, 95% CI ‐0.13 to 0.95) may have resulted in a trivial improvement in quality of life on this scale. Differences across treatments were found and are shown in <a href="./appendices#CD011381-sec-0124">Appendix 11</a>. </p> <p>Quality of life impairment (non‐MS related; mental subscale) was available from three studies involving 2417 participants with RRMS (6.61% of those included in this review) (<a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a>; <a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a>; <a href="./references#CD011381-bbs2-0049" title="ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(3):247-56. FreedmanMS , MorawskiJ , ThangaveluK . Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. Mult Scler J Exp Transl Clin2018;4(2):2055217318775236. [DOI: 10.1177/2055217318775236] [PMID: 29796289]MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MäurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol2014;261(9):1781-8. [DOI: 10.1007/s00415-014-7395-7] [PMID: 24972678]MillerAE , XuX , MacdonellR , VucicS , TruffinetP , BenamorM , et al. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. J Clin Neurosci2019;59:229-231. [DOI: 10.1016/j.jocn.2018.09.012] [PMID: 30348586]QiuW , HuangDH , HouSF , ZhangMN , JinT , DongHQ , et al, TOWER Trial Chinese Group. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study. Chin Med J (Engl)2018;131(23):2776-2784. [DOI: 10.4103/0366-6999.246067] [PMID: 30511679]">TOWER 2014</a>) and assessing three treatments. One treatment, assessed in one study, was compared to placebo, and two treatments were evaluated in head‐to‐head comparisons in two studies. Compared to placebo, teriflunomide may have resulted in a trivial improvement in quality of life (non‐MS related; mental subscale) (SMD 0.1 SD, 95% CI ‐0.02 to 0.22). </p> <p>Quality‐of‐life impairment (MS related; mental) was available from six studies involving 6261 participants with RRMS (17% of those included in this review) (<a href="./references#CD011381-bbs2-0007" title="CreeBAC , GoldmanMD , CorboyJR , SingerBA , FoxEJ , ArnoldDL , et al, ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020 ;78(1):1–13. [DOI: 10.1001/jamaneurol.2020.2950] [PMID: 32852530]">ASSESS 2020</a>; <a href="./references#CD011381-bbs2-0019" title="BenedictRH , CohanS , LynchSG , RiesterK , WangP , Castro-BorreroW , et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler2018 ;24(6):795-804. [DOI: 0.1177/1352458517707345]KapposL , HavrdovaE , GiovannoniG , KhatriBO , GauthierSA , GreenbergSJ , et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler2017;23(13):1736-1747. [DOI: 10.1177/1352458516683266]KapposL , WiendlH , SelmajK , ArnoldDL , HavrdovaE , BoykoA , et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2015;373(15):1418-28. [DOI: 10.1056/NEJMoa1501481]KruegerJG , KircikL , HougeirF , FriedmanA , YouX , LucasN , et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther2016;33(7):231-45. [DOI: 10.1007/s12325-016-0353-2]LiuY , VollmerT , HavrdovaE , RiesterK , LeeA , PhillipsG , et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;11:18-24. [DOI: 10.1016/j.msard.2016.11.005]NCT01064401. Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01064401 (accessed 30 September 2014). RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40.. [DOI: 10.1016/j.msard.2017.06.006]">DECIDE 2015</a>; <a href="./references#CD011381-bbs2-0038" title="MokhberN , AzarpazhoohA , OroujiE , KhorramB , Modares GharaviM , KakhiS , KhallaghiH , AzarpazhoohMR . Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis. Psychiatry Clin Neurosci.2015;69(10):649-57. [DOI: 10.1111/pcn.12308] [PMID: 25907350]MokhberN , AzarpazhoohA , OroujiE , RaoSM , KhorramB , SahraianMA , ForoghipoorM , GharaviMM , KakhiS , NikkhahK , AzarpazhoohMR . Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. J Neurol Sci2014;342(1-2):16-20. [DOI: 10.1016/j.jns.2014.01.038] [PMID: 24841321]">Mokhber 2014</a>; <a href="./references#CD011381-bbs2-0044" title="CohenJA , ComiG , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019;18(11):1021-1033. [DOI: 10.1016/S1474-4422(19)30238-8] [PMID: 31492652]NCT01628393. Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study). https://clinicaltrials.gov/show/NCT016283932012. ">RADIANCE 2019</a>; <a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a>; <a href="./references#CD011381-bbs2-0047" title="ComiG , KapposL , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology2019 ;18(11):1009-1020. [DOI: 10.1016/S1474-4422(19)30239-X]DeLucaJ , SchipplingS , MontalbanX , KapposL , CreeBAC , ComiG , et al. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Mult Scler Relat Disord2021;48:102673. [DOI: 10.1016/j.msard.2020.102673]NCT02294058. Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS). https://ClinicalTrials.gov/show/NCT022940582014. ">SUNBEAM 2019</a>) and assessing six treatments. One treatment, assessed in one study, was compared to placebo, and six treatments were evaluated in head‐to‐head comparisons in five studies. Using placebo as a common comparator, interferon beta‐1b (SMD 0.30 SD, 95% CI ‐0.24 to 0.84) may have resulted in a small improvement in quality of life (MS related; mental subscale). Treatment with daclizumab (SMD 0.12 SD, 95% CI ‐0.05 to 0.28), iozanimod (SMD 0.05 SD, 95% CI ‐0.15 to 0.26) and interferon beta‐1a(SMD 0.03 SD, 95% CI ‐0.17 to 0.22) may have resulted in a trivial improvement in quality of life (MS related; mental subscale). Differences across treatments were found and are shown in <a href="./appendices#CD011381-sec-0125">Appendix 12</a>. </p> </section> </section> </section> <section id="CD011381-sec-0085"> <h5 class="title">2.2 Safety</h5> <section id="CD011381-sec-0086"> <h6 class="title">MS‐related mortality</h6> <section id="CD011381-sec-0087"> <p><b>Pairwise meta‐analysis (direct comparisons)</b></p> <p>Treatment estimates for pairwise meta‐analyses are reported in <a href="./references#CD011381-fig-0025" title="">Analysis 3.11</a>. </p> </section> <section id="CD011381-sec-0088"> <p><b>Network meta‐analysis estimates (combination of direct and indirect comparisons) of treatment effects</b></p> <p>The network geometry is presented in <a href="#CD011381-fig-0005">Figure 5</a>, and <a href="./appendices#CD011381-sec-0126">Appendix 13</a> shows the network estimates of each treatment against placebo or against another treatment within the network. </p> <p>Data on mortality were available from 33 studies involving 34,500 participants with RRMS (94% of those included in this review) (<a href="./references#CD011381-bbs2-0002" title="CalabresiPA , KieseierBC , ArnoldDL , BalcerLJ , BoykoA , PelletierJ , et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurology2014;13:657-65. HuX , CuiY , WhiteJ , ZhuY , DeykinA , NestorovI , HungS . Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. British Journal of Clinical Pharmacology2015;79(3):514-22. [DOI: 10.1111/bcp.12521] [PMID: 25265472]ScottTF , KieseierBC , NewsomeSD , ArnoldDL , YouX , HungS , Sperling B. Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis.. Mult Scler J Exp Transl Clin. 2016 ;2:2055217316676644. [DOI: 10.1177/2055217316676644] [PMID: 28607743]">ADVANCE 2014</a>; <a href="./references#CD011381-bbs2-0003" title="BalcerLJ , GalettaSL , PolmanCH , EggenbergerE , CalabresiPA , ZhangA , et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.. J Neurol Sci2012;318(1-2):119-24. [DOI: 10.1016/j.jns.2012.03.009] [PMID: 22521274]LublinFD , CutterG , GiovannoniG , PaceA , CampbellNR , BelachewS . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.. Mult Scler Relat Disord2014;3(6):705-11. [DOI: 10.1016/j.msard.2014.08.005] [PMID: 25891549]PolmanCH , O'ConnorPW , HavrdovaE , HutchinsonM , KapposL , MillerDH , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):899-910. Weinstock-GuttmanB , GalettaSL , GiovannoniG , HavrdovaE , HutchinsonM , KapposL , et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology2012;259((5)):898-905. [DOI: 10.1007/s00415-011-6275-7] [PMID: 22008873]">AFFIRM 2006</a>; <a href="./references#CD011381-bbs2-0004" title="ComiG , JefferyD , KapposL , MontalbanX , BoykoA , RoccaMA , et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. New England Journal of Medicine2012;366(11):1000-9. FilippiM , RoccaMA , PaganiE , De StefanoN , JefferyD , KapposL , et al, ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry2014;85(8):851-8. [DOI: 10.1136/jnnp-2013-306132] [PMID: 24029546]">ALLEGRO 2012</a>; <a href="./references#CD011381-bbs2-0005" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS I 2020</a>; <a href="./references#CD011381-bbs2-0006" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS II 2020</a>; <a href="./references#CD011381-bbs2-0007" title="CreeBAC , GoldmanMD , CorboyJR , SingerBA , FoxEJ , ArnoldDL , et al, ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020 ;78(1):1–13. [DOI: 10.1001/jamaneurol.2020.2950] [PMID: 32852530]">ASSESS 2020</a>; <a href="./references#CD011381-bbs2-0009" title="O'ConnorP , FilippiM , ArnasonB , ComiG , CookS , GoodinD , et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology2009;8(10):889-97. SchipplingS , O'ConnorP , KnappertzV , PohlC , BogumilT , SuarezG , et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol2016;263(7):1418-26. [DOI: 10.1007/s00415-016-8146-8]">BEYOND 2009</a>; <a href="./references#CD011381-bbs2-0011" title="VollmerTL , SorensenPS , SelmajK , ZippF , HavrdovaE , CohenJA , et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology2014;261(4):773-83. ">BRAVO 2014</a>; <a href="./references#CD011381-bbs2-0012" title="CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786-801. FoxEJ , WynnD , ColesAJ , PalmerJ , MargolinDH , CAMMS223 Investigators. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. J Neurol Sci2016;363:188-94. [DOI: 10.1016/j.jns.2016.02.025]">CAMMS223 2008</a>; <a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a>; <a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a>; <a href="./references#CD011381-bbs2-0015" title="AfolabiD , AlborC , ZalewskiL , AltmannDR , BakerD , SchmiererK . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler2018 ;24(11):1461-1468. [DOI: 10.1177/1352458517726380] [PMID: 28817997]ComiG , CookSD , GiovannoniG , RammohanK , RieckmannP , SørensenPS , et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol2013;260(4):1136-46. [DOI: 10.1007/s00415-012-6775-0] [PMID: 23263473]De StefanoN , GiorgioA , BattagliniM , De LeucioA , HickingC , DangondF , et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018;24(2):222-226. [DOI: 10.1177/1352458517690269] [PMID: 28140753]GiovannoniG , ComiG , CookS , RammohanK , RieckmannP , Soelberg SørensenP , et al, CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):416-26. [DOI: 10.1056/NEJMoa0902533] [PMID: 20089960]GiovannoniG , Soelberg SorensenP , CookS , RammohanKW , RieckmannP , ComiG , et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler2019;25(6):819-827. [DOI: 10.1177/1352458518771875] [PMID: 29716436]HermannR , LitwinJS , FribergLE , DangondF , MunafoA . Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Br J Clin Pharmacol2019 ;85(7):1484-1494. [DOI: 10.1111/bcp.13919] [PMID: 30883839]VermerschP , GalazkaA , DangondF , DamianD , WongSL , JackD , et al. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Curr Med Res Opin2021;37(3):459-464. [DOI: 10.1080/03007995.2020.1865888] [PMID: 33331183]">CLARITY 2010</a>; <a href="./references#CD011381-bbs2-0016" title="LublinFD , CofieldSS , CutterGR , ConwitR , NarayanaPA , NelsonF , et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology2013;73(3):327-40. ">CombiRx 2013</a>; <a href="./references#CD011381-bbs2-0017" title="ComiG , DadonY , SassonN , SteinermanJR , KnappertzV , VollmerTL , et al. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler2022;28(4):608-619. [DOI: 10.1177/13524585211032803] [PMID: 34378456]NCT01707992. The Efficacy, Safety, and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). https://clinicaltrials.gov/show/NCT017079922012. ">CONCERTO 2021</a>; <a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a>; <a href="./references#CD011381-bbs2-0020" title="ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014;261(9):1794-802. [DOI: 10.1007/s00415-014-7412-x] [PMID: 24989666]ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol2014;261(12):2429-37. [DOI: 10.1007/s00415-014-7504-7] [PMID: 25270680]Bar-OrA , GoldR , KapposL , ArnoldDL , GiovannoniG , SelmajK , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol2013 ;260(9):2297-305. [DOI: 10.1007/s00415-013-6954-7] [PMID: 23797999]Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012] [PMID: 28751099]GoldR , KapposL , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine2012;367(12):1098-107. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272] [PMID: 28328179]KapposL , GoldR , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler2014;20(2):243-52. [DOI: 10.1177/1352458513507817] [PMID: 24150779]">DEFINE 2012</a>; <a href="./references#CD011381-bbs2-0019" title="BenedictRH , CohanS , LynchSG , RiesterK , WangP , Castro-BorreroW , et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler2018 ;24(6):795-804. [DOI: 0.1177/1352458517707345]KapposL , HavrdovaE , GiovannoniG , KhatriBO , GauthierSA , GreenbergSJ , et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler2017;23(13):1736-1747. [DOI: 10.1177/1352458516683266]KapposL , WiendlH , SelmajK , ArnoldDL , HavrdovaE , BoykoA , et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2015;373(15):1418-28. [DOI: 10.1056/NEJMoa1501481]KruegerJG , KircikL , HougeirF , FriedmanA , YouX , LucasN , et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther2016;33(7):231-45. [DOI: 10.1007/s12325-016-0353-2]LiuY , VollmerT , HavrdovaE , RiesterK , LeeA , PhillipsG , et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;11:18-24. [DOI: 10.1016/j.msard.2016.11.005]NCT01064401. Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01064401 (accessed 30 September 2014). RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40.. [DOI: 10.1016/j.msard.2017.06.006]">DECIDE 2015</a>; <a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a>; <a href="./references#CD011381-bbs2-0025" title="CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(6):545-56. VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , Freedman MS A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017 3;3:2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS II 2014</a>; <a href="./references#CD011381-bbs2-0026" title='DavisMD , AshtamkerN , SteinermanJR , KnappertzV . Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study. 2017 Neurol Neuroimmunol Neuroinflamm;4(2):e327. [DOI: 10.1212/NXI.0000000000000327] [PMID: 28210662]KhanO , RieckmannP , BoykoA , SelmajK , ZivadinovR , GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Annals of Neurology2013;73(6):705-13. ZivadinovR , DwyerM , BarkayH , SteinermanJR , KnappertzV , Khan O. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis. J Neurol2015;262(3):648-53. [DOI: 10.1007/s00415-014-7616-0] [PMID: 25542295]ZivadinovR , DwyerMG , RamasamyDP , DavisMD , SteinermanJR , KhanO . The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. J Neuroimaging2015;25(6):989-95. [DOI: 10.1111/jon.12293] [PMID: 26394270]'>GALA 2013</a>; <a href="./references#CD011381-bbs2-0028" title="ComiG , PattiF , RoccaMA , MattioliFC , AmatoMP , GalloP , CentonzeD , PozzilliC , SaccàF , BerghFT , BartezaghiM , TurriniR , FilippiM , Golden Study Group. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol2017;264(12):2436-2449. [DOI: 10.1007/s00415-017-8642-5] [PMID: 29063244]">GOLDEN 2017</a>; <a href="./references#CD011381-bbs2-0039" title="JacobsL , CookfairD , RudickR , HerndonR , RichertJ , SalazarA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology1996;39:285-94. ">MSCRG 1996</a>; <a href="./references#CD011381-bbs2-0043" title="EbersGC . Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet1998;352(9139):1498-1504. [DOI: 10.1016/S0140-6736(98)03334-0]TraboulseeA , LiDKB , CascioneM , FangJ , DangondF , MillerA . Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. BMC Neurol2018;18(1):143. [DOI: 10.1186/s12883-018-1145-x] [PMID: 30217172]">PRISMS 1998</a>; <a href="./references#CD011381-bbs2-0040" title="A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01247324 (accessed 30 September 2014). HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , JulianL , KöndgenH , LiC , NapieralskiJ , ZhengH , WolinskyJS . Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , BuffelsR , FioreD , GarrenH , HanJ , HauserSL . Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA I 2017</a>; <a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a>; <a href="./references#CD011381-bbs2-0042" title="KapposL , FoxRJ , BurcklenM , FreedmanMS , HavrdováEK , HennessyB , et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol 2021 May 1;;78(5):558-567. [DOI: 10.1001/jamaneurol.2021.0405] [PMID: 33779698]">OPTIMUM 2021</a>; <a href="./references#CD011381-bbs2-0044" title="CohenJA , ComiG , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019;18(11):1021-1033. [DOI: 10.1016/S1474-4422(19)30238-8] [PMID: 31492652]NCT01628393. Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study). https://clinicaltrials.gov/show/NCT016283932012. ">RADIANCE 2019</a>; <a href="./references#CD011381-bbs2-0045" title="MikolD , BarkhofF , ChangP , CoyleP , JefferyD , SchwidS , et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology2008;7(10):903-14. ">REGARD 2008</a>; <a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a>; <a href="./references#CD011381-bbs2-0047" title="ComiG , KapposL , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology2019 ;18(11):1009-1020. [DOI: 10.1016/S1474-4422(19)30239-X]DeLucaJ , SchipplingS , MontalbanX , KapposL , CreeBAC , ComiG , et al. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Mult Scler Relat Disord2021;48:102673. [DOI: 10.1016/j.msard.2020.102673]NCT02294058. Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS). https://ClinicalTrials.gov/show/NCT022940582014. ">SUNBEAM 2019</a>; <a href="./references#CD011381-bbs2-0049" title="ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(3):247-56. FreedmanMS , MorawskiJ , ThangaveluK . Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. Mult Scler J Exp Transl Clin2018;4(2):2055217318775236. [DOI: 10.1177/2055217318775236] [PMID: 29796289]MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MäurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol2014;261(9):1781-8. [DOI: 10.1007/s00415-014-7395-7] [PMID: 24972678]MillerAE , XuX , MacdonellR , VucicS , TruffinetP , BenamorM , et al. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. J Clin Neurosci2019;59:229-231. [DOI: 10.1016/j.jocn.2018.09.012] [PMID: 30348586]QiuW , HuangDH , HouSF , ZhangMN , JinT , DongHQ , et al, TOWER Trial Chinese Group. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study. Chin Med J (Engl)2018;131(23):2776-2784. [DOI: 10.4103/0366-6999.246067] [PMID: 30511679]">TOWER 2014</a>; <a href="./references#CD011381-bbs2-0048" title="MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al, Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler2012;18(11):1625-32. [DOI: 10.1177/1352458512450354] [PMID: 22723573]O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293-303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol2013;260(10):2472-80. [DOI: 10.1007/s00415-013-6979-y] [PMID: 23852658]RadueEW , SprengerT , GaetanoL , Mueller-LenkeN , CavalierS , ThangaveluK , et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm2017;4(5):e390. [DOI: 10.1212/NXI.0000000000000390] [PMID: 28828394]WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013 ;19(10):1310-9. [DOI: 10.1177/1352458513475723] [PMID: 23447359]">TEMSO 2011</a>; <a href="./references#CD011381-bbs2-0050" title="BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler2014;20(13):1704-13. [DOI: 10.1177/1352458514532317] [PMID: 24812043]CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402-15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol2013;260(8):2023-32. [DOI: 10.1007/s00415-013-6932-0] [PMID: 23632946]KhatriBO , PelletierJ , KapposL , HartungHP , ComiG , BarkhofF , et al, TRANSFORMS Study Group. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord2014;3(3):355-63. [DOI: 10.1016/j.msard.2013.11.006] [PMID: 25876473]MengX , ChinPS , HashmonayR , Zahur IslamM , CutterG . Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemp Clin Trials2015;41:69-74. [DOI: 10.1016/j.cct.2014.12.011] [PMID: 25545026]">TRANSFORMS 2010</a>) and assessing 16 treatments. </p> <p>Ten treatments assessed in 15 studies were compared to placebo, thirteen treatments were evaluated in head‐to‐head comparisons in 15 studies and two studies involving 2751 participants had both a placebo and active treatment arms. Using placebo as a common comparator, a trivial reduction in the number of deaths probably occurred in people treated with daclizumab (OR 0.32, 95% CI 0.04 to 2.37) and laquinimod (OR 0.51, 95% CI 0.12 to 2.18). A trivial reduction in the number of deaths may have occurred in people treated with ponesimod (OR 0.30, 95% CI 0.01 to 13.20), interferon beta‐1b (OR 0.37, 95% CI 0.02 to 5.81), fingolimod (OR 0.38, 95% CI 0.07 to 1.98), ocrelizumab (OR 0.39, 95% CI 0.03 to 4.50), ofatumumab (OR 0.49, 95% CI 0.01 to 24.84), glatiramer acetate (OR 0.49, 95% CI 0.10 to 2.38), pegylated interferon (OR 0.49, 95% CI 0.07 to 3.51), interferon beta‐1a (OR 0.63, 95% CI 0.18 to 2.17), and dimethyl fumerate (OR 0.75, 95% CI 0.11 to 5.24). A trivial increase in the number of deaths probably occurred in the people treated with cladribine (OR 0.98, 95% CI 0.18 to 5.39). A trivial increase in the number of deaths may have occurred in the people treated with ozanimod (OR 0.96, 95% CI 0.03 to 29.63), alemtuzumab (OR 1.38, 95% CI 0.16 to 12.14), teriflunomide (OR 1.50, 95% CI 0.16 to 14.45) and natalizumab (OR 2.52, 95% CI 0.12 to 52.69). Differences across treatments were found and are shown in <a href="./appendices#CD011381-sec-0126">Appendix 13</a>. </p> <p>Relative treatment rankings (SUCRA and mean rank) for each primary and secondary outcome are presented in <a href="./appendices#CD011381-sec-0127">Appendix 14</a>. Due to the small number of studies for comparisons and large number of treatments, interpretation of these results should be considered with caution. </p> </section> </section> </section> </section> <section id="CD011381-sec-0089"> <h4 class="title">3. Assessment of heterogeneity and incoherence within the network analyses</h4> <p>We performed an assessment of heterogeneity and incoherence within the network analyses for all analyses whenever possible. The values for common heterogeneity (τ2) for the network for each outcome seem to show no evidence of heterogeneity (<a href="./appendices#CD011381-sec-0128">Appendix 15</a>). Assessment of incoherence was possible for disability worsening over 24 months, relapses over 12 and 24 months, number of patients with any serious adverse events, number of patients who discontinued due to adverse events, and mortality (<a href="./appendices#CD011381-sec-0129">Appendix 16</a>). We observed evidence of local statistical incoherence, estimated as a difference between direct and indirect treatment estimates in networks, for one loop for relapses over 24 months, for the number of patients with any serious adverse events, and for treatment discontinuation due to adverse events. </p> </section> <section id="CD011381-sec-0090"> <h4 class="title">4. Subgroup and sensitivity analyses</h4> <section id="CD011381-sec-0091"> <h5 class="title">Subgroup analysis</h5> <p>In the subgroup analysis by diagnostic criteria, for the efficacy outcomes, we didn't find any relevant difference in the dimension or direction of the effect for those drugs that were represented in both subgroups. For safety outcomes, we found that, in the studies using Poser criteria, the incidence of SAEs was higher for some drugs compared to studies using Mc Donald criteria; however, the estimates were highly imprecise (<a href="./appendices#CD011381-sec-0130">Appendix 17</a>). </p> <p>We could not perform a subanalysis based on previous treatment with immunomodulators or immunosuppressants because the vast majority of the included studies did not report data about previous treatments with DMTs or included a mixed population of patients with and without previous treatment with DMTs, but did not report separate outcome data for the two subgroups. Moreover, amongst the studies including people with MS previously treated with DMTs, we found notable heterogeneity in the definition of “previous treatment”, with different washout criteria adopted for different DMTs. </p> </section> <section id="CD011381-sec-0092"> <h5 class="title">Sensitivity analysis</h5> <p>In the analysis including only studies at low risk of selection bias (allocation concealment), we did not find any important difference in the direction or dimension of the effect estimate for all outcomes except "discontinuation due to adverse events". For this outcome, the direction of the effect remained the same and the dimension increased for some drugs while decreased for others. The direction of the effect changed only for pegylated interferon beta‐1a. </p> <p>In the analysis, including only studies at low risk of attrition bias, the estimates of the effect of the interventions changed in the dimension of the effect, increasing for some drugs and decreasing for others, but not in the direction for all the outcomes for several drugs. For disability at 24 months, the estimate of effect of fingolimod changed direction (<a href="./appendices#CD011381-sec-0131">Appendix 18</a>). </p> <p>We did not perform sensitivity analyses excluding studies with a sample size smaller than 50 randomised participants because only two studies satisfied this criterion. </p> </section> </section> <section id="CD011381-sec-0093"> <h4 class="title">5. Reporting bias</h4> <p>We did not produce a contour‐enhanced funnel plot for each pairwise comparison due to the low number of studies. We employed a comparison‐adjusted funnel plot for all placebo‐controlled trials for relapses over 12 and 24 months and disability worsening over 24 months. Small study effects (not necessarily due to reporting bias) appeared to be present for relapses over 12 and 24 months, but not for disability worsening over 24 months (data not shown). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011381-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011381-sec-0094"></div> <section id="CD011381-sec-0095"> <h3 class="title" id="CD011381-sec-0095">Summary of main results</h3> <p>This updated review of the effects of treatments for RRMS included 50 studies involving 36,541 randomised adult participants. Twenty‐five (50%) studies were placebo‐controlled and 25 (50%) were head‐to‐head comparisons. The majority of studies were short‐term trials, with the median treatment duration being 24 months. Four studies reported a 36‐month follow‐up; therefore, the effects of these treatments beyond two years remain uncertain. </p> <section id="CD011381-sec-0096"> <h4 class="title">1. Recurrence of relapses</h4> <p>Considering placebo as a common comparator, 12‐month follow‐up treatment with natalizumab resulted in a large reduction of people with relapses. Treatment with fingolimod, daclizumab, and immunoglobulins probably resulted in a large reduction of people with relapses. Treatment with mitoxantrone, teriflunomide, glatiramer acetate and pegylated interferon beta‐1a may result in a large reduction of people with relapses. Treatment with interferon beta‐1a (Avonex, Rebif) may moderately reduce people with relapses. Treatment with interferon beta‐1b may moderately reduce the number of people with relapses, but the evidence is very uncertain. When interferon beta 1‐a and beta 1‐b were both used in the same intervention, there may have been a large increase in the number of people with relapses, but the evidence is very uncertain. </p> <p>At 24 months follow‐up, treatment with cladribine, alemtuzumab, and natalizumab resulted in a large decrease in people with relapses. Treatment with fingolimod, dimethyl fumarate and ponesimod probably resulted in a large decrease in people with relapses. Treatment with glatiramer acetate and interferon beta‐1a (Avonex, Rebif), probably moderately decreases people with relapses. Treatment with mitoxantrone and immunoglobulins may result in a large decrease in people with relapses. Treatment with interferon beta‐1b (Betaferon) and laquinimod may moderately decrease people with relapses. Treatment with teriflunomide and azathioprine may moderately decrease people with relapses, but the evidence is very uncertain. When interferon beta 1‐a and beta 1‐b were both used in the same intervention arm, there may have been a moderate increase in the number of people with relapses, but the evidence is very uncertain. </p> <p>At 36 months follow‐up, we found that interferon beta‐1b (Betaferon) may moderately decrease the number of people with relapses, but the evidence is very uncertain. </p> </section> <section id="CD011381-sec-0097"> <h4 class="title">2. Disability worsening</h4> <p>At 24 months follow‐up, treatment with natalizumab probably results in a moderate reduction of people with disability worsening. Treatment with dimethyl fumarate, alemtuzumab, and fingolimod may moderately reduce people with disability worsening. Treatment with cladribine and interferon beta‐1b (Betaferon) may result in a small reduction of people with disability worsening. Treatment with mitoxantrone may result in a large reduction of people who experience disability worsening, but the evidence is very uncertain. Treatment with interferon beta‐1a may result in a trivial reduction in the number of people who experience disability worsening. Treatment with mitoxantrone may result in a large reduction of people who experience disability worsening, but the evidence is very uncertain. Treatment with ofatumumab, ocrelizumab, azathioprine and ponesimod may moderately reduce the number of people who experience disability worsening, but the evidence is very uncertain. Treatment with glatiramer acetate, teriflunomide, immunoglobulins and laquinimod may result in a small reduction of people who experience disability worsening, but the evidence is very uncertain. When interferon beta 1‐a and beta 1‐b were both used in the same intervention arm, there may have been a large increase in the number of people with disability progression, but the evidence is very uncertain. When treated with ozanimod, there may have been a trivial increase in the number of people with disability progression, but the evidence is very uncertain. </p> <p>At 36 months follow‐up, we did not find any study that compared our drugs of interest with placebo. </p> </section> <section id="CD011381-sec-0098"> <h4 class="title">3. Safety</h4> <p>Using placebo as the common comparator, treatment with alemtuzumab probably results in a trivial reduction of people who discontinued treatment due to adverse events. Treatment with ocrelizumab may result in a trivial reduction in people who discontinue treatment due to adverse events. Treatment with daclizumab, fingolimod, teriflunomide, interferon beta‐1a, laquinimod, natalizumab, and glatiramer acetate probably result in a trivial increase in people who discontinued due to adverse events. Treatment with interferon beta‐1b, ofatumumab, cladribine, and dimethyl fumarate may result in a trivial increase in people who discontinued due to adverse events. Treatment with ozanimod may have little to no effect on people who discontinued due to adverse effects. Treatment with pegylated interferon beta‐1a, azathioprine, and ponesimod may result in a small increase in people who discontinued due to adverse events, but the evidence is very uncertain. Treatment with immunoglobulins and interferon beta 1a‐1b may result in a trivial increase in people who discontinued due to adverse effects, but the evidence is very uncertain. </p> <p>Compared to placebo, treatment with interferon beta‐1b probably results in a trivial reduction in people who experience serious adverse effects. Treatment with fingolimod and glatiramer acetate may result in a trivial reduction in people who experience SAEs. Treatment with mitoxantrone may result in a trivial reduction in people who experience SAEs, but the evidence is very uncertain. Treatment with daclizumab may result in a small increase in people with SAEs. Treatment with dimethyl fumarate and natalizumab may result in a trivial increase in people who experience SAEs. Treatment with ocrelizumab may result in little or no effect on people who experience SAEs, but the evidence is very uncertain. Treatment with the remaining DMTS may result in a trivial increase in the people experiencing SAEs, but the evidence is very uncertain: alemtuzumab, cladribine, interferon beta‐1a, laquinimod, pegylated beta‐1a; ofatumumab, ozanimod, ponesimod and teriflunomide (very low‐certainty evidence). </p> </section> </section> <section id="CD011381-sec-0099"> <h3 class="title" id="CD011381-sec-0099">Overall completeness and applicability of evidence</h3> <p>Nine critical outcomes were identified by the Multiple Sclerosis Essential Medicines Panel appointed by the Multiple Sclerosis International Federation. These informed the current review, but the outcomes were further differentiated into primary and secondary outcomes and assessed solely for certainty and efficacy/harm, in line with standard Cochrane methodology. The data underlying the review, from all nine outcomes, served as the evidence base for the MEMP guideline panel, where it was contextualised with the perspective of low‐resource settings by considering further evidence related to other domains, in line with GRADE Evidence to Decision Framework methodology (<a href="./references#CD011381-bbs2-0128" title="Alonso-CoelloP , SchünemannHJ , MobergJ , Brignardello-PetersenR , AklEA , DavoliM , et al, GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ2016;353:i2016. [DOI: 10.1136/bmj.i2016] [PMID: 27353417]">Alonso‐Coello 2016</a>; <a href="./references#CD011381-bbs2-0129" title="Alonso-CoelloP , OxmanAD , MobergJ , Brignardello-PetersenR , AklEA , DavoliM , et al, GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ 2016;353:i2089. [DOI: 10.1136/bmj.i2089]">Alonso‐Coello 2016b</a>). The MEMP recommendations were used as the basis of an application for the inclusion of disease‐modifying treatments in the 23rd WHO Model List of Essential Medicines. </p> <p>Many of the trials included in this review provided evidence on the proportion of participants who experienced new relapses, disability worsening, and adverse events over 12 or 24 months' follow‐up, but only five studies reported data on these outcomes over 36 months. Considering that MS is a chronic disease of 30 to 40 years' duration, such findings limit the applicability of the available evidence for both efficacy and safety, particularly for long‐term and uncommon adverse events. </p> <p>Evidence relevant to 29 treatments considered in this review was derived from 50 studies involving 36,541 adult participants, half of which (25/50 studies; 17,294 participants, 50% of those included in this review) compared the intervention with placebo and not with another DMT. There is, therefore, uncertainty whether the results of the review fit into the context of current practice since about 50% of people with MS are treated with at least one DMT (<a href="./references#CD011381-bbs2-0140" title="CarrollCA , FairmanKA , LageMJ . Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data. BMC Health Services Research2014;14:286. [http://www.biomedcentral.com/1472-6963/14/286]">Carroll 2014</a>). </p> <p>The reasons why the 50 available randomised studies for RRMS are mostly placebo‐controlled and outcome data are reported mainly over 24 months, are probably due to the following reasons: i) comparison with placebo in one double‐blind, superiority RCT is sufficient for approval of DMTs for RRMS by many national regulatory agencies ; ii) the lack of interest by pharmaceutical companies in conducting longer and more expensive studies, given that it is only recently that some regulatory agencies have recommended a duration of three years for confirmatory trials (<i>EMA ‐ Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis, 2015 https://www.ema.europa.eu/documents/scientific‐guideline/guideline‐clinical‐investigation‐medicinal‐products‐treatment‐multiple‐sclerosis‐revision‐2_en.pdf)</i>; iii) the unlikely advantage of pharmaceutical companies in conducting head‐to‐head trials directly comparing active treatments. </p> <p>In order to increase the comprehensiveness of this review, in addition to outcomes present in the previous version of the review, this update also included new/enlarging T1‐ and T2‐weighted MRI lesions, cognitive and quality of life as secondary outcomes, which are considered relevant by people with MS (<a href="#CD011381-sec-0027">Secondary outcomes</a>). </p> </section> <section id="CD011381-sec-0100"> <h3 class="title" id="CD011381-sec-0100">Quality of the evidence</h3> <p>Considering the risk of bias, the most frequent concern was related to the role of the sponsor in the authorship of the study report or in data management and analysis, for which we judged that 68% of the studies were at high risk of bias. The other most frequent concerns were performance bias with 34% of the studies at high risk of bias and attrition bias with 32% of studies at high risk of bias. </p> <p>The most frequent reasons for downgrading the certainty of evidence were study limitations and imprecision, across all the outcomes and comparisons. </p> <p>For relapses at 12 and 24 months, we judged several treatments as having high (natalizumab, alemtuzumab, cladribine) and moderate (daclizumab, fingolimod, immunoglobulins, dimethylfumarate, glatiramer acetate, interferon beta‐1a, ponesimod) certainty of evidence. On the other hand, for the outcome disability at 24 months, we found moderate certainty of evidence only for natalizumab, while the certainty of evidence for all the other treatments was low or very low. </p> <p>For treatment discontinuation due to adverse events, we judged several treatments as having moderate certainty of evidence (natalizumab, alemtuzumab, daclizumab, fingolimod, glatiramer acetate, interferon beta‐1a, laquinimod, and teriflunomide). For the outcome SAEs, only interferon beta‐1b provided a moderate certainty of evidence. </p> <p>Considering all the outcomes, natalizumab was the drug for which we found the highest certainty of evidence. </p> </section> <section id="CD011381-sec-0101"> <h3 class="title" id="CD011381-sec-0101">Potential biases in the review process</h3> <section id="CD011381-sec-0102"> <h4 class="title">1. Transitivity assumption</h4> <p>We assumed that any patient who met the inclusion criteria was, in principle, equally likely to have been randomised to any of the eligible interventions. However, as we discussed in the <a href="#CD011381-sec-0009">Background</a> section, several participant characteristics have changed in newer trials, and thus a transitivity hypothesis may not have been a reasonable assumption to make, due to differences in patient or trial characteristics. Thus, we evaluated the assumption of transitivity by assessing differences in patient characteristics such as age, disease duration, and baseline Expanded Disability Status Scale (EDSS) scores across the trials and by comparing the predefined potential effect modifiers across the different comparisons in the networks. We did not find any evidence that important variables varied across comparisons or altered the effectiveness of the treatments; although some confounders may be hidden and unmeasured, it might be reasonable to analyse the network as a whole. Thus, we assumed that the transitivity held and a network meta‐analytical approach was reasonable. However, few studies per comparison were available and limitations in study reporting cannot exclude the possibility of intransitivity. </p> </section> <section id="CD011381-sec-0103"> <h4 class="title">2. Heterogeneity and inconsistency</h4> <p>We did not find any strong evidence of the presence of heterogeneity either in direct pairwise comparisons or in the entire networks. Similarly, the loop‐specific approach and the 'design‐by‐treatment' model did not provide any clear indication of the presence of inconsistency either locally or in the entire networks. Thus, we believe that the consistency assumption is reasonable for this type of data. However, the power of these tests and approaches to detect inconsistency is low, particularly for networks with few included studies per comparison. </p> </section> <section id="CD011381-sec-0104"> <h4 class="title">3. Subgroup and sensitivity analyses</h4> <p>In the subgroup analysis by diagnostic criteria, for the efficacy outcomes, we didn't find any relevant difference in the dimension or direction of the effect for those drugs that were represented in both subgroups. For safety outcomes, we found that, in the studies using Poser criteria, the incidence of SAEs was higher for some drugs compared to studies using Mc Donald criteria; however, the estimates were highly imprecise. </p> <p>In sensitivity analysis including only studies at low risk of selection bias, we found that the outcome "discontinuation due to adverse effects" changed in the dimension of the effect, increasing for some treatments and decreasing for others. When we included only studies at low risk of attrition bias, this phenomenon happened also for other outcomes, though differences were not substantial. These findings indicate that attrition bias could have an impact on the dimension of the estimates, though it is not possible to identify a consistent direction across the interventions. </p> </section> <section id="CD011381-sec-0105"> <h4 class="title">4. Reporting bias</h4> <p>The possible presence of reporting bias, partially supported by the comparison‐adjusted funnel plot for comparisons versus placebo for relapses over 12 and 24 months, could not be totally excluded. </p> </section> <section id="CD011381-sec-0106"> <h4 class="title">5. Certainty of the evidence</h4> <p>As reported in the <a href="#CD011381-sec-0031">Data collection and analysis</a> (Summary of findings and assessment of the certainty of the evidence) section, the certainty of the evidence for this review was assessed using a fully contextualised approach, involving the definition of quantitative thresholds to determine the magnitude ('trivial', 'small', 'moderate', and 'large') of each health effect measured by each outcome. Quantitative thresholds between magnitudes of health effects were considered when assessing imprecision, one of the domains contributing to the certainty of the evidence. Thresholds were calculated from outcome‐specific numerical health state utility values (HSUVs). Whenever HSUVs were not obtainable from published evidence, they were set through panel judgement, therefore reflecting the panel members' potentially biased views and expectations. </p> </section> </section> <section id="CD011381-sec-0107"> <h3 class="title" id="CD011381-sec-0107">Agreements and disagreements with other studies or reviews</h3> <p>In this review, which included 50 RCTs on 29 pharmacological treatments for patients with RRMS, we found with high certainty that, compared to placebo, people with RRMS receiving natalizumab, cladribine or alemtuzumab for 24 months had a lower risk of experiencing new relapses at both 12 and 24 months compared to people receiving other DMTs. Moreover, people receiving natalizumab may also have a lower risk of disability progression at 24 months. Results from our previous review (<a href="./references#CD011381-bbs2-0264" title="TramacereI , Del GiovaneC , SalantiG , D'AmicoR , FilippiniG . Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD011381. [DOI: 10.1002/14651858.CD011381.pub2]">Tramacere 2015</a>) on disability worsening at 24 months were confirmed and extended in this current review update. </p> <p>In terms of safety, compared to those receiving placebo, we are moderately confident that a higher proportion of people treated with daclizumab, fingolimod, teriflunomide, interferon beta‐1a, laquinimod, natalizumab, and glatiramer or glatiramer acetate are at a higher risk of withdrawing due to AEs. Our certainty that the same conclusion could be drawn for the other DMTs except alemtuzumab (all with higher risk than placebo) was low or very low. Indirect comparisons show that alemtuzumab was the only DMT with a lower number of patients discontinuing for AEs than placebo (moderate certainty). </p> <p>Daclizumab, dimethyl fumerate and natalizumab are associated with a higher proportion of severe adverse events than other DMTs, when taking placebo as the common comparator, although the certainty of such evidence is low. There is low‐certainty evidence that people treated with interferon beta‐1b, fingolimod and glatiramer acetate may experince a slightly lower number of SAEs. For the remaining DMTs, we found only very low‐certainty evidence. </p> <p>According to an NMA (<a href="./references#CD011381-bbs2-0218" title="LiH , HuF , ZhangY , LiK . Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. J Neurol2020;267:3489-98. [DOI: 10.1007/s00415-019-09395-w]">Li 2020</a>) including 23 RCTs on DMTs for RRMS with methodology similar to that of our review, in that the authors adopted the GRADE methodology to assess certainty in the evidence, alemtuzumab, natalizumab, ocrelizumab and fingolimod were the regimens associated with both the lowest risks of relapse rate and of treatment discontinuation due to AEs. However, in interpreting such similarities and differences in the results compared to those of our review, it has to be noted that this NMA considered only studies with a minimum follow‐up of 24 months assessing the 12 DMTs approved by the FDA, and did not include cladribine and daclizumab. </p> <p>A recent NMA (<a href="./references#CD011381-bbs2-0220" title="LiuZ , LiaoQ , WenH , ZhangY . Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis. Autoimmun Rev2021;20:102826. [DOI: 10.1016/j.autrev.2021.102826]">Liu 2021</a>), including 21 studies involving 23 DMTs, showed that all of them, except interferon beta‐1b, were more effective than placebo in reducing the annualised relapse rate (ARR) over 24 months while, in a multi‐comparison analysis, ofatumumab ranked as the most effective, and alemtuzumab, dimethyl fumarate and ocrelizumab were ranked in second place. Considering the effectiveness in reducing relapse frequency and tolerability in terms of discontinuation rate due to AEs, alemtuzumab showed the best combination and, according to the authors, could be considered the optimal treatment, together with ofatumumab and natalizumab. In terms of undesirable effects, drug discontinuation due to AEs was more frequent with most DMTs compared to placebo, but such difference was not statistically significant, except for dimethyl fumarate. Although conclusions on alemtuzumab and natalizumab may be considered as in agreement with our review, and safety relative to discontinuation due to AEs is in disagreement, it should be noted that, in contrast to our review, in the review by Liu and colleagues, the risk of bias of the included studies was assessed by means of the Cochrane Risk of Bias 2 (RoB2) but outcome‐specific certainty of the reported estimates according to the GRADE methodology was not assessed. </p> <p>Similar to our conclusions, in respect to placebo, a NMA on the safety of immunotherapies for MS (<a href="./references#CD011381-bbs2-0250" title="TramacereI , VirgiliG , PerducaV , LucenteforteE , BenedettiMD , CapobussiM , et al. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews (in press).">Tramacere 2023</a>) found an increased proportion of people discontinuing treatment for teriflunomide, interferon beta‐1a, interferon beta‐1b, glatiramer acetate, fingolimod, immunoglobulins, and daclizumab. </p> <p>Favourable results relative to alemtuzumab and natalizumab in terms of efficacy were also reported by a NMA (<a href="./references#CD011381-bbs2-0224" title="LucchettaRC , ToninFS , BorbaHHL , LeonartLP , FerreiraVL , BonettiAF , et al. Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis. CNS Drugs2018;32:813-26. [DOI: 10.1007/s40263-018-0541-5.]">Lucchetta 2018</a>), including most of the available licensed DMTs for RRMS, and azathioprine and rituximab as off‐label treatments. In contrast to our review, ocelizumab also, together with alemtuzumab and natalizumab, were reported as the most effective DMTs in reducing ARR and disability accumulation. This NMA, though, included studies with a minimum follow‐up of 12 weeks and used interferon beta‐1a as a common comparator in the NMA. </p> <p>A NMA of RCTs on DMTs for RRMS (<a href="./references#CD011381-bbs2-0191" title="FogartyE , SchmitzS , TubridyN , WalshC , BarryM . Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis. Mult Scler Relat Disord.2016;9:23-30. [DOI: 10.1016/j.msard.2016.06.001]">Fogarty 2016</a>), considering ARR and disability progression as primary efficacy outcomes, found that natalizumab and alemtuzumab ranked higher than other DMTs across outcomes. This review, however, did not include amongst the considered interventions most of the recent selective immunosuppressors (i.e. ponesimod, siponimod, ozanimod, ofatumumab, daclizumab), cladribine and off‐label treatments. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011381-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow chart* Several of the studies were reported in the same reports: ASCLEPIOS I 2020; ASCLEPIOS II 2020 (reported in Hauser 2020); CARE‐MS I 2012; CARE‐MS II 2012 (reported in Arroyo 2017); OPERA I 2017; OPERA II 2017 (reported in the same four reports); CONFIRM 2012; DEFINE 2012 (reported in Fernandez 2017 and Havrdova 2017); FREEDOMS 2010; FREEDOMS II 2014 (reported in Vermersch 2017); DECIDE 2015; SELECT 2013 (reported in Giovannoni 2016 and Rose 2017)." data-id="CD011381-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow chart</p> <p>* Several of the studies were reported in the same reports: <a href="./references#CD011381-bbs2-0005" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS I 2020</a>; <a href="./references#CD011381-bbs2-0006" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS II 2020</a> (reported in Hauser 2020); <a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a>; <a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a> (reported in Arroyo 2017); <a href="./references#CD011381-bbs2-0040" title="A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01247324 (accessed 30 September 2014). HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , JulianL , KöndgenH , LiC , NapieralskiJ , ZhengH , WolinskyJS . Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , BuffelsR , FioreD , GarrenH , HanJ , HauserSL . Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA I 2017</a>; <a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a> (reported in the same four reports); <a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a>; <a href="./references#CD011381-bbs2-0020" title="ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014;261(9):1794-802. [DOI: 10.1007/s00415-014-7412-x] [PMID: 24989666]ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol2014;261(12):2429-37. [DOI: 10.1007/s00415-014-7504-7] [PMID: 25270680]Bar-OrA , GoldR , KapposL , ArnoldDL , GiovannoniG , SelmajK , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol2013 ;260(9):2297-305. [DOI: 10.1007/s00415-013-6954-7] [PMID: 23797999]Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012] [PMID: 28751099]GoldR , KapposL , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine2012;367(12):1098-107. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272] [PMID: 28328179]KapposL , GoldR , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler2014;20(2):243-52. [DOI: 10.1177/1352458513507817] [PMID: 24150779]">DEFINE 2012</a> (reported in Fernandez 2017 and Havrdova 2017); <a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a>; <a href="./references#CD011381-bbs2-0025" title="CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(6):545-56. VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , Freedman MS A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017 3;3:2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS II 2014</a> (reported in Vermersch 2017); <a href="./references#CD011381-bbs2-0019" title="BenedictRH , CohanS , LynchSG , RiesterK , WangP , Castro-BorreroW , et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler2018 ;24(6):795-804. [DOI: 0.1177/1352458517707345]KapposL , HavrdovaE , GiovannoniG , KhatriBO , GauthierSA , GreenbergSJ , et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler2017;23(13):1736-1747. [DOI: 10.1177/1352458516683266]KapposL , WiendlH , SelmajK , ArnoldDL , HavrdovaE , BoykoA , et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2015;373(15):1418-28. [DOI: 10.1056/NEJMoa1501481]KruegerJG , KircikL , HougeirF , FriedmanA , YouX , LucasN , et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther2016;33(7):231-45. [DOI: 10.1007/s12325-016-0353-2]LiuY , VollmerT , HavrdovaE , RiesterK , LeeA , PhillipsG , et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;11:18-24. [DOI: 10.1016/j.msard.2016.11.005]NCT01064401. Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01064401 (accessed 30 September 2014). RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40.. [DOI: 10.1016/j.msard.2017.06.006]">DECIDE 2015</a>; <a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a> (reported in Giovannoni 2016 and Rose 2017). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011381-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011381-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Network plots of treatment comparisons for primary efficacy and safety outcomes (Primary outcomes). The width of the lines is proportional to the precision of each pair of treatments, and the size of every circle is proportional to the number of trials comparing every pair of treatments.AE, adverse effects; SAE, serious adverse events." data-id="CD011381-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-04.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Network plots of treatment comparisons for primary efficacy and safety outcomes (<a href="#CD011381-sec-0024">Primary outcomes</a>). The width of the lines is proportional to the precision of each pair of treatments, and the size of every circle is proportional to the number of trials comparing every pair of treatments. </p> <p>AE, adverse effects; SAE, serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-04.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Network plots of treatment comparisons for secondary efficacy and safety outcomes (Secondary outcomes). The width of the lines is proportional to the precision of each pair of treatments, and the size of every circle is proportional to the number of trials comparing every pair of treatments.Gd, gadolinium; MRI, magnetic resonance imaging; w, weighted." data-id="CD011381-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-05.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Network plots of treatment comparisons for secondary efficacy and safety outcomes (<a href="#CD011381-sec-0027">Secondary outcomes</a>). The width of the lines is proportional to the precision of each pair of treatments, and the size of every circle is proportional to the number of trials comparing every pair of treatments. </p> <p>Gd, gadolinium; MRI, magnetic resonance imaging; w, weighted.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-05.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Network plots of treatment comparisons for cognitive decline and quality of life*. The width of the lines is proportional to the precision of each pair of treatments, and the size of every circle is proportional to the number of trials comparing every pair of treatments.* Please refer to Effects of interventions for further details on the quality‐of‐life scales used.Abbreviations: MH,; MSQOL,: PH,; SF‐36,." data-id="CD011381-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-06.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Network plots of treatment comparisons for cognitive decline and quality of life*. The width of the lines is proportional to the precision of each pair of treatments, and the size of every circle is proportional to the number of trials comparing every pair of treatments. </p> <p>* Please refer to <a href="#CD011381-sec-0070">Effects of interventions</a> for further details on the quality‐of‐life scales used. </p> <p>Abbreviations: MH,; MSQOL,: PH,; SF‐36,.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-06.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Network meta‐analysis (NMA) estimates of primary efficacy and safety outcomes in comparisons against placebo.AE, adverse effects; CI, confidence interval; RR, risk ratio; SAE, serious adverse events." data-id="CD011381-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-07.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Network meta‐analysis (NMA) estimates of primary efficacy and safety outcomes in comparisons against placebo. </p> <p>AE, adverse effects; CI, confidence interval; RR, risk ratio; SAE, serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-FIG-07.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Treatment efficacy (primary outcomes): pairwise comparisons, Outcome 1: Comparisons for relapse (12 months)" data-id="CD011381-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Treatment efficacy (primary outcomes): pairwise comparisons, Outcome 1: Comparisons for relapse (12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Treatment efficacy (primary outcomes): pairwise comparisons, Outcome 2: Comparisons for relapse (24 months)" data-id="CD011381-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Treatment efficacy (primary outcomes): pairwise comparisons, Outcome 2: Comparisons for relapse (24 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Treatment efficacy (primary outcomes): pairwise comparisons, Outcome 3: Comparisons for relapse (36 months)" data-id="CD011381-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Treatment efficacy (primary outcomes): pairwise comparisons, Outcome 3: Comparisons for relapse (36 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Treatment efficacy (primary outcomes): pairwise comparisons, Outcome 4: Comparisons for disability worsening (24 months)" data-id="CD011381-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Treatment efficacy (primary outcomes): pairwise comparisons, Outcome 4: Comparisons for disability worsening (24 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Treatment efficacy (primary outcomes): pairwise comparisons, Outcome 5: Comparisons for disability worsening (36 months)" data-id="CD011381-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Treatment efficacy (primary outcomes): pairwise comparisons, Outcome 5: Comparisons for disability worsening (36 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Treatment safety (primary outcomes): pairwise comparisons, Outcome 1: Number of patients who discontinued treatment due to adverse effects" data-id="CD011381-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Treatment safety (primary outcomes): pairwise comparisons, Outcome 1: Number of patients who discontinued treatment due to adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Treatment safety (primary outcomes): pairwise comparisons, Outcome 2: Number of patients with any serious adverse effect" data-id="CD011381-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Treatment safety (primary outcomes): pairwise comparisons, Outcome 2: Number of patients with any serious adverse effect </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 1: Comparisons for new gadolinium‐enhancing positive T1‐weighted MRI lesions (12 months)" data-id="CD011381-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 1: Comparisons for new gadolinium‐enhancing positive T1‐weighted MRI lesions (12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 2: Comparisons for new gadolinium‐enhancing positive T1‐weighted MRI lesions (24 months)" data-id="CD011381-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 2: Comparisons for new gadolinium‐enhancing positive T1‐weighted MRI lesions (24 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 3: Comparisons for new or enlarging T2‐weighted MRI lesions (12 months)" data-id="CD011381-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 3: Comparisons for new or enlarging T2‐weighted MRI lesions (12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 4: Comparisons for new or enlarging T2‐weighted MRI lesions (24 months)" data-id="CD011381-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 4: Comparisons for new or enlarging T2‐weighted MRI lesions (24 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 5: Comparisons for quality of life total (non‐MS related: EQ‐5D VAS)" data-id="CD011381-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 5: Comparisons for quality of life total (non‐MS related: EQ‐5D VAS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 6: Comparisons for quality of life total (non‐MS related) (INDEX)" data-id="CD011381-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 6: Comparisons for quality of life total (non‐MS related) (INDEX) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 7: Comparisons for quality of life ‐ physical (non‐MS related: SF‐36)" data-id="CD011381-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 7: Comparisons for quality of life ‐ physical (non‐MS related: SF‐36) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 8: Comparisons for quality of life ‐ physical (MS related: MSQOL‐54 PH; MSQoL‐54; MSIS29 Psychological)" data-id="CD011381-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 8: Comparisons for quality of life ‐ physical (MS related: MSQOL‐54 PH; MSQoL‐54; MSIS29 Psychological) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 9: Comparisons for quality of life ‐ mental (Non‐MS related: SF‐36)" data-id="CD011381-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 9: Comparisons for quality of life ‐ mental (Non‐MS related: SF‐36) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 10: Comparisons for quality of life ‐ mental (MS related: MSQOL‐54 PH; MSQoL‐54; MSIS29 Psychological)" data-id="CD011381-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 10: Comparisons for quality of life ‐ mental (MS related: MSQOL‐54 PH; MSQoL‐54; MSIS29 Psychological) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011381-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/urn:x-wiley:14651858:media:CD011381:CD011381-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 11: Mortality" data-id="CD011381-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_t/tCD011381-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Treatment efficacy and safety (secondary outcomes): pairwise comparisons, Outcome 11: Mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/media/CDSR/CD011381/image_n/nCD011381-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011381-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Relapses at 12 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Population:</b> Patients with RRMS </p> <p><b>Interventions:</b> Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b, interferon beta‐1b (Betaferon), interferon beta‐1a (Avonex, Rebif), pegylated interferon beta‐1a, mitoxantrone, natalizumab, teriflunomide </p> <p><b>Comparator (reference):</b> Placebo </p> <p><b>Outcome:</b> Relapses at 12 months </p> <p><b>Setting(s):</b> Outpatient </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Intervention (no. of studies/participants)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect**</b> </p> <p><b>(95% CrI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effect***(95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With placebo</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With intervention</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Azathioprine</b> </p> <p>(Direct evidence; 1 RCT; 59 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.91</b><br/>(0.58 to 1.43) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>375 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>37 fewer per 1000</b><br/>(from 173 fewer to 177 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Daclizumab</b> </p> <p>(Direct evidence; 1 RCT; 621 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.55</b><br/>(0.42 to 0.73) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>227 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>185 fewer per 1000</b><br/>(from 239 fewer to 111 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fingolimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.48</b><br/>(0.39 to 0.57) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>198 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>214 fewer per 1000</b><br/>(from 251 fewer to 177 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Glatiramer acetate</b> </p> <p>(Direct evidence; 2 RCTs; 1454 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.64</b><br/>(0.55 to 0.75) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>264 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>148 fewer per 1000</b><br/>(from 185 fewer to 103 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Immunoglobulins</b> </p> <p>(Direct evidence; 2 RCTs; 91 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.60</b><br/>(0.47 to 0.79) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>247 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>165 fewer per 1000</b><br/>(from 218 fewer to 87 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta 1a‐1b</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 1.42</b><br/>(0.78 to 2.60) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>585 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>173 more per 1000</b> </p> <p>(from 91 fewer to 659 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1b (Betaferon)</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.82</b><br/>(0.50 to 1.33) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>338 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>74 fewer per 1000</b><br/>(from 206 fewer to 136 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1a (Avonex, Rebif)</b> </p> <p>(Direct evidence; 1 RCT; 560 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.76</b><br/>(0.68 to 0.85) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>313 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>99 fewer per 1000</b> </p> <p>(from 132 fewer to 62 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pegylated interferon beta‐1a</b> </p> <p>(Direct evidence; 1 RCT; 1512 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.68</b><br/>(0.56 to 0.82) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>280 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>132 fewer per 1000</b><br/>(from 181 fewer to 74 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mitoxantrone</b> </p> <p>(Direct evidence; 1 RCT; 51 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.40</b><br/>(0.21 to 0.74) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>165 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>247 fewer per 1000</b><br/>(from 326 fewer to 107 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Natalizumab</b> </p> <p>(Direct evidence; 1 RCT; 942 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.52</b><br/>(0.43 to 0.63) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>214 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>198 fewer per 1000</b><br/>(from 235 fewer to 152 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>High<sup>9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Teriflunomide</b> </p> <p>(Direct evidence; 1 RCT; 1169 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.66</b><br/>(0.55 to 0.78) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>272 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>140 fewer per 1000</b><br/>(from 185 fewer to 91 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>NMA‐SoF table definitions</b> </p> <p>** Network Meta‐analysis estimates are reported as risk ratios. CI: confidence interval.</p> <p>*** Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group. </p> <p><b>GRADE Working Group grades of evidence (or certainty in the evidence)</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> <p>1 Absolute observed point estimate falls in the small positive effect, 95% CI range from large positive effect to large negative effect: downgraded three levels. </p> <p>2 Absolute observed point estimate falls in the large positive effect, 95% CI range from large positive effect to moderate positive effect: downgraded one level. </p> <p>3 Downgraded one level for risk of bias. Absolute observed point estimate falls in the large positive effect, 95% CIs contained within positive effect. </p> <p>4 Absolute observed point estimate falls in the large positive effect, 95% CI range from large positive effect to moderate positive effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>5 Absolute observed point estimate falls in the large negative effect, 95% CI range from moderate positive effect to large negative effect: downgraded three levels. Further downgraded one level for risk of bias </p> <p>6 Absolute observed point estimate falls in the moderate positive effect, 95% CI range from large positive effect to large negative effect: downgraded three levels. Further downgraded one level for risk of bias </p> <p>7 Absolute observed point estimate falls in the moderate positive effect, 95% CI range from large positive effect to small positive effect: downgraded two levels. </p> <p>8 Absolute observed point estimate falls in the large positive effect, 95% CI range from large positive effect to moderate positive effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>9 Absolute observed point estimate falls in the large positive effect, 95% CIs contained within positive effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Relapses at 12 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011381-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Relapses at 24 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Population:</b> Patients with RRMS </p> <p><b>Interventions:</b> alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate, immunoglobulins, interferon beta 1a‐1b, interferon beta‐1b (Betaferon), interferon beta‐1a (Avonex, Rebif, laquinimod, mitoxantrone, natalizumab, ponesimod, teriflunomide </p> <p><b>Comparator (reference):</b> Placebo </p> <p><b>Outcome:</b> Relapses at 24 months </p> <p><b>Setting(s):</b> Outpatient </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Intervention (no. of studies/participants)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect**</b> </p> <p><b>(95% CrI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effect***(95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With placebo</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With</i> intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alemtuzumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.57</b><br/>(0.47 to 0.68) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>291 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>219 fewer per 1000</b><br/>(from 270 fewer to 163 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>High<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Azathioprine</b> </p> <p>(Direct evidence; 1 RCT; 59 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.77</b> </p> <p>(0.51 to 1.18)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>392 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>117 fewer per 1000</b><br/>(from 250 fewer to 92 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cladribine</b> </p> <p>(Direct evidence; 1 RCT; 1326 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.53</b><br/>(0.44 to 0.64) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>270 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>240 fewer per 1000</b><br/>(from 285 fewer to 183 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>High<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dimethylfumarate</b> </p> <p>(Direct evidence; 2 RCTs; 2307 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.62</b><br/>(0.55 to 0.70) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>316 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>194 fewer per 1000</b><br/>(from 229 fewer to 153 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fingolimod</b> </p> <p>(Direct evidence; 2 RCTs; 2355 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.54</b><br/>(0.48 to 0.60) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>275 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>234 fewer per 1000</b><br/>(from 265 fewer to 204 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Glatiramer acetate</b> </p> <p>(Direct evidence; 3 RCsT; 1014 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.84</b><br/>(0.76 to 0.93) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>428 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>82 fewer per 1000</b><br/>(from 122 fewer to 36 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Immunoglobulins</b> </p> <p>(Direct evidence; 2 RCTs; 192 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.73</b><br/>(0.59 to 0.90) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>372 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>138 fewer per 1000</b><br/>(from 209 fewer to 51 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta 1a‐1b</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 1.21</b><br/>(0.66 to 2.19) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>617 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>107 more per 1000</b><br/>(from 173 fewer to 607 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I<b>nterferon beta‐1b (Betaferon)</b> </p> <p>(Direct evidence; 1 RCT; 372 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.85</b><br/>(0.76 to 0.94) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>433 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>76 fewer per 1000</b><br/>(from 122 fewer to 31 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1a (Avonex, Rebif)</b> </p> <p>(Direct evidence; 3 RCTs; 1629 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.84</b><br/>(0.78 to 0.91) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>428 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>82 fewer per 1000</b><br/>(from 112 fewer to 46 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laquinimod</b> </p> <p>(Direct evidence; 3 RCTs; 3457 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.83</b><br/>(0.76 to 0.91) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>423 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>87 fewer per 1000</b><br/>(from 122 fewer to 46 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mitoxantrone</b> </p> <p>(Direct evidence; 1 RCT; 51 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.47</b><br/>(0.27 to 0.80) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>240 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>270 fewer per 1000</b><br/>(from 372 fewer to 102 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>10</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Natalizumab</b> </p> <p>(Direct evidence; 1 RCT; 942 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.56</b><br/>(0.48 to 0.65) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>285 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>224 fewer per 1000</b><br/>(from 265 fewer to 178 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>High<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ponesimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.58</b><br/>(0.48 to 0.70) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>214 fewer per 1000</b><br/>(from 265 fewer to 153 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Teriflunomide</b> </p> <p>(Direct evidence; 1 RCT; 1088 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.82</b><br/>(0.71 to 0.94) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>418 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>92 fewer per 1000</b><br/>(from 148 fewer to 31 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>11</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>NMA‐SoF table definitions</b> </p> <p>** Network Meta‐analysis estimates are reported as risk ratios. CI: confidence interval.</p> <p>*** Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group. </p> <p><b>GRADE Working Group grades of evidence (or certainty in the evidence)</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> <p><b>Explanatory Footnotes</b> </p> <p>1 Absolute observed point estimate falls in the large positive effect, 95% CIs contained within positive effect. </p> <p>2 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from large positive effect to moderate negative effect: downgraded three levels </p> <p>3 Downgraded one level for risk of bias. Absolute observed point estimate falls in the large positive effect, 95% CIs contained within positive effect. </p> <p>4 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to small positive effect: downgraded one level </p> <p>5 Absolute observed point estimate falls in the large positive effect, 95% CIs range from large positive effect to small positive effect: downgraded two levels </p> <p>6 Absolute observed point estimate falls in the moderate negative effect, 95% CIs range from large positive effect to large negative effect: downgraded three levels. Further downgraded one level for risk of bias </p> <p>7 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels </p> <p>8 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to small positive effect: downgraded one level </p> <p>9 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to small positive effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>10 Absolute observed point estimate falls in the large positive effect, 95% CIs range from large positive effect to moderate positive effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>11 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from large positive effect to trivial positive effect: downgraded three levels. Further downgraded one level for risk of bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Relapses at 24 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011381-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Relapses at 36 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patients:</b> Patients with RRMS </p> <p><b>Interventions:</b> interferon beta‐1b (Betaferon) </p> <p><b>Comparator (reference):</b> Placebo </p> <p><b>Outcome:</b> Relapses at 36 months </p> <p><b>Setting(s):</b> Outpatient </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Intervention (no. of studies/participants)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect**</b> </p> <p><b>(95% CrI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effect***(95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With placebo</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With</i> <i>intervention</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1b (Betaferon)</b> </p> <p>(Direct evidence; 2 RCTs; 403 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.86</b><br/>(0.67 to 1.11) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>862 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>741 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>121 fewer per 1000</b><br/>(from 284 fewer to 95 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>NMA‐SoF table definitions</b> </p> <p>** Network Meta‐analysis estimates are reported as risk ratios. CI: confidence interval.</p> <p>*** Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group. </p> <p><b>GRADE Working Group grades of evidence (or certainty in the evidence)</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> <p><b>Explanatory Footnotes</b> </p> <p>1 Absolute observed point estimate falls in the moderate positive effect, 95% CI ranges from large positive effect to moderate negative effect: downgraded three levels </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Relapses at 36 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011381-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Disability at 24 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Population:</b> Patients with RRMS </p> <p><b>Interventions:</b> Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate, immunoglobulins, interferon beta 1a‐1b, interferon beta‐1b (Betaferon), interferon beta‐1a (Avonex, Rebif), laquinimod, mitoxantrone, natalizumab, ocrelizumab, ofatumumab, ozanimod, ponesimod, teriflunomide </p> <p><b>Comparator (reference):</b> Placebo </p> <p><b>Outcome:</b> Disability at 24 months </p> <p><b>Setting(s):</b> Outpatient </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Intervention</b> </p> <p><b>(no. of studies and participants)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect**</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effect***(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With placebo</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With intervention</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alemtuzumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.67</b><br/>(0.46 to 0.99) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>126 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>62 fewer per 1000</b><br/>(from 101 fewer to 2 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Azathioprine</b> </p> <p>(Direct evidence; 1 RCT; 59 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.60</b><br/>(0.22 to 1.63) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>113 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>75 fewer per 1000</b><br/>(from 146 fewer to 118 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cladribine</b> </p> <p>(Direct evidence; 1 RCT; 1326 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.72</b><br/>(0.56 to 0.91) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>135 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>53 fewer per 1000</b><br/>(from 83 fewer to 17 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dimethylfumarate</b> </p> <p>(Direct evidence; 2 RCTs; 2307 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.65</b><br/>(0.55 to 0.77) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>122 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>66 fewer per 1000</b><br/>(from 84 fewer to 43 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fingolimod</b> </p> <p>(Direct evidence; 2 RCTs; 2355 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.68</b><br/>(0.56 to 0.83) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>128 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>60 fewer per 1000</b><br/>(from 83 fewer to 32 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Glatiramer acetate</b> </p> <p>(Direct evidence; 3 RCTs; 1014 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.74</b><br/>(0.61 to 0.89) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>139 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>49 fewer per 1000</b><br/>(from 73 fewer to 21 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Immunoglobulins</b> </p> <p>(Direct evidence; 2 RCTs; 190 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.75</b><br/>(0.41 to 1.37) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>141 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>47 fewer per 1000</b><br/>(from 111 fewer to 69 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta 1a‐1b</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 3.19</b><br/>(0.31 to 33.21) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>599 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>411 more per 1000</b> </p> <p>(from 130 fewer to 1000 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1b (Betaferon)</b> </p> <p>(Direct evidence; 1 RCT; 372 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.77</b><br/>(0.62 to 0.94) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>145 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>43 fewer per 1000</b><br/>(from 71 fewer to 11 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1a (Avonex, Rebif)</b> </p> <p>(Direct evidence; 2 RCTs; 1069 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b><br/>(0.73 to 1.16) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>173 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15 fewer per 1000</b><br/>(from 51 fewer to 30 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>10</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laquinimod</b> </p> <p>(Direct evidence; 3 RCTs; 3451 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.78</b><br/>(0.63 to 0.96) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>146 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41 fewer per 1000</b><br/>(from 69 fewer to 8 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>11</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mitoxantrone</b> </p> <p>(Direct evidence; 1 RCT; 51 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.20</b><br/>(0.05 to 0.83) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>38 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>150 fewer per 1000</b><br/>(from 178 fewer to 32 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>12</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Natalizumab</b> </p> <p>(Direct evidence; 1 RCT; 942 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.59</b><br/>(0.46 to 0.75) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>111 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>77 fewer per 1000</b><br/>(from 101 fewer to 47 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>13</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocrelizumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.61</b><br/>(0.41 to 0.90) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>115 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>73 fewer per 1000</b><br/>(from 111 fewer to 19 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>14</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ofatumumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.54</b><br/>(0.38 to 0.77) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>101 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>86 fewer per 1000</b><br/>(from 116 fewer to 43 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>15</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ozanimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 1.19</b><br/>(0.74 to 1.91) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>223 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6 more per 1000</b><br/>(from 49 fewer to 171 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>16</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ponesimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.63</b><br/>(0.41 to 0.96) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>118 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>69 fewer per 1000</b><br/>(from 111 fewer to 8 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>17</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Teriflunomide</b> </p> <p>(Direct evidence; 1 RCT; 1088 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>RR 0.76</b><br/>(0.61 to 0.95) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>143 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>45 fewer per 1000</b><br/>(from 73 fewer to 9 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>18</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>NMA‐SoF table definitions</b> </p> <p>** Network Meta‐analysis estimates are reported as risk ratios. CI: confidence interval.</p> <p>*** Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group. </p> <p><b>GRADE Working Group grades of evidence (or certainty in the evidence)</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> <p><b>Explanatory footnotes</b> </p> <p>1 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to trivial positive: downgraded three levels </p> <p>2 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from large positive effect to large negative effect: downgraded two levels </p> <p>3 Absolute observed point estimate falls in the small positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels </p> <p>4 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to small positive effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>5 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to small positive effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>6 Absolute observed point estimate falls in the small positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels. Further downgraded one level for risk of bias </p> <p>7 Absolute observed point estimate falls in the small positive effect, 95% CIs range from moderate positive effect to moderate negative effect: downgraded three levels </p> <p>8 Absolute observed point estimate falls in the large negative effect, 95% CIs range from large positive effect to large negative effect: downgraded three levels. Further downgraded one level for risk of bias </p> <p>9 Absolute observed point estimate falls in the small positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels </p> <p>10 Absolute observed point estimate falls in the trivial positive effect, 95% CIs range from small positive effect to trivial negative effect: downgraded two levels </p> <p>11 Absolute observed point estimate falls in the small positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels. Further downgraded one level for risk of bias </p> <p>12 Absolute observed point estimate falls in the large positive effect, 95% CIs range from large positive effect to small positive effect: downgraded two levels. Further downgraded one level for risk of bias </p> <p>13 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to small positive effect: downgraded one level </p> <p>14 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels. Further downgraded one level for risk of bias </p> <p>15 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from large positive effect to small positive effect: downgraded two levels. Further downgraded one level for risk of bias </p> <p>16 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from small positive effect to large negative effect: downgraded three levels </p> <p>17 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels. Further downgraded one level for risk of bias </p> <p>18 Absolute observed point estimate falls in the moderate positive effect, 95% CIs range from moderate positive effect to trivial positive effect: downgraded two levels. Further downgraded one level for risk of bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Disability at 24 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011381-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Discontinuation due to adverse effects</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Population:</b> Patients with RRMS </p> <p><b>Interventions:</b> Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, immunoglobulins, interferon beta 1a‐1b, interferon beta‐1b (Betaferon), interferon beta‐1a (Avonex, Rebif), laquinimod, pegylated interferon beta1a, natalizumab, ocrelizumab, ofatumumab, ozanimod, ponesimod, teriflunomide </p> <p><b>Comparator (reference):</b> Placebo </p> <p><b>Outcome:</b> Treatment discontinuation due to adverse events </p> <p><b>Setting(s):</b> Outpatient </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Intervention (no. of studies/participants)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect**</b> </p> <p><b>(95% CrI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effect***(95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With placebo</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With</i> <i>intervention</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alemtuzumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 0.39</b><br/>(0.19 to 0.79) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>30 fewer per 1000</b><br/>(from 40 fewer to 10 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Azathioprine</b> </p> <p>(Direct evidence; 1 RCT; 54 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 6.26</b><br/>(0.67 to 58.05) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>246 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>196 more per 1000</b><br/>(from 16 fewer to 702 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cladribine</b> </p> <p>(Direct evidence; 1 RCT; 1326 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.38</b><br/>(0.46 to 4.15) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>67 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18 more per 1000</b><br/>(from 26 fewer to 128 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Daclizumab</b> </p> <p>(Direct evidence; 1 RCT; 600 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 2.55</b><br/>(1.40 to 4.63) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>117 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>68 more per 1000</b><br/>(from 18 more to 145 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dimethylfumarate</b> </p> <p>(Direct evidence; 2 RCTs; 2300 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.35</b><br/>(0.94 to 1.95) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>66 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16 more per 1000</b><br/>(from 3 fewer to 43 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fingolimod</b> </p> <p>(Direct evidence; 2 RCTs; 2355 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.84</b><br/>(1.31 to 2.57) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>87 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>38 more per 1000</b><br/>(from 14 more to 69 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Glatiramer acetate</b> </p> <p>(Direct evidence; 4 RCTs; 2419 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.48</b><br/>(1.02 to 2.14) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>72 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22 more per 1000</b><br/>(from 1 more to 51 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Immunoglobulins</b> </p> <p>(Direct evidence; 3 RCTs; 243 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 2.49</b><br/>(0.37 to 16.50) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>115 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>65 more per 1000</b><br/>(from 31 fewer to 413 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta 1a‐1b</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 3.02</b><br/>(0.27 to 33.65) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>136 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>86 more per 1000</b><br/>(from 36 fewer to 587 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1b</b> </p> <p>(Direct evidence; 1 RCT; 372 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 2.27</b><br/>(1.05 to 4.91) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>106 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>56 more per 1000</b><br/>(from 2 more to 154 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1a</b> </p> <p>(Direct evidence; 2 RCTs; 1457 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.48</b><br/>(0.99 to 2.20) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>72 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22 more per 1000</b><br/>(from 0 fewer to 53 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laquinimod</b> </p> <p>(Direct evidence; 3 RCTs; 3457 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.46</b><br/>(1.00 to 2.15) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>71 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>21 more per 1000</b><br/>(from 0 fewer to 51 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pegylated interferon beta‐1a</b> </p> <p>(Direct evidence; 1 RCT; 1512 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 3.58</b><br/>(1.47 to 8.73) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>157 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>108 more per 1000</b><br/>(from 22 more to 263 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Natalizumab</b> </p> <p>(Direct evidence; 1 RCT; 939 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.57</b><br/>(0.81 to 3.05) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>76 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>26 more per 1000</b><br/>(from 9 fewer to 88 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>10</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocrelizumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 0.82</b><br/>(0.42 to 1.60) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9 fewer per 1000</b><br/>(from 28 fewer to 27 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>11</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ofatumumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 2.00</b><br/>(1.05 to 3.81) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>94 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>45 more per 1000</b><br/>(from 2 more to 116 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>12</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ozanimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.01</b><br/>(0.52 to 1.95) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 fewer per 1000</b><br/>(from 23 fewer to 43 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>13</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ponesimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 5.04</b> <br/><b>(2.15 to 11.82)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>208 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>158 more per 1000</b><br/>(from 51 more to 332 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>14</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Teriflunomide</b> </p> <p>(Direct evidence; 2 RCTs; 2253 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.82</b><br/>(1.19 to 2.79) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>87 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>37 more per 1000</b><br/>(from 9 more to 77 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to risk of bias<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>NMA‐SoF table definitions</b> </p> <p>** Network Metanalysis estimates are reported as risk ratios. CI: confidence interval.</p> <p>*** Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group. </p> <p><b>GRADE Working Group grades of evidence (or certainty in the evidence)</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> <p><b>Explanatory Footnotes</b> </p> <p>1 Downgraded one level for risk of bias. Absolute observed point estimate falls in the trivial positive effect; 95% CIs contained within positive effect. </p> <p>2 Absolute observed point estimate falls in the small negative effect, 95% CIs range from trivial positive effect to large negative effect: downgraded three levels </p> <p>3 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from trivial positive effect to small negative effect: downgraded two levels </p> <p>4 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from trivial negative effect to small negative effect: downgraded one level </p> <p>5 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from trivial positive effect to trivial negative effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>6 Downgraded one level for risk of bias. Absolute observed point estimate falls in the trivial negative effect; 95% CIs contained within negative effect. </p> <p>7 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from trivial positive effect to large negative effect: downgraded three levels </p> <p>8 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from trivial negative effect to small negative effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>9 Absolute observed point estimate falls in the small negative effect, 95% CIs range from trivial negative effect to large negative effect: downgraded two levels. Further downgraded one level for risk of bias </p> <p>10 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from trivial positive effect to trivial negative effect: downgraded one level </p> <p>11 Absolute observed point estimate falls in the trivial positive effect, 95% CIs range from trivial positive effect to trivial negative effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>12 Absolute observed point estimate falls in the trivial negative effect, 95% CIs range from trivial negative effect to small negative effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>13 Absolute observed point estimate falls in the null effect, 95% CIs range from trivial positive effect to trivial negative effect: downgraded one level. Further downgraded one level for risk of bias </p> <p>14 Absolute observed point estimate falls in the small negative effect, 95% CIs range from trivial negative effect to moderate negative effect: downgraded two levels. Further downgraded one level for risk of bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Discontinuation due to adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011381-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Serious adverse events</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> Patients with RRMS </p> <p><b>Interventions:</b> Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon beta‐1b (Betaferon), interferon beta‐1a (Avonex, Rebif), laquinimod, pegylated interferon beta‐1a, mitoxantrone, natalizumab, ocrelizumab, ofatumumab, ozanimod, ponesimod, teriflunomide </p> <p><b>Comparator (reference):</b> Placebo </p> <p><b>Outcome:</b> Serious adverse events </p> <p><b>Setting(s):</b> Outpatient </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Intervention (no. of studies/participants)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect**</b> </p> <p><b>(95% CrI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effect***(95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With placebo</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b><i>With intervention</i> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alemtuzumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.52</b><br/>(0.94 to 2.48) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>120 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>36 more per 1000</b><br/>(from 4 fewer to 96 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cladribine</b> </p> <p>(Direct evidence; 1 RCT; 1326 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.39</b><br/>(0.80 to 2.40) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>106 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>27 more per 1000</b><br/>(from 15 fewer to 92 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Daclizumab</b> </p> <p>(Direct evidence; 1 RCT; 600 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.90</b><br/>(1.21 to 2.99) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>140 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>61 more per 1000</b><br/>(from 15 more to 125 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dimethylfumarate</b> </p> <p>(Direct evidence; 2 RCTs; 2300 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.04</b><br/>(0.71 to 1.52) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>82 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3 more per 1000</b><br/>(from 22 fewer to 36 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fingolimod</b> </p> <p>(Direct evidence; 2 RCTs; 2355 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 0.86</b><br/>(0.64 to 1.13) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>69 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10 fewer per 1000</b><br/>(from 27 fewer to 9 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Glatiramer acetate</b> </p> <p>(Direct evidence; 3 RCTs; 2371 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 0.94</b><br/>(0.68 to 1.28) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>75 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4 fewer per 1000</b><br/>(from 24 fewer to 20 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision and risk of bias<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1b (Betaferon)</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 0.92</b><br/>(0.55 to 1.54) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>73 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6 fewer per 1000</b><br/>(from 34 fewer to 38 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕◯</p> <p>Moderate</p> <p>due to imprecision<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interferon beta‐1a (Rebif, Avonex)</b> </p> <p>(Direct evidence; 1 RCT; 897 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.21</b><br/>(0.88 to 1.67) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>94 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15 more per 1000</b><br/>(from 9 fewer to 46 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laquinimod</b> </p> <p>(Direct evidence; 3 RCTs; 3457 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.25</b><br/>(0.92 to 1.70) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>97 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18 more per 1000</b><br/>(from 6 fewer to 48 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pegylated interferon beta‐1a</b> </p> <p>(Direct evidence; 1 RCT; 1512 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.08</b><br/>(0.59 to 1.96) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>85 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6 more per 1000</b><br/>(from 31 fewer to 65 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mitoxantrone</b> </p> <p>(Direct evidence; 1 RCT; 53 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 0.89</b><br/>(0.02 to 47.22) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>71 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8 fewer per 1000</b><br/>(from 77 fewer to 723 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>10</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Natalizumab</b> </p> <p>(Direct evidence; 1 RCT; 939 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.24</b><br/>(0.73 to 2.09) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>96 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>17 more per 1000</b><br/>(from 20 fewer to 73 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕◯◯</p> <p>Low</p> <p>due to imprecision<sup>11</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocrelizumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.00</b><br/>(0.58 to 1.72) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 fewer per 1000</b><br/>(from 32 fewer to 50 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>12</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ofatumumab</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.52</b><br/>(0.89 to 2.57) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>115 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>36 more per 1000</b><br/>(from 8 fewer to 102 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>13</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ozanimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.50</b><br/>(0.85 to 2.64) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>114 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>35 more per 1000</b><br/>(from 11 fewer to 106 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision<sup>14</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ponesimod</b> </p> <p>No direct evidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.24</b><br/>(0.66 to 2.35) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>96 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>17 more per 1000</b><br/>(from 25 fewer to 89 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>15</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Teriflunomide</b> </p> <p>(Direct evidence; 2 RCTs; 2253 participants)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>OR 1.16</b><br/>(0.81 to 1.64) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>90 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>11 more per 1000</b><br/>(from 14 fewer to 44 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕◯◯◯</p> <p>Very low</p> <p>due to imprecision and risk of bias<sup>16</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference Comparator</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>NMA‐SoF table definitions</b> </p> <p>** Network Metanalysis estimates are reported as risk ratio. CI: confidence interval.</p> <p>*** Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group. </p> <p><b>GRADE Working Group grades of evidence (or certainty in the evidence)</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> <p><b>Explanatory Footnotes</b> </p> <p>1 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to moderate negative effect: downgraded three levels. Further downgraded one level for risk of bias. </p> <p>2 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to moderate negative effect: downgraded three levels. </p> <p>3 Absolute observed point estimate falls in the small negative effect, 95% CI range from trivial negative effect to moderate negative effect: downgraded two levels. </p> <p>4 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to trivial negative effect: downgraded one level. Further downgraded one level for risk of bias. </p> <p>5 Absolute observed point estimate falls in the trivial positive effect: (below small effect threshold), 95% CI range from trivial positive effect to trivial negative effect: downgraded one level. Further downgraded one level for risk of bias. </p> <p>6 Absolute observed point estimate falls in the trivial positive effect: (below small effect threshold), 95% CI range from trivial positive effect to trivial negative effect: downgraded one level. </p> <p>7 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to small negative effect: downgraded two levels. Further downgraded one level for risk of bias. </p> <p>8 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to small negative effect: downgraded two levels. Further downgraded one level for risk of bias. </p> <p>9 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to small negative effect: downgraded two levels. Further downgraded one level for risk of bias. </p> <p>10 Absolute observed point estimate falls in the trivial positive effect: (below small effect threshold), 95% CI range from moderate positive effect to large negative effect: downgraded three levels. Further downgraded one level for risk of bias. </p> <p>11 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to small negative effect: downgraded two levels. </p> <p>12 Absolute observed point estimate falls in the null effect, 95% CI range from trivial positive effect to small negative effect: downgraded two levels. Further downgraded one level for risk of bias. </p> <p>13 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to moderate negative effect: downgraded three levels. Further downgraded one level for risk of bias. </p> <p>14 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to moderate negative effect: downgraded three levels. </p> <p>15 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to moderate negative effect: downgraded three levels. Further downgraded one level for risk of bias. </p> <p>16 Absolute observed point estimate falls in the trivial negative effect: (below small effect threshold), 95% CI range from trivial positive effect to small negative effect: downgraded two levels. Further downgraded one level for risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011381-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Assessment of adverse events/serious adverse events in included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Did the researchers actively monitor for adverse events (AEs) or did they simply provide spontaneous reporting of AEs that arose?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Did the authors define serious AEs (SAEs) according to an accepted international classification and report the number of SAEs?</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0001" title="AchironA , GabbayU , GiladR , HassinB , BarakY , GornishM , et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology1998;50(2):398-402. ">Achiron 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0002" title="CalabresiPA , KieseierBC , ArnoldDL , BalcerLJ , BoykoA , PelletierJ , et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurology2014;13:657-65. HuX , CuiY , WhiteJ , ZhuY , DeykinA , NestorovI , HungS . Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. British Journal of Clinical Pharmacology2015;79(3):514-22. [DOI: 10.1111/bcp.12521] [PMID: 25265472]ScottTF , KieseierBC , NewsomeSD , ArnoldDL , YouX , HungS , Sperling B. Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis.. Mult Scler J Exp Transl Clin. 2016 ;2:2055217316676644. [DOI: 10.1177/2055217316676644] [PMID: 28607743]">ADVANCE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0003" title="BalcerLJ , GalettaSL , PolmanCH , EggenbergerE , CalabresiPA , ZhangA , et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.. J Neurol Sci2012;318(1-2):119-24. [DOI: 10.1016/j.jns.2012.03.009] [PMID: 22521274]LublinFD , CutterG , GiovannoniG , PaceA , CampbellNR , BelachewS . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.. Mult Scler Relat Disord2014;3(6):705-11. [DOI: 10.1016/j.msard.2014.08.005] [PMID: 25891549]PolmanCH , O'ConnorPW , HavrdovaE , HutchinsonM , KapposL , MillerDH , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine2006;354(9):899-910. Weinstock-GuttmanB , GalettaSL , GiovannoniG , HavrdovaE , HutchinsonM , KapposL , et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology2012;259((5)):898-905. [DOI: 10.1007/s00415-011-6275-7] [PMID: 22008873]">AFFIRM 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Treating neurologists were responsible for all aspects of patient care, including the management of adverse events".</i> Participants <i>"visited the clinic every 12 weeks for ... blood chemical and hematologic analyses, evaluation of adverse events...</i>" (page 901). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0004" title="ComiG , JefferyD , KapposL , MontalbanX , BoykoA , RoccaMA , et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. New England Journal of Medicine2012;366(11):1000-9. FilippiM , RoccaMA , PaganiE , De StefanoN , JefferyD , KapposL , et al, ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry2014;85(8):851-8. [DOI: 10.1136/jnnp-2013-306132] [PMID: 24029546]">ALLEGRO 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Safety assessments were performed at screening, at baseline, and every 3 months until month 24</i>" (page 1002). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0005" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS I 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"<i>Adverse events were recorded at all visits and graded according to the Common Terminology</i> <br/><i>Criteria for Adverse Events (CTCAE)."</i> (page 548)<i>. "Additional safety assessments included laboratory tests, physical examination (including examination of skin), vital sign measures, ECG evaluations and assessment of suicidality"</i> (page 21, Appendix). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>A serious adverse event (SAE) was defined as any adverse event [appearance of (or worsening of any pre‐existing)] undesirable sign(s), symptom(s) or medical conditions(s)which met any one of the following criteria:</i> <br/><i>• was fatal or life‐threatening</i> <br/><i>• resulted in persistent or significant disability/incapacity</i> <br/><i>• constituted a congenital anomaly/birth defect</i> <br/><i>• required in‐patient hospitalisation or prolongation of existing hospitalisation, unless hospitalisation was for:</i> <br/><i>‐ routine treatment or monitoring of the studied indication, not associated with any deterioration in condition (e.g. hospitalisation for multiple sclerosis relapse treatment)</i> <br/><i>‐ elective or pre‐planned treatment for a pre‐existing condition that was unrelated to the indication under trial and had not worsened since signing the informed consent to treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospital admission</i> <br/><i>‐ social reasons and respite care in the absence of any deterioration in the patient’s general condition</i> <br/><i>• was medically significant, e.g. defined as an event that jeopardised the patient or may require medical or surgical intervention."</i> (Appendix, page 22). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0006" title="HauserSL , Bar-OrA , CohenJA , ComiG , CorrealeJ , CoylePK , et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine2020;383(6):546-557. [DOI: 10.1056/NEJMoa1917246] [PMID: 32757523]">ASCLEPIOS II 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"Adverse events were recorded at all visits and graded according to the Common Terminology Criteria for Adverse Events (CTCAE)"</i> (page 548)<i>. "Additional safety assessments included laboratory tests, physical examination (including examination of skin), vital sign measures, ECG evaluations and assessment of suicidality"</i> (page 21, Appendix). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"A serious adverse event (SAE) was defined as any adverse event [appearance of (or</i> <br/><i>worsening of any pre‐existing)] undesirable sign(s), symptom(s) or medical conditions(s)</i> <br/><i>which met any one of the following criteria:</i> <br/><i>• was fatal or life‐threatening</i> <br/><i>• resulted in persistent or significant disability/incapacity</i> <br/><i>• constituted a congenital anomaly/birth defect</i> <br/><i>• required in‐patient hospitalisation or prolongation of existing hospitalisation, unless</i> <br/><i>hospitalisation was for:</i> <br/><i>‐ routine treatment or monitoring of the studied indication, not associated with</i> <br/><i>any deterioration in condition (e.g. hospitalisation for multiple sclerosis</i> <br/><i>relapse treatment)</i> <br/><i>‐ elective or pre‐planned treatment for a pre‐existing condition that was</i> <br/><i>unrelated to the indication under trial and had not worsened since signing the informed consent</i> <br/><i>‐ treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospital admission</i> <br/><i>‐ social reasons and respite care in the absence of any deterioration in the patient’s general condition</i> <br/><i>• was medically significant, e.g. defined as an event that jeopardised the patient or may require medical or surgical intervention."</i> (Appendix, page 22). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0007" title="CreeBAC , GoldmanMD , CorboyJR , SingerBA , FoxEJ , ArnoldDL , et al, ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020 ;78(1):1–13. [DOI: 10.1001/jamaneurol.2020.2950] [PMID: 32852530]">ASSESS 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0008" title="BrownRA , NarayananS , StikovN , CookS , CadavidD , WolanskyL , et al. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. Neurology2016;87(9):905-11. [DOI: 10.1212/WNL.0000000000003043] [PMID: 27473139]CadavidD , WolanskyLJ , SkurnickJ , LincolnJ , CheriyanJ , SzczepanowskiK , et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology2009;72(23):1976-83. CheriyanJ , KimS , WolanskyLJ , CookSD , CadavidD . Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol2012;69(1):82-8. [DOI: 10.1001/archneurol.2011.674]">BECOME 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>After the initial interim analysis failed to raise any safety concerns with the use of monthly triple dose gadolinium, all patients still in the study were offered the option of obtaining additional monthly MRI scans for a second year of treatment</i>" (page 1977). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0009" title="O'ConnorP , FilippiM , ArnasonB , ComiG , CookS , GoodinD , et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology2009;8(10):889-97. SchipplingS , O'ConnorP , KnappertzV , PohlC , BogumilT , SuarezG , et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol2016;263(7):1418-26. [DOI: 10.1007/s00415-016-8146-8]">BEYOND 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Clinic visits were scheduled every 3 months to assess ... safety, and tolerability. The occurrence of new neurological symptoms and adverse events was assessed by telephone, 6 weeks after each visit</i>" (page 891). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0010" title="BornsteinMB , MillerA , SlagleS , WeitzmanM , Crystal, DrexlerE , et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New England Journal of Medicine1987;317(7):408-14. ">Bornstein 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Self‐evaluation reported to a clinical assistant</i>" (page 409) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0011" title="VollmerTL , SorensenPS , SelmajK , ZippF , HavrdovaE , CohenJA , et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology2014;261(4):773-83. ">BRAVO 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Patients were evaluated at 12 scheduled visits: months ‐1 (screening), 0 (baseline), 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24. Safety assessments (laboratory measures, vital signs) were performed at all visits, and electrocardiograms (ECGs) were performed at months ‐1, 0, 1, 2, 3, 6, 12, 18, and 24/early termination</i>" (page 775). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0012" title="CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786-801. FoxEJ , WynnD , ColesAJ , PalmerJ , MargolinDH , CAMMS223 Investigators. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. J Neurol Sci2016;363:188-94. [DOI: 10.1016/j.jns.2016.02.025]">CAMMS223 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Safety was assessed quarterly by the treating neurologist, who was aware of study‐group assignment</i> " (page 1787); "<i>Thyroid function and levels of antithyrotropin receptor antibodies and lymphocyte subpopulations were measured quarterly at a central laboratory</i> "; and "<i>All adverse events with an onset up to 36 months are reported. In addition, all serious adverse events and autoimmune‐associated disorders occurring before March 1, 2008, are listed</i>" (page 1788). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0013" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler2017;23(10):1367-1376. [DOI: 10.1177/1352458516677589]CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819-28. ">CARE‐MS I 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>To assess safety, we undertook monthly questionnaire follow‐up of patients, and did complete blood counts, serum creatinine, urinalysis, and microscopy monthly (every three months in patients in the interferon beta 1a group), and thyroid function tests every 3 months</i> "; "<i>Circulating lymphocyte subsets were assessed every 3 months in all patients and 1 month after alemtuzumab administration. We screened for anti‐alemtuzumab antibodies with a bridging ELISA before and at 1 month, 3 months, and 12 months after each dosing</i> "; and "<i>We measured interferon beta 1a‐neutralising antibodies at baseline and at 24 months with a cytopathic effect inhibition assay</i>" (page 1821). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0014" title="Arroyo GonzálezR , KitaM , CraytonH , HavrdovaE , MargolinDH , LakeSL , et al, CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 2017;10:1367-1376. [DOI: 10.1177/1352458516677589]ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829-39. GiovannoniG , CohenJA , ColesAJ , HartungHP , HavrdovaE , SelmajKW , et al, CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology2016;87(19):1985-1992. [DOI: 10.1212/WNL.0000000000003319] [PMID: 27733571]">CARE‐MS II 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>To assess safety, we undertook monthly questionnaire follow‐up of patients, and did complete blood counts, serum creatinine, and urinalysis with microscopy monthly (every 3 months in patients in the interferon beta 1a group), and thyroid function tests every 3 months</i> "; "<i>We assessed circulating lymphocyte subsets every 3 months in all patients and 1 month after every course of alemtuzumab. We screened for anti‐alemtuzumab antibodies with ELISA before and at 1 month, 3 months and 12 months after each dosing</i> "; and "<i>We measured interferon beta 1a‐neutralising antibodies at baseline and at 24 months with a cytopathic effect inhibition assay</i>" (page 1832). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0015" title="AfolabiD , AlborC , ZalewskiL , AltmannDR , BakerD , SchmiererK . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler2018 ;24(11):1461-1468. [DOI: 10.1177/1352458517726380] [PMID: 28817997]ComiG , CookSD , GiovannoniG , RammohanK , RieckmannP , SørensenPS , et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol2013;260(4):1136-46. [DOI: 10.1007/s00415-012-6775-0] [PMID: 23263473]De StefanoN , GiorgioA , BattagliniM , De LeucioA , HickingC , DangondF , et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018;24(2):222-226. [DOI: 10.1177/1352458517690269] [PMID: 28140753]GiovannoniG , ComiG , CookS , RammohanK , RieckmannP , Soelberg SørensenP , et al, CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):416-26. [DOI: 10.1056/NEJMoa0902533] [PMID: 20089960]GiovannoniG , Soelberg SorensenP , CookS , RammohanKW , RieckmannP , ComiG , et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler2019;25(6):819-827. [DOI: 10.1177/1352458518771875] [PMID: 29716436]HermannR , LitwinJS , FribergLE , DangondF , MunafoA . Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Br J Clin Pharmacol2019 ;85(7):1484-1494. [DOI: 10.1111/bcp.13919] [PMID: 30883839]VermerschP , GalazkaA , DangondF , DamianD , WongSL , JackD , et al. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Curr Med Res Opin2021;37(3):459-464. [DOI: 10.1080/03007995.2020.1865888] [PMID: 33331183]">CLARITY 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0016" title="LublinFD , CofieldSS , CutterGR , ConwitR , NarayanaPA , NelsonF , et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology2013;73(3):327-40. ">CombiRx 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Safety was assessed by recording all adverse events, serious and nonserious</i>" (page 329). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information on SAE definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0017" title="ComiG , DadonY , SassonN , SteinermanJR , KnappertzV , VollmerTL , et al. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler2022;28(4):608-619. [DOI: 10.1177/13524585211032803] [PMID: 34378456]NCT01707992. The Efficacy, Safety, and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). https://clinicaltrials.gov/show/NCT017079922012. ">CONCERTO 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Safety endpoints included assessment of adverse events (AEs) throughout the study, and vital signs, electrocardiograms (ECGs), and clinical laboratory<br/>parameters at specific scheduled site visits. ECG findings<br/>assessed as “abnormal, clinically significant” were evaluated by the data monitoring committee<br/>(DMC) cardiologist. Assessment of tolerability included evaluation of the proportion of patients who prematurely discontinued treatment, including those with ETD due to AEs" (page 2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0018" title="Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther 2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012]FoxRJ , MillerDH , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine2012;367(12):1087-97. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272]HutchinsonM , FoxRJ , MillerDH , PhillipsJT , KitaM , HavrdovaE , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol2013;260(9):2286-96. [DOI: 10.1007/s00415-013-6968-1] [PMID: 23749293]KitaM , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , SardaSP , et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler2014;20(2):253-7. [DOI: 10.1177/1352458513507818] [PMID: 24150778]MillerDH , FoxRJ , PhillipsJT , HutchinsonM , HavrdovaE , KitaM , et al, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology2015;84(11):1145-52. [DOI: 10.1212/WNL.0000000000001360] [PMID: 25681448]">CONFIRM 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Throughout the course of the study, every effort was made to remain alert to possible adverse events (AEs)</i> " and "<i>Any AE or SAE experienced by the subject was recorded on the CRF, regardless of the severity of the event or its relationship to study treatment</i>" (pages 66‐7 of Protocol) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0019" title="BenedictRH , CohanS , LynchSG , RiesterK , WangP , Castro-BorreroW , et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler2018 ;24(6):795-804. [DOI: 0.1177/1352458517707345]KapposL , HavrdovaE , GiovannoniG , KhatriBO , GauthierSA , GreenbergSJ , et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler2017;23(13):1736-1747. [DOI: 10.1177/1352458516683266]KapposL , WiendlH , SelmajK , ArnoldDL , HavrdovaE , BoykoA , et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2015;373(15):1418-28. [DOI: 10.1056/NEJMoa1501481]KruegerJG , KircikL , HougeirF , FriedmanA , YouX , LucasN , et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther2016;33(7):231-45. [DOI: 10.1007/s12325-016-0353-2]LiuY , VollmerT , HavrdovaE , RiesterK , LeeA , PhillipsG , et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;11:18-24. [DOI: 10.1016/j.msard.2016.11.005]NCT01064401. Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01064401 (accessed 30 September 2014). RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40.. [DOI: 10.1016/j.msard.2017.06.006]">DECIDE 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"A serious adverse event (SAE) is any untoward medical occurrence that at any dose:<br/>• results in death<br/>• in the view of the Investigator, places the subject at immediate risk of death (a life‐threatening event); however, this does not include an event that, had it occurred in a more severe form, might have caused death<br/>• requires inpatient hospitalisation or prolongation of existing hospitalisation<br/>• results in persistent or significant disability/incapacity, or<br/>• results in a congenital anomaly/birth defect.<br/>An SAE may also be any other medically important event that, in the opinion of the Investigator, may jeopardise the subject or may require intervention to prevent one of the other outcomes listed in the definition above" (Protocol). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0020" title="ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol2014;261(9):1794-802. [DOI: 10.1007/s00415-014-7412-x] [PMID: 24989666]ArnoldDL , GoldR , KapposL , Bar-OrA , GiovannoniG , SelmajK , et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol2014;261(12):2429-37. [DOI: 10.1007/s00415-014-7504-7] [PMID: 25270680]Bar-OrA , GoldR , KapposL , ArnoldDL , GiovannoniG , SelmajK , et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol2013 ;260(9):2297-305. [DOI: 10.1007/s00415-013-6954-7] [PMID: 23797999]Fernández Ó, GiovannoniG , FoxRJ , GoldR , PhillipsJT , PottsJ , et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther2017;39(8):1671-1679. [DOI: 10.1016/j.clinthera.2017.06.012] [PMID: 28751099]GoldR , KapposL , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine2012;367(12):1098-107. HavrdovaE , GiovannoniG , GoldR , FoxRJ , KapposL , PhillipsJT , et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol2017;24(5):726-733. [DOI: 10.1111/ene.13272] [PMID: 28328179]KapposL , GoldR , ArnoldDL , Bar-OrA , GiovannoniG , SelmajK , et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler2014;20(2):243-52. [DOI: 10.1177/1352458513507817] [PMID: 24150779]">DEFINE 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Study visits were scheduled every 4 weeks for safety assessments, including the monitoring of laboratory values</i>" (page 1100). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0021" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica2006;113(5):283-7. ">Etemadifar 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0022" title="EtemadifarM , JanghorbaniM , ShaygannejadV . Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. Journal of Neurology2007;254(12):1723-8. ">Etemadifar 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Adverse events, vital signs and blood tests were monitored monthly</i>" (page 1724). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0023" title="FazekasF , DeisenhammerF , Strasser-FuchsS , NahlerG , MamoliB . Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet1997;349(9052):589-93. ">Fazekas 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants "<i>asked about safety monthly...</i>" (page 590). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0024" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang-AubersonL , AgoropoulouC , et al, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol2012;11(5):420-8. [DOI: 10.1016/S1474-4422(12)70056-X] [PMID: 22494956]KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387-401. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang-AubersonL , vonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord2014;3(3):341-9. [DOI: 10.1016/j.msard.2013.10.006] [PMID: 25876471]RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , Mueller-LenkeN , AgoropoulouC , HoldbrookF , deVeraA , Zhang-AubersonL , FrancisG , BurtinP , KapposL , FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol2012;69(10):1259-69. [PMID: 10.1001/archneurol.2012.1051] [PMID: 22751847]SormaniMP , De StefanoN , FrancisG , SprengerT , ChinP , RadueEW , Kappos L Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler. 2015 21;7:916-24. [DOI: 10.1177/1352458515569099] [PMID: 25662353]VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , FreedmanMS . A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin2017;3(3):2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>An independent data and safety monitoring board evaluated the safety</i> " and "S<i>tudy visits, including safety assessments, were scheduled at 2 weeks and 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24 months after randomization</i>" (page 389). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0025" title="CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(6):545-56. VermerschP , RadueEW , PutzkiN , RitterS , MerschhemkeM , Freedman MS A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017 3;3:2055217317730096. [DOI: 10.1177/2055217317730096] [PMID: 28989795]">FREEDOMS II 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"...<i>safety assessments, were scheduled at 2 weeks and 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24 months after randomization</i>" (Appendix, page 2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0026" title='DavisMD , AshtamkerN , SteinermanJR , KnappertzV . Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study. 2017 Neurol Neuroimmunol Neuroinflamm;4(2):e327. [DOI: 10.1212/NXI.0000000000000327] [PMID: 28210662]KhanO , RieckmannP , BoykoA , SelmajK , ZivadinovR , GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Annals of Neurology2013;73(6):705-13. ZivadinovR , DwyerM , BarkayH , SteinermanJR , KnappertzV , Khan O. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis. J Neurol2015;262(3):648-53. [DOI: 10.1007/s00415-014-7616-0] [PMID: 25542295]ZivadinovR , DwyerMG , RamasamyDP , DavisMD , SteinermanJR , KhanO . The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. J Neuroimaging2015;25(6):989-95. [DOI: 10.1111/jon.12293] [PMID: 26394270]'>GALA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Safety assessments included adverse events (AEs), standard clinical laboratory tests, vital signs, and electrocardiographic (ECG) measurements</i>" (page 707). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information on SAE definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0027" title="GobbiC , MeierDS , CottonF , SintzelM , LeppertD , GuttmannCR , ZeccaC . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol2013;13:101. [DOI: 10.1186/1471-2377-13-101] [PMID: 23915113]ZeccaC , RiccitelliGC , CalabreseP , PravatàE , CandrianU , GuttmannCR , Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol2014;14:38. [DOI: 10.1186/1471-2377-14-38] [PMID: 24576156]">Gobbi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0028" title="ComiG , PattiF , RoccaMA , MattioliFC , AmatoMP , GalloP , CentonzeD , PozzilliC , SaccàF , BerghFT , BartezaghiM , TurriniR , FilippiM , Golden Study Group. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol2017;264(12):2436-2449. [DOI: 10.1007/s00415-017-8642-5] [PMID: 29063244]">GOLDEN 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"AEs, SAEs and vital signs were assessed at each study visit"</i> (page 18). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information on SAE definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0029" title="GoodkinD , BaillyR , TeetzenM , HertsgaardD , BeattyW . The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology1991;41:20-5. ">Goodkin 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Side effects were reported to the treating neurologist every 6 months</i>" (page 21). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0030" title="IFNBMSG . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology1993;43(4):655-61. ">IFNB MS Group 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Treating neurologist reviewed side effects, laboratory findings for toxicity ...</i>" (page 656). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0031" title="DurelliL , VerdunE , BarberoP , BerguiM , VersinoE , GhezziA , et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002;359:1453-60. ">INCOMIN 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Safety assessments included adverse events, vital signs, physical examination, and concomitant medications. Patients underwent haematology and biochemical tests, including liver‐function tests, every 2 weeks for the first 8 weeks, and then every 3 months</i>" (page 1455). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0032" title="JohnsonK , BrooksB , CohenJ , FordC , GoldsteinJ , LisakR , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology1995;45(7):1268-76. ">Johnson 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>The evaluating physician monitored safety every 3 months..."</i> (page 1270). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0033" title="KnoblerRL , GreensteinJI , JohnsonKP , LublinFD , PanitchHS , ConwayK , et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. Journal of Interferon Research1993;13(5):333-40. ">Knobler 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"At each patient visit, a nurse coordinator collected patient diaries of daily events and documented adverse events noted in these records."</i> (page 335). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0034" title="Koch-HenriksenN , SørensenP , ChristensenT , FrederiksenJ , RavnborgM , JensenK , et al. A randomised study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology2006;66(7):1056-60. ">Koch‐Henriksen 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Patients were interviewed about side effects and had routine blood tests including hematology and liver function tests every 3 months and thyroid tests and neutralizing antibodies every 6 months</i>" (page 1057). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0035" title="LewanskaM , Siger-ZajdelM , SelmajK . No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. European Journal of Neurology2002;9(6):565-72. ">Lewanska 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Laboratory safety examinations were made at the beginning and at the end of the study period</i>" (page 566). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0036" title="MassacesiL , TramacereI , AmorosoS , BattagliaMA , BenedettiMD , FilippiniG , et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One2014;9(11):e113371. ">MAIN 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>At scheduled (quarterly) and unscheduled (i.e. at the onset of new symptoms or complications) follow‐up visits the treating neurologist recorded symptoms, blood test results, clinical AEs and their management</i>". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0037" title="MillefioriniE , GasperiniC , PozzilliC , D'AndreaF , BastianelloS , TrojanoM , et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology1997;244(3):153-9. ">Millefiorini 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>The safety of the treatment was assessed on the basis of adverse events volunteered by the patient either spontaneously or on questioning and monitoring of the main laboratory parameters</i>" (page 155). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0038" title="MokhberN , AzarpazhoohA , OroujiE , KhorramB , Modares GharaviM , KakhiS , KhallaghiH , AzarpazhoohMR . Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis. Psychiatry Clin Neurosci.2015;69(10):649-57. [DOI: 10.1111/pcn.12308] [PMID: 25907350]MokhberN , AzarpazhoohA , OroujiE , RaoSM , KhorramB , SahraianMA , ForoghipoorM , GharaviMM , KakhiS , NikkhahK , AzarpazhoohMR . Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. J Neurol Sci2014;342(1-2):16-20. [DOI: 10.1016/j.jns.2014.01.038] [PMID: 24841321]">Mokhber 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAEs not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0039" title="JacobsL , CookfairD , RudickR , HerndonR , RichertJ , SalazarA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology1996;39:285-94. ">MSCRG 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Study visits were scheduled at baseline and every 6 months. Treating physicians reviewed toxicity test results, examined patients, and made all medical decisions</i>" (page 286). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0040" title="A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01247324 (accessed 30 September 2014). HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , JulianL , KöndgenH , LiC , NapieralskiJ , ZhengH , WolinskyJS . Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , BuffelsR , FioreD , GarrenH , HanJ , HauserSL . Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA I 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A serious adverse event is defined as any adverse event that, at any dose, fulfils at least one of the<br/>following criteria:<br/> Is fatal; (results in death*; please note: death is an outcome, not an event)<br/> Is life‐threatening (please note: the term “life‐threatening” refers to an event in which the patient was at immediate risk of death at the time of the event; it does not refer to an event which could hypothetically have caused a death had it been more severe)<br/> Requires in‐patient hospitalisation or prolongation of existing hospitalisation<br/> Results in persistent or significant disability/incapacity<br/> Is a congenital anomaly/birth defect<br/> Is medically significant or requires intervention to prevent one or other of the outcomes listed above (Appendix) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0041" title="HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med2017;376(3):221-234. [DOI: 10.1056/NEJMoa1601277] [PMID: 28002679]MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord2019;30:236-243. [DOI: 10.1016/j.msard.2019.01.044] [PMID: 30844611]NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis. https://clinicaltrials.gov/ct2/show/study/NCT01412333 (accessed 30 September 2014). TurnerB , CreeBAC , KapposL , MontalbanX , PapeixC , WolinskyJS , et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019;266(5):1182-1193. [DOI: 10.1007/s00415-019-09248-6] [PMID: 30820738]">OPERA II 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A serious adverse event is defined as any adverse event that, at any dose, fulfils at least one of the<br/>following criteria:<br/> Is fatal; (results in death*; please note: death is an outcome, not an event)<br/> Is life‐threatening (please note: the term “life‐threatening” refers to an event in which the patient was at immediate risk of death at the time of the event; it does not refer to an event which could hypothetically have caused a death had it been more severe)<br/> Requires in‐patient hospitalisation or prolongation of existing hospitalisation<br/> Results in persistent or significant disability/incapacity<br/> Is a congenital anomaly/birth defect<br/> Is medically significant or requires intervention to prevent one or other of the outcomes listed above (Appendix) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0042" title="KapposL , FoxRJ , BurcklenM , FreedmanMS , HavrdováEK , HennessyB , et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol 2021 May 1;;78(5):558-567. [DOI: 10.1001/jamaneurol.2021.0405] [PMID: 33779698]">OPTIMUM 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"Safety assessments included adverse events recorded</i> <br/><i>verbatim and later coded in accordance with MedDRA version 21 (International Council for Harmonisation) and predefined adverse events of special interest (AESIs)"</i> (page 560). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An SAE is defined by the ICH guidelines as any AE fulfilling at least one of the following criteria: </p> <p> <ul id="CD011381-list-0008"> <li> <p>Fatal;</p> </li> <li> <p>Life‐threatening: refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event that hypothetically might have caused death had it been more severe; </p> </li> <li> <p>Requiring inpatient hospitalisation or prolongation of existing hospitalisation;</p> </li> <li> <p>Resulting in persistent or significant disability or incapacity;</p> </li> <li> <p>Congenital anomaly or birth defect;</p> </li> <li> <p>Medically significant: refers to important medical events that may not immediately result in death, be life‐threatening, or require hospitalisation but may be considered to be SAEs when, based upon appropriate medical judgement, they may jeopardise the subject and may require medical or surgical intervention to prevent one of the outcomes listed in the definitions above (Protocol). </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0043" title="EbersGC . Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet1998;352(9139):1498-1504. [DOI: 10.1016/S0140-6736(98)03334-0]TraboulseeA , LiDKB , CascioneM , FangJ , DangondF , MillerA . Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. BMC Neurol2018;18(1):143. [DOI: 10.1186/s12883-018-1145-x] [PMID: 30217172]">PRISMS 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>A “treating” neurologist was responsible for overall medical management of the patient, including treatment of any side‐effects</i>" (page 1499). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0044" title="CohenJA , ComiG , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019;18(11):1021-1033. [DOI: 10.1016/S1474-4422(19)30238-8] [PMID: 31492652]NCT01628393. Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study). https://clinicaltrials.gov/show/NCT016283932012. ">RADIANCE 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"Adverse events were assessed at each visit"</i> (page 123). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0045" title="MikolD , BarkhofF , ChangP , CoyleP , JefferyD , SchwidS , et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology2008;7(10):903-14. ">REGARD 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Adverse events (including pregnancy), withdrawals owing to adverse events, serious adverse events, and laboratory results were obtained for safety comparisons</i>" (page 905). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on SAEs definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0046" title="GiovannoniG , KapposL , GoldR , KhatriBO , SelmajK , UmansK , et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016 ;9:36-46. [DOI: 10.1016/j.msard.2016.05.010]GiovannoniG , RadueEW , HavrdovaE , RiesterK , GreenbergS , MehtaL , et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol2014;261(2):316-23. [DOI: 10.1007/s00415-013-7196-4]GoldR , GiovannoniG , SelmajK , HavrdovaE , MontalbanX , RadueEW , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet2013;381(9884):2167-75. HavrdovaE , GiovannoniG , StefoskiD , ForsterS , UmansK , MehtaL , et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler2014;20(4):464-70. [DOI: 10.1177/1352458513502113]PhillipsG , GuoS , BenderR , HavrdováE , ProskorovskyI , VollmerT . Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler Relat Disord2016 ;6:66-72. [DOI: 10.1016/j.msard.2016.02.001]RadueEW , SprengerT , VollmerT , GiovannoniG , GoldR , HavrdovaE , et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2016 ;23(2):412-5. [DOI: 10.1111/ene.12922]RoseJW , GiovannoniG , WiendlH , GoldR , HavrdováE , KapposL , et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2017;17:32-40. [DOI: 10.1016/j.msard.2017.06.006]">SELECT 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Safety parameters were assessed at all visits</i>" (page 2168). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information on SAE definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011381-bbs2-0047" title="ComiG , KapposL , SelmajKW , Bar-OrA , ArnoldDL , SteinmanL , et al, SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology2019 ;18(11):1009-1020. [DOI: 10.1016/S1474-4422(19)30239-X]DeLucaJ , SchipplingS , MontalbanX , KapposL , CreeBAC , ComiG , et al. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Mult Scler Relat Disord2021;48:102673. [DOI: 10.1016/j.msard.2020.102673]NCT02294058. Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS). https://ClinicalTrials.gov/show/NCT022940582014. ">SUNBEAM 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"Adverse events were assessed at each visit"</i> (page 1012). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information on SAE definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0048" title="MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al, Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler2012;18(11):1625-32. [DOI: 10.1177/1352458512450354] [PMID: 22723573]O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293-303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol2013;260(10):2472-80. [DOI: 10.1007/s00415-013-6979-y] [PMID: 23852658]RadueEW , SprengerT , GaetanoL , Mueller-LenkeN , CavalierS , ThangaveluK , et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm2017;4(5):e390. [DOI: 10.1212/NXI.0000000000000390] [PMID: 28828394]WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013 ;19(10):1310-9. [DOI: 10.1177/1352458513475723] [PMID: 23447359]">TEMSO 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>A treating neurologist at each site was responsible for recording and managing adverse events and monitoring safety assessments</i> " and "<i>Safety was evaluated on the basis of adverse events reported by study participants or investigators. Laboratory tests were performed at the time of screening, at baseline, every 2 weeks for the first 24 weeks, and then every 6 weeks until study completion. Physical and neurologic examinations were performed at week 12 and then every 24 weeks. An abdominal ultrasonographic examination to assess for pancreatic abnormalities was performed before the study and then every 24 weeks, because of previous infrequent reports of pancreatitis associated with leflunomide use</i>" (pages 1294‐5). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0049" title="ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology2014;13(3):247-56. FreedmanMS , MorawskiJ , ThangaveluK . Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. Mult Scler J Exp Transl Clin2018;4(2):2055217318775236. [DOI: 10.1177/2055217318775236] [PMID: 29796289]MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MäurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol2014;261(9):1781-8. [DOI: 10.1007/s00415-014-7395-7] [PMID: 24972678]MillerAE , XuX , MacdonellR , VucicS , TruffinetP , BenamorM , et al. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. J Clin Neurosci2019;59:229-231. [DOI: 10.1016/j.jocn.2018.09.012] [PMID: 30348586]QiuW , HuangDH , HouSF , ZhangMN , JinT , DongHQ , et al, TOWER Trial Chinese Group. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study. Chin Med J (Engl)2018;131(23):2776-2784. [DOI: 10.4103/0366-6999.246067] [PMID: 30511679]">TOWER 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>Safety was assessed through adverse event reporting (upon occurrence), clinical laboratory tests (every 2 weeks until week 24, then every 6 weeks while still on treatment), vital signs (at weeks 2 and 6, then every 6 weeks until week 24, then every 12 weeks while still on treatment), abdominal ultrasonography (at week 24, then every 24 weeks), and electrocardiography (at baseline and end of treatment)</i>" (page 248). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011381-bbs2-0050" title="BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler2014;20(13):1704-13. [DOI: 10.1177/1352458514532317] [PMID: 24812043]CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402-15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol2013;260(8):2023-32. [DOI: 10.1007/s00415-013-6932-0] [PMID: 23632946]KhatriBO , PelletierJ , KapposL , HartungHP , ComiG , BarkhofF , et al, TRANSFORMS Study Group. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord2014;3(3):355-63. [DOI: 10.1016/j.msard.2013.11.006] [PMID: 25876473]MengX , ChinPS , HashmonayR , Zahur IslamM , CutterG . Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemp Clin Trials2015;41:69-74. [DOI: 10.1016/j.cct.2014.12.011] [PMID: 25545026]">TRANSFORMS 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>An independent data and safety monitoring board evaluated overall safety in the fingolimod phase 3 program</i> " and <i>"Safety assessments were conducted during screening, at baseline, and at months 1, 2, 3, 6, 9, and 12</i>" (page 404). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>AE: adverse events<br/>CRF:<br/>CTCAE:<br/>DMC:<br/>ECG:<br/>ELISA:<br/>ETD:<br/>ICH:<br/>SAE: serious adverse events </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Assessment of adverse events/serious adverse events in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011381-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Netleague: Relapse (12 months)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Teriflunomide</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.52 (1.28,1.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.80,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.61,1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.31,1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.16 (1.16,4.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.74,2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.94,1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.67,1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.78,1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.72 (0.56,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.61,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.38 (0.85,2.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.66 (0.55,0.78) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo/no treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.68 (0.56,0.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.52 (0.43,0.63 </b>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.40 (0.21,0.74) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 (0.78,2.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.50,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.76 (0.68,0.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.60 (0.47,0.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.55,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.48 (0.39,0.57) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55 (0.42,0.73) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.58,1.43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.75,1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.47 (1.22,1.78) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pegylated interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.58,1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.30,1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.10 (1.12,3.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.71,2.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.90,1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.65,1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.75,1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.70 (0.54,0.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.58,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.82,2.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.99,1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.93 (1.60,2.33) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.31 (1.00,1.71) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Natalizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.40,1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.75 (1.46,5.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.58 (0.94,2.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.47 (1.18,1.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.85,1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.98,1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.70,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.76,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76 (1.08,2.87)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67 (0.87,3.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.53 (1.35,4.73) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.72 (0.89,3.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.31 (0.68,2.52)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mitoxantrone</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.61 (1.51,8.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.07 (0.94,4.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.92 (1.02,3.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 (0.78,3.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.63 (0.86,3.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.20 (0.63,2.31) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.40 (0.71,2.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.30 (1.06,4.99) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.46 (0.25,0.87) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.38,1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.48 (0.25,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.36 (0.19,0.68) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.28 (0.12,0.66) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a and ‐1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.26,1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.53 (0.29,0.98) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42 (0.22,0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.45 (0.24,0.84) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.33 (0.18,0.63) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.39 (0.20,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.43,0.95) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.48,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.75,1.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.49,1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 (0.38,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.22,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.74 (0.80,3.78)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1b Betaferon</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.57,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.43,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.49,1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.58 (0.36,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.39,1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.57,2.17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.71,1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.32 (1.18,1.47) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.72,1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.68 (0.55,0.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.52 (0.28,0.98) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.88 (1.02,3.46) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.66,1.75)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.60,1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.71,1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.63 (0.53,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.73 (0.54,0.98) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.75,1.91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.80,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.65 (1.27,2.15) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.81,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.62,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.33,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.36 (1.22,4.54) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.78,2.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.94,1.67)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Immunoglobulins</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.79,1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.57,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.62,1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (0.89,2.54)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.81,1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.55 (1.33,1.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.83,1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.63,1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.32,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.21 (1.19,4.11) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.78,2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.99,1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.69,1.27)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glatiramer acetate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.74 (0.61,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.63,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.87,2.27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.39 (1.07,1.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.10 (1.74,2.54) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.43 (1.09,1.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.83,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.43,1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.00 (1.59,5.63) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.72 (1.07,2.76 </b>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.60 (1.34,1.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.92,1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.36 (1.11,1.65) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fingolimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.83,1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.91 (1.17,3.13) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.86,1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.81 (1.37,2.39) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.88,1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.67,1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.36,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.58 (1.33,5.00) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48 (0.84,2.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.37 (1.02,1.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.75,1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.85,1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.61,1.20)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Daclizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.65 (0.97,2.80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.45,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.70,1.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.46,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.57 (0.35,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.43 (0.20,0.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.57 (1.05,2.33) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.46,1.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.52,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.39,1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.44,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.52 (0.32,0.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.36,1.03)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Azathioprine</b> </p> </th> </tr> </tbody> <tfoot> <tr> <td colspan="13"> <div class="table-footnote"> <p>Significant results are bolded and underlined</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Netleague: Relapse (12 months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011381-tbl-0009"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Netleague: Relapse (24 months)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Teriflunomide</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.70 (0.62,0.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.22 (1.06,1.40) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.68 (0.55,0.84) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.57 (0.33,0.99) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.86,1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.47 (0.79,2.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.86,1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.87,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.68,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.86,1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.65 (0.55,0.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.75 (0.63,0.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.51,0.81) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.60,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.55,0.86)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.42 (1.25,1.63) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ponesimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.73 (1.43,2.10) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.76,1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.46,1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.44 (1.16,1.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.09 (1.11,3.92) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.47 (1.18,1.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.46 (1.19,1.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.94,1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.45 (1.17,1.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.74,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.86,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.70,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.84,2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.75,1.28)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.82 (0.71,0.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.58 (0.48,0.70) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo/no treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.56 (0.48,0.65) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.47 (0.27,0.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.83 (0.76,0.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.66,2.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.85 (0.76,0.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.84 (0.78,0.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.59,0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.84 (0.76,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.54 (0.48,0.60) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.62 (0.55,0.70) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.53 (0.44,0.64 </b>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.51,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.47,0.68)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.47 (1.19,1.81) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.80,1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.79 (1.53,2.09) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Natalizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.48,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.48 (1.24,1.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.16 (1.16,4.00) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.51 (1.25,1.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.51 (1.26,1.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30 (0.99,1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.50 (1.24,1.81) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.79,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.91,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.74,1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.38 (0.88,2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.79,1.29)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.76 (1.01,3.06) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.70,2.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.14 (1.25,3.66) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.68,2.09)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mitoxantrone</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.77 (1.03,3.05) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.58 (1.15,5.76) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.81 (1.05,3.13) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.80 (1.05,3.10) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55 (0.87,2.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.79 (1.04,3.09) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.66,1.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.76,2.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.64,1.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.65 (0.84,3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.69,2.13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.84,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.70 (0.56,0.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.21 (1.10,1.32) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.56,0.81) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.56 (0.33,0.97) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laquinimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.79,2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.89,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.91,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.69,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.88,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.65 (0.56,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.75 (0.64,0.87) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.52,0.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.61,1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.56,0.83)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.37,1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.48 (0.26,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.46,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.46 (0.25,0.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.39 (0.17,0.87) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.38,1.26)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta 1a and 1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.38,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.38,1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.32,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.38,1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.45 (0.24,0.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.51 (0.28,0.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.44 (0.23,0.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.42,0.98) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.47 (0.25,0.88) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.82,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.68 (0.55,0.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.18 (1.06,1.31) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.66 (0.55,0.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55 (0.32,0.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.85,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 (0.78,2.61)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.88,1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.68,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.89,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.54,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.73 (0.63,0.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.62 (0.50,0.77) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.91 (0.59,1.41) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.55,0.81) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.83,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.68 (0.56,0.84) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.19 (1.10,1.28) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.66 (0.56,0.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55 (0.32,0.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.88,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43 (0.78,2.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.89,1.13)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.69,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.88,1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.56,0.73) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.73 (0.64,0.84) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.63 (0.51,0.77) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.60,1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.57,0.79) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.88,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.60,1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.38 (1.11,1.71) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.59,1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.36,1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.91,1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66 (0.88,3.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.92,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.93,1.46)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Immunoglobulins</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.91,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.74 (0.58,0.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.67,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.73 (0.55,0.97) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.67,1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.59,1.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.83,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.69 (0.55,0.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.19 (1.08,1.32) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.55,0.81) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.56 (0.32,0.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.86,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (0.79,2.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.91,1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.90,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.68,1.10)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glatiramer acetate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.55,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.74 (0.64,0.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.63 (0.51,0.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.60,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.55,0.82) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.53 (1.28,1.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.86,1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.86 (1.66,2.09) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.85,1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.50,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.54 (1.33,1.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.24 (1.22,4.12) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.57 (1.34,1.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.57 (1.36,1.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.35 (1.06,1.72) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.56 (1.33,1.82) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fingolimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.98,1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.79,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (0.93,2.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.85,1.30)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.33 (1.10,1.59) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.74,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.61 (1.43,1.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.74,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.44,1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.34 (1.15,1.55) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.95 (1.06,3.58) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.37 (1.17,1.60) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.36 (1.18,1.57) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.92,1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.35 (1.17,1.56) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.74,1.02)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dimethyl fumarate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.68,1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.81,1.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.74,1.13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.55 (1.23,1.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.84,1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.89 (1.57,2.28) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.83,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.50,1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.57 (1.28,1.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.28 (1.22,4.26) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.60 (1.29,1.98) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.59 (1.30,1.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.37 (1.03,1.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.58 (1.28,1.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.82,1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.94,1.46)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cladribine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.46 (0.92,2.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.82,1.38)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.68,1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.47,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.85,1.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.46,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.31,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.70,1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.56 (1.02,2.39) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.71,1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.71,1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.59,1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.70,1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.45,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.52,1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.43,1.08)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Azathioprine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.46,1.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.45 (1.16,1.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.78,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.77 (1.48,2.12) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.78,1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.47,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.47 (1.20,1.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.13 (1.14,3.99) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.50 (1.23,1.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.49 (1.27,1.76) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28 (0.97,1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.48 (1.22,1.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.77,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.88,1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.72,1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 (0.87,2.16)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alemtuzumab</b> </p> </th> </tr> </tbody> <tfoot> <tr> <td colspan="16"> <div class="table-footnote"> <p>Significant results are bolded and underlined</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Netleague: Relapse (24 months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011381-tbl-0010"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Netleague: Relapse (36 months)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.57,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.60,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.45 (0.32,0.65) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.92,1.75<b>) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glatiramer acetate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.61,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.58 (0.36,0.93) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.49 (1.33,1.67) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.83,1.64)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Daclizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.46,0.98) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.20 (1.54,3.16) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.74 (1.07,2.81) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.48 (1.02,2.16) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alemtuzumab</b> </p> </th> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Significant results are bolded and underlined</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Netleague: Relapse (36 months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011381-tbl-0011"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Netleague: Disability (24 months)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Teriflunomide</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.57,1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.31 (1.05,1.63) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.56 (0.92,2.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.71 (0.54,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.51,1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.56,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (0.06,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.76,1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.17 (0.40,43.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.74,1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.88,1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.51,1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.72,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.67,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.65,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.68,1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.29,2.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.57,1.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.84,1.77)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ponesimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.60 (1.04,2.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.90 (1.00,3.60) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.54,1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.54,1.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.57,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32 (0.07,1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.77,2.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.09 (0.47,55.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.76,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.47 (0.90,2.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.57,2.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.74,1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.68,1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.65,1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.70,1.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.33,2.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.60,1.91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.76 (0.61,0.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.63 (0.41,0.96) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo/no treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.74,1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54 (0.38,0.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.61 (0.41,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.59 (0.46,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.20 (0.05,0.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.78 (0.63,0.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.19 (0.31,33.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.62,0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.73,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.41,1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.74 (0.61,0.89) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.68 (0.56,0.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.65 (0.55,0.77) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.72 (0.56,0.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.22,1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.67 (0.46,0.99) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.38,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53 (0.28,1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.52,1.35)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ozanimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.45 (0.25,0.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.51 (0.30,0.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.50 (0.29,0.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.17 (0.04,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.40,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.68 (0.25,29.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.40,1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.51,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 (0.29,1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.39,1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.58 (0.35,0.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55 (0.33,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.35,1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.17,1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.57 (0.34,0.95) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.41 (1.08,1.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.73,1.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.85 (1.30,2.63) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.20 (1.22,3.96) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ofatumumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.66,1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.71,1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.08,1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (0.96,2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.90 (0.55,63.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 (0.94,2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.71 (1.12,2.59) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.69,2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 (0.92,2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.85,1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.82,1.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.86,2.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.39,3.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.74,2.09)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.80,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.58,1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.65 (1.11,2.45) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.96 (1.16,3.31) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.53,1.51)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ocrelizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.61,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.07,1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.84,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.26 (0.49,56.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.85,1.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.52 (1.10,2.09 </b>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.60,2.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.82,1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.73,1.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.71,1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.74,1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.34,2.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.71,1.73)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.93,1.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.65,1.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.69 (1.33,2.16) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.01 (1.18,3.42) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.60,1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.65,1.63)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Natalizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.08,1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.96,1.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.39 (0.51,56.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30 (0.94,1.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.56 (1.12,2.18) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.66,2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.92,1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.85,1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.82,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.86,1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.37,2.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.72,1.79)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.87 (0.91,16.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.17 (0.71,14.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.06 (1.21,21.16) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6.01 (1.33,27.11) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.74 (0.63,11.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.07 (0.70,13.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.99 (0.70,12.76)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mitoxantrone</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.95 (0.93,16.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16.13 (1.04,251.30) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.87 (0.91,16.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.66 (1.10,19.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.79 (0.80,17.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.74 (0.88,15.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.46 (0.82,14.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.30 (0.78,13.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.62 (0.85,15.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.06 (0.54,17.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.40 (0.77,14.95)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.72,1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.50,1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28 (1.04,1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 (0.92,2.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.46,1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.50,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.55,1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25 (0.06,1.07)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laquinimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.08 (0.39,42.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.73,1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.88,1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.50,1.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.72,1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.66,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.64,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.67,1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.28,2.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.56,1.31)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24 (0.02,2.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (0.02,2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31 (0.03,3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.03,4.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17 (0.02,1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19 (0.02,2.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19 (0.02,1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.06 (0.00,0.97) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24 (0.02,2.58)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta 1a and 1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24 (0.02,2.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (0.03,3.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 (0.02,2.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 (0.02,2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 (0.02,2.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (0.02,2.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22 (0.02,2.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19 (0.02,1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 (0.02,2.27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.74,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.51,1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.31 (1.06,1.61) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55 (0.97,2.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.47,1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.53,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.56,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (0.06,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.76,1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.16 (0.40,43.81)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.95,1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.51,1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.81,1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.67,1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.66,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.68,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.29,2.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.60,1.29)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.60,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.42,1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.86,1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.85,1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.59 (0.39,0.89) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.66 (0.48,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.46,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.21 (0.05,0.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.63,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.46 (0.33,36.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.66,1.05)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.42,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.64,1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.55,1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.71 (0.54,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.56,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.24,1.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.73 (0.54,0.99) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.53,1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.40,1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.73,2.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.59 (0.73,3.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.36,1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.39,1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.41,1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (0.06,1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.55,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.26 (0.38,47.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.54,1.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.64,2.35)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Immunoglobulins</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.52,1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.48,1.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.46,1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.50,1.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.25,2.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.44,1.84)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.77,1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.53,1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.35 (1.12,1.64) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.61 (1.00,2.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.49,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.55,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.59,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27 (0.06,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.80,1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.31 (0.41,45.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.87,1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.99,1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.54,1.91)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glatiramer acetate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.70,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.71,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.71,1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.30,2.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.62,1.34)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.83,1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.57,1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.46 (1.20,1.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.74 (1.04,2.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.53,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.57,1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.63,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (0.07,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.86,1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.66 (0.44,48.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.84,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (1.00,1.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.58,2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.82,1.42)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fingolimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.73,1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.76,1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.32,2.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.64,1.51)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.89,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.60,1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.53 (1.29,1.82) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.82 (1.11,2.99) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.56,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.61,1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.67,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (0.07,1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.92,1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.88 (0.47,51.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.91,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.41 (1.08,1.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.61,2.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.91,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.81,1.36)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dimethyl fumarate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.82,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.34,2.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.68,1.55)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.77,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.53,1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.40 (1.10,1.78) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66 (0.98,2.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.49,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.53,1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.59,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 (0.06,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.79,1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.45 (0.42,47.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.78,1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.92,1.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.54,2.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.76,1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.70,1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.68,1.23)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cladribine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.30,2.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.60,1.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.46,3.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.35,3.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66 (0.61,4.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.97 (0.65,5.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.31,2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.34,2.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.35,2.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.06,1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.47,3.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.27 (0.63,44.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.46,3.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 (0.55,4.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.39,3.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.44,3.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.41,3.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.39,2.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.43,3.29)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Azathioprine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.38,3.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.73,1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.52,1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.49 (1.01,2.19) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.77 (1.06,2.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.48,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.58,1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.56,1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (0.07,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.76,1.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.74 (0.44,51.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.77,1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.37 (1.01,1.87) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.54,2.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.75,1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.66,1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.64,1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.68,1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.31,2.61)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alemtuzumab</b> </p> </th> </tr> </tbody> <tfoot> <tr> <td colspan="19"> <div class="table-footnote"> <p>Significant results are bolded and underlined</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Netleague: Disability (24 months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011381-tbl-0012"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Netleague: Disability (36 months)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.82,1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.72 (0.58,0.90) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.37 (0.20,0.68) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.64,1.23)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glatiramer acetate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.43,0.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.33 (0.17,0.66) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.39 (1.12,1.73) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.57 (1.06,2.33) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Daclizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.52 (0.27,0.99) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.68 (1.47,4.88) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.03 (1.53,6.03) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.93 (1.01,3.68) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alemtuzumab</b> </p> </th> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Significant results are bolded and underlined</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Netleague: Disability (36 months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011381-tbl-0013"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Netleague: Discontinuation due to adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Teriflunomide</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.76 (1.32,5.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55 (0.36,0.84) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.96 (0.73,5.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.25,1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.67,1.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.45 (0.20,0.99) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.39,1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.45,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66 (0.14,19.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.52,3.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.45,1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36 (0.20,9.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.46,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.59,1.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.42,1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.40 (0.67,2.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.23,2.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.43 (0.36,33.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.21 (0.09,0.49) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.36 (0.17,0.76) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ponesimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.20 (0.08,0.47) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.21,2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.20 (0.07,0.59) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.40 (0.16,0.96) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.16 (0.05,0.48) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.31 (0.11,0.92) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.29 (0.11,0.74) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.05,7.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 (0.14,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.29 (0.11,0.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49 (0.06,3.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.29 (0.12,0.74) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.36 (0.15,0.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.27 (0.11,0.68) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.18,1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27 (0.07,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.11,13.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.08 (0.03,0.23) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.82 (1.19,2.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.04 (2.15,11.82) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo/ no treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.58 (1.47,8.73 </b>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.52,1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.00 (1.05,3.81) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.42,1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.57 (0.81,3.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.46 (1.00,2.15) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.02 (0.27,33.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.27 (1.05,4.91) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48 (0.99,2.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.49 (0.37,16.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.48 (1.02,2.14) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.84 (1.31,2.57) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.94,1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.55 (1.40,4.63) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.38 (0.46,4.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.26 (0.67,58.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.39 (0.19,0.79) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.19,1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.41,4.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.28 (0.11,0.68) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pegylated interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.28 (0.09,0.85) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.19,1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.23 (0.07,0.70) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.14,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 (0.15,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.06,11.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 (0.19,2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 (0.16,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.09,5.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 (0.16,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.20,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.38 (0.14,0.99) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.24,2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 (0.09,1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.75 (0.16,19.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.11 (0.03,0.34) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.81 (0.83,3.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.01 (1.70,14.73) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.51,1.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.56 (1.17,10.80) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ozanimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.99 (0.79,5.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.38,1.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.56 (0.61,3.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.71,3.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.25,36.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.25 (0.88,5.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.47 (0.87,2.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.47 (0.33,18.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.47 (0.76,2.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.83 (0.93,3.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.65,2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.53 (1.25,5.13) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 (0.38,4.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.22 (0.61,63.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.38 (0.17,0.86) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.56,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.52 (1.04,6.10) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.50 (0.26,0.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.79 (0.60,5.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50 (0.20,1.27)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ofatumumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 (0.16,1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.31,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.35,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.51 (0.12,18.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.42,3.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.35,1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.17,9.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.35,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.44,1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.32,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.53,3.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.19,2.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.13 (0.31,31.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.19 (0.07,0.51) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.23 (1.01,4.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6.16 (2.08,18.25) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.62,2.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.38 (1.43,13.37) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.58,2.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.44 (0.96,6.20)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ocrelizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.92 (0.75,4.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.79 (0.86,3.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.69 (0.30,45.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.77 (1.07,7.18) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.81 (1.05,3.11) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.04 (0.41,22.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.81 (0.92,3.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.24 (1.13,4.46) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.65 (0.79,3.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.11 (1.52,6.38) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.69 (0.47,6.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.65 (0.75,78.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47 (0.21,1.07)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.53,2.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.21 (1.09,9.43) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.33,1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.28 (0.75,6.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.25,1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.51,3.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.20,1.34)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Natalizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.43,2.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.92 (0.16,23.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (0.53,3.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.43,2.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.58 (0.21,11.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.44,2.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.56,2.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.40,1.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (0.66,3.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.24,3.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.98 (0.39,40.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.25 (0.09,0.65) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.70,2.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.45 (1.35,8.77) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.47,1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.45 (0.93,6.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.33,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 (0.65,2.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.27,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.50,2.31)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laquinimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.06 (0.18,23.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55 (0.66,3.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.62,1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.70 (0.25,11.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.61,1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.77,2.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.55,1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.74 (0.89,3.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.29,3.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.28 (0.45,40.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.26 (0.12,0.58) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.05,6.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67 (0.13,21.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.03,3.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.09,15.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.03,4.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.05,8.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27 (0.02,3.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.04,6.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.04,5.56)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta 1a and 1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.06,9.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49 (0.04,5.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.04,17.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49 (0.04,5.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.05,6.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 (0.04,5.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.07,10.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.03,6.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.07 (0.82,5.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13 (0.01,1.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.33,1.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.22 (0.70,7.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.44 (0.20,0.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.58 (0.49,5.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.17,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.32,2.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.36 (0.14,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.26,1.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.28,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 (0.11,16.69)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.30,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.14,8.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.32,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.37,1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.26,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.46,2.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.16,2.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.76 (0.26,29.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.17 (0.06,0.46) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.69,2.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.41 (1.33,8.73) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.45,1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.42 (0.91,6.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.40,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.63,2.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55 (0.32,0.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.49,2.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.60,1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.04 (0.18,23.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.54 (0.70,3.35)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.68 (0.24,11.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.67,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.82,1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.55,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.72 (1.08,2.75) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.29,3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.23 (0.44,40.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (0.14,0.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.11,5.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.03 (0.25,16.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.06,2.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (0.18,11.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.05,3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.11,5.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.04,2.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 (0.09,4.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 (0.09,4.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.06,26.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.12,7.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 (0.09,4.12)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Immunoglobulins</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 (0.09,4.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.11,5.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54 (0.08,3.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.14,7.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.06,4.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.52 (0.14,46.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 (0.02,1.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.70,2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.41 (1.35,8.64) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.68 (0.47,0.98) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.43 (0.92,6.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.35,1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.64,2.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.28,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.50,2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.59,1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.05 (0.18,23.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.54 (0.75,3.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.67,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.68 (0.24,11.58)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glatiramer acetate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.83,1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.59,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.72 (0.95,3.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.29,2.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.24 (0.44,40.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.26 (0.13,0.54) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.58,1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.74 (1.10,6.86) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.54 (0.39,0.76) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.95 (0.75,5.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.28,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.53,2.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.45 (0.22,0.89) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.41,1.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.49,1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64 (0.14,18.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.56,2.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.53,1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.20,9.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.54,1.20)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fingolimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.46,1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.75,2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.24,2.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.41 (0.36,32.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.21 (0.10,0.44) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.77,2.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.73 (1.48,9.42) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.51,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.65 (1.01,6.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.36,1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48 (0.71,3.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.29,1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.55,2.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.64,1.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.24 (0.20,25.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.68 (0.74,3.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.66,1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.84 (0.27,12.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.70,1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36 (0.85,2.18)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dimethyl fumarate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.88 (0.96,3.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.32,3.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.63 (0.48,44.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (0.13,0.63)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.34,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.98 (0.70,5.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.39 (0.22,0.71) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.48,4.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.39 (0.19,0.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.33,1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32 (0.16,0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.25,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.29,1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.10,14.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.36,2.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.58 (0.36,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.13,7.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.32,1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.39,1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53 (0.27,1.04)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Daclizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54 (0.16,1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.46 (0.24,24.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.15 (0.07,0.33) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.41,4.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.65 (0.91,14.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.24,2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.59 (0.63,10.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.20,2.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.40,5.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.59 (0.16,2.15) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.32,4.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.33,3.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19 (0.15,30.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64 (0.43,6.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.33,3.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.80 (0.20,16.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.33,3.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 (0.42,4.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.31,3.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.84 (0.53,6.44)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cladribine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.53 (0.38,54.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 (0.08,1.04)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (0.03,2.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.07,8.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 (0.02,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.05,6.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 (0.02,1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32 (0.03,3.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13 (0.01,1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25 (0.02,2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 (0.02,2.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.19,1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 (0.03,3.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24 (0.02,2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.02,7.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24 (0.02,2.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (0.03,2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22 (0.02,2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 (0.04,4.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22 (0.02,2.65)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Azathioprine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06 (0.01,0.64)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.72 (2.05,10.89) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>13.04 (4.27,39.80) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.59 (1.26,5.32) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9.27 (2.95,29.14) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.60 (1.16,5.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.17 (1.97,13.60) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.12 (0.94,4.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.07 (1.53,10.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.79 (1.74,8.25) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.82 (0.63,96.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.87 (2.16,15.92) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.82 (2.08,7.03) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.43 (0.85,48.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.82 (1.84,7.95) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.75 (2.27,9.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.50 (1.59,7.68) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6.59 (3.05,14.27) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.58 (0.96,13.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16.19 (1.56,168.25) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alemtuzumab</b> </p> </th> </tr> </tbody> <tfoot> <tr> <td colspan="20"> <div class="table-footnote"> <p>Significant results are bolded and underlined</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Netleague: Discontinuation due to adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011381-tbl-0014"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Netleague: Serious adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Teriflunomid</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.63,1.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.61,1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.47,1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30 (0.67,2.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.31 (0.88,1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.45,1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.57,2.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.01,41.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.68,1.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.43,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.65,1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.51,1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.47,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.53,1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64 (0.93,2.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.62,2.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.72,2.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.55,1.58)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ponesimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.43,1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.36,2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.51,2.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.63,2.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.35,1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.44,2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.01,39.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.50,2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.33,1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.48,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.37,1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.34,1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.40,1.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 (0.70,3.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.48,2.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.55,2.73)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.81,1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.66,2.35)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo/ no treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.59,1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (0.85,2.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 (0.89,2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.58,1.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.73,2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.02,47.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.92,1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.55,1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.88,1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.68,1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.64,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.71,1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.90 (1.21,2.99) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.80,2.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 (0.94,2.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.54,2.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.48,2.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.51,1.69)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pegylated interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.61,3.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.63,3.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.41,2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.52,2.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.01,45.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.59,2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.39,1.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.57,2.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.44,1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.41,1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.47,1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76 (0.83,3.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.57,2.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.65,3.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.40,1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.35,1.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.38,1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.32,1.64)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ozanimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.47,2.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.35,1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.38,1.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 (0.01,32.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.45,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.31,1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.50,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.35,1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.32,1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.36,1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.69,2.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.42,2.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.56,1.85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.51,1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.42,1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.39,1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.32,1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.46,2.14)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ofatumumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.31,1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.39,1.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 (0.01,32.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.45,1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.29,1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.43,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.33,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.31,1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.36,1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.63,2.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.43,1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.49,2.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.61,2.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.54,2.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.58,1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.48,2.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (0.79,2.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.51 (0.71,3.22)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ocrelizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.58,2.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.02,48.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.69,2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.47,1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.78,1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.54,1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.49,1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.55,1.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.90 (1.07,3.39) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.38 (0.64,2.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 (0.86,2.69)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.50,1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.44,2.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.48,1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.39,1.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.56,2.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.58,2.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.38,1.72)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Natalizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.01,39.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.55,1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.36,1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.53,1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.41,1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.38,1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.44,1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.54 (0.77,3.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.52,2.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.60,2.52)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30 (0.02,69.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.03,77.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.02,59.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.02,67.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.68 (0.03,92.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.70 (0.03,93.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.02,61.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.03,76.26)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mitoxantrone</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.40 (0.03,75.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.02,56.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36 (0.03,72.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.02,56.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.02,51.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (0.02,62.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.13 (0.04,116.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55 (0.03,85.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.71 (0.03,93.46)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.58,1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.49,2.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.59,1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.44,1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.64,2.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.66,2.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.44,1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.54,1.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.01,38.21)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laquinimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.41,1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.64,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.49,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.46,1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.51,1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 (0.90,2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.59,2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.70,2.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.67,2.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.59,3.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.65,1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.53,2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (0.81,3.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64 (0.79,3.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.55,2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.65,2.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.02,52.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36 (0.75,2.44)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.31 (0.78,2.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.67,1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.55,1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.62,2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.06 (1.11,3.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (0.71,3.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.65 (0.88,3.12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.59,1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.50,2.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.60,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.45,1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.78,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.68,2.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.54,1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.55,1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.01,39.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.69,1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.46,1.28)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interferon beta‐1a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.56,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.71 (0.51,0.99) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.53,1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.57 (1.07,2.30) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.61,2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.87,1.82)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.77,1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 (0.65,2.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.78,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.59,2.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.60 (0.91,2.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (0.88,2.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.62,1.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.72,2.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.02,51.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.87,2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.65,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.93,1.79)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glatiramer acetate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.65,1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.71,1.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.03 (1.26,3.28) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48 (0.78,2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.63 (1.00,2.66) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35 (0.86,2.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.72,2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.88,1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.65,2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.75 (0.99,3.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.77 (0.97,3.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.68,2.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.80,2.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.02,55.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.46 (0.97,2.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.63,1.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.41 (1.01,1.97) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.78,1.54)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fingolimod</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.77,1.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.22 (1.37,3.60) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (0.87,3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.78 (1.09,2.92) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.66,1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.57,2.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.66,1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.51,2.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.74,2.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.46 (0.76,2.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.51,1.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.62,2.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.02,46.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 (0.74,1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.49,1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.73,1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.58,1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.52,1.30)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dimethyl fumarate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.83 (1.03,3.26) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.68,2.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.47 (0.81,2.67)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.34,1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.30,1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.53 (0.33,0.83) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.27,1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.43,1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.40,1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.53 (0.30,0.94) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.32,1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47 (0.01,25.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.39,1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49 (0.26,0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.64 (0.43,0.93) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.49 (0.31,0.79) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.45 (0.28,0.73) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.55 (0.31,0.97) </b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Daclizumab</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.36,1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.47,1.36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.43,1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.39,2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.42,1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.35,1.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.49,2.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.51,2.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.33,1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.42,1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.01,35.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.48,1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.31,1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.46,1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.36,1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.33,1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.38,1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 (0.67,2.80)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cladribine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.53,2.30)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.42,1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.37,1.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.40,1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.33,1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.54,1.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.48,2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.37,1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.40,1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.01,31.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.47,1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.32,1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.55,1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.38,1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.56 (0.34,0.92) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.37,1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 (0.73,2.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.44,1.89)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alemtuzumab</b> </p> </th> </tr> </tbody> <tfoot> <tr> <td colspan="18"> <div class="table-footnote"> <p>Significant results are bolded and underlined</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Netleague: Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/full#CD011381-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011381-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Treatment efficacy (primary outcomes): pairwise comparisons</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Comparisons for relapse (12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Azathioprine versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.58, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Daclizumab versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.42, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Glatiramer acetate versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.39, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Glatiramer acetate versus fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.97, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.5 Immunoglobulins versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.47, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.6 Interferon beta‐1a and 1b versus azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.05, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.7 Interferon beta‐1b (Betaferon) versus fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.05, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.8 Interferon beta‐1b (Betaferon) versus glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.48, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.9 Interferon beta‐1a (Avonex, Rebif) versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.67, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.10 Interferon beta‐1a (Avonex, Rebif) versus fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.32, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.11 Pegylated interferon beta‐1a versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.56, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.12 Mitoxantrone versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.21, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.13 Natalizumab versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.43, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.14 Natalizumab versus interferon beta‐1b (Betaferon)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 3.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.15 Teriflunomide versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.55, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Comparisons for relapse (24 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Azathioprine versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.51, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Cladribine versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.44, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Dimethyl fumarate versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.54, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 Fingolimod versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.47, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.5 Glatiramer acetate versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.72, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.6 Glatiramer acetate versus dimethyl fumurate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.99, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.7 Immunoglobulins versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.59, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.8 Interferon beta‐1a and 1b versus azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.02, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.9 Interferon beta‐1b (Betaferon) versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.81, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.10 Interferon beta‐1b (Betaferon) versus glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.74, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.11 Interferon beta‐1a (Avonex, Rebif) versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.77, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.12 Interferon beta‐1a (Avonex, Rebif) versus alemtuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.14, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.13 Interferon beta‐1a (Avonex, Rebif) versus glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.77, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.14 Interferon beta‐1a (Avonex, Rebif) versus interferon beta‐1b (Betaferon)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.00, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.15 Laquinimod versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.76, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.16 Laquinimod versus interferon beta‐1a (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.91, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.17 Mitoxantrone versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.27, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.18 Natalizumab versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.48, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.19 Teriflunomide versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.73, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.20 Teriflunomide versus ponesimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.27, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Comparisons for relapse (36 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Interferon beta‐1b (Betaferon) versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.67, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Interferon beta‐1b (Avonex, Rebif) versus alemtuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [1.54, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Interferon beta‐1b (Avonex, Rebif) versus daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.33, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Interferon beta‐1b (Avonex, Rebif) versus glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.92, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Comparisons for disability worsening (24 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Azathioprine versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.22, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Cladribine versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.56, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Dimethyl fumerate versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.56, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 Fingolimod versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.56, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.5 Glatiramer acetate versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.58, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.6 Glatiramer acetate versus dimethyl fumerate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.90, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.7 Immunoglobulins versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.41, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.8 Interferon beta‐1a and 1b versus azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.27 [0.63, 44.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.9 Interferon beta‐1a and 1b versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.61, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.10 Interferon beta‐1a and 1b versus glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.87, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.11 Interferon beta‐1a (Avonex, Rebif) versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.51, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.12 Interferon beta‐1a (Avonex, Rebif) versus alemtuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.01, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.13 Interferon beta‐1a (Avonex, Rebif) versus glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.87, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.14 Interferon beta‐1a (Avonex, Rebif) versus interferon beta‐1b (Betaferon)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.86, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.15 Laquinimod versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.59, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.16 Laquinimod versus interferon beta‐1a (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.51, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.17 Mitoxantrone versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.05, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.18 Natalizumab versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.46, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.19 Ocrelizumab versus interferon beta‐1a (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.48, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.20 Ozanimod versus interferon beta‐1a (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.85, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.21 Teriflunomide versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.61, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.22 Teriflunomide versus ofatumumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.08, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.23 Teriflunomide versus ponesimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.84, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Comparisons for disability worsening (36 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Interferon beta‐1a (Avonex, Rebif) versus alemtuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [1.52, 4.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Interferon beta‐1a (Avonex, Rebif) versus daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.12, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Interferon beta‐1a (Avonex, Rebif) versus glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.64, 1.22]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Treatment efficacy (primary outcomes): pairwise comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011381-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Treatment safety (primary outcomes): pairwise comparisons</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Number of patients who discontinued treatment due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Azathioprine versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.26 [0.70, 56.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Cladribine versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.49, 3.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Daclizumab versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.74 [0.85, 16.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 Dimethyl fumarate versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.93, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.5 Fingolimod versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.29, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.6 Glatiramer acetate versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.77, 3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.7 Glatiramer acetate versus dimethyl fumarate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.53, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.8 Glatiramer acetate versus fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.71, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.9 Immunoglobulins versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [0.38, 16.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.10 Interferon beta‐1a and 1b versus azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.19, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.11 Interferon beta‐1b (Betaferon) versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.82 [1.02, 59.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.12 Interferon beta‐1b (Betaferon) versus fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.07, 7.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.13 Interferon beta‐1b (Betaferon) versus glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.47, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.14 Interferon beta‐1a (Avonex, Rebif) versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.82, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.15 Interferon beta‐1a (Avonex, Rebif) versus alemtuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.18 [1.87, 9.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.16 Interferon beta‐1a (Avonex, Rebif) versus daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.45, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.17 Interferon beta‐1a (Avonex, Rebif) versus fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.26, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.18 Interferon beta‐1a (Avonex, Rebif) versus glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.84, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.19 Interferon beta‐1a (Avonex, Rebif) versus interferon beta‐1b (Betaferon)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.02, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.20 Laquinimod versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.08, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.21 Laquinimod versus interferon beta‐1a (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.46, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.22 Pegylated interferon beta‐1a versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.58 [1.61, 7.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.23 Natalizumab versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>939</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.94, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.24 Natalizumab versus interferon beta‐1b (Betaferon)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.01, 7.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.25 Ocrelizumab versus interferon beta‐1a (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.35, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.26 Ozanimod versus interferon beta‐1a (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.44, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.27 Teriflunomide versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.97, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.28 Teriflunomide versus ofatumumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.61, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.29 Teriflunomide versus ponesimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.19, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Number of patients with any serious adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Cladribine versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.88, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Daclizumab versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.71, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Dimethyl fumarate versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.68, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.4 Fingolimod versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.69, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.5 Glatiramer acetate versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.65, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.6 Glatiramer acetate versus dimethyl fumarate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.63, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.7 Glatiramer acetate versus fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.53, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.8 Interferon beta‐1b (Betaferon) versus fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.03, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.9 Interferon beta‐1b (Betaferon) versus glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.78, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.10 Interferon beta‐1b (Avonex, Rebif) versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.43, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.11 Interferon beta‐1b (Avonex, Rebif) versus alemtuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.55, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.12 Interferon beta‐1b (Avonex, Rebif) versus daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.43, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.13 Interferon beta‐1b (Avonex, Rebif) versus fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [1.54, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.14 Interferon beta‐1b (Avonex, Rebif) versus glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.84, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.15 Laquinimod versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.86, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.16 Laquinimod versus interferon beta‐1b (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.67, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.17 Pegylated interferon beta‐1a versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.65, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.18 Natalizumab versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>939</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.79, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.19 Natalizumab versus interferon beta‐1b (Betaferon)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.11, 83.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.20 Ocrelizumab versus interferon beta‐1b (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.57, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.21 Ozanimod versus interferon beta‐1b (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.82, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.22 Teriflunomide versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.88, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.23 Teriflunomide versus ofatumumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.55, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.24 Teriflunomide versus ponesimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.61, 1.42]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Treatment safety (primary outcomes): pairwise comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011381-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Treatment efficacy and safety (secondary outcomes): pairwise comparisons</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Comparisons for new gadolinium‐enhancing positive T1‐weighted MRI lesions (12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Daclizumab versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.97, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Glatiramer acetate versus fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.23, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Interferon beta‐1b (Avonex, Rebif) versus fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [1.50, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 Interferon beta‐1b (Avonex, Rebif) versus interferon beta‐1b (Betaferon)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [1.03, 5.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.5 Natalizumab versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.07, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.6 Ozanimod versus interferon beta‐1b (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.43, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Comparisons for new gadolinium‐enhancing positive T1‐weighted MRI lesions (24 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Dimethyl fumarate versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.37, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Fingolimod versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.23, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 Glatiramer acetate versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.42, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.4 Glatiramer acetate versus dimethyl fumarate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.81, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.5 Interferon beta‐1a and 1b versus azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.17, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.6 Interferon beta‐1a (Avonex, Rebif) versus alemtuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [1.90, 3.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.7 Interferon beta‐1a (Avonex, Rebif) versus glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.42, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.8 Interferon beta‐1a (Avonex, Rebif) versus interferon beta‐1b (Betaferon)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [1.32, 3.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.9 Natalizumab versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.07, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.10 Ocrelizumab versus interferon beta‐1a (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.22, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.11 Ozanimod versus interferon beta‐1a (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.77, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Comparisons for new or enlarging T2‐weighted MRI lesions (12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Daclizumab versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.97, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Glatiramer acetate versus fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.14, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 Interferon beta‐1b (Betaferon) versus fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1083</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.99, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.4 Interferon beta‐1b (Betaferon) versus immunoglobulins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [1.27, 3.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.5 Interferon beta‐1a (Avonex, Rebif) versus placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.45, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.6 Interferon beta‐1a (Avonex, Rebif) versus immunoglobulins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.22, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.7 Natalizumab versus interferon beta‐1b (Betaferon)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.89, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Comparisons for new or enlarging T2‐weighted MRI lesions (24 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Fingolimod versus placebo/ no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.56, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Interferon beta 1a and 1b versus azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.75, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.3 Interferon beta 1a (Avonex, Rebif) versus alemtuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.02, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.4 Interferon beta 1a (Avonex, Rebif) versus glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.82, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.5 Interferon beta 1a (Avonex, Rebif) versus interferon beta 1b (Betaferon)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.20, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.6 Natalizumab versus placebo/ no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.45, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.7 Ocrelizumab versus interferon beta 1a (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.57, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.8 Ozanimod versus interferon beta 1a (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.88, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Comparisons for quality of life total (non‐MS related: EQ‐5D VAS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Cladribine versus Placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1042</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.06, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Comparisons for quality of life total (non‐MS related) (INDEX) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Comparisons for quality of life ‐ physical (non‐MS related: SF‐36) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Teriflunomide versus Placebo/ no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.02, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Comparisons for quality of life ‐ physical (MS related: MSQOL‐54 PH; MSQoL‐54; MSIS29 Psychological) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 Interferon beta 1a Avonex/Rebif versus Daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.23, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.2 Interferon beta 1b Betaferon versus Interferon beta 1a Avonex Rebif</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.55, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.3 Interferon beta 1a Avonex Rebif versus Ozanimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.06, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.4 Daclizumab versus Placebo/No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.05, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Comparisons for quality of life ‐ mental (Non‐MS related: SF‐36) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 Teriflunomide versus Placebo/ no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.02, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Comparisons for quality of life ‐ mental (MS related: MSQOL‐54 PH; MSQoL‐54; MSIS29 Psychological) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.1 Interferon beta 1a Avonex/Rebif versus Daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.18, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.2 Interferon beta 1b Betaferon versus Interferon beta 1a Avonex Rebif</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.78, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.3 Interferon beta 1a Avonex Rebif versus Ozanimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.05, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.4 Daclizumab versus Placebo/No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.05, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.1 Cladribine versus placebo/ no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.18, 5.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.2 Daclizumab versus placebo/ no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.06, 35.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.3 Dimethyl fumarate versus placebo/ no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.14, 8.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.4 Fingolimod versus placebo/ no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.03, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.5 Glatiramer acetate versus placebo/ no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.06, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.6 Glatiramer acetate versus dimethyl fumarate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.13, 32.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.7 Interferon beta 1b (Betaferon) versus glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.08, 7.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.8 Interferon beta 1a (Avonex, Rebif) versus placebo/ no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.13, 4.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.9 Interferon beta 1a (Avonex, Rebif) versus alemtuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.08, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.10 Interferon beta 1a (Avonex, Rebif) versus daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.99 [0.45, 35.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.11 Interferon beta 1a (Avonex, Rebif) versus fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.02, 8.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.12 Interferon beta 1a (Avonex, Rebif) versus glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.20, 13.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.13 Laquinimod versus placebo/ no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.11, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.14 Laquinimod versus interferon beta 1a (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.06, 16.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.15 Laquinimod versus placebo/ no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.07, 3.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.16 Natalizumab versus placebo/ no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [0.12, 52.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.17 Ocrelizumab versus interferon beta 1a (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.08, 5.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.18 Ozanimod versus interferon beta 1a (Avonex, Rebif)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.06, 37.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.19 Teriflunomide versus placebo/ no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.16, 14.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.20 Teriflunomide versus ofatumumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>955</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [0.12, 74.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.21 Teriflunomide versus ponesimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.01 [0.24, 104.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Treatment efficacy and safety (secondary outcomes): pairwise comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011381.pub3/references#CD011381-tbl-0017">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011381.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011381-note-0019">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011381-note-0026">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011381-note-0030">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011381-note-0025">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011381-note-0024">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD011381-note-0029">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD011381-note-0028">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD011381-note-0021">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD011381-note-0023">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011381-note-0031">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD011381-note-0022">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD011381-note-0020">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011381-note-0027">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011381\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011381\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011381\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011381\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011381\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011381.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011381.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011381.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011381.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011381.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715993367"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011381.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715993371"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011381.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d949fbe2f9368',t:'MTc0MDcxNTk5My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 